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Abstract
Novel antibiotic chemotherapies are in high demand for the treatment of drugresistant and hypervirulent bacterial infections. Clostridium difficile has been identified as
the costliest bacterial pathogen – both in terms of financial burden and human mortality.
Furthermore, the current treatments that exist for C. difficile infection (CDI) are inadequate
and expensive. Therefore, an ongoing collaborative effort has focused on the design and
development of novel antibacterial chemotherapeutics for the treatment of CDI. Sixty-two
novel biarylpeptide derivatives were synthesized from 17 unique scaffolds and tested for
antimicrobial efficacy against a wide range of pathogenic bacteria and fungi at multiple
laboratories. An efficient, modular and scalable synthesis that utilized 11 key building block
precursors was designed and employed in the realization of the novel biarylpeptide scaffolds.
The modular approach allowed for facile diversification and derivatization of the target
scaffolds.
One or two peptidomimetic 1,2,3-triazole rings were installed into the peptide backbone of
the biarylpeptide derivatives to achieve increased metabolic resistance. Subsequent
derivatization of these scaffolds produced a wide array of compounds with structural
variation in the following moieties: the hydrophobic aromatic core (biphenyl or binaphthyl),
the cationic amino acid residues (lysine and/or arginine) and the hydrophobic termini (mainly
aryl or alkyl substituents). All synthesized derivatives exhibited some level of antimicrobial
activity – i.e. minimum inhibitory concentration (MIC) values ≤ 16 μg/mL against S. aureus.
The bis-triazole dicationic compound 80b exhibited the best broad-spectrum antibacterial
activity, displaying MIC values of 2 μg/mL against S. aureus, 4 μg/mL against MRSA, and
8 μg/mL against both A. baumannii and P. aeruginosa.
x

The results of the antimicrobial assays were utilized to explore the structure-activity
relationship trends of the compounds so as to aid in the identification of the pharmacophore
elements required for C. difficile antibacterial selectivity and broad-spectrum antibacterial
activity. The structural modifications that were introduced to the biarylpeptide scaffold led
to an increase in compound solubility and a substantial increase in antibacterial efficacy
against Gram-negative bacteria in the bis-triazole dicationic derivatives. The monocationic
derivatives (e.g. compound 77c) were generally not as potent as their dicationic analogues,
but they exhibited strong Gram-positive selectivity, which is beneficial for a CDI
chemotherapeutic. The pursuit of novel antibacterial molecules from lead biarylpeptide
compounds led to the development of two distinct structural scaffolds (i.e. 80b and 77c) that
exhibited desirable traits for an antibacterial chemotherapeutic. Compound 77c exhibited an
increase in selectivity for C. difficile and Gram-positive bacteria; the molecule was also
structurally simple and easier to synthesize, therefore making an ideal candidate for a
potential CDI chemotherapeutic. Additionally, compound 80b exhibited a notable increase
in the overall Gram-negative antibacterial efficacy; this could allow the biarylpeptide
derivatives to be investigated for use in the treatment of topical and skin-related Gramnegative bacterial infections.
A solubility assay was developed and utilized to allow for solubility comparisons between
similar derivatives; this also allowed for correlations to be drawn between a compound’s
solubility and its in vitro and in vivo antibacterial activities. Four compounds with varying
solubilities were selected based upon their in vitro activities against C. difficile and
subsequently tested in an in vivo CDI mouse model. The Gram-positive selective compound
77c exhibited promising preliminary results and has been selected for testing in further in
xi

vivo CDI mouse models. The expected lack of systemic bioavailability following oral
administration of the biarylpeptides was proven via pharmacokinetics assay on the mouse
blood and faeces. A cytotoxicity assay was also employed in conjunction with the in vitro
antimicrobial testing; compound 80b exhibited some cytotoxicity (CC50 = 16.4 μg/mL) while
compound 77c failed to exhibit any cytotoxic effects at the concentrations tested. Compound
77c exhibited increased selectivity for C. difficile (and other Gram-positive bacteria),
structural simplicity and reduced cytotoxicity; these traits make compound 77c a prime
candidate for further biological studies (i.e. in vitro and in vivo assays) and optimization.
Therefore, compound 77c has been selected for ongoing biological and chemical assays to
ascertain its efficacy and potential as a novel CDI chemotherapeutic.

xii

1.0 – Introduction
1.1 – Antibiotic resistance
Bacterial resistance to known antibiotic drugs is a serious threat to modern
healthcare and global security.1-6 Infectious disease is the second leading killer globally
(17 million deaths annually) and drug resistant bacterial infections are now considered an
“emergent global disease” by the World Health Organization (WHO) and the US Centers
for Disease Control and Prevention (CDC).6-7 The CDC estimates that antibiotic resistance
is responsible for more than two million infections and 23,000 deaths each year in the
USA.2 The WHO has initiated a “Global Action Plan” to reduce the prevalence of drug
resistance and both organizations have published lists of drug resistant bacteria that are
currently considered a major threat.1,

3, 8

Bacterial strains have emerged that exhibit

resistance to our most valued antibiotics and the prevalence of hypervirulent strains only
potentiates the problem.9-10 Thus, the need for novel antibacterial compounds with new
modes of action is of utmost importance. The threat of these resistant and/or hypervirulent
prokaryotes is a serious concern in today’s healthcare sector and this concern is the impetus
behind the ongoing need for and development of new antibiotic medications.
In the past eighty years, a plethora of natural and synthetic antibacterial compounds have
been discovered and yet, resistant bacterial strains have been reported for virtually all
antibiotics.9 Bacteria can develop resistance to antibiotics rapidly, due to their short
regeneration time and their ability to spread resistance to other bacteria via horizontal gene
transfer.5, 9 Bacterial resistance to anthropogenic antibiotics has been developing at an
alarming rate since the introduction of penicillin in the 1930s; by the end of the 1950s,
almost 85% of clinically isolated staphylococci were penicillin-resistant.9
1

Vancomycin was rapidly approved for use as an antibiotic because an effective treatment
for penicillin-resistant bacteria was urgently needed.11 Methicillin, the first semi-synthetic
penicillin, was developed in 1959 and it soon became the antibiotic of choice for penicillinresistant bacteria.11 The subsequent emergence of methicillin-resistant Staphylococcus
aureus (MRSA) and its acquired resistance to most other common antibiotics led to
vancomycin becoming the ‘gold standard’ for MRSA treatment.11 This lead to an increase
in vancomycin use in the 1970s – not only for MRSA treatment but also to treat the growing
number of severe Clostridium difficile infection (CDI) cases.11 Extensive oral vancomycin
use for the treatment of CDI led to the emergence of vancomycin-resistant enterococci
(VRE) in 1986,11 while vancomycin-resistant S. aureus (VRSA) also emerged in 2002. In
the latter case, the VRSA acquired resistance via horizontal gene transfer from VRE in a
human patient who had been intermittently treated with vancomycin.11 Furthermore, some
bacteria have developed resistance against multiple drug classes – these multi-drug
resistant (MDR) bacteria are a serious concern facing modern healthcare.4, 7, 12-13 Resistant
bacterial isolates, colloquially known as “superbugs”, are extremely worrying and they
have provided a strong impetus for the discovery of novel antibiotic molecules.
Recent potential vancomycin replacements for treating VRSA, MRSA and other Grampositive bacterial infections include linezolid, quinupristin/dalfopristin, daptomycin and
tigecycline.10-11 Both daptomycin and linezolid have been used extensively for treating
Gram-positive, drug-resistant infections; as a result, resistance to both drugs has already
been documented.11, 14 Gram-negative bacteria are inherently more resistant to antibiotics
due to their impermeable outer membrane and their broad-substrate transmembrane efflux
pumps (for transporting unwanted molecules out of the cell).13 Multi-drug resistance
2

amongst Gram-negative bacteria has been on the increase and there is an unmet need for
novel antibiotics capable of treating such infections.13 Therefore, the research focus has
now shifted towards developing new antibiotic molecules for treatment of MDR Gramnegative bacterial infections.5, 13 The ESKAPE pathogens (i.e. Enterococcus faecium,
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas
aeruginosa and Enterobacter spp.) are six antibiotic resistant bacterial species that have
been identified by multiple agencies (including the Infectious Diseases Society of
America) as key pathogens behind the majority of nosocomial infections.5 These bacteria
have been identified due to their virulence, tenacity, propensity for resistance and
pathogenicity.5 Notably, P. aeruginosa and A. baumannii exhibit a particularly strong
ability to resist antibiotic molecules, likely due to their ability to withstand toxic
environments.13 There are limited chemotherapeutic treatments for MDR bacterial
infections and pan-drug resistant (PDR) Gram-negative strains have also been identified
(i.e. resistant to all known antibiotic treatment options).13 The lack of viable treatment
options for Gram-negative bacterial infections has even led to the reintroduction of
polymyxin B and polymyxin E (colistin), despite known toxicity issues – polymyxins are
large, cyclic cationic peptides with potent antibacterial activity.5, 13
Unfortunately, bacterial resistance is inevitable for almost all antibiotic molecules; bacteria
will eventually find a way to negate, destroy, pacify, eliminate or withstand the target
antibiotic.5 Resistance becomes possible as soon as bacteria have been exposed to an
antibacterial agent. By increasing the exposure to the antibiotic, there is an increased
chance for a resistant bacterial strain to develop. Therefore, the increased use of antibiotics
by the agriculture industry (for animal growth – which accounts for > 50% of antibiotics
3

consumed) and by modern medicine (i.e. misuse and overuse) only serves to exacerbate
the problem of resistance by accelerating the process.7, 15 The overuse of antibiotics is such
a big problem that the US White House instituted a 5-year plan in 2015 to reduce the
unnecessary use of antibiotics in farm animal growth.7 Furthermore, the US White House
has created the ‘National Action Plan for Combating Antibiotic-Resistant Bacteria’ – this
plan aims to fund novel antibiotic drug discovery for treating MDR bacterial infections.7
The antibiotic resistance problem has become so severe that the WHO now warns of a
‘post-antibiotic era’ where common infections and minor injuries will prove lethal due to
the lack of viable antibiotic therapies.16 Thus, novel antibacterial compounds with unique
mechanisms of action are always needed to help combat the constantly evolving threat of
bacterial resistance.

1.2 – Clostridium difficile infection (CDI)
C. difficile is a Gram-positive, anaerobic bacterium that causes mild to serious
infections in the gastrointestinal (GI) tract due to the potent toxins and resilient endospores
that are produced by the organism (Figure 1.1).17-18

Figure 1.1 - Transmission electron micrograph of C.
difficile forming an endospore (red).19

4

CDI occurs when the normal GI microbiota is compromised; this allows C. difficile to
flourish in the GI tract due to the absence of the usual enteric microbiome.17-18 Most
common oral antibiotics, including penicillins, can destroy the normal GI microflora – this
unwanted side-effect allows C. difficile to infect up to 20% of hospital patients
administered oral antibiotics.17 C. difficile produces robust endospores that are spread by
the faecal-oral route; these spores are resistant to most antibiotics, alcohol-based hand
sanitizers and heat.20 The hospital setting provides a prime ‘breeding ground’ for C.
difficile spores, which can stay viable for months at a time.17-18 It is often considered a
nosocomial infection; the disease is most prevalent in the hospital setting because the main
risk factor for CDI is previous antibiotic therapy.18 Broad spectrum antibiotic therapy
indiscriminately destroys the GI microflora, but fails to eradicate C. difficile spores.20
Almost all broad-spectrum antibiotics can instigate CDI by eliminating the commensal GI
microflora; however, antibiotics such as ampicillin/amoxicillin, cephalosporins,
clindamycin and fluoroquinolones are most commonly associated with CDI.17
GI infection from C. difficile can result in symptoms such as diarrhoea, abdominal pain
and pseudomembranous colitis (PMC – a severe gastric disease). PMC is caused by colonic
inflammation due to infection which leads to the appearance of white “pseudomembranes”
that inhibit normal colonic function.17-18, 21 CDI-associated PMC can be so severe as to
warrant colectomy (i.e. resection of the colon) for which there is a ~55% mortality rate for
patients that undergo such surgery/procedures.21 Furthermore, toxic megacolon can also
result from CDI, wherein the patient suffers from severe colonic inflammation and
abdominal distension.20 CDI exhibits an overall mortality rate of up to 8%18 and infection

5

recurrence occurs in up to 20% of cases treated with first-line medications (i.e. vancomycin
or metronidazole).22
Once the infectious spores have reached the GI tract, the presence of bile salts initiates
germination of the spores to produce the vegetative C. difficile cells.20 Disease caused by
CDI is primarily the result of two virulence factors (Toxin A and Toxin B) that are excreted
by the vegetative C. difficile cells; these toxins promote colonic inflammation and
epithelial tissue damage which causes fluid loss (i.e. diarrhoea).20 A third toxin (known as
CDT or binary toxin) is found in high levels in hypervirulent C. difficile strains, although
the role of this toxin in disease has not yet been elucidated.20
Recently, both the severity and incidence of CDI cases has increased due to epidemics of
hypervirulent C. difficile strains, e.g. ribotype 027 – also known as strain B1/NAP1/027.1718

The hypervirulent ribotype 027 produces higher levels of toxins than normal C. difficile

strains – these toxins are thought to be responsible for disease symptoms like diarrhoea and
PMC.18 As a result, ribotype 027 exhibits a mortality rate that is three times higher than
normal C. difficile isolates.17
The prevalence of C. difficile infection results in a massive financial burden on the modern
healthcare system (>$1 billion/year in the USA);17, 23 another estimate put CDI-related
healthcare costs in 2008 at $4.8 billion.18 The CDC issued a report in 2013 entitled
‘Antibiotic Resistance Threats’; C. difficile was listed as the number one bacterial threat
facing the healthcare sector and humans in general.3 A recent update by the CDC reports
that CDI is responsible for approximately 500,000 infections and 15,000 deaths annually
in the USA – the highest of any of the bacterial threats listed by the CDC.23 Therefore, the
6

heightened concern over CDI is understandably justified and the alarm over impending
resistance and hypervirulence only complicates the situation. Due to the high levels of
infection, recurrence, mortality, cost, and the lack of adequate treatments for CDI, there
exists a substantial incentive to pursue novel chemotherapeutics that effectively combat
CDI.
Antibacterial selectivity for C. difficile is an essential component for a fully effective CDI
chemotherapeutic. The elimination of all GI bacteria by broad spectrum antibacterial
activity provides an ideal habitat for C. difficile spores to grow; therefore, the maintenance
and/or restoration of commensal GI microflora is essential for preventing CDI
recurrence.17-18,

20

This explains why CDI is so difficult to eradicate with traditional

antibiotics and why CDI recurs in 15-30% of patients treated with vancomycin.17 Faecal
transplantation has thus become a viable method for treating cases of chronic/severe CDI,
as it physically replaces the commensal GI microflora.17-18, 21 The classic chemotherapeutic
treatments for CDI (i.e. vancomycin and metronidazole) suffer from efficacy issues, most
notably CDI recurrence due to their lack of selectivity for C. difficile and inability to
prevent sporulation.17-18 CDI recurrence is also linked with the inability to form a specific
antibody response to the toxins released by C. difficile; healthy adults normally form an
antibody against toxin A.17 Non-chemotherapeutic treatments (i.e. surgery) are available,
but they are generally only used when classic chemotherapeutics fail. Surgical treatments
are drastic and permanent – most involve subtotal colectomy in an attempt to physically
remove the infection and diseased bowel.18 Current C. difficile treatment options are
lacking in completely effective CDI medications. There exists a drastic need for more
efficacious C. difficile chemotherapeutics for the treatment of CDI; a well-tolerated and
7

safe medication that could selectively target C. difficile (and its spores), while leaving the
enteric microbiome intact, would prove invaluable in the treatment of severe and recurrent
CDI.

1.3 – Current chemotherapeutic treatments for CDI
There are currently only three medications that are widely-used and accepted as
treatments for CDI; vancomycin, metronidazole and fidaxomicin.17, 20, 22, 24 Vancomycin
was the only FDA-approved treatment for CDI until 2011 when fidaxomicin was approved.
Metronidazole is widely used off-label as a first-line treatment for mild-to-moderate cases
of CDI (despite not being FDA-approved for the aforementioned purpose), whereas oral
vancomycin is commonly used for moderate-to-severe or recurrent cases of CDI.

1.3.1 – Vancomycin
Vancomycin (Figure 1.2) is the prototypical glycopeptide antibiotic.9 The
glycopeptides represent a complex class of molecular structures; the main cyclic scaffold
is comprised of sugars and amino acids joined via peptide bonds. Vancomycin was
discovered in 1959 by the Eli Lilly pharmaceutical company – the compound was isolated
from a soil sample from the rainforests of Borneo and is now known to be produced by a
microorganism named Amycolatopsis orientalis.9 Fermentation of A. orientalis yields a
broth rich in vancomycin; this production method is economically more viable than
synthesis because the drug’s structure is so complex.11 As a result, vancomycin is rather
costly (~$31 USD/dose) compared to synthetic, small-molecule medications (e.g.
metronidazole).9, 25

8

Figure 1.2 – The glycopeptide antibiotic vancomycin.

Vancomycin is known to work by interfering with bacterial manufacture of the
peptidoglycan cell wall by binding to the two terminal D-alanine residues of the
peptidoglycan precursor that participates in enzymatic cross-linking. The binding of
vancomycin to the terminal D-alanine residues prevents the transglycosylase enzyme from
cross-linking the peptide as part of the cell wall manufacture.9 Vancomycin exhibits potent
antibacterial activity against Gram-positive bacteria; minimum inhibitory concentration
(MIC) values of ≤ 0.50 µg/mL were observed for 207 C. difficile strains that were tested.26
Vancomycin exhibits many traits that make it ideal for severe CDI treatment such as a low
oral bioavailability and a potent MIC value against C. difficile; unfortunately, it has several
drawbacks such as production/cost, lack of selectivity for C. difficile, and recurrence of
CDI following treatment.9, 11, 25 Vancomycin’s broad-spectrum antibacterial activity results
in indiscriminate annihilation of the enteric microbiota; this allows the resilient C. difficile
spores (which are resistant to most antibiotics) to recolonize the colon due to a lack of
viable competition, resulting in infection recurrence. Most importantly, because
vancomycin fills an important role in treating MRSA and other MDR bacteria, it will never

9

be given full license for treatment of mild or moderate CDI. The threat of widespread
vancomycin resistance limits the compound’s use to only the more severe cases.9, 11

1.3.2 – Metronidazole
Metronidazole (Figure 1.3) is a nitroimidazole derivative that exhibits antimicrobial
activity and has been in use for more than 45 years.27 The medication was originally used
for the treatment of protozoal infections (e.g. Trichomonas vaginalis and giardiasis) and
was eventually found to be effective against anaerobic bacteria (both Gram-positive and
Gram-negative infections).27-28

Figure 1.3 – Metronidazole (a nitroimidazole antibiotic).

Metronidazole was renowned for having a very low resistance profile because during the
first thirty years of use, there was very little resistance observed.28 The drug is very versatile
because it can be administered intravenously, orally, topically and vaginally; it exhibits
ideal pharmacokinetics for a systemic antibiotic.27-28 The chemical structure of
metronidazole is very simple and this allows for cheap production of the drug on a large
scale (cost = ~$0.86 USD/dose).25
Metronidazole exhibits activity through a free radical mechanism whereby the nitro group
is reduced in vivo to create an unstable ‘nitro radical anion’ which rapidly decomposes to
give an imidazole radical and a nitrite ion.20, 28 The imidazole radical and nitrite ion cause
oxidative damage to DNA strands, resulting in apoptosis. The intracellular reduction of
metronidazole occurs via electron capture from a reduced ferredoxin oxidoreductase
enzyme.28 Metronidazole has become a very common-place treatment for mild-to10

moderate CDI, despite not being formally approved by the FDA for CDI treatment. 25, 27-28
Metronidazole has replaced vancomycin as the main treatment for milder cases of CDI as
it is much cheaper to manufacture, has a similar efficacy profile in mild cases and its use
does not contribute to vancomycin resistance.25 The majority of oral metronidazole is
absorbed systemically which is not ideal for the treatment of a gastric bacterium like C.
difficile.27-28 A low oral bioavailability is essential for any oral treatment of CDI as the drug
must stay available in the gut and not be absorbed systemically. Metronidazole’s usage as
a treatment for CDI will wane as newer and more efficacious CDI chemotherapeutics
become available.

1.3.3 – Fidaxomicin
Fidaxomicin (Figure 1.4) is the prototypical macrocycle antibiotic and it was
approved in 2011 by the FDA specifically for the treatment of CDI.25 Fidaxomicin is a
relatively complex unsaturated macrolide with two sugar derivatives attached; the drug is
isolated from the fermentation broth of Dactylosporangium aurantiacum.22 Fidaxomicin is
very expensive (~$156 USD/dose) and the molecule is currently under patent.25

Figure 1.4 – The macrolide antibiotic fidaxomicin.

Importantly, fidaxomicin exhibits narrow-spectrum antibacterial activity; the drug
selectively eliminates C. difficile and does not harm important commensal GI bacteria.20, 29
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Fidaxomicin allows the commensal GI microbiome (i.e. Bacteroides spp.) to stay intact
and it is also known to prevent spore formation.30 These two combined effects are thought
to be responsible for fidaxomicin’s reduced recurrence rates.20, 29 Fidaxomicin exhibits
approximately 50% less CDI recurrence when compared to treatment with vancomycin; a
recurrence rate of 22.6% was observed for vancomycin versus 11.7% recurrence for
fidaxomicin.30
Fidaxomicin works by inhibiting bacterial RNA polymerase where it binds to a site distinct
from the rifamycin-type antibiotics.29 Systemic absorption of fidaxomicin is negligible and
therefore its notable cytotoxicity is not a problem.20 The drug is well-tolerated and it
exhibited similar tolerability to a comparator medication (i.e. an accepted medication).29
Fidaxomicin also exhibited an MIC value of 0.008 – 0.25 μg/mL for 90% of C. difficile
isolates tested and it has given promising results in the treatment of CDI.22 Fidaxomicin
inhibits virulent strains of C. difficile better than vancomycin.25 The lower CDI recurrence
rate is likely a result of fidaxomicin’s greater ability to leave the intestinal microflora intact
while simultaneously inhibiting C. difficile (when compared to vancomycin).25
Fidaxomicin has been shown to lessen the spore load (i.e. the quantity of C. difficile spores
in the intestine) of a patient following successful CDI treatment and it is thought that this
plays a major role in eliminating CDI recurrence. 29 Following treatment cessation with
fidaxomicin, there is an extended “post-antibiotic effect” relative to the other common CDI
treatments – this period of “sterility” would also help to prevent recolonization by C.
difficile spores.25 There are studies currently being conducted to ascertain whether
fidaxomicin could function as a prophylactic for CDI or as a post-antibiotic ‘chaser’ to
prevent antibiotic therapy-induced CDI.25
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1.3.4 – Rifaximin
Rifaximin (Figure 1.5) is a semi-synthetic derivative of the rifamycin antibiotic
family which includes such drugs as rifampicin. It has broad-spectrum activity and is
extremely potent against C. difficile; rifaximin exhibited an MIC value of ≤ 0.015 µg/mL
for 110 toxigenic C. difficile strains.25, 31 Rifaximin has poor water solubility and as such,
it maintains a high intestinal concentration following oral administration; so high, that 97%
of a dose can be reclaimed as unchanged rifaximin in the faeces.32 The result is a systemic
bioavailability of less than 0.4% – this is ideal for the treatment of C. difficile.32

Figure 1.5 – Rifaximin.

Recent studies have shown that rifaximin can be useful in the treatment of resistant CDI –
as a “salvage therapy” when the multiple classic treatments have failed.25, 33 These studies
have also shown that rifaximin is well-tolerated by the majority of patients and that it has
had some success in treating resilient cases of CDI, including some strains belonging to
the NAP1/BI/027 ribotype.33 Resistance to rifamycins by C. difficile is a developing issue
with approximately 2% of current strains exhibiting rifaximin resistance; there is growing
concern that this number could rise.33
Rifaximin’s extreme potency against C. difficile and its usefulness in treating resilient cases
of CDI will result in its continued use in the modern repertoire of CDI treatments –
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although concern over rifamycin-resistant C. difficile will prevent the drug from becoming
the new “standard treatment” for CDI – it will likely remain a useful alternative treatment
to utilize when other drugs are ineffective.

1.3.5 – C. difficile resistance to the current chemotherapeutics
C. difficile has been shown to exhibit reduced susceptibility to the common
chemotherapeutics (vancomycin, metronidazole and fidaxomicin), but the resistance is not
widespread. For example, C. difficile isolates with reduced susceptibility to metronidazole
(MIC > 32 μg/mL) have been documented in recent years.34 The Anaerobe Research Unit
in the UK found that four C. difficile isolates, out of 30 tested, showed reduced
susceptibility to metronidazole.34 The reduced susceptibility to metronidazole exhibited by
C. difficile is not long-lived as it is often lost after freeze-thawing or passaging of the
bacteria.20 Reduced susceptibility to vancomycin and fidaxomicin (MIC values of 4 μg/mL
and 16 μg/mL, respectively) has also been observed in C. difficile isolates. The reduced
susceptibility to metronidazole has clinical significance because concentrations < 32 μg/g
faeces are obtained following oral administration of metronidazole (due to the high
systemic absorption).20 The implications of reduced susceptibility to vancomycin and
fidaxomicin are less significant, because high concentrations ( > 1000 μg/g faeces) of the
drugs are obtained in the GI tract due to their low systemic bioavailability following oral
administration.20 The spread of C. difficile resistance is a growing concern and multiple
new chemotherapeutics are currently being developed to aid in the fight against the C.
difficile epidemic.
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1.4 – Potential CDI chemotherapeutics
There exists a wide array of novel C. difficile inhibitors that are currently in various
stages of development. Due to the recent high demand for novel CDI chemotherapeutics,
a plethora of unique molecules are currently undergoing preclinical and clinical trials for
potential application as CDI treatments.20, 22, 25 Some of the more promising antibiotic
compounds will be discussed briefly in terms of their potential for CDI treatment.
Surotomycin
Surotomycin (previously CB-183,315) (Figure 1.5) is a cyclic lipopeptide
antibiotic that is structurally related to daptomycin and was developed for CDI treatment
by Cubist Pharmaceuticals.20,

35

Daptomycin is manufactured via precursor-directed

fermentation of S. roseosporus and surotomycin is manufactured through a similar
process.35

Figure 1.5 – Cyclic lipopeptide surotomycin (previously CB-183,315).

Surotomycin exhibited an MIC value of 0.5 µg/mL against C. difficile and exhibited MIC
values > 8192 µg/mL for other intestinal bacteria such as “the Bacteroides fragilis group,
Prevotella spp., Gram-negative cocci (Veillonella spp. and Acidaminococcus spp.), E. coli,
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Enterobacter spp. and Klebsiella spp.” – this strong preference for C. difficile over other
commensal bacteria makes surotomycin a prime candidate for CDI treatment.36
A phase II clinical trial evaluated the safety/efficacy of the medication as a CDI treatment;
the study concluded that surotomycin was safe and well-tolerated at two doses of 125 mg
or 250 mg per day and that the drug “sustained better cure rates” than vancomycin. 37
Surotomycin was then subjected to a similar phase III clinical trial, but the compound failed
to meet noninferiority criteria relative to vancomycin.38 Surotomycin displayed efficacy
and tolerability that was on par with vancomycin (clincal cure rates of 79 % and 83.6% for
surotomycin and vancomycin, respectively).38 Overall, surotomycin exhibited potential as
a novel CDI chemotherapeutic, but it failed to meet initial phase III criteria for progression
into a marketable pharmaceutical.
CRS3123
CRS3123 (Figure 1.6) is a novel diaryldiamine that is currently being developed
by the National Institute for Allergy and Infectious Diseases (NIAID); the chemical is
active against Gram-positive bacteria like C. difficile.22, 39 CRS3123 works by inhibiting
bacterial methionyl-tRNA synthetase and as a result, the chemical exhibits activity against
numerous clinically relevant bacteria (e.g. MRSA and Enterococcus faecium).39

Figure 1.6 – CRS3123 (previously REP3123).
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CRS3123 exhibited potent MIC values (1.0 µg/mL) against 108 C. difficile clinical
isolates.39 Treatment of lethal CDI in a hamster model by CRS3123 resulted in a substantial
increase in survival rate vs. vancomycin. All vancomycin-treated hamsters were dead by
day 17, whereas 62% and 75% of the hamsters treated with CRS3123 (at dose rates of 0.5
mg/kg and 5 mg/kg, respectively) were alive at day 35.22 CRS3123 has recently undergone
phase I clinical trials assessing tolerability and safety with positive results.40
LFF571
LFF571 (Figure 1.7) is a semi-synthetic thiopeptide that was recently developed as
part of an investigation into the activity of 4-aminothiazolyl analogues of GE2270A (a
known, natural product antibiotic – see Figure 1.7) for the identification of potential CDI
chemotherapetuics.41

Figure 1.7 – LFF571 (left) and GE2270A (right).

GE2270A was discovered in 1991 by researchers at the Lepetit Research Institute – it was
isolated from the fermentation broth of Planobispora rosea.41 The compound was found
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to inhibit prokaryotic chaperone elongation factor Tu via inhibition of aa-tRNA binding;
this translation inhibition mechanism imparts strong antibacterial activity against a broad
spectrum of Gram-positive bacteria.41-43 This novel mechanism of action is important
because it prevents the development of cross-resistance to “standard-of-care” antibiotics.43
One study indicated that LFF571 exhibits an MIC value of ≤ 0.5 µg/mL for all C. difficile
isolates tested (whereas vancomycin exhibits an MIC90 value ≤ 2.0 µg/mL).42 In a hamster
model of CDI, LFF571 was more effective than vancomycin (at a lower dose and with
fewer recurrences of CDI); LFF571 substantially reduced the risk of death when compared
to both saline and vancomycin.42 Novartis Pharmaceuticals has recently performed a phase
II clinical trial of LFF571 as a possible treatment for CDI; results showed the drug to be
comparable to vancomycin in efficacy and safety.44
Nitazoxanide and derivatives
Nitazoxanide (Figure 1.8) is a nitrothiazolide derivative that is licensed by the FDA
for use against intestinal parasites like giardiasis and cryptosporidiosis; the medication is
now being explored for treatment of CDI.22, 25, 45

Figure 1.8 – Nitazoxanide (left) and amixicile (right).

Nitazoxanide is known to disrupt cellular metabolism via inhibition of the
pyruvate:ferredoxin oxidoreductase system.22, 25 The drug competes with pyruvate for the
thiamine pyrophosphate vitamin cofactor of the pyruvate:ferredoxin oxidoreductase
complex; by acting upon and inhibiting the co-factor and not the enzyme itself, it is
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theorized that nitazoxanide and its derivatives will not be susceptible to the same mutationbased resistance that plagues other enzyme-targeting drugs.46 The pyruvate:ferredoxin
oxidoreductase enzyme system is a semi-selective C. difficile target as many beneficial
enteric microflora do not utilize pyruvate:ferredoxin oxidoreductase because they make
use of pyruvate dehydrogenase.46
Nitazoxanide has been shown to exhibit MIC values between 0.3-1.0 µg/mL against C.
difficile isolates.22 When the chemical was first trialled against CDI, it was found to be at
least as effective as metronidazole and effective in cases where metronidazole was not.45, 47
Further small studies tested the efficacy of nitazoxanide compared with vancomycin in a
double-blind study – the results indicated that nitazoxanide was equally effective against
CDI when compared to vancomycin.47
Nitazoxanide suffers from poor water solubility and this property makes it accumulate in
the intestine following consumption.46 Amixicile (Figure 1.8) is a chemical derivative of
nitazoxanide that was identified amongst 250+ nitazoxanide derivatives as a lead
compound with increased solubility and thus increased pyruvate:ferredoxin oxidoreductase
inhibitory activity.46 This new nitazoxanide derivative was tested in an optimized murine
model of CDI and the chemical exhibited a greater survival rate (56%) than both
vancomycin (15%) and nitazoxanide (22%).46 CDI recurrence was not observed in mice
treated with amixicile and nitazoxanide while the other drugs tested (i.e. vancomycin,
fidaxomicin, etc.) exhibited CDI recurrence.46
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Thus, the nitrothiazolide derivatives represent a promising new class of potential CDI
inhibitors. Further pharmacological study into these chemicals is required before they can
be relied upon as safe, effective CDI treatments.
NVB302
NVB302 (Figure 1.9) is a chemically modified derivative of the peptide
deoxyactagardine B, which is isolated from Actinoplanes liguriae.48 The peptide works by
inhibiting cell wall biosynthesis via lipid II binding (at a site distinct from that of
vancomycin); the drug also exhibits selectivity for C. difficile over other intestinal
bacteria.48

Figure 1.9 – Antibacterial peptide NVB302.

Furthermore, NVB302 has been shown to be stable in the environment of the gut, as up to
60% of the unmetabolized drug is recoverable from the faeces of dosed rats. 22 NVB302
initially exhibited MIC values in the range of 0.5 µg/mL to 2.0 µg/mL against C. difficile;
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further activity studies against 91 clinical isolates showed an average MIC value of 1.04
µg/mL against C. difficile.22 Furthermore, NVB302 was shown to exhibit MIC values of
>256 µg/mL for fusobacteria and Bacteroides fragilis – as well as reduced activity against
other intestinal microflora (e.g. MIC value of 64 – 256 µg/mL for Prevotella spp.).22 In a
comparative study of NVB302 versus vancomycin in a human gut model of CDI, NVB302
was found to be non-inferior to vancomycin and it also exhibited less detrimental effects
against intestinal microflora like the Bacteroides fragilis group.48 NVB302 has now
completed phase I clinical trials with Novacta Biosystems;20 unfortunately, the drug has
been found to be ineffective at eliminating C. difficile spores, much like vancomycin and
other common CDI treatments.22
Ridinilazole
Ridinilazole (previously known as SMT19969) (Figure 1.10) is a bisbenzimidazole derivative that exhibits strong antibacterial selectivity for C. difficile over
other bacteria (including S. aureus and intestinal microflora).49-50 Ridinilazole selectively
targets specific Clostridia spp. without affecting the other commensal GI microflora (both
Gram-positive and Gram-negative species); the drug generally shows MIC values of 0.125
– 0.25 µg/mL against most C. difficile strains.50

Figure 1.10 – Ridinilazole (formerly SMT19969).

Summit Pharmaceuticals has completed phase I clinical trials with ridinilazole exhibiting
good tolerability, low systemic absorption rates and selectivity for Clostridium spp.;
furthermore, ridinilazole passed superiority criteria against vancomycin in a multicentre
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phase II trial of 100 CDI patients.50 The antibacterial mechanism of action is not
completely understood, but studies indicate that ridinilazole is implicated in the inhibition
of cell division – the drug is also known to reduce toxin titre levels and spore loads.50 The
company is currently pursuing phase III trials and further development.50
Cadazolid
Cadazolid (Figure 1.11) is a oxazolidinone and quinolone antibiotic hybrid that
exhibits strong potential as a novel CDI chemotherapeutic.51 The drug exhibits
antibacterial efficacy via inhibition of protein synthesis without cross-resistance to the
quinolone class or oxazolidinone class of antibiotics.51-52 Cadazolid also exhibits inhibition
of toxin production and sporulation; furthermore, the drug has a low oral bioavailability
and it exhibits respectable selectivity for C. difficile over intestinal microflora.51-52

Figure 1.11 – Cadazolid (hybrid quinolone and oxazolidinone antibiotic).

Cadazolid exhibits MIC values ranging from 0.125 – 0.50 µg/mL against C. difficile
isolates.51-52 The compound passed initial phase I and II clinical trials, showing similar
tolerability and efficacy relative to vancomycin. Recent global phase III clinical trials have
been concluded with mixed results (currently unpublished); progression to further phase
III trials is currently underway.53
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Other novel CDI treatments
A plethora of other potential CDI therapies are currently under investigation – these
include chemotherapeutics (including small molecules, polymers and larger biological
molecules) and non-invasive non-drug therapies (e.g. faecal transplant therapy).20, 22, 24
For example, ramoplanin is a lipodepsipeptide antibiotic owned by Nanotherapeutics that
is currently undergoing clinical trials for CDI treatment and relapse prevention. 20
Tigecycline is a known antibiotic drug that is also under investigation for potential use as
a CDI chemotherapeutic.20,

25

Furthermore, various synthetic derivatives of purines,54

macrolides,55 nitroheterocycles,56 glycopeptides,57 tetramic acids,58 antimicrobial
peptidomimetics59, nylon-3 polymers60 and bis-indoles61 have been shown to exhibit
significant antibacterial activity against C. difficile; these molecular classes are generally
under explored and more investigation is certainly warranted as novel, efficacious CDI
medications are currently in high demand.
Immunotherapeutic approaches include vaccination and passive antibody therapy; so far,
these therapies have all focused on the C. difficile toxins. There are three vaccines currently
being independently investigated in clinical trials by Sanofi-Pasteur, Pfizer and Intercell.20
In October 2016, bezlotoxumab (Merck’s monoclonal antibody targeting C. difficile toxin
B) was given FDA approval as an adjunct therapy for patients who are currently
undergoing antibiotic therapy for CDI treatment and are at high risk of recurrent
infection.62

1.5 – Antibacterial binaphthylpeptide derivatives
In our laboratory, there has been an ongoing project focused on the development of
novel antibacterial compounds originally based upon a binaphthylpeptide scaffold.59, 63-69
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The key structural moieties that confer antibacterial activity to this class of compounds are
outlined on lead compound 1 (Figure 1.12) as a rudimentary pharmacophore. The essential
structural features include a hydrophobic biaryl moiety with an alkyloxy substituent
attached to one ring system and a peptide chain attached to the other aromatic ring. The
peptide chain comprises one to three amino acid residues; importantly, at least one of the
amino acid residues must contain a cationic (i.e. basic) side chain functionality. Lysine
(Lys) and arginine (Arg) have been found to be key amino acids for establishing
antibacterial activity amongst this class of compounds. A hydrophobic terminus is essential
for ensuring potent antibacterial activity, although bifurcation of the terminus does not
seem to be vital.59, 69

Figure 1.12 – General pharmacophore for binaphthylpeptide compounds
(shown on lead compound 1).

These binaphthylpeptide derivatives generally exhibit broad-spectrum Gram-positive
antibacterial activity, e.g. compound 1 exhibits an MIC = 2.0 µg/mL against VRSA and
4.0 µg/mL against VRE.64 Notably, compound 1 also exhibited potent antibacterial activity
against MRSA and S. aureus strains that were resistant to linezolid. The compound
displayed reduced activity against Gram-negative bacteria, including E. coli and K.
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pneumoniae with MIC values of 16.0 µg/mL and > 32.0 µg/mL, respectively. 64 Compound
1 was licensed to Valevia Pharmaceuticals in 2010 and the company was pursuing topical
use of the drug in catheter and wound related infections.70
In vitro studies also indicated that resistance to the binaphthylpeptides develops extremely
slowly compared to vancomycin; 18 generations of S. aureus were required for
development of vancomycin resistance, whereas compound 1 required over 50 generations
of S. aureus for the development of in vitro resistance.64 Bacteria that eventually developed
reduced susceptibility to 1 did not exhibit cross-resistance to vancomycin.64 These data
indicate that vancomycin and compound 1 do not share a common mechanism of action.
Recent studies in our laboratory indicated potent antibacterial activity (MIC = 2.0 – 8.0
µg/mL) against C. difficile by various oxazole and triazole derivatives of compound 1.59, 68
Lead compound 2 was developed as a peptidomimetic derivative of compound 1 and it was
found to exhibit notable in vitro antibacterial activities against both S. aureus and
hypervirulent C. difficile (Figure 1.13).69
Compound 2 was subsequently tested in an in vivo murine model of CDI with some
promising initial results.71 Attempts are currently being made to increase antibacterial
activity and introduce C. difficile selectivity. Notably, these biarylpeptide derivatives are
non-drug like as the presence of many heteroatoms and its dicationic nature confers poor
membrane permeability to the molecules. This property makes these compounds perfect
candidates for a potential new CDI treatment as they are not absorbed systemically; this
allows for a high gastrointestinal concentration of the drug to be maintained, which is
essential for CDI treatment. Thus, a library of novel derivatives, based upon lead
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compound 2, will be pursued in an attempt to develop a drug that can effectively and safely
treat CDI.

Figure 1.13 – Lead compound 2 with a table of antibacterial activities against S. aureus
(ATCC 29213), MRSA (NCTC 10442), E. faecalis (ATCC 29212), S. pneumoniae (ATCC
49619), C. difficile (ATCC 700057, C. difficile (RT027 – NSW132) and E. coli
(ATCC25922).

1.6 – Target design: concepts and synthetic strategy
1.6.1 – Peptidomimetic bioisostere incorporation
The human GI tract is acidic and contains numerous peptidases (i.e. peptidecleaving enzymes) and other metabolic enzymes; these conditions cause peptide bond
degradation via acidic hydrolysis or enzymatic cleavage.72 Peptide bond decomposition
can be avoided by replacing an amide moiety (Figure 1.14a – blue circle) in the target
molecule with a peptidomimetic bioisostere, such as a 1,4-disubstituted-1,2,3-triazole ring
(Figure 1.14c – blue portion).
Studies have shown that the 1,2,3-triazole ring exhibits a similar planarity, dipole (Figure
1.14b and 1.14c) and spatial arrangement (for the 1,4-substituents) to that of a normal
peptide moiety.73-74 Notably, 1,4-disubstituted-1,2,3-triazoles exhibit the same potential to
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accept and donate hydrogen bonds as normal amides yet they are considered more resistant
to enzymatic cleavage, hydrolysis and oxidation.74

Figure 1.14 – a) Portion of lead compound 1 with targeted amide group (blue circle)
b) Amide moiety (blue) and corresponding dipole moment (red) c) 1,2,3-Triazole
moiety (blue) and corresponding dipole moment (red).

Peptidomimetic replacement of the first amide (Figure 1.14a – blue circle) in the peptide
chain of binaphthylpeptide 1, by a 1,2,3-triazole moiety, led to derivatives like compound
2. These triazole moieties were most reliably installed via a Cu-catalyzed azide-alkyne [3
+ 2]-cycloaddition (CuAAC), i.e. a ‘click’ reaction.73-75 The precursors necessary for the
formation of the triazole moieties were an alkyne fragment (e.g. compound 4) and the
requisite azido-substituted fragment (e.g. azide 5), as shown in Scheme 1.1.

Scheme 1.1 – Retrosynthesis of the internal triazole moiety (compound 3 - blue
portion) gives alkyne 4 and azide 5.

Furthermore, previous research in our laboratory has also led to the development of
compounds with terminal 1,2,3-triazole moieties substituted for the amide terminus, e.g.
compound 659 (Figure 1.15).
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Figure 1.15 – Lead compound 6 with a table of antibacterial activities against S. aureus
(ATCC 29213), MRSA (NCTC 10442), E. faecalis (ATCC 29212), S. pneumoniae (ATCC
49619), C. difficile (ATCC 700057, C. difficile (RT027 – NSW132) and E. coli
(ATCC25922).

1.6.2 – Peptide chain orientation
The synthesis of the internal triazole moiety via a ‘click’ reaction allows for two
potential peptide chain orientations; the resulting orientation is governed by the placement
of the azide precursor functionality on the amino acid starting material (see Scheme 1.2).
The amino acid precursor (7) can be functionalized in two ways, giving rise to either a βazido-amine (i.e. compound 8 in Pathway A – Scheme 1.2) or an α-azido-acid (i.e.
compound 9 in Pathway B – Scheme 1.2). Subsequent ‘click’ reactions with these azide
derivatives gives either scaffold orientation A or scaffold orientation B. Both peptide
orientations have been utilized in previous research on the biarylpeptides and both
orientations are known to produce active compounds.59, 69, 76 Therefore, it was decided that
both scaffold orientations, A and B, would be pursued and they would be classified into
two broad categories, Series A and Series B (respectively).
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Scheme 1.2 – Effect of azide functionality placement on the resultant scaffold's peptide backbone
orientation. Pathway A shows the potential β-azido-amine and the resulting scaffold orientation
(A). Pathway B shows the potential α-azido-acid and the resulting scaffold orientation (B).

1.6.3 – Aromatic core modification
A hydrophobic aromatic core (red circle in Figure 1.12) is essential for the
antimicrobial activity of the binaphthylpeptide derivatives. Previous research has shown
that the substitution of the binaphthalene moiety (10) with an analogous biphenyl core (11)
(Scheme 1.3) produces compounds with similar antimicrobial efficacy.65-66

Scheme 1.3 – Aromatic core replacement showing the change from
a binaphthalene core (10) to a biphenyl core (11).
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The solubility and structure of the binaphthylpeptide derivatives will be modified by the
introduction of a biphenyl aromatic core, which will allow for more variation in the target
compound library.
1.6.4 – Target compounds: scaffold variation and derivatization
A large number of structurally different biarylpeptide analogues will be designed
and synthesized based upon lead compounds 2 and 6. A range of unique scaffolds will be
synthesized, and each scaffold will be derivatized into a small number of analogues. The
following structural scaffold parameters will be varied to give different scaffolds: the
number of peptidomimetic 1,2,3-triazoles (Section 1.6.1), the peptide bond orientation
(Section 1.6.2), the aromatic core (Section 1.6.3) and amino acid residues (i.e. number,
type and orientation). Permutation of these scaffold variations will give rise to a large
number of potential scaffold configurations. There are too many possibilities to synthesize
them all, so selected scaffold variations will be synthesized to allow for key structureactivity relationship (SAR) comparisons between specific analogues. Examples of the
targeted scaffold variations for Series A, B and C are displayed in Figures 1.16, 1.17 and
1.18, respectively. Previous research has shown that monocationic derivatives can display
useful antibacterial potency;59, 69 therefore, simple monocationic derivatives (i.e. scaffold
types 12 and 15) will be targeted as well, because smaller and more synthetically-accessible
molecules are always preferable. Each synthesized scaffold will be derivatized by variation
of the hydrophobic terminus (R); peptide coupling or CuAAC reactions will be utilized for
reliable installation of the terminal amide or 1,2,3-triazole moieties, respectively.
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Figure 1.16 – Series A scaffold variations: note the variable structural elements (i.e.
amino acid residues (AA), hydrophobic terminus (R) and the biaryl core).

Figure 1.17 – Series B scaffold variations: note the variable structural elements (i.e. amino
acid residues (AA), hydrophobic terminus (R) and the biaryl core).
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Figure 1.18 – Series C scaffold variations: note the variable hydrophobic terminus
(R).

Derivatization of the scaffold fragments allows for the synthesis of multiple analogues for
each scaffold type, increasing the productivity of the synthetic approach – more molecules
translates to an increased number of potential hit compounds. A small number of molecules
without an internal triazole moiety (i.e. Series C) will also be synthesized purely for SAR
data.
1.6.5 – Modular approach to scaffold synthesis
To allow for easy synthetic access to multiple scaffold variations, a modular
approach to scaffold synthesis will be adopted. The variable structural components of the
scaffolds in both Series A and B are primarily attached by peptide bonds and 1,2,3-triazole
rings; therefore, peptide coupling and CuAAC reactions will allow for the facile and
reliable construction of numerous scaffold configurations from a number of primary
building blocks (Figure 1.19) that contain these key reactive functionalities: amines
(-NH2), acids (-COOH), azides (-N3) and alkynes (-C≡CH). The alkyne building blocks
can be combined with the requisite azide building blocks to construct the necessary 1,2,3triazole moieties. Furthermore, any acid building blocks can be joined to any primary
amine functionalities through formation of the required amide bond.
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Figure 1.19 – Precursor building blocks for the modular approach to scaffold
synthesis: azide and alkyne functionalities (blue) can be readily linked together via
CuAAC reactions while the amine and acid moieties (red) can also join together via
peptide coupling methods.

Dual functionalization of the amino acid residues with both an azide and a group capable
of peptide coupling (i.e. an amine or carboxylic acid) allows for the combination of
multiple precursor building blocks to build the scaffolds; for example, the more complex
scaffold types can be constructed from just three modular buildings blocks (Scheme 1.4).
Previous research69 has shown that CuAAC reactions do not work well with the
unprotected β-azido-amines 22 and 25, so N-protected derivatives 23, 26, and 27 were
utilized for CuAAC reactions that required the β-azido-amine structures.
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Scheme 1.4 – Modular approach to scaffold synthesis: azide and alkyne
functionalities (blue) are combined into a 1,2,3-triazole moiety while the
amine and acid moieties (red) are coupled together via an amide bond.
Note the dual functionalization of the amino acid derivatives that allows
for the modular synthesis; the remaining terminal azide handle (green)
allows for scaffold derivatization.

1.6.6 – Synthesis: proposed pathway and considerations
The aforementioned precursor building blocks (Figure 1.19) will be achieved
through the utilization of known synthetic methodologies; these precursors will be
combined through CuAAC and peptide coupling reactions to achieve the aforementioned
scaffolds (Section 1.6.4). The various scaffolds will be subsequently derivatized by either
CuAAC or peptide coupling reactions followed by side-chain N-deprotection and HCl
salting; such iterative derivatization of the various scaffold types will allow for the creation
of a small library of novel antibacterial compounds.
Importantly, the proposed synthesis requires the use of four protecting groups, i.e. Boc,
Cbz, Pbf and Fmoc (Figure 1.20), all of which are utilized for the protection of nucleophilic
nitrogens atoms.
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Figure 1.20 – Nitrogen protecting group structures and abbreviations.

Three of the groups (Boc, Cbz, and Fmoc) form carbamates with free amines while the
other group (Pbf) protects guanidino residues via arylsulfonimide formation. Previous
syntheses64-65 have utilized the Boc and Pbf groups for protection of the lysine and arginine
amino acid side-chains, respectively. Importantly, these two groups can be simultaneously
cleaved by acidolysis as a final step, which allows the side chains to remain protected
throughout the entire synthetic process. In peptide synthesis, the backbone (or α) nitrogen
is most commonly protected by the base-labile Fmoc group.77 The “Boc/Fmoc” orthogonal
deprotection strategy (i.e. acid for Boc/Pbf, base for Fmoc) has been employed in the
synthesis of previous binaphthylpeptide antibacterials64-65 and a similar orthogonal
protocol will be utilized for the realization of the targeted cationic biarylpeptides. Instead,
the Cbz protecting group will be utilized for protection of the α-nitrogen on the amino acid
precursors (when required), as this protecting group is stable to the pursuant azidation
conditions.69 Furthermore, the Cbz protecting group is also ideal because it allows for
selective deprotection, in the presence of a Boc group, via catalytic hydrogenolysis.78 The
Fmoc group will only be utilized in known synthetic procedures for building the
unprotected β-azido-amine precursors 22 and 25, because the N-protecting group is not
required after azidation for these amine building blocks.
The proposed synthetic pathways (Schemes 1.5, 1.6 and 1.7) allow for the divergent
synthesis of multiple scaffold types from simpler scaffold molecules. For example, the
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larger scaffold types (e.g. 14) will be synthesized from the smaller scaffold precursors (e.g.
amine scaffold 38 – see Scheme 1.5); this divergent synthetic approach allows for simple
diversification of the scaffold types with minimal synthetic labour. This modular synthetic
approach will allow for multiple scaffold variations to be synthesized from the same key
precursor building blocks. This approach also allows for derivatization of each scaffold
type, allowing for the facile synthesis of a large number of antibacterial compounds.

Scheme 1.5 – Potential synthetic pathway to Series A scaffold types 12 and 14.
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Scheme 1.6 – Potential synthetic pathway to Series B scaffold types 15 and 17.
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Scheme 1.7 – Potential synthetic pathway to Series C scaffold types 18 and 19. Precursor
compound 42 was gifted from previous researcher (S. Wales). Precursor compound 29 will be
synthesized from Fmoc-(D)-Arg(Pbf)-OH via methyl esterification followed by N-Fmoc
deprotection.

1.7 – Project Aims
It is evident that there exists a strong, unmet need for novel antibacterial
compounds to effectively treat CDI. Therefore, a joint research project (NHRMC Project
Grant# APP1124032) to pursue the synthesis and development of effective CDI
chemotherapeutics was established between the University of Wollongong (design and
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synthesis), the University of Western Australia (microbiology) and Monash University
(pharmacology). The aims of this project are:


To incorporate an increased number of peptidomimetic bioisosteres (i.e. a 1,2,3triazole moiety) into the peptide backbone of the lead binaphthylpeptides 2 and 6
– in an attempt to increase gastrointestinal stability by replacing amide moieties
with bioisosteres that exhibit increased resistance to enzymatic cleavage;73



To design and establish a viable, multi-gram synthesis of numerous novel triazolecontaining scaffolds;



To simplify the hydrophobic aromatic core in these scaffolds in an attempt to
increase compound solubility;



To vary the number and orientation of cationic amino acid residues embedded in
these novel scaffolds;



To synthesize a small library of novel antibacterial derivatives by installing
various hydrophobic termini on the new scaffolds;



To ascertain the antimicrobial activity of the synthesized derivatives against a
range of pathogenic Gram-negative bacteria, Gram-positive bacteria and fungi via
MIC assays;



To ascertain the general toxicity of the synthesized compounds via cytotoxicity
assay;



To explore the structure-activity relationship of the compounds by utilizing the
obtained MIC data;



To incorporate the structure-activity relationship findings into the target design;
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To design and identify a novel hit compound that could be utilized in the effective
treatment of CDI;



To ascertain the efficacy of the compound as a CDI chemotherapeutic via testing
in an in vivo CDI mouse model;



To develop and utilize a comparative solubility assay for determining the relative
solubilities of the synthesized compounds;
and



To perform a rudimentary pharmacokinetics study on the biarylpeptides by testing
the blood and faeces of mice from the in vivo CDI model.

These goals represent a multi-faceted approach to designing and creating an effective CDI
chemotherapeutic based upon the lead binaphthylpeptide scaffolds 2 and 6. The knowledge
gained in this project will also contribute to our overall understanding of the biarylpeptide
antibacterial class.
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2.0 – Synthesis: results and discussion
2.1 – Synthesis of precursor building blocks
This section describes the synthesis of the scaffold precursor building blocks from
commercially available precursors. The known compounds are marked by a reference to the
previous literature. All compounds were synthesized with modified literature procedures.
Schemes detailing each reaction mechanism can be found in Appendix A – Section A1.

2.1.1 – Synthesis of aromatic cores
2.1.1.1 – Synthesis of alkyne 20
The synthesis of alkyne 20 from precursor 45 was accomplished in two steps:
O-alkylation followed by O-propargylation (Scheme 2.1). The base-promoted mono-Oalkylation of (S)-BINOL63 (45) (500 mg, 1.75 mmol) with 1-bromo-3-methylbutane was
achieved with K2CO3 in acetone at reflux (Scheme 2.1) and produced ether 46 in 81% yield.
The reaction was also successfully conducted on larger scales with comparable yields – e.g.
10.00 g (34.92 mmol) of (S)-BINOL gave a 78% yield of ether 46.

Scheme 2.1 – Two-step synthesis of key alkyne 20: first, O-alkylation of compound 45 to
give ether 46 and then O-propargylation of 46 to yield target alkyne 20.

Target alkyne 20 was then realized in 98% yield via base-promoted O-propargylation of
intermediate 4679 (1.50 g, 4.21 mmol) with propargyl bromide and K2CO3 in acetonitrile at
reflux for 48 h. This reaction was also conducive to larger scale as 9.00 g (25.30 mmol) of
starting material 46 was reacted to produce alkyne 20 in 95% yield. These compounds (46
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and 20) exhibited spectroscopic data that were in agreement with those values reported
previously.63, 69, 79
2.1.1.2 – Synthesis of alkyne 21
The synthesis of alkyne 21 from precursor 47 was accomplished in two steps:
O-alkylation followed by O-propargylation (Scheme 2.2). The base-promoted mono-Oalkylation of 2,2′-biphenol66 (47) (3.00 g, 16.11 mmol) with 1-bromo-3-methylbutane was
achieved with K2CO3 in acetone at reflux (Scheme 2.2) and produced ether 48 in 89% yield.
The reaction was also successfully conducted on larger scales with comparable yields – e.g.
10.00 g (53.70 mmol) of 2,2′-biphenol gave an 81% yield of ether 48.

Scheme 2.2 – Two-step synthesis of key alkyne 21: first, O-alkylation of compound 47 to
give ether 48 and then O-propargylation of 48 to yield target alkyne 21.

Target alkyne 21 was then realized in 99% yield via base-promoted O-propargylation of
intermediate 48 (1.50 g, 5.85 mmol) with propargyl bromide and K2CO3 in acetonitrile at
reflux for 48 h. This reaction was also amenable to larger scale as 7.80 g (30.43 mmol) of
starting material 48 was reacted to produce alkyne 21 in 96% yield. Ether 48 exhibited
spectroscopic data that were in agreement with those values reported previously.66
The 1H NMR spectrum for alkyne 21 displayed a characteristic triplet resonance at δ 2.43
that was absent in the 1H NMR spectrum of the starting ether 48 – this resonance exhibited a
small coupling constant (J = 2.3 Hz) which is characteristic of long-range propargylic
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coupling with the adjacent methylene protons. Therefore, the resonance at δ 2.43 was
assigned to the alkyne proton (-CH2C≡C-H); this assignment was further confirmed by a
corresponding gHSQC correlation with a 13C NMR carbon resonance at δ 75.2, which had
been assigned as the alkyne methine carbon (-C≡C-H). The 13C NMR spectrum of compound
21 displayed two unique resonances (δ 79.3 and 75.2) that were not present in the 13C NMR
spectrum of the starting ether 48; these 13C NMR resonances were assigned to the quaternary
(-C≡C-H) and methine (-C≡C-H) alkyne carbons, respectively. The molecular structure was
verified by the presence of a peak at m/z 295.1692 in the HRMS that was assigned to the
protonated molecular ion [M + H]+ (calcd for C20H23O2 295.1698).

2.1.2 – Synthesis of lysine derivatives
2.1.2.1 – Synthesis of azide 23
The synthesis of the doubly N-protected azide 23 from commercially available H-(D)Lys(Boc)-OH (49) was completed in a three step reaction sequence: Cbz protection,80
carboxylic acid reduction,81 and then a two-step, one-pot mesylation/azidation procedure82
(Scheme 2.3). Installation of the Cbz protecting group on substrate 49 (4.00 g, 16.24 mmol)
gave Cbz-Lys(Boc)-OH (50) in 95% yield by reaction with benzyl chloroformate and
aqueous NaOH solution. This reaction required a substantially modified work-up procedure,
due to the solubility of the sodium carboxylate product in organic solvents. A traditional
acid/base work-up could not be employed; the product was extracted directly from the
reaction mixture into EtOAc as the sodium carboxylate salt followed by back-extraction into
distilled H2O. The intermediate acid 50 (804 mg, 2.11 mmol) was then subjected to a ‘mixed
anhydride reduction’ technique: the acid was converted into a mixed carbonic-carboxylic
anhydride by reaction with isobutyl chloroformate in the presence of N-methylmorpholine.
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The resultant mixed anhydride was then reduced by an aqueous solution of NaBH4 to give
the desired alcohol (51) in near quantitative yield (98%). This reaction was also implemented
on larger scales – 6.81 g (17.90 mmol) of acid 50 produced a 96% yield of alcohol 51. This
intermediate alcohol was then subsequently utilized in the two-step, one-pot synthesis of
azide 23.

Scheme 2.3 – Synthesis of key azide 23, from the lysine precursor 49, in three steps: N-Cbz
protection to give compound 50, then reduction of the acid functionality to give alcohol 51,
followed by consecutive mesylation/azidation to furnish the target azide 23.

The alcohol substrate 51 (6.56 g, 17.90 mmol) was first converted in situ to a mesylate via
MsCl/NEt3/CH2Cl2 followed by a biphasic, SN2-type azidation reaction with NaN3, toluene,
H2O, and the phase transfer catalyst (Bu)4NBr;83 azide 23 was thus isolated in 83% yield over
the two steps. Compounds 50, 51 and 23 exhibited spectroscopic data that were in agreement
with those values reported previously.69, 82
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2.1.2.2 – Synthesis of azide 22
The synthesis of azide 22 from commercially available Fmoc-(D)-Lys(Boc)-OH (52)
was achieved by carboxylic acid reduction81 followed by mesylation and subsequent
azidation/N-deprotection84 (Scheme 2.4). Reduction of the starting acid 52 (4.00 g, 8.54
mmol) via a mixed anhydride reduction with isobutyl chloroformate, N-methylmorpholine
and NaBH4 gave alcohol 53 in 92% yield.

Scheme 2.4 – Synthesis of azide 22 from the lysine precursor 52: reduction of the
carboxylic acid functionality to give alcohol 53, followed by mesylation and then
sequential azidation/N-deprotection to furnish target azide 22.

The intermediate alcohol 53 (100 mg, 0.22 mmol) was then subjected to mesylation with
MsCl/NEt3/CH2Cl2 followed by azidation and N-Fmoc deprotection84 with NaN3 in DMF at
50 °C to give the target azide 22 in 46% yield over two steps. It was assumed that the
azidation of the mesylate intermediate occured rapidly followed by N-Fmoc deprotection
with the excess NaN3 acting as a base to promote the deprotection step (see Appendix A,
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Schemes A1.5 and A1.7 for related mechanisms).84 Compounds 53 and 22 exhibited
spectroscopic data that were in agreement with those values reported previously.59, 85
2.1.2.3 – Synthesis of azide 24
The synthesis of azide 24 from commercially available H-(D)-Lys(Boc)-OH (54) was
achieved by copper-catalysed diazotransfer reaction86 with freshly prepared imidazole-1sulfonyl azide87-88 (Scheme 2.5). The diazotransfer reagent (imidazole-1-sulfonyl azide) was
prepared in an EtOAc solution as previously described.87 The EtOAc solution of imidazole1-sulfonyl azide was stirred with amino acid 54 (2.20 g, 8.93 mmol) in the presence of
CuSO4·5H2O and K2CO3 in MeOH at rt; the product α-azido acid 24 was thus furnished in
98% yield utilizing a modified work-up procedure.87 The purification procedure was
modified to eliminate flash chromatography in favour of an acid/base extraction purification
with Et2O. This modification allowed for a faster purification and isolation with less chemical
waste. Compound 24 exhibited spectroscopic data that were in agreement with those values
reported previously.89-90

Scheme 2.5 – Synthesis of α-azido acid 24 from the lysine precursor 54 via
diazotransfer reaction.
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2.1.3 – Synthesis of arginine derivatives
2.1.3.1 – Synthesis of azide 26
The synthesis of the doubly N-protected azide 26 from commercially available Cbz(D)-Arg(Pbf)-OH (55) was achieved by carboxylic acid reduction81 followed by a two-step,
one-pot mesylation/azidation procedure82 (Scheme 2.6).

Scheme 2.6 – Synthesis of azide 26 from the arginine precursor 55: reduction of the
carboxylic acid functionality to give alcohol 56 followed by mesylation and then
azidation to furnish target azide 26.

The acid 55 (5.00 g, 8.92 mmol) was converted into a mixed carbonic-carboxylic anhydride
by reaction with isobutyl chloroformate in the presence of N-methylmorpholine followed by
reduction with aqueous NaBH4 to give the desired alcohol (56) in 78% yield.
Evidence of the carbonyl reduction was seen in the 1H NMR spectrum of compound 56 as a
new multiplet resonance centred at δ 3.60. This multiplet integrated to three protons and it
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was not present in the starting material 55. Therefore, the multiplet was assigned to the newly
installed methylene protons (-CH2OH) in conjunction with the adjacent methine proton
(-CHNHCbz). The methine assignment was confirmed by gCOSY correlation to the
resonance at δ 5.62 (assigned as the carbamate proton (-NHCbz)).
Furthermore, this multiplet resonance displayed gHSQC correlations with two resonances
(δ 64.8 and 52.8) in the 13C NMR spectrum of compound 56 – these resonances were assigned
to the corresponding methylene carbon (-CH2OH) and methine (-CHNHCbz) carbon,
respectively. The molecular structure of compound 56 was verified by the presence of a peak
at m/z 547.2589 in HRMS that was assigned to the protonated molecular ion [M + H]+
(calculated for C27H39N4O6S 547.2590). This intermediate alcohol was then subsequently
utilized in the two-step, one-pot synthesis of azide 26.
The alcohol substrate 56 (3.79 g, 6.94 mmol) was first converted in situ to a mesylate via
MsCl/NEt3/CH2Cl2 followed by a biphasic, SN2-type azidation reaction with NaN3, toluene,
H2O, and a phase transfer catalyst;83 azide 26 was thus isolated in 71% yield over the two
steps. The 1H NMR spectrum of azide 26 displayed a 2H multiplet resonance at δ 3.31 which
was assigned to the methylene protons (-CH2N3) adjacent to the azide moiety; this assignment
was confirmed by a gHSQC correlation with a 13C NMR resonance at δ 54.9 (assigned as the
corresponding methylene carbon) and by gCOSY correlation with a 1H NMR resonance at δ
3.73 (assigned to the adjacent methine proton (-CHNHCbz)).
Additionally, the multiplet resonance at δ 3.60 in the 1H NMR spectrum of the starting
alcohol 56 (assigned to the corresponding methylene protons (-CH2OH)) was no longer
visible in the 1H NMR spectrum of the product azide 26. The resonance at δ 3.31 (assigned
48

to the methylene protons in the 1H NMR spectrum of the azide) was shifted upfield (i.e. more
shielded) relative to the signal at δ 3.60 (assigned to the corresponding methylene protons
(-CH2OH)) in the 1H NMR spectrum of the starting alcohol 56 – this upfield shift is to be
expected, given the greater deshielding effect of the alcohol group relative to the azide
moiety. Analysis of the IR spectrum of azide 26 revealed a characteristic band at 2098 cm-1
that was assigned to the newly installed azide moiety. The molecular structure of compound
26 was verified by the presence of a peak at m/z 572.2677 in HRMS that was assigned to the
protonated molecular ion [M + H]+ (calcd for C27H38N7O5S 572.2655).
2.1.3.2 – Synthesis of azide 25
The synthesis of β-azido-amine 25 from commercially available Fmoc-(D)-Arg(Pbf)OH (57) was achieved by carboxylic acid reduction, iodination and subsequent azidation/Ndeprotection (Scheme 2.7) as previously described.59 Reduction of the starting acid 57 (4.00
g, 6.17 mmol) via a mixed anhydride reduction with isobutyl chloroformate,
N-methylmorpholine and NaBH4 gave alcohol 58 in 80% yield. The intermediate alcohol 58
(3.10 g, 4.88 mmol) was then subjected to iodination with I2/PPh3/imidazole in CH2Cl2 at rt
followed by azidation and N-Fmoc deprotection84 with NaN3 in DMF to give the target azide
25 in 80% yield over two steps.
A modified procedure was developed to enhance the yield and reduce the labour required:
the azidation and N-Fmoc deprotection were carried out independently by allowing the
azidation to proceed at rt first before allowing the N-Fmoc deprotection reaction to occur by
heating the reaction to 50 °C. This modification was introduced to prevent the observed
oxazolidinone by-product from forming via SN2 displacement of the iodide leaving group
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with the carbamic anion produced during N-Fmoc removal (see Scheme A1.6 in Appendix
A).

Scheme 2.7 – Synthesis of azide 25 from the arginine precursor 57: reduction of the
carboxylic acid functionality to give alcohol 58, followed by iodination and then
azidation/N-deprotection to furnish target azide 26.

Furthermore, a traditional acid/base work-up procedure was utilized to purify the β-azidoamine product instead of flash chromatography. These modifications led to a substantially
increased yield over the literature method (61%59 to 80%) and significantly easier isolation
procedure. Compounds 58 and 25 exhibited spectroscopic data that were in agreement with
those values reported previously.59
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2.1.3.3 – Synthesis of azide 27
The synthesis of azide 27 was achieved by a traditional N-Boc protection of β-azidoamine (26).91 The substrate amine 25 (100 mg, 0.23 mmol) was reacted with Boc2O in CH2Cl2
at rt for 2 h to give the target N-Boc amine 27 in 98% yield (Scheme 2.8).
The 1H NMR spectrum of compound 27 displayed a prominent singlet resonance at δ 1.43
that was not found in the 1H NMR spectrum of the starting material 25; this 9H singlet was
assigned to the newly introduced t-butyl protons (-C(CH3)3).

Scheme 2.8 – Synthesis of azide 27 from β-azido-amine 25 via N-Boc protection.

The installation of the N-Boc protecting group was further confirmed by the appearance of a
new 13C NMR resonance at δ 156.1 which was assigned as the new carbamate carbon (C=O).
The presence of the N-Boc protecting group was further confirmed by the new 1H NMR
resonance at δ 4.89 (assigned as the -NHBoc proton) – this broad doublet resonance was not
present in the starting β-azido-amine 25 and this resonance displayed coupling by gCOSY
correlation with the resonance at δ 3.69 (which was assigned to the adjacent methine proton).
The molecular structure of compound 27 was verified by the presence of a peak at m/z
538.2811 in the HRMS that was assigned to the protonated molecular ion [M + H]+ (calcd
for C24H40N7O5S 538.2812).
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2.1.3.4 – Synthesis of azide 28
The synthesis of azide 28 from commercially available H-(D)-Arg(Pbf)-OH (60) was
achieved by copper-catalysed diazotransfer reaction86 with imidazole-1-sulfonyl azide87-88
(Scheme 2.9). The EtOAc solution of imidazole-1-sulfonyl azide was then stirred with
precursor 60 (2.00 g, 4.69 mmol) in the presence of CuSO4·5H2O and K2CO3 in MeOH at rt;
the product α-azido-acid 28 was thus furnished in 83% yield.87 The purification procedure
was modified to eliminate flash chromatography in favour of an acid/base isolation work-up
with Et2O. Compound 28 exhibited spectroscopic data that were in agreement with those
values reported previously.92

Scheme 2.9 – Synthesis of α-azido-acid 28 from the arginine precursor 60 via
diazotransfer reaction.

2.1.3.5 – Synthesis of amine 29
The synthesis of amine 29 from commercially available Fmoc-(D)-Arg(Pbf)-OH (61)
was achieved by esterification followed by base-promoted N-Fmoc deprotection (Scheme
2.10).59, 79, 91 The starting compound 61 (1.00 g, 1.54 mmol) in MeOH was treated with SOCl2
to afford an intermediate methyl ester (i.e. Fmoc-(D)-Arg(Pbf)-OMe) – this ester was then
stirred with piperidine in MeOH at rt to furnish the target amine 29 in 80% yield over two
steps. Compound 29 exhibited spectroscopic data that were in agreement with those
previously reported.59
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Scheme 2.10 – Synthesis of amine 29 from the arginine precursor
61: esterification followed by base-promoted N-Fmoc deprotection.

2.2 – Series A synthesis: scaffolds and derivatives
2.2.1 – Synthesis of monocationic derivatives (Series A1)
2.2.1.1 – Synthesis of Series A1 scaffolds via CuAAC and N-deprotection
2.2.1.1.1 – 1,2,3-Triazole formation via a ‘click reaction’
The synthesis and incorporation of 1,4-disubstituted-1,2,3-triazole rings in novel
pharmaceuticals has become an extremely widespread practice and the common ‘click
reaction’ (i.e. a Cu-catalysed azide-alkyne cycloaddition (CuAAC)) has become the most
reliable methodology for the formation of these moieties.73-75, 93-94 Therefore, formation of
the key scaffold intermediates 62a-d (Scheme 2.11) was realized via CuAAC reactions.
For example, scaffold 62a was achieved by following General Procedure A (Section 6.2),
wherein azide 23 (1.50 g, 3.83 mmol) and alkyne 21 (2.0 eq) were treated with
Cu(II)/ascorbate in t-BuOH/H2O59, 75 for 48 h at rt to give a 75% yield of compound 62a after
purification by flash chromatography. Furthermore, this reaction methodology was effective
on a larger scale, as an 88% yield of 62a was obtained from 2.64 g (6.74 mmol) of precursor
azide 23.
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Scheme 2.11 - Cu-catalysed [3 + 2] cycloaddition reactions between an alkyne building block (20
or 21 - blue triple bond) and an azide precursor (23, 26 or 27 - blue portion) to give the key scaffold
intermediates 62a-d for Series A1.

The 1H NMR spectrum of compound 62a displayed resonances that corresponded to
fragments from both starting materials (alkyne 21 and azide 23) – see Appendix C (Figures
C1.1 and C1.2) for the NMR spectra. The most noteworthy and diagnostic difference was the
disappearance of the 1H NMR singlet resonance at δ 2.43 (-CC-H) that was seen in the 1H
NMR spectrum of alkyne 21 and the appearance of a significantly more downfield resonance
at δ 7.17 (triazole CH) in the 1H NMR spectrum of 62a. This significant difference in
chemical shift was indicative of triazole formation; the terminal alkyne proton in compound
21 had now become the lone proton on the newly formed aromatic triazole ring – this results
in a strong deshielding of the proton (relative to the alkyne proton) and results in a large
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downfield chemical shift. Two unique aromatic 13C NMR resonances at δ 145.2 and 123.3
were present in the

13

C NMR spectrum of compound 62a and they were assigned to the

methine and quaternary triazole carbons, respectively. The resonance at δ 145.2 was
extremely diagnostic because few other aromatic carbon resonances appear in that region
(i.e. δ 141-150). As expected, the 13C NMR resonance at δ 123.3 (triazole CH) displayed a
correlation in the gHSQC spectrum with the 1H NMR resonance at δ 7.17 (triazole CH).
Furthermore, the appearance of these two unique

13

C NMR resonances coincided with the

disappearance of the two alkyne (-CC-) 13C NMR resonances at δ 79.3 and 75.2 that are
evident in the 13C NMR spectrum of starting alkyne 21. These two alkyne carbons (-CC-)
had now become the aromatic triazole carbons – this explains the associated large downfield
chemical shifts. HRMS analysis confirmed the molecular identity, as a peak was observed at
m/z 708.3755 that was assigned to the sodiated molecular ion, [M + Na]+ (calcd for
C39H51N5O6Na 708.3737).
Scaffold intermediates 62a-d (Scheme 2.11) were obtained by implementation of the
aforementioned General Procedure A. Evidence for the regioselective outcome of the 1,2,3triazole formation (i.e. solely the 1,4-isomer and not the 1,5-isomer) was established for the
scaffold amine (i.e. the Nα-deprotected derivative) of 62a (i.e. compound 63a) via analysis
of the relevant gHMBC spectrum; this evidence is discussed in Section 4.2.
The CuAAC reaction requires the presence of a catalytic quantity of Cu(I); this catalyst can
be added directly or prepared in situ by reduction of a Cu(II) salt with an excess of an
antioxidant75 (e.g. single electron transfer by sodium ascorbate – Scheme 2.12). The latter
method is generally preferred, as the presence of an excess amount of reducing agent (relative
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to the catalyst) prevents the disproportionation or oxidation of the active catalytic species
(i.e. Cu(I)) to the inactive Cu(II) species.75, 93-94 Most importantly, this allows the reaction to
be successfully conducted under open-air conditions without the need for an inert
atmosphere.
The regioselective construction of the 1,4-disubstituted-1,2,3-triazole is controlled by the
relative binding orientation of the alkyne and azide precursors to the active Cu(I) catalyst
complex (Scheme 2.12). The coordination of the primary azide nitrogen to the terminal Cuacetylide complex restricts the orientation of the resultant [3 + 2]-cycloaddition (Scheme 2.12
– transition state) so that only the 1,4-regioisomer is produced.75, 93-94 This regioselectivity
occurs because the two substituents are forcibly oriented in opposite directions during the
catalysed cycloaddition.
The proposed mechanism in Scheme 2.12 represents the currently accepted CuAAC catalysis
model, based upon multiple CuAAC studies such as kinetic analysis and DFT
calculations.75, 93-96 Kinetic analysis has found that the reaction is 2nd order with respect to
the concentration of Cu(I); this implicates the likely role of a di-nuclear acetylide-bridged
Cu(I) complex as the active catalytic species,93-94 as illustrated in the transition state complex
in Scheme 2.12. Furthermore, experimental evidence for the involvement of alkynyl
dicopper(I) complexes in the CuAAC reaction has been published.93, 97 Importantly, the mild
catalytic conditions required for the CuAAC reaction allowed for reliable, clean and highyielding installation of a 1,4-disubstituted-1,2,3-triazoles during scaffold synthesis.
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Scheme 2.12 – Proposed catalytic cycle for the CuACC reaction:75, 93, 95-96
[Cu] represents a Cu(I) complex that is coordinated to the requisite number
of ancillary ligands. The mechanism allows for control over the
regioselectivity of the cycloaddition by restricting the relative orientation of
the 1,4-substituents.

2.2.1.1.2 – N-deprotection: Cbz or Boc removal
Removal of the N-Cbz protecting group can be achieved through a variety of reaction
conditions; the most common methodologies are catalytic hydrogenolysis (e.g. Pd/C and H2
gas) and acid-promoted nucleophilic cleavage (e.g. HBr/AcOH).78, 80 To avoid deprotection
of the acid-labile Boc group, scaffold intermediate 62a (1.90 g, 2.77 mmol) was subjected to
catalytic hydrogenolysis, by reaction with 10% w/w palladium-on-carbon (Pd-C – 0.15 eq)
in a mixture of MeOH/AcOH under an atmosphere of H2 gas (via a balloon attached to the
reaction flask), furnishing a 99% yield of scaffold amine 63a (Scheme 2.13).
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Scheme 2.13 – Removal of the N-protecting group from intermediates 62a-d to give scaffold
amines 63a-d: N-Cbz removal by catalytic hydrogenolysis (A) or N-Boc removal by acidolytic
cleavage (B).

Analysis of the 1H NMR spectrum of amine 63a revealed the lack of key N-Cbz diagnostic
resonances at δ 5.06 (-CH2Ph) and 7.21 – 7.38 (phenyl) that were present in the spectrum of
scaffold intermediate 62a. The removal of the N-Cbz protecting group was further supported
by the lack of the characteristic downfield resonance at δ 66.9 (-OCH2Ph) normally seen in
the

13

C NMR spectrum of starting compound 62a. Furthermore, the disappearance of an

additional four aromatic 13C NMR resonances (i.e. the phenyl carbons) provided substantial
evidence of N-Cbz removal.
TLC analysis of the product compound (63a) revealed a more polar compound has been
produced and a strong purple colour after staining with ninhydrin confirmed the presence of
a free amine. The product identity was confirmed via HRMS analysis; a peak observed at m/z
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552.3564 was assigned to the protonated molecular ion, [M + H]+ (calcd for C31H46N5O4
552.3550).
Scaffold amines 63b and 63c (Scheme 2.13) were also achieved by implementation of the
aforementioned catalytic hydrogenolysis procedure. Attempts to isolate scaffold amine 63d
through the same methodology (i.e. N-Cbz removal via catalytic hydrogenolysis) failed due
to the occurrence of multiple amine by-products (as confirmed by TLC and NMR analysis).
The most prevalent by-product exhibited a peak in the LRMS with an m/z value that was 28
amu heavier than that of the protonated molecular ion for the desired product (63d). With
longer reactions times (> 24 h), notably larger quantities of this by-product were observed –
these impurities could not be separated by flash chromatography or by recrystallization. In
an attempt to solve these issues, the N-Boc protecting group was utilized as it would likely
allow acidolytic cleavage in the presence of a side-chain N-Pbf protecting group. The
arginine side-chain protecting group (N-Pbf) requires a strong acid for deprotection (e.g.
TFA) and hydrogen-bonding solvents like MeOH, EtOH and H2O are known to suppress the
acidolytic N-Pbf deprotection reaction.98-99 Therefore, reaction conditions employing 1.0 M
HCl in MeOH/Et2O were utilized to successfully remove the N-Boc group from compound
62d (113 mg, 0.12 mmol) without cleaving the N-Pbf side chain protecting group; a 95%
yield of scaffold amine 63d was realized after 18 h at rt. See Section 2.2.1.2 for more
information regarding N-Boc deprotection (i.e. mechanism and reaction details).
MeOH is one of the most effective and widely used solvents for catalytic hydrogenolysis of
the N-Cbz protecting group and the addition of acetic acid is helpful for protonation of the
resultant amine product; this prevents coordination of the free amine to the palladium which
can cause inactivation of the catalyst.100-102 Ideally, the only by-products produced are
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volatile (i.e. CO2 and toluene) which makes for an extremely clean reaction and work-up.
Benzyl carbamates (i.e. N-Cbz groups) are readily cleaved via Pd-catalysed hydrogenolysis
due to their highly activated benzylic position and their ability to coordinate to the Pd catalyst
through either aryl or oxygen coordination.101 The mechanism for catalytic hydrogenolysis
of benzyl carbamates has not been completely elucidated, but certain key steps are
understood.100 The most important and least understood step in the mechanism is the
heterolysis of the benzylic C–O bond (Scheme 2.14– red bond scission); this essential step is
thought to occur in a manner similar to the deprotection of O-benzyl or N-benzyl
substituents,100 i.e. through coordination of the Cbz functionality to the Pd surface, followed
by hydrogenolytic cleavage of the C–O bond which generates the unstable carbamic acid
derivative and toluene (Scheme 2.14).

Scheme 2.14 – Known aspects of the Pd-catalysed hydrogenolysis
of benzyl carbamates (black arrows) with the theoretical
heterolysis mechanism (blue arrows).

Following proton transfer, the carbamic acid derivative readily decomposes to give CO2 and
the desired free amine.78 One proposed mechanism for the heterolysis step involves PdII-π
aryl electron coordination followed by formation of a η3-PdII-benzyl cation complex with
concomitant displacement of the carbamate anion (Scheme 2.14 – blue pathway).
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2.2.1.2 – Synthesis of Series A1 derivatives via amide coupling and N-deprotection
The derivatization of mono-amino acid scaffolds required a two-step transformation:
installation of the terminal amide moieties followed by side-chain N-deprotection to yield the
target amines as hydrochloride salts. Previous syntheses of the binaphthylpeptides have
utilized the common EDCI/HOBt† peptide coupling reagent system to form the necessary
peptide bonds while N-Boc and/or N-Pbf deprotection was previously achieved with
TFA/CH2Cl2.59, 64-66, 68-69
The formation of amide bonds from carboxylic acids and amines (e.g. amino acid derivatives)
via peptide coupling was an extremely crucial component in the synthesis of the target
biarylpeptide derivatives. Therefore, a general amide coupling procedure (General
Procedure B – Section 6.2) with literature precedent59 was developed and utilized in all
subsequent amide coupling reactions.
The acidolytic cleavage of the N-Boc and/or N-Pbf protecting groups is easily achieved with
a variety of acids – with trifluoroacetic acid (TFA) being used most often.77, 103 The ability
of these two protecting groups to be cleaved independently or simultaneously by relatively
mild acidic conditions was an essential feature to this general reaction. As such, a general Ndeprotection reaction procedure (General Procedure C – Section 6.2) was developed by
modifying the previously published procedure59, 66 and employed for the final deprotection
of most N-Boc and N-Pbf protected side chain residues. The mono-lysine derivatives, from
both Series A and B, exhibited increased solubility relative to the arginine derivatives and a

†

Structures for EDCI and HOBt can be found in the amide coupling mechanism in Scheme 2.21 in Section

2.2.2.
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modified work-up procedure for the N-deprotection reaction (i.e. General Procedure D,
Section 6.2) was required to enable precipitation of the final hydrochloride salts.
Therefore, for Series A1 derivatives, General Procedure B was utilized to install the
terminal amide moiety (see Reaction (i) in Schemes 2.15 – 2.17); the resultant N-protected
amide derivatives were then immediately subjected to acidolytic N-Boc or N-Pbf cleavage
followed by work-up with ethereal HCl (General Procedure C or D: Reaction (ii) in
Schemes 2.15 – 2.17) to achieve the target amine salts (64a-b, 65a-b and 66a-b).

Scheme 2.15 – Derivatization of scaffold 63a: installation of the terminal amide moiety
(R) followed by removal of the N-Boc side chain protecting group to give scaffold
derivatives 64a-b as hydrochloride salts. The synthetic pathway to realize compound 64c
from N-Cbz protected scaffold precursor 62a is also displayed.
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Target amines 64c, 65c and 66c were realized directly from scaffold intermediates 62a, 62b
and the N-Cbz analogue of 62d (respectively) via N-Boc or N-Pbf deprotection following
General Procedure C or General Procedure D.
Importantly, yields of the final derivatives were undertaken over a two-step process. Reaction
completion and product purity of the intermediate N-protected amides were monitored by
TLC and/or MS analysis prior to subsequent N-deprotection. This methodology reduced the
number of novel compounds that required extensive characterization, which allowed for
facile and efficient derivatization of the scaffolds.
For example, the synthesis of derivative 64a (Scheme 2.15) was realized in 96% yield over
two steps from scaffold amine 63a (50 mg, 0.09 mmol) by reaction with phenylacetic acid
(1.2 eq), EDCI and HOBt in acetonitrile at rt for 24 h to give the corresponding amide which
was immediately subjected to N-Boc deprotection with TFA in CH2Cl2 at rt for 18 h followed
by work-up with ethereal HCl.
The 1H NMR spectrum of derivative 64a displayed a new singlet resonance at δ 3.38
(-CH2Ph) and a broad multiplet resonance at δ 7.36 – 7.10 (phenyl). These new 1H NMR
resonances support the installation of the terminal benzyl amide in compound 64a. The
presence of the new amide moiety was further confirmed by the following

13

C NMR

resonances assignments: δ 174.3 (amide C=O), four resonances in the aromatic region
(phenyl carbons) and δ 44.1 (-CH2Ph) – these resonances were not seen in the

13

C NMR

spectrum of the starting amine 63a. Evidence of N-Boc deprotection was clearly seen by the
lack of the 9H singlet resonance at δ 1.44 in the 1H NMR spectrum of amine salt 64a –
whereas this N-Boc resonance was present in the protected starting amine 63a. Additionally,
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the lack of key N-Boc resonances at δ 156.0 (Boc C=O), 79.2 (-C(CH3)3) and 28.5 (-C(CH3)3)
in the

13

C NMR spectrum of compound 64a provided further evidence that the N-Boc

protecting group had been successfully removed. The molecular structure of the product was
verified by the appearance of a peak at m/z 570.3451 in the HRMS that was assigned to the
protonated molecular ion, [M + H]+ (calcd for C34H44N5O3 570.3444).

Scheme 2.16 – Derivatization of scaffold 63b: installation of the terminal amide moiety (R)
followed by removal of the N-Pbf side chain protecting group to give scaffold derivatives
65a-b as hydrochloride salts. The synthetic pathway to realize compound 65c from the NCbz protected scaffold precursor 62b is also displayed.

In another example, the synthesis of derivative 65a (Scheme 2.16) was realized in 84% yield
over two steps from scaffold amine 62b (50 mg, 0.09 mmol) by a coupling reaction with
phenylacetic acid (1.2 eq), EDCI and HOBt in acetonitrile at rt for 24 h to give the
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corresponding amide which was immediately subjected to N-Pbf deprotection with TFA and
H2O in CH2Cl2 at rt for 18 h followed by work-up with ethereal HCl.

Scheme 2.17 – Derivatization of scaffold 63d: installation of the terminal amide moiety (R)
followed by removal of the N-Pbf side chain protecting group to give scaffold derivatives 66a-b as
hydrochloride salts. The synthetic pathway to realize compound 66c from the N-Cbz protected
scaffold precursor 62d is also displayed.

The 1H NMR spectrum of the final derivative 65a displayed resonances that were
characteristic of the new terminal amide moiety (i.e. δ 3.33 (-CH2Ph) and 7.35 – 7.08
(phenyl)). Evidence of N-Pbf deprotection was clearly seen by the lack of the five
characteristic singlet resonances (δ 2.92, 2.56, 2.47, 2.06 and 1.43) in the 1H NMR spectrum
of compound 65a – these resonances were present in the 1H NMR spectrum of starting amine
63b and were assigned to the protons of the N-Pbf protecting group. Additionally, the lack
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of six distinct quaternary aromatic resonances in the 13C NMR spectrum of compound 65a
provided further evidence for the removal of the N-Pbf protecting group. Six key nonaromatic N-Pbf resonances at δ 86.5 (-C(CH3)3), 43.4 (ArCH2-), 28.7 (-C(CH3)2) and 19.4,
18.1 and 12.6 (3 x ArCH3) in the 13C NMR spectrum of starting amine 63b were also missing
from the 13C NMR spectrum of final compound 65a, further proving the successful removal
of the N-Pbf protecting group. The molecular structure of the product was verified by the
appearance of a peak at m/z 598.3510 in the HRMS that was assigned to the protonated
molecular ion, [M + H]+ (calcd for C34H44N7O3 598.3506).
Modifications to the previous published procedure66 included reporting the synthetic yield
over two steps for facile and efficient derivatization and the incorporation of a more recent
published extractive aqueous work-up59 followed by flash chromatography (only when
required) for the peptide coupling reaction. This vastly improved derivatization and
purification procedure allowed for the rapid turn-over of multiple derivatives simultaneously,
obviating the need for extensive flash chromatography for the majority of derivatization
reactions.
The most important modification to the N-deprotection procedure was the incorporation of
20 equivalents of water to all N-Pbf deprotection reactions. This modification was introduced
after large quantities of N-sulfonation by-products were observed (by NMR and HPLC – See
Figures A2.2 and A2.3 in Appendix A) during synthetic scale-up for in vivo murine models.
During small scale (≤ 0.10 mmol) synthesis, enough H2O/moisture was present in the TFA
and on the flask walls to adequately scavenge the SO3 by-product produced during N-Pbf
deprotection (see Scheme 2.19). During larger scale (> 1.00 mmol) synthesis, there was
insufficient water present and N-sulfonation of the desired deprotected product would
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occur.104 Therefore, it was theorized that a small volume but sufficient molar excess (20.0
eq) of H2O would prevent N-sulfonation by reacting with the SO3 to produce H2SO4; the
overall volume percentage of H2O was kept down to prevent inhibition of the N-Pbf
deprotection reaction.98 Thioanisole is traditionally used to scavenge the SO3104 and promote
deprotection,105 but H2O was found to be a cost-effective, clean and safe alternative for these
reactions conditions.
The N-Boc protecting group is extremely susceptible
to acidic conditions; TFA has been observed to fully
deprotect the N-Boc side chain residue in less than 10
min. Deprotection of the N-Boc carbamate gives rise
to the amine product (as the TFA salt) and two volatile
by-products: CO2 and isobutene (Scheme 2.18).78 The
acidolytic

cleavage

mechanism

proceeds

via

protonation of the carbamate oxygen followed by
heterolytic cleavage of the O–C(CH3)3 bond to
release the carbamic acid intermediate and the stable
t-butyl carbocation (Scheme 2.18); it is the stability

Scheme 2.18 – Mechanism of t-butyl
carbamate acidolysis by TFA to give
the desired amine (blue) and byproducts (green).

of the resultant carbocation that makes the Boc carbamate susceptible to acidolysis. Proton
transfer allows for spontaneous decomposition of the deprotonated carbamic acid derivative
to give CO2 and the free amine product (which rapidly protonates upon reaction with excess
TFA); the t-butyl carbocation undergoes proton abstraction to give isobutene as a byproduct.78
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The N-Pbf protecting group is more resistant to acidolytic cleavage than the N-Boc group
and less amenable to synthesis because it requires notably longer reaction times and side
reactions are possible, if a SO3 scavenger is not utilized.105 The mechanism for acidolysis
(Scheme 2.19) proceeds via protonation of the guanidino residue followed by heterolytic
cleavage of the N–S bond to give the product guanidine (as its TFA salt) and an arylsulphonyl
cation.103, 105-106

Scheme 2.19 – Mechanism for the acidolysis of an N-Pbf group to give the product guanidine
(blue) and by-products (green). N-Sulfonation of the product guanidine (side reaction - red arrow)
and scavenging of the SO3 (green arrow) are also shown.

The ability of the N-Pbf group to undergo acidolysis relies on the ability of the arylsulphonyl
group to stabilize the resulting cation.105-106 The arylsulphonyl cation then combines with the
trifluoroacetate anion to generate an intermediate – subsequent protonation and H2O attack
causes decomposition to give 2,2,4,6,7-pentamethyldihydrobenzo[b]furan, TFA, and SO3.
The resultant SO3 by-product is electrophilic and will combine with the free guanidine
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product to give sulfamic acid derivative by-products,104 hence the need for a scavenger (i.e.
H2O or thioanisole).
The simple acidolytic conditions required for both N-Boc and N-Pbf deprotection allowed
for the isolation of the crude TFA-amine salt by simple solvent removal. Solvent-aided anionexchange with anhydrous HCl in ether then allowed for the simple isolation of the final
compounds as the hydrochloride salts by precipitation from Et2O. The general procedure that
was developed allowed for 18 h reaction time to ensure complete deprotection of the N-Pbf
group, as shorter reaction periods have been observed to give incomplete acidolysis. Due to
the volatility of the N-Boc deprotection by-products, no resultant impurities were ever
observed for N-Boc protected derivatives. For N-Pbf protected derivatives, the final salt
required repeated precipitation and trituration of the final hydrochloride salt to remove the
benzofuran by-product. The relative ease, speed and resultant product purity of the acidolytic
deprotection and HCl salting allowed for the fast turn-over of multiple derivatives.

2.2.2 – Synthesis of dicationic derivatives (Series A2)
2.2.2.1 – Synthesis of Series A2 scaffolds via amide coupling
Traditional peptide coupling107-108 allowed for the construction of amide bonds from
carboxylic acids and amines (e.g. amino acid derivatives) and provided a simple and reliable
methodology for the synthesis of dual-amino acid (i.e. Series A2) scaffolds.59,
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The

scaffolds for Series A2 (67a-c) were constructed by the formation of a key amide bond
between a mono-amino acid scaffold (i.e. Series A1) and a precursor amino acid derivative
(Scheme 2.20); this transformation was accomplished by EDCI/HOBt in acetonitrile59
utilizing the aforementioned General Procedure B (Section 6.2).
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This procedure was utilized for the formation of all amide bonds (i.e. for both scaffold
formation and derivatization). For example, the synthesis of scaffold azide 67a was realized
in 89% yield by reaction of scaffold amine 63a (300 mg, 0.54 mmol) with precursor α-azidoacid 28 (1.2 eq), EDCI and HOBt in acetonitrile at rt for 48 h followed by purification by
flash chromatography.

Scheme 2.20 – Synthesis of scaffolds 67a-c: amide coupling between amine scaffolds 63a-c and
an α-azido-acid precursor (24 or 28) to give the scaffold azides 67a-c for Series A2.

Analysis of the 1H NMR spectrum of compound 67a confirmed the presence of resonances
that were assigned to functionalities from both precursors 63a and 28. The broad resonance
at δ 3.02 –3.10 (-CHNH2) in the 1H NMR spectrum of starting amine 63a was no longer
observed in the spectrum of 67a; there was however, a new more deshielded resonance at
δ 4.35 that was assigned to the lysine α-methine proton. This evidence indicated that the
methine proton, adjacent to the primary amine in precursor 63a, experienced a downfield
chemical shift due to the newly installed amide bond. Furthermore, a gHMBC correlation
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was observed between the 1H NMR resonance at δ 4.35 (assigned to the α-lysine methine
proton) and the 13C NMR resonance at δ 170.9 (assigned to the new amide carbonyl). The
molecular structure of the product was further verified by the appearance of a peak at m/z
986.5325 in HRMS, that was assigned to the protonated molecular ion, [M + H]+ (calcd for
C50H72N11O8S 986.5286).
The reliable and mild conditions afforded by the amide coupling reagents EDCI and HOBt
were essential for the synthesis and derivatization of these multi-functionalized molecules.
An uncatalysed reaction between the carboxylic acid and amine components generates an
ammonium carboxylate salt; subsequent amide condensation requires intense heat, which
would be incompatible with highly functionalized molecules.108 Therefore, peptide coupling
reagents (or ‘activators’) are utilized to increase the electrophilicity of the acyl moiety; these
reagents allow amide bond formation via aminolysis of an activated acyl species under much
milder conditions.107-110
Carbodiimides (e.g. 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI))
are employed to generate an active O-acylisourea intermediate (Scheme 2.21) by reaction
with the carboxylate anion. This intermediate can undergo aminolysis by the precursor amine
to give the desired product amide.107-108 In a possible side reaction, the highly activated
O-acylisourea intermediate can undergo intramolecular acyl transfer to give an inactive
N-acylurea by-product (Scheme 2.21 – red pathway),107-108, 110 thus consuming the precursor
acid without formation of the product amide.
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Scheme 2.21 – Mechanism of EDCI/HOBt promoted amide coupling: both the
product pathway (blue) and the undesired side reaction (red) are displayed.

To avoid this deleterious side reaction and the possibility of racemization, nucleophilic
additives such as HOBt (1-hydroxy-1H-benzotriazole) are added to the reaction.107-110 HOBt
reacts with the active O-acylisourea intermediate to generate an activated HOBt ester with
the key acyl moiety (Scheme 2.21 – blue pathway). Crucially, this reaction occurs faster than
the intramolecular acyl transfer, thus preventing the side reaction but still generating an
activated acid derivative for subsequent aminolysis to the product amide. 107-108 Epimerization
of the stereogenic α-carbon on the O-acylisourea intermediate is another possible side
reaction and it can occur through two mechanisms – simple enolate formation by
deprotonation of the α-hydrogen (resulting in epimerization at the stereogenic centre) or via
formation of the planar 5(4H)-oxazolone intermediate, in which the α-hydrogen is readily
deprotonated due the resonance stabilization of the resulting carbanion. HOBt helps to
prevent epimerization as the intermediate HOBt ester that is preferentially formed is less
activated than the O-acylisourea, i.e. the -OBt functionality is less electron-withdrawing than
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the corresponding isourea substituent and therefore the adjacent α-hydrogen is less prone to
enolization.107, 110 The lack of epimerization observed during the performed amide coupling
reactions was likely a result of the HOBt. Epimerization would result in the formation of
diastereomeric products that could be detected by 1H NMR and/or TLC analysis. Based on
such analyses, the isolated amide products were obtained as single diastereomers.
2.2.2.2 – Synthesis of Series A2 derivatives via CuAAC and N-deprotection
The derivatization of the dual-amino acid scaffolds for Series A2 required a two-step
transformation: installation of the terminal triazole moieties by CuAAC followed by sidechain N-deprotection to yield the target amines as dihydrochloride salts. The derivatization
of scaffold azides to achieve terminal triazole biarylpeptides has been accomplished
previously via CuACC reaction59 while subsequent N-Boc and N-Pbf deprotection was
previously achieved with TFA/CH2Cl2.59, 69
Therefore, CuAAC reactions (General Procedure A) were employed to derivatize scaffolds
67a-c and to install the terminal triazole moieties (Reaction (i) in Schemes 2.22 – 2.24); the
resultant N-protected triazole derivatives were then immediately subjected to acidolytic
N-Boc and N-Pbf cleavage followed by work-up with ethereal HCl (General Procedure C:
Reaction (ii) in Schemes 2.22 – 2.24) to afford the target amines as their dihydrochloride
salts (68a-d, 69a-d and 70a-b). Much like Series A1, the derivatization of scaffolds 67a-c
for Series A2 was conducted in two consecutive steps; CuAAC reaction completion and
product purity was monitored by TLC and/or MS analysis prior to subsequent
N-deprotection.
For example, the synthesis of compound 68a (Scheme 2.22) was realized in 86% yield over
two steps from scaffold azide 67a (50 mg, 0.05 mmol) by reaction with 3-phenyl-1-propyne
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(3.0 eq), Cu(OAc)2·H2O, and sodium ascorbate in t-BuOH/H2O at rt for 20 h to give the
intermediate N-protected triazole derivative, which was then subjected to N-Boc/N-Pbf
deprotection with TFA and H2O in CH2Cl2 at rt for 18 h followed by treatment with ethereal
HCl and purification by precipitation. Scaffold azide 67b (50 mg, 0.05 mmol) was also
directly deprotected with TFA and H2O in CH2Cl2 at rt for 18 h followed by treatment with
ethereal HCl and purification by precipitation to give final compound 69d in 97% yield
(Scheme 2.23).

Scheme 2.22 – Derivatization of scaffold 67a: installation of the terminal triazole moiety
(with R substituent) followed by removal of the side chain N-protecting groups to give
scaffold derivatives 68a-d as dihydrochloride salts.
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The 1H NMR spectrum of the final derivative 68a displayed characteristic resonances that
were assigned to the terminal benzyl moiety (i.e. a singlet resonance at δ 4.07 (-CH2Ph) and
a broad multiplet resonance at δ 7.34 – 7.10 (phenyl)).

Scheme 2.23 – Derivatization of scaffold 67b: installation of the terminal triazole moiety
(with R substituent) followed by removal of the side chain N-protecting groups to give
scaffold derivatives 69a-c as dihydrochloride salts. The direct N-deprotection of scaffold 67b
to give compound 69d is also displayed.

Importantly, a new degenerate resonance at δ 7.86 (2H) in the 1H NMR spectrum of
compound 68a was observed and assigned to the protons on both triazole rings. The presence
of the new triazole moiety was further confirmed by the 13C NMR resonance assignments:
δ 148.4 (quaternary triazole carbon – only observed by gHMBC), four resonances in the
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aromatic region (phenyl carbons), δ 124.5 (triazole CH – only observed by gHSQC/gHMBC)
and 32.4 (-CH2Ph) – these resonances were not seen in the 13C NMR spectrum of the starting
azide 67a. Evidence for successful N-Boc deprotection was clearly seen by the lack of the
9H singlet resonance at δ 1.44 (assigned as the t-butyl protons (-C(CH3)3)) in the 1H NMR
spectrum of amine salt 68a. Additionally, the lack of key resonances at δ 156.3 (Boc C=O),
79.2 (-C(CH3)3) and 28.5 (-C(CH3)3) in the 13C NMR spectrum of compound 68a provided
further evidence that the N-Boc protecting group had been successfully removed.

Scheme 2.24 – Derivatization of scaffold 67c: installation of the terminal triazole moiety (with
R substituent) followed by removal of the side chain N-protecting groups to give scaffold
derivatives 70a-b as dihydrochloride salts.
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Conclusive evidence for N-Pbf deprotection was clearly seen by the lack of the five
characteristic Pbf singlet resonances (δ 2.95, 2.58, 2.51, 2.09 and 1.46) in the 1H NMR
spectrum of compound 68a and the lack of corresponding N-Pbf resonances in the 13C NMR
spectrum. The molecular structure of the product was verified by the appearance of a peak at
m/z 750.4587 in HRMS that was assigned to the protonated molecular ion, [M + H] + (calcd
for C41H56N11O3 750.4568).
For more information on both the CuAAC and the N-deprotection reactions (e.g. reaction
mechanism and details), see Section 2.2.1.1.
2.2.2.3 –Series A2 exceptions
The synthesis of dicationic derivatives with terminal amide moieties for Series A2
was attempted via an analogous pathway to those procedures utilized for Series A1 and A2
derivatives. Unfortunately, realization of the required scaffold amine 71 proved difficult.
Initial attempts utilized the N-Cbz protecting group for the arginine residue; repeated
attempts to remove this protecting group via catalytic hydrogenolysis resulted in a complex
mixture of amine products consisting of the target amine along with at least four other
compounds (observed by TLC and MS analysis). MS analysis revealed the major sideproduct to be 14 amu heavier than the target amine 71. The target product could not be
adequately separated from these side-products, so the N-Cbz route was abandoned. Instead,
the N-Fmoc protecting group was utilized; classic N-Fmoc deprotection with piperidine was
attempted but a mixture of amine products was also obtained – MS analysis revealed the
major side-product to be 40 amu heavier than the target amine 71. Catalytic hydrogenolysis
was then attempted to remove the N-Fmoc group,111 but this methodology also gave a
complex mixture of amine products. After extensive trial reactions, the amine scaffold 71
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was isolated and was deemed of sufficient purity (> 90%) for further derivatization (but not
characterization). Ultimately, amine 71 was synthesized from scaffold amine 63a (400 mg,
0.73 mmol) in 58% yield over two steps by reaction with Fmoc-(D)-Arg(Pbf)-OH (1.2 eq),
EDCI and HOBt in acetonitrile at rt followed by base-promoted N-Fmoc deprotection with
tris-(2-aminoethyl)amine (TAEA)112 in acetonitrile (Scheme 2.25).

Scheme 2.25 – Synthesis of scaffold 71: addition of the arginine residue by amide coupling
followed by base-promoted removal of the N-Fmoc group.

The impure amine 71 (53 mg, 0.06 mmol) was then derivatized in the same manner as Series
A1 scaffolds: amide coupling (General Procedure B: Reaction (i) in Scheme 2.26) to install
the terminal benzyl amide moiety followed by N-Boc/N-Pbf side chain deprotection
(General Procedure C: Reaction (ii) in Scheme 2.26) to give final compound 73 as a
dihydrochloride salt in 61% yield over two steps. Reaction success for derivatization (i.e.
amidation and subsequent N-deprotection) was verified in the same manner as Series A1
derivatives; NMR spectral analysis confirmed the installation of the benzyl amide and the
removal of the N-Boc/N-Pbf protecting groups (see Section 2.2.1.2 for specific details).
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Furthermore, the molecular identity was confirmed by the appearance of a peak at m/z
748.4288 in the HRMS, which was assigned to the sodiated molecular ion [M + Na]+. The
derivatization procedures eliminated the side-product impurity that was present in the starting
amine 71; the precipitation and trituration of the final HCl salt helped to remove most
impurities that may have been present from previous reactions. Recrystallization of the final
HCl salts can also be achieved by slow evaporation of a MeOH/CH2Cl2 solvent mixture (see
Figure A2.4 in Appendix A).

Scheme 2.26 – Derivatization of scaffold 71: installation of the terminal amide group (R) via amide
coupling followed by side chain N-deprotection to give compound 73 as a dihydrochloride salt.
The synthetic pathway to realize to compound 74 by side chain N-deprotection of the N-Fmoc
scaffold 72 is also displayed.

Additionally, General Procedure C was utilized to realize compound 74 in 95% yield by
direct side chain N-deprotection of scaffold intermediate 72 (50 mg, 0.04 mmol) (Scheme
2.26).
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2.3 – Series B synthesis: scaffolds and derivatives
2.3.1 – Synthesis of monocationic derivatives (Series B1)
2.3.1.1 – Synthesis of Series B1 scaffolds via CuAAC
The traditional click reaction (i.e. CuAAC)75 allowed for the construction of 1,4disubstituted-1,2,3-triazoles from alkyne and azide precursor components; this provided a
simple and reliable methodology for the synthesis of mono-amino acid (i.e. Series B1)
scaffolds.59, 69 The scaffolds for Series B1 (75a-d) were constructed from a biaryl alkyne and
an α-azido acid precursor by the CuAAC reaction (Scheme 2.27); this transformation was
accomplished by utilizing the aforementioned General Procedure A (Section 6.2).

Scheme 2.27 – Cu-catalysed [3 + 2] cycloaddition reaction between an alkyne building
block (20 or 21 - blue triple bond) and an azide precursor (24 or 28 - blue portion) to
give the key scaffold acids 75a-d for Series B1.
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For example, scaffold acid 75a was achieved in 85% yield by reaction of α-azido acid 24
(400 mg, 1.47 mmol) with alkyne 21 (2.0 eq), Cu(OAc)2·H2O and sodium ascorbate in
t-BuOH/H2O at rt for 26 h followed by purification by flash chromatography (Scheme 2.27).
Interestingly, the 1H and 13C NMR spectra of scaffold acids 75a-d in CD3OD were lacking
some key resonances; the spectra had to be collected in DMSO-d6 to ensure all resonances
were observed. Despite using DMSO-d6, the binaphthyl scaffold acids 75c and 75d failed to
display 13C NMR resonances for the carboxyl carbon (C=O) or the adjacent α-methine carbon
(-CHC=O). Furthermore, the resonances assigned to the α-methine proton in the 1H NMR
spectra of compounds 75c or 75d exhibited significant broadening. These NMR anomalies
are explored in more detail in Section 4.6.
The 1H NMR spectrum of compound 75a displayed resonances that corresponded to
fragments from both starting materials (alkyne 21 and azide 24). The most diagnostic
difference was the disappearance of the 1H NMR singlet resonance at δ 2.43 (-CC-H) that
was seen in the 1H NMR spectrum of alkyne 21 and the appearance of the significantly
downfield resonance at δ 7.89 (triazole CH) in the 1H NMR spectrum of 75a. The terminal
alkyne proton in compound 21 had now become the lone proton on the newly formed triazole
ring in scaffold 75a – this results in a strong deshielding of the proton (relative to the alkyne
proton) and a large downfield chemical shift. Two unique aromatic 13C NMR resonances at
δ 142.9 and 123.3 were present in the

13

C NMR spectrum of scaffold acid 75a – these

resonances were assigned to the methine and quaternary triazole carbons, respectively. The
resonance at δ 142.9 was extremely diagnostic because few other aromatic carbon resonances
appear in that region (i.e. δ 141-150). As expected, the

13

C NMR resonance at δ 123.3
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(triazole CH) displayed a correlation in the gHSQC spectrum with the 1H NMR resonance at
δ 7.89 (triazole CH). Furthermore, the appearance of these two unique 13C NMR resonances
coincided with the disappearance of the two alkyne (-CC-) 13C NMR resonances at δ 79.3
and 75.2 that are evident in the 13C NMR spectrum of starting alkyne 21. These two alkyne
carbons (-CC-) had now become the aromatic triazole carbons – this explains the associated
large downfield chemical shift. Additionally, the methine proton (adjacent to the acid moiety)
was assigned to a downfield resonance at δ 5.19 in the 1H NMR spectrum of compound 75a
– this proton was originally assigned to a resonance at δ 3.95 in the 1H NMR spectrum of
starting α-azido acid 24. This large downfield shift occured due to the formation of the new
adjacent triazole ring, which strongly deshielded the nearby methine proton. The molecular
identity was confirmed as HRMS analysis displayed a peak at m/z 589.2993 that was assigned
to the sodiated molecular ion, [M + Na]+ (calcd for C31H42N4O6Na 589.3002).
2.3.1.1 – Synthesis of Series B1 derivatives via amide coupling and N-deprotection
The derivatization of the mono-amino acid scaffolds for Series B1 required a twostep transformation: installation of the terminal amide moieties followed by side-chain
N-deprotection to yield the target amines as hydrochloride salts. Previous syntheses of
binaphthylpeptides have utilized the common EDCI/HOBt peptide coupling reagent system
to form the necessary peptide bonds while N-Boc and/or N-Pbf deprotection was previously
achieved with TFA/CH2Cl2.59, 64-66, 68-69 The derivatization for Series B1 was achieved using
the same methodology as Series A1 (see Section 2.2.1.2).
Therefore, for Series B1 derivatives, General Procedure B was utilized to install the
terminal amide moiety (see Reaction (i) in Schemes 2.28 – 2.30); the resultant N-protected
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amide derivatives were then immediately subjected to acidolytic N-Boc or N-Pbf cleavage
followed by work-up with ethereal HCl (General Procedure C or D: Reaction (ii) in
Schemes 2.28 – 2.30) to achieve the target amine salts (76a-f, 77a-l and 78a-b) in high
purities.

Scheme 2.28 - Derivatization of scaffold 75a: installation of the terminal amide
moiety (R) followed by removal of the N-Boc side chain protecting group to give
scaffold derivatives 76a-f as hydrochloride salts.

For example, the synthesis of derivative 76a (Scheme 2.28) was realized in 95% yield over
two steps from scaffold amine 75a (50 mg, 0.09 mmol) by reaction with benzylamine (1.2
eq), EDCI and HOBt in acetonitrile at rt for 24 h to give the corresponding amide which was
immediately subjected to N-Boc deprotection with TFA in CH2Cl2 at rt for 18 h followed by
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treatment with ethereal HCl and purification by precipitation. Much like Series A, the
derivatization of scaffolds 75a-b and 75d for Series B1 was conducted in two consecutive
steps; reaction completion and product purity for the amide coupling reactions was monitored
by TLC and/or MS analysis prior to subsequent N-deprotection.
The 1H NMR spectrum of the final compound 76a displayed resonances that were assigned
to the benzyl amide substituent (i.e. δ 4.37 (-CH2Ph) and δ 7.34 – 7.10 (phenyl)). The
presence of the new amide moiety was further confirmed by the following

13

C NMR

resonances: δ 169.8 (amide C=O), four resonances in the aromatic region (phenyl carbons)
and δ 44.6 (-CH2Ph), which were not seen in the 13C NMR spectrum of the starting acid 75a.
Evidence of N-Boc deprotection was seen by the lack of the diagnostic 1H NMR singlet
resonance at δ 1.44 (-C(CH3)3) and the lack of key
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C NMR resonances at δ 155.5 (Boc

C=O), 77.3 (-C(CH3)3) and 28.2 (-C(CH3)3) in the spectra of compound 76a. The molecular
structure of the product was verified by the appearance of a peak at m/z 556.3302 in HRMS
that was assigned to the protonated molecular ion, [M + H]+ (calcd for C33H42N5O3
556.3288).
In another example, the synthesis of derivative 77a (Scheme 2.29) was realized in 94% yield
over two steps from scaffold acid 75b (50 mg, 0.07 mmol) by reaction with benzylamine (1.2
eq), EDCI and HOBt in acetonitrile at rt for 22 h to give the intermediate amide which was
immediately subjected to N-Pbf deprotection with TFA and H2O in CH2Cl2 at rt for 18 h
followed by treatment with ethereal HCl and purification by precipitation. NMR spectral
analysis confirmed the installation of the benzyl amide and the removal of the N-Pbf
protecting group as per previous examples (see Section 2.2.1.2). The molecular structure of
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the product was verified by the appearance of a peak at m/z 584.3373 in HRMS that was
assigned to the protonated molecular ion, [M + H]+ (calcd for C33H42N7O3 584.3349).

Scheme 2.29 – Derivatization of scaffold 75b: installation of the terminal amide moiety
(R) followed by removal of the N-Pbf side chain protecting group to give scaffold
derivatives 77a-l as hydrochloride salts.
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Scheme 2.30 – Derivatization of scaffold 75d: installation of the terminal amide moiety (R)
followed by removal of the N-Pbf side chain protecting group to give scaffold derivatives 78a-b
as hydrochloride salts.

2.3.2 – Synthesis of dicationic derivatives (Series B2)
2.3.2.1 – Synthesis of Series B2 scaffolds via amide coupling
The synthesis of dual-amino acid scaffolds for Series B2 was conducted in a manner
analogous to the synthesis of Series A2 scaffolds (Section 2.2.2.1). A second amino acid
residue was attached to a scaffold from Series B1 via the reliable amide coupling
methodology (General Procedure B) to generate scaffolds 79a-d (Scheme 2.31).
For example, scaffold azide 79a was isolated in 82% yield from starting acid 75a (176 mg,
0.31 mmol) by treatment with amine 25 (1.2 eq), EDCI and HOBt in acetonitrile at rt for 48 h
followed by purification by flash chromatography.
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Scheme 2.31 – Synthesis of scaffolds 79a-d: amide coupling between scaffold acids 75a-d and
a β-azido-amine precursor (22 or 25) to give the scaffold azides 79a-d for Series B2.

Analysis of the 1H NMR spectrum of scaffold azide 79a confirmed the presence of
resonances that were assigned to functionalities from both precursors 75a and 25. The singlet
resonance at δ 2.81 (-CHNH2) in the 1H NMR spectrum of starting acid 75a was no longer
observed in the spectrum of 79a; however, a new resonance at δ 3.96 (1H) was observed and
it was assigned to the arginine α-methine proton. The methine proton, adjacent to the primary
amine in precursor amine 25, had experienced a downfield chemical shift due to the newly
installed amide bond. The
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C NMR spectrum of scaffold azide 79a did not display a

resonance at δ 156.6 (assigned to the carboxylic acid carbon, C=O); instead, the spectrum
exhibited a new resonance at δ 168.5 that was assigned to the new amide carbonyl (C=O).
Furthermore, a gHMBC correlation was observed between the 1H NMR resonance at δ 3.96
(assigned to the arginine methine proton) and the 13C NMR resonance at δ 168.5 (assigned
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to the new amide carbonyl) – providing further evidence of successful amide bond formation.
The molecular structure was verified by the appearance of a peak at m/z 986.5335 in HRMS,
that was assigned to the protonated molecular ion, [M + H]+ (calcd for C50H72N11O8S
986.5286).
2.3.2.2 – Synthesis of Series B2 derivatives via CuAAC and N-deprotection
The derivatization of the dual-amino acid scaffolds 79a-d (for Series B2) was
accomplished via utilization of the same two-step methodology that was employed for the
derivatization of Series A2 scaffolds (see Section 2.2.2.2); the terminal triazole moieties were
installed via CuAAC reactions (General Procedure A: Reaction (i) in Schemes 2.32 – 2.35)
followed by acidolytic N-Boc/N-Pbf deprotection and HCl salting (General Procedure C:
Reaction (ii) in Schemes 2.32 – 2.35) to give the target compounds (80a-d, 81a-d, 82a-b and
83a-b) as their dihydrochloride salts. As per Series A2, the derivatization of scaffolds 79a-d
for Series B2 was conducted in two consecutive steps; CuAAC reaction completion and
product purity was monitored by TLC and/or MS analysis prior to subsequent Ndeprotection.
For example, derivative 80a was afforded in 95% yield over two steps from scaffold azide
79a (50 mg, 0.05 mmol) by reaction with 3-phenyl-1-propyne (3.0 eq), Cu(OAc)2·H2O and
sodium ascorbate in t-BuOH/H2O at rt for 24 h followed by N-Boc/N-Pbf deprotection with
TFA and H2O in CH2Cl2 at rt for 18 h followed by treatment with ethereal HCl and
purification by precipitation.
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Scheme 2.32 – Derivatization of scaffold 79a: installation of the terminal triazole moiety
(with R substituent) followed by removal of the side chain N-protecting groups to give
scaffold derivatives 80a-d as dihydrochloride salts.

The 1H NMR spectrum of the final derivative 80a displayed 1H NMR resonances that were
assigned to the new benzyl substituent (i.e. δ 4.08 (-CH2Ph) and δ 7.36 – 7.09 (phenyl)).
Furthermore, a new downfield singlet resonance at δ 7.92 (1H) in the 1H NMR spectrum of
compound 80a was observed and assigned to the proton on the newly installed triazole ring.
The presence of the new triazole moiety was confirmed by assignment of the
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C NMR

resonances: δ 148.3 (quaternary triazole carbon – only observed by gHMBC), four
resonances in the aromatic region (phenyl carbons), δ 125.7 (triazole CH) and 32.4 (-CH2Ph),
which were not seen in the 13C NMR spectrum of the starting azide 79a.
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NMR spectral analysis of compound 80a confirmed the removal of the N-Boc/N-Pbf
protecting groups as per previous examples (see Section 2.2.2.2). The molecular structure of
the product was verified by the appearance of a peak at m/z 750.4570 in HRMS that was
assigned to the protonated molecular ion, [M + H]+ (calcd for C41H56N11O3 750.4568).

Scheme 2.33 – Derivatization of scaffold 79b: installation of the terminal triazole moiety
(with R substituent) followed by removal of the side chain N-protecting groups to give
scaffold derivatives 81a-d as dihydrochloride salts.
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Scheme 2.34 – Derivatization of scaffold 79c: installation of the terminal triazole moiety (with
R substituent) followed by removal of the side chain N-protecting groups to give scaffold
derivatives 82a-b as dihydrochloride salts.
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Scheme 2.35 – Derivatization of scaffold 79d: installation of the terminal triazole moiety
(with R substituent) followed by removal of the side chain N-protecting groups to give
scaffold derivatives 83a-b as dihydrochloride salts.

2.3.2.2 –Series B2 exceptions: terminal amide derivatives
The synthesis of dicationic derivatives with terminal amide moieties for Series B was
accomplished via the construction of scaffold acid 84 by amide coupling the arginine
derivative 29 onto scaffold 75c69 followed by base-promoted hydrolysis of the methyl ester
group (Scheme 2.36). Scaffold acid 84 was then derivatized to afford compounds 85a-c as
dihydrochloride salts via the same two-step methodology employed for Series B1: amide
coupling (General Procedure B: Reaction (i) in Scheme 2.37) to install the terminal amide
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moiety followed by side chain N-deprotection and HCl salting (General Procedure C:
Reaction (ii) in Scheme 2.37).

Scheme 2.36 – Synthesis of scaffold 84: amide coupling between scaffold acid 75c and amine 29
followed by base-promoted removal of the methyl ester protecting group to give scaffold acid 84.

Scaffold acid 84 was achieved in 86% yield over steps from scaffold 75c (150 mg, 0.23
mmol) by reaction with amine 29 (1.2 eq), EDCI and HOBt in acetonitrile at rt for 18 h
followed by hydrolysis with LiOH·H2O in THF/H2O at rt for 24 h and subsequent
acidification with 1.0 M aqueous HCl (Scheme 2.36). Initial examination of the 1H and 13C
NMR spectra of scaffold acid 84 suggested the presence of impurities with doubling up of
many 1H and

13

C NMR resonances (see Figures C1.11 – C1.13 in Appendix C). The

compound appeared pure by TLC analysis (one spot) and product identity was confirmed by
HRMS analysis (one peak at m/z 1073.5156 – assigned as the deprotonated molecular ion,
[M − H]− (calcd for C58H73N8O10S 1073.5170)). The extra resonances in the NMR spectra of
scaffold acid 84 were found to be a result of syn- and anti-carbamate and amide rotamers –
this topic is explored in detail in Section 4.3.

93

Scheme 2.37 - Derivatization of scaffold 84: installation of the terminal amide moiety
(with R substituent) followed by removal of the side chain N-protecting groups to give
scaffold derivatives 85a-c as dihydrochloride salts.

In one example of derivatization, compound 85a was afforded in 79% yield over two steps
from scaffold acid 84 (50 mg, 0.05 mmol) by reaction with benzylamine (1.2 eq), EDCI and
HOBt in acetonitrile at rt for 24 h followed by side chain N-deprotection with TFA and H2O
in CH2Cl2 at rt for 18 h – subsequent HCl salting with HCl/Et2O and purification by
precipitation gave the product as a dihydrochloride salt (Scheme 2.37). The derivatization of
scaffold 84 was conducted in two consecutive steps without full spectroscopic
characterization of the N-Boc/N-Pbf protected intermediates. Amide coupling reaction
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completion and product purity was monitored by TLC and/or MS analysis prior to subsequent
N-deprotection.
Reaction success for derivatization (i.e. amidation and subsequent N-deprotection) was
verified in the same manner as Series B1 derivatives; NMR spectral analysis confirmed the
installation of the benzyl amide and the removal of the N-Boc/N-Pbf protecting groups (see
Section 2.2.1.2 for specific details). Furthermore, the molecular identity was confirmed by
the appearance of a peak at m/z 812.4604 in the HRMS, which was assigned to the protonated
molecular ion, [M + H]+ (calcd for C47H58N9O4 812.4612).

2.4 – Series C synthesis: scaffolds and derivatives
2.4.1 – Synthesis of monocationic derivatives (Series C)
Series C constitutes two biarylpeptide scaffolds (and their derivatives) that did not
contain an internal triazole linker in the peptide backbone; one series with no triazoles (Series
C1) and one series with terminal triazoles moieties only (Series C2).
2.4.1.1 – Synthesis of Series C1
The scaffold acid 86 for Series C1 was realized in 82% over two steps from aromatic acid
42† (246 mg, 0.59 mmol) from the reaction with amine 29 (1.2 eq), EDCI and HOBt in
acetonitrile at rt for 21 h followed by hydrolysis with LiOH·H2O in THF/H2O at rt for 18 h
and subsequent acidification with 1.0 M aqueous HCl (Scheme 2.38).
The 1H NMR spectrum of acid 86 displayed resonances that were assigned to both the
binaphthyl and arginine precursor fragments. Evidence of the newly installed amide bond

†

Compound gifted from previous researcher (S. Wales).
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was seen by the appearance of a broad resonance at δ 7.75 (1H) in the 1H NMR spectrum of
scaffold 86, assigned as the amide proton (N-H).

Scheme 2.38 – Synthesis of scaffold 86: amide coupling of aromatic acid 42 and
arginine residue 29 followed by base-promoted removal of the methyl ester
protecting group to give scaffold acid 86.

Notably, the

13

C NMR spectrum of compound 86 (in CD3OD) was missing six N-Pbf

resonances that were observable only through gHMBC correlations with the protons of the
attached -CH3 groups. The guanidine carbon (C=N) could not be assigned to a resonance in
the 13C NMR spectrum but was shown to be present in subsequent derivatives (87a-c). It has
been observed that carboxylic acid containing derivatives can exhibit weak aromatic N-Pbf
13

C NMR resonances.

The derivatization of scaffold 86 was conducted in two consecutive steps; amide coupling
reaction completion and product purity were monitored by TLC and/or MS analysis prior to
subsequent N-deprotection. For example, derivative 87a was isolated in 97% yield over two
steps from scaffold acid 86 by reaction with benzylamine (1.2 eq), EDCI, HOBt in
acetonitrile at rt for 22 h followed by N-Pbf deprotection with TFA and H2O in CH2Cl2 at rt
for 18 h with subsequent HCl salting (Scheme 2.39).
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Scheme 2.39 - Derivatization of scaffold 86: installation of the terminal amide moiety
(with R substituent) followed by removal of the side chain N-Pbf group to give scaffold
derivatives 87a-c (Series C1) as hydrochloride salts.

The 1H NMR spectrum of the final derivative 87a displayed resonances that were
characteristic of the benzyl amide substituent (i.e. δ 4.25 (-CH2Ph) and δ 7.39 – 7.15 (phenyl);
As seen in previous examples, the lack of key N-Pbf resonances in the NMR spectra of
compound 87a provided further evidence for the removal of the N-Pbf protecting group. The
molecular structure of the product was verified by the appearance of a peak at m/z 660.3553
in HRMS that was assigned to the protonated molecular ion, [M + H]+ (calcd for C40H46N5O4
660.3550).
2.4.1.2 – Synthesis of Series C2 (terminal triazoles)
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The scaffold azide 88 for Series C2 was realized in 94% from acid 42 (207 mg, 0.50
mmol) by reaction with amine 22 (1.2 eq), EDCI and HOBt in acetonitrile at rt for 24 h
(Scheme 2.40) followed by purification by flash chromatography.

Scheme 2.40 – Synthesis of scaffold azide 88: amide coupling between aromatic
acid 42 and β-azido-amine 22.

The 1H NMR spectrum of azide 88 displayed resonances that were assigned to both the
binaphthyl and lysine precursor fragments. Evidence of the newly installed amide bond was
seen by the appearance of a new resonance at δ 5.60 (1H) in the 1H NMR spectrum of scaffold
88 – this broad singlet resonance was assigned as the new amide proton (N-H). Furthermore,
the broad singlet at δ 2.89 (-CHNH-) in the 1H NMR spectrum of starting amine 22 was no
longer present in the spectrum of scaffold azide 88 – the α-methine proton was assigned to a
new downfield resonance at δ 3.75 in the 1H NMR spectrum of target azide 88 and was a
direct result of the newly installed amide bond. Additionally, the resonance at δ 167.9 in the
13

C NMR spectrum was assigned to the amide carbonyl (C=O) and was confirmed by a

heteronuclear gHMBC correlation with the 1H NMR resonance at δ 3.75 (-CHNH-). Analysis
of the IR spectrum of azide 88 revealed a strong characteristic band at 2101 cm-1 that was
assigned to the azide moiety.
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The derivatization of scaffold 88 to realize compounds 89a-c (Scheme 2.41) was conducted
in two consecutive steps; CuAAC reaction completion and product purity was monitored by
TLC and/or MS analysis prior to subsequent N-deprotection.

Scheme 2.41 – Derivatization of scaffold 88: installation of the terminal triazole
moiety (with R substituent) followed by removal of the side chain N-Boc group to
give scaffold derivatives 89a-c (Series C2) as hydrochloride salts.

For example, derivative 89a was isolated in 50% yield over two steps from scaffold azide 88
by reaction with 3-phenyl-1-propyne (3.0 eq), Cu(OAc)2·H2O and sodium ascorbate in
t-BuOH/H2O at rt for 20 h followed by N-Boc deprotection with TFA in CH2Cl2 at rt for 18
h and subsequent treatment with ethereal HCl and purification by precipitation (Scheme
2.41).
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The 1H NMR spectrum of the final derivative 89a displayed resonances that were assigned
to the terminal benzyl moiety (i.e. δ 3.95 (-CH2Ph) and δ 7.22 – 7.08 (phenyl)). The presence
of the triazole moiety was confirmed by assignment of the following 13C NMR resonances:
δ 148.2 (quaternary triazole carbon), 124.3 (methine triazole carbon), four resonances in the
aromatic region (phenyl carbons) and δ 32.0 (-CH2Ph), which were not seen in the 13C NMR
spectrum of the starting azide 88. The resonance at δ 7.20 (triazole CH) in the 1H NMR
spectrum of derivative 89a displayed a gHMBC correlation and a gHSQC correlation with
the resonances at δ 148.2 and 124.3 (triazole carbons), respectively. As per previous
examples, evidence of N-Boc deprotection was seen by the lack the characteristic 1H and 13C
NMR resonances typical of the N-Boc protecting group. The molecular structure of the
product was verified by the appearance of a peak at m/z 692.3611 in HRMS that was assigned
to the sodiated molecular ion, [M + Na]+ (calcd for C42H47N5O3Na 692.3577).
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3.0 – Biological and pharmacological assays: results and discussion
3.1 – Background information
This chapter reports the results of the in vitro, in vivo and pharmacological assays
performed on the library of synthesized biarylpeptide derivatives. All final derivatives were
subjected to a multi-phase testing procedure, as outlined in Figure 3.1.

Figure 3.1 – Overview of the three-phase biological testing procedure
utilized to determine the antimicrobial activity of the synthesized compounds.

Primary in vitro MIC screening (against Gram-positive bacteria including C. difficile – see
Table 3.1) was performed at the University of Western Australia by project collaborators.†
Secondary in vitro MIC screening (against Gram-negative bacteria/fungi – see Table 3.1) and

† Prof. Thomas V. Riley, Dr. Katherine A. Hammer and Dr. Dan Knight.
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a cytotoxicity assay was performed by CO-ADD.‡ Compounds that exhibited significant MIC
values in the primary and secondary screening phases were then sent to collaborators§ at
Monash University for a third round of in vitro MIC testing against the hypervirulent C.
difficile strain (RT027–M7404); compounds that performed well in vitro against the virulent
C. difficile strain at Monash University were then selected for testing in an in vivo murine
model of CDI. The in vivo murine model of CDI was developed and performed by
collaborators§ at Monash University; this assay was used to ascertain the viability and
efficacy of identified hit compounds as potential CDI chemotherapeutics.
In conjunction with the in vivo CDI mouse models, a comparative solubility assay was
developed and utilized to gauge and compare compound solubilities. Furthermore, a
rudimentary pharmacokinetic analysis via low resolution ESI-MS was performed at the
University of Wollongong on the blood and faeces of the mice from the in vivo studies to
ensure that the compounds were not being absorbed systemically after oral administration.

3.2 – In vitro assays: MIC and cytotoxicity
MIC assays provide a quantitative measurement (in μg/mL) of a compound’s ability
to inhibit bacterial or fungal growth. The MIC assays were conducted against a range of
various pathogenic microbes, including four Gram-positive and four Gram-negative bacterial
species (Table 3.1) in total. Furthermore, compounds were also tested against two pathogenic
fungal species. The compounds were tested against this wide set of pathogenic bacteria and

‡ Community for Open Antimicrobial Drug Discovery (www.co-add.org) – funded by the Wellcome Trust
(UK) and The University of Queensland

§ Prof. Dena Lyras, Dr. Melanie Hutton, Dr. Amy King and Dr. Yogi Srikhanta
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fungi to gauge their broad-spectrum activity (i.e. activity against a range of species including
five of the six ESKAPE pathogens5) and their activity against the various C. difficile strains
(to identify potential CDI chemotherapeutics or lead compounds).
Testing Facility
Gram +ve Bacterial Species
Staphylococcus aureus
Clostridium difficile
Enterococcus faecalis
Streptococcus pneumoniae

UWA
ATCC 29213
NCTC 10442
(MRSA)
ATCC 700057
NSW132 (RT027)
ATCC 29212
ATCC 49619

CO-ADD

Monash

ATCC 43300 (MRSA)

-

-

M7404 (RT027)
-

Gram −ve Bacterial Species
Escherichia coli
ATCC 25922
Klebsiella pneumoniae
Acinetobacter baumannii
Pseudomonas aeruginosa
-

ATCC 25922
ATCC 700603 (MDR)
ATCC 19606
ATCC 27853

-

Fungal Species
Candida albicans
Cryptococcus neoformans

ATCC 90028
ATCC 208821

-

-

Table 3.1 – Bacterial and fungal species that were tested against in the various in vitro MIC assays.

3.2.1 – General methodology for MIC and cytotoxicity assays
The MIC assays were performed in multi-well micro-titre plates and the wells were
filled with inoculated growth medium and varying, incremental concentrations of the
compounds to be tested. The plates were then cultured and the resulting bacterial growth
inhibition was observed. Compound concentrations ranging from 0.125 μg/mL to 128 μg/mL
were typically employed and vancomycin, colistin and fluconazole were utilized as positive
controls for Gram-positive bacteria, Gram-negative bacteria and fungi, respectively. For
CO-ADD screening, a single point concentration (32 μg/mL) of each compound was first
tested to confirm antibacterial activity; compounds that displayed activity at this
concentration were then subjected to a comprehensive MIC assay. Compound cytotoxicity
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was measured at CO-ADD against human embryonic kidney cells (HEK-293 – ATCC CRL1573) with tamoxifen as a control and the data is reported as the concentration required to
inhibit cell growth by 50% (CC50). The experimental methodologies for the different MIC
assays and cytotoxicity assay are reported in Section 6.4.1

3.2.2 – MIC assay results: overview and lead compound identification
The synthesized compounds exhibited antibacterial activities that ranged from
inactive (> 128 μg/mL) to potent (2 μg/mL). The results show that some level of antibacterial
activity was exhibited by every compound synthesized – see Tables 3.2 – 3.6 for the primary
and secondary MIC screening data. For a set of the MIC data with the corresponding
compound structures, please see Tables B1.1 – B2.9 in Appendix B.
Most of the compounds exhibited a decreased propensity to inhibit Gram-negative bacteria
relative to the Gram-positive bacteria that were tested. These Gram-negative bacteria
required concentrations of drug that were approximately two to four times higher than the
corresponding Gram-positive MIC values; for example, compound 64a exhibits an MIC =
8 μg/mL against S. aureus but an MIC = 32 μg/mL against E. coli (as seen in Table 3.2). The
extra membrane inherent to Gram-negative bacteria is known to impede the absorption and
therefore the action of various antibiotics.13 Klebsiella pneumoniae was the least susceptible
species to the majority of tested compounds and no compound displayed an MIC below 16
μg/mL for this bacterial species. The compounds generally did not exhibit MIC values below
8 μg/mL for the Gram-negative bacteria that were tested (Tables 3.4 – 3.6), whereas activities
around 2 – 4 μg/mL were common for the Gram-positive bacterial species (Tables 3.2 and
3.3). Furthermore, C. difficile proved to be the most resilient of the Gram-positive bacteria
that were tested; the hypervirulent C. difficile strain (RT027) also displayed decreased
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susceptibility to the tested compounds, when compared with the normal C. difficile strain
(Tables 3.2 and 3.3).
Out of the 62 antibiotics synthesized and tested, eight structures were identified as potential
broad-spectrum lead antibacterial compounds. These novel biphenyl-triazole peptidomimetic
compounds (i.e. 68a-d, 69b, 80b and 81c-d) were found to exhibit broad-spectrum activity
against both Gram-positive and Gram-negative bacteria; these compounds displayed active
MIC values (≤ 16 μg/mL) against all tested bacterial species. Compound 80b from Series B
was the best broad-spectrum lead compound, as it was the only compound to display an MIC
value of 8 μg/mL against both P. aeruginosa and A. baumannii (Figure 3.2 and Table 3.6).
Furthermore, four compounds (i.e. 68c-d, 77c and 87a) were identified as potential CDI
chemotherapeutics due to their in vitro activities against C. difficile (MIC ≤ 8 μg/mL) and
solubility profiles; these compounds were then synthesized on larger scale (approximately
500 – 1000 mg) for in vivo testing in a murine model of CDI (see Section 3.3.3).
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Primary Screening Data
S. aureus
Compound
64a
64b
64c
65a
65b
65c
66a
66b
66c
68a
68b
68c
68d
69a
69b
69c
69d
70a
70b
73
74
76a
76b
76c
76d
76e
76f
77a
77b
77c
77d
Vancomycin

ATCC NCTC
29213 10442

E.
S.
faecalis pneumoniae
ATCC
29212

ATCC
49619

E.
coli

C. difficile

ATCC ATCC
132
25922 700057 (RT027)

8
8
16
16
16
4
4
4
4
8
4
8
4
4
4
4
16
4
4
8
4
8
8
8
8
4
4
4
2
4
4

8
4
16
16
16
4
4
4
4
8
4
4
4
4
4
4
16
4
4
8
4
16
8
16
8
4
8
8
2
4
4

8
8
16
16
16
8
8
8
8
16
8
8
4
8
8
8
16
4
4
8
4
16
8
16
8
4
8
8
4
4
8

8
8
32
16
32
16
8
8
8
4
8
4
4
4
4
4
8
4
4
8
4
8
8
8
8
8
8
4
4
4
8

32
16
32
64
64
32
32
>128
>128
64
64
64
32
32
32
32
64
16
16
32
64
32
16
32
16
16
16
32
16
16
32

32
8
8
64
128
32
64
16
32
16
8
4
4
64
16
32
64
16
8
16
32
32
32
16
16
32
32
32
8
8
32

32
16
32
16
16
32
64
16
32
16
8
8
4
64
16
32
32
16
16
16
32
32
32
32
32
32
64
64
32
16
64

1

1

4

1

>16

0.5

0.5

Table 3.2 – Primary antimicrobial screening data for all synthesized compounds reported as
the MIC values (μg/mL).
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Primary Screening Data (cont.)
S. aureus
Compound
77e
77f
77g
77h
77i
77j
77k
77l
78a
78b
80a
80b
80c
80d
81a
81b
81c
81d
82a
82b
83a
83b
85a
85b
85c
87a†
87b
87c
89a
89b
89c
Vancomycin

E.
S.
faecalis pneumoniae

E.
coli

C. difficile

ATCC NCTC
29213 10442

ATCC
29212

ATCC
49619

ATCC ATCC
132
25922 700057 (RT027)

16
4
8
4
2
4
16
4
4
8
4
4
16
4
8
4
8
4
4
4
4
4
8
8
8
2
2
>128
4
4
8

16
4
8
8
2
4
32
4
8
8
4
4
16
4
8
8
8
4
4
4
4
4
8
8
8
2
2
>128
8
4
8

16
4
8
8
2
4
32
4
2
4
8
8
16
4
8
8
8
4
4
4
4
4
8
4
8
2
4
>128
4
4
4

32
4
16
8
2
4
8
2
8
16
4
8
32
8
4
2
2
2
4
4
2
2
8
8
8
2
2
>128
32
32
32

64
32
32
32
16
32
64
32
>128
>128
32
16
64
32
32
16
16
16
16
16
8
8
32
32
16
>128
>128
>128
>128
>128
128

128
64
32
32
16
32
64
16
16
16
8
16
64
16
32
16
8
8
16
16
16
8
16
16
16
8
32
>128
16
8
16

128
64
32
64
32
32
128
16
16
64
16
16
128
16
16
16
16
16
16
16
16
8
16
32
32
8
32
64
16
8
16

1

1

4

1

>16

0.5

0.5

Table 3.3 – Primary antimicrobial screening data for all synthesized compounds reported as
the MIC values (μg/mL). † MIC = 2 μg/mL against C. diff. (RT027 – M7404).
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Secondary Screening - Control Data
S.
aureus
ATCC

Compound

43300
(MRSA)

Vancomycin
Colistin
Fluconazole
Tamoxifen

1
>32
-

P.
aeruginosa

K.
pneumoniae

A.
baumannii

E.
coli

C.
albicans

C.
Cytotoxicity
(CC50)
neoformans

ATCC

27853

ATCC
700603

ATCC
19606

ATCC
25922

ATCC
90028

208821

>32
0.25
-

>32
0.25
-

>32
0.25
-

>32
0.125
-

0.125
-

8
-

ATCC

(HEK-293)
ATCC
CRL-1573

13.06

Table 3.4 – MIC or CC50 values for the various control inhibitors utilized in the secondary antimicrobial screening – reported in μg/mL.
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Secondary Screening Data
Compound
64a
64b
64c
65a
65b
65c
66a
66b
66c
68a
68b
68c
68d
69a
69b
69c
69d
70a
70b
73
74
76a
76b
76c
76d
76e
76f
77a
77b
77c
77d

S.
aur.
16
16
16
16
16
8
4
4
4
4
2
4
2
4
2
4
8
4
2
4
4
16
8
8
8
8
8
8
8
4
4

P.
aer.
32
32
32
>32
>32
>32
>32
>32
>32
16
8
8
16
16
8
8
32
32
32
32
>32
32
>32
32
>32
>32
>32
>32
>32
>32
>32

K.
pneu.
>32
32
>32
>32
>32
>32
>32
>32
>32
16
16
16
16
32
16
32
32
>32
>32
32
>32
>32
>32
>32
>32
>32
>32
>32
>32
>32
>32

A.
bau.
32
>32
32
>32
>32
>32
>32
>32
>32
8
16
16
8
16
16
8
16
32
16
32
>32
32
32
32
32
32
16
32
32
32
>32

E.
coli
>32
32
32
>32
>32
>32
>32
>32
>32
16
8
8
4
8
4
8
16
>32
32
16
>32
>32
>32
>32
>32
>32
>32
>32
>32
>32
>32

C.
alb.
32
>32
16
>32
>32
8
32
32
16
32
32
32
>32
32
32
32
>32
8
4
32
>32
>32
>32
32
32
>32
>32
16
16
16
32

C.
neo.
32
16
32
32
32
16
8
8
4
32
4
4
4
4
2
2
4
2
2
2
8
>32*
>32*
32*
16*
32*
12*
16
32
16
32

CC50

14.2
4.8
4.7
29.0
>32
>32
16.5
15.9
13.8
21.9
>32
14.2
>32
17.8
17.4
15.3
>32
>32
>32
28.7
16.5
>32
>32
>32
5.6
>32
5.5
16.8
17.9
19.7
16.9

Table 3.5 – Secondary antimicrobial screening data for all synthesized compounds
reported as the MIC or CC50 values (μg/mL). * Cryptococcus neoformans data was not
consistent with initial screening data – compounds need to be rescreened.
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Secondary Screening Data (cont.)
Compound
77e
77f
77g
77h
77i
77j
77k
77l
78a
78b
80a
80b
80c
80d
81a
81b
81c
81d
82a
82b
83a
83b
85a
85b
85c
87a
87b
87c

S.
aur.
16
16
16
4
8
8
32
8
8
8
4
2
4
2
8
4
4
8
2
2
4
32
4
2
2
4
4
4

P.
aer.
>32
>32
>32
>32
>32
>32
>32
>32
>32
>32
16
8
16
32
16
16
8
16
16
32
32
32
32
32
16
>32
>32
>32

K.
pneu.
>32
>32
>32
>32
>32
>32
>32
>32
>32
>32
32
16
16
16
32
16
16
16
>32
>32
>32
>32
32
16
16
>32
>32
>32

A.
bau.
>32
>32
>32
>32
>32
>32
>32
>32
>32
>32
16
8
8
8
32
32
16
16
8
8
32
32
32
8
8
>32
>32
>32

E.
coli
>32
>32
>32
>32
>32
>32
>32
>32
>32
>32
8
8
8
8
>32
16
16
16
>32
>32
>32
>32
>32
>32
32
>32
>32
>32

C.
alb.
>32
>32
>32
>32
>32
>32
>32
32
16
32
32
32
32
16
32
32
32
32
4
4
32
32
16
16
16
>32
32
>32

C.
neo.
32
32
>32
4
32
>32
>32
32
8
16
4
4
4
4
4*
2*
2*
2*
2
1
1*
1*
4
2
4
16*
16*
16*

CC50

>32
19.1
22.9
>32
21.6
12.2
20.0
19.7
16.5
>32
17.1
16.4
19.8
19.1
>32
>32
>32
>32
>32
16.6
>32
>32
17.4
15.2
16.8
>32
>32
>32

Table 3.6 – Secondary antimicrobial screening data for all synthesized compounds
reported as the MIC or CC50 values (μg/mL). * Cryptococcus neoformans data was not
consistent with initial screening data – compounds need to be rescreened.
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Figure 3.2 – Structures, MIC and CC50 values for lead compounds 68d and 80b. See Table 3.1 for
the specific bacterial strains that were tested.

The broad-spectrum lead compound 80b displayed the best antibacterial activity against
Gram-negative bacteria of any compound tested; despite this, it did not display the best
activity against Gram-positive bacteria (Figure 3.2). Many other compounds displayed better
Gram-positive activities, especially against the target species C. difficile; therefore,
compound 80b was not chosen for subsequent in vivo assay. However, compound 68d
displayed a similar Gram-negative activity profile to compound 80b while maintaining an
excellent Gram-positive activity profile (MIC values ≤ 4 μg/mL – Figure 3.2) with no
observable cytotoxicity (unlike compound 80b). Notably, this compound compared quite
favourably with vancomycin, which exhibited MIC values between 1 - 4 μg/mL for the same
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Gram-positive bacteria. Thus, both compound 68d and a similar derivative, 68c, where
chosen for testing in the in vivo CDI model.
The other two compounds selected for the in vivo CDI mouse model study were compounds
77c and 87a (Figure 3.3); both compounds exhibited strong activity against most Grampositive bacteria (MIC values ≤ 4 μg/mL) with an MIC value of 8 μg/mL against C. difficile
in preliminary testing. Follow-up testing against the hypervirulent C. difficile strain (M7404
– RT027) at the Monash University laboratory revealed an MIC value of 2 μg/mL for
compound 87a.

Figure 3.3 – Structures, MIC values and CC50 values for selected compounds 77c and 87a.
† Compound 87a exhibited MIC = 2 μg/mL against C. difficile (M7404 - RT027) when tested at
the Monash University laboratory. See Table 3.1 for the specific bacterial strains that were tested.
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3.2.3 – MIC assay results: structure-activity relationship (SAR) trends
Sixty-two antibacterial compounds were synthesized from 17 unique scaffolds; this
allowed for a large diversity in compound structure and orientation. There was no observable
major difference in the antibacterial activities of the two peptide bonding orientations (blue
arrow in Figure 3.4) that were investigated (i.e. Series A vs. Series B) as both series produced
highly active derivatives (e.g. 68d and 80b) that exhibited broad spectrum activity against
both Gram-positive and Gram-negative bacteria (see Figure 3.2). The dicationic derivatives
were notably more active than the monocationic compounds and these findings were
consistent with previous research.69 The dicationic derivatives generally exhibited slightly
increased antibacterial potency (2 – 4 times more active) against Gram-positive bacterial
species – e.g. the activity of dicationic compound 80a against S. aureus (MIC = 4 μg/mL)
was notably stronger than the activity of the similar monocationic derivative 76a (MIC = 8
– 16 μg/mL) – see Tables 3.2 and 3.3. Furthermore, many of the dicationic derivatives (Series
A2 and B2) now exhibited significant activity against Gram-negative bacteria, whereas the
mono-cationic derivatives (Series A1 and B1) were virtually inactive against Gram-negative
bacteria – e.g. the monocationic compounds 65a-c and the dicationic derivatives 68a-d in
Table 3.5. The introduction of a second cationic amino acid residue conferred a large increase
in antimicrobial potency with broad-spectrum activity against both Gram-positive and Gramnegative bacteria. For example, compound 64b did not exhibit Gram-negative antibacterial
activity, but the dicationic analogue (compound 68b) exhibited activity against all Gramnegative bacteria; it also displayed an MIC = 2 μg/mL against S. aureus, whereas the monocationic derivative (64b) exhibited an MIC = 16 μg/mL (see Tables 3.2 and 3.5). The addition
of a second cationic side-chain residue likely allows for strong binding to the outer anionic
bacterial membrane. It has been shown previously69 that arginine residues are slightly more
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potent than their corresponding lysine analogues; the current SAR data confirms this finding
(e.g. arginine derivative 77a was generally more potent than the lysine analogue 76a – see
Table 3.2).
While previous dicationic binaphthylpeptide derivatives have been known to exhibit potent
antibacterial activity against Gram-positive bacteria, they were not as successful against
Gram-negative bacteria. The more soluble biphenyl aromatic core was substituted for the
traditional binaphthyl aromatic core (red arrow in Figure 3.4) in an attempt to increase
compound solubility without compromising activity; this increase in solubility led to a
notable increase in compound activity against Gram-negative bacteria. For example, both
binaphthyl dicationic derivatives 70a and 70b were effectively inactive against Gramnegative bacteria (Table 3.5); substitution of the biphenyl aromatic core to generate
analogues 68b and 68d led to observed antibacterial activity against Gram-negative species
(MIC values = 4 – 16 μg/mL, see Table 3.5). Interestingly, the biphenyl core did not lead to
an increase in Gram-positive antibacterial potency relative to the binaphthyl aromatic core
(i.e. the binaphthyl derivative 78a was more potent against Gram-positive bacteria (e.g. C.
difficile MIC = 16 μg/mL) than its biphenyl analogue 77a (C. difficile MIC = 32 – 64 μg/mL)
– see Tables 3.2 and 3.3. The substitution of a biphenyl aromatic core increased the solubility
of the compound (relative to the binaphthyl aromatic core – see Section 3.4.1); this increase
in solubility was likely responsible for the increase in antimicrobial efficacy against Gramnegative bacteria. The resilient Gram-negative species are notably impermeable to antibiotics
due to their secondary membrane layer; this increase in compound solubility and smaller
molecular size may allow for better diffusion into the bacterial cell membrane, hence the
increase in antibacterial activity.
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Figure 3.4 – Diagram showing the structural modifications that were
investigated: biphenyl core substitution (red), peptide bond orientation
(blue), peptidomimetic 1,2,3-triazole incorporation (green), amino
acid residue variation (black) and hydrophobic termini variation
(magenta).

The addition of a second triazole moiety (green arrow in Figure 3.4) was also key for
conferring Gram-negative activity; a biphenyl analogue of lead compound 2 (i.e. compound
73) was not active against four of the five Gram-negative bacteria tested but the addition of
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a second terminal triazole moiety gave a compound (i.e. 68a) that was active against all the
Gram-negative bacteria tested (Tables 3.5 and 3.6).
Interestingly, derivatives 85a-c did not contain a terminal triazole moiety nor a biphenyl
aromatic core, yet these derivatives still exhibited some Gram-negative activity with MIC
values ranging from 8 μg/mL to > 32 μg/mL – see Table 3.6.
Compounds that contained the more flexible termini (e.g. phenethyl compared to benzyl
derivatives) exhibited slightly better antibacterial activity; for example, compound 68b
(phenethyl derivative) was approximately 2 – 4 times more active than its corresponding
benzyl analogue (compound 68a – Tables 3.2 and 3.5) against most of the bacteria tested.
The same was true for the cyclohexyl (Cy) and cyclohexylmethyl (CH2Cy) derivatives; the
more flexible CH2Cy termini generally gave more active derivatives (e.g. compare
compounds 80c and 80d in Tables 3.3 and 3.6). This increase in activity is likely due to the
flexible termini’s ability to adopt more conformations and therefore, there is an increased
chance for a more active conformation to be achieved.
The relative positioning of the arginine and lysine amino acid residues in the peptide
backbone was found to have a notable influence over the antibacterial efficacy of the
molecules. For example, when the order of the two cationic amino acids was switched in
compounds 68a-c to give compounds 69a-c, there was a loss of antibacterial activity against
C. difficile (e.g. MIC = 4 μg/mL to 32 μg/mL – see Table 3.2). In the Series B analogues, the
same alteration in amino acid order led to an increase in antibacterial efficacy against C.
difficile for some derivatives (see compounds 80c-d and 81c-d – Table 3.3). It was concluded
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that the relative orientation of the cationic amino acid residues was important but predicting
the result from such structural changes was not possible.

3.2.4 – Mechanism of action
Minimum bactericidal concentration (MBC) values were also recorded for the
bacterial species tested at UWA. The MBC data was not included because most compounds
exhibited MBC values that were more or less congruent with the observed MIC values; this
is indicative of a bactericidal mechanism, as there is little variation between inhibition of cell
growth and cell death. Various studies113-116 have previously implicated membrane
depolarization as a likely mechanism for the antibacterial activity of many cationic peptide
derivatives. Lysis of the cellular membrane is thought to be achieved by aggregation of the
amphipathic compounds on and in the membrane which results in pore formation.113, 116 The
electrochemical gradient that drives cellular biological processes becomes disrupted and this
results in cell death.113 Such a mechanism of action for the biarylpeptide derivatives would
explain the lack of disparity between the observed MIC and MBC values. A membrane
depolarization mechanism would also explain the increased activity seen with compounds
having two cationic amino acid side chains compared to a single cationic side chain, because
these moieties are necessary for electrostatic attraction to the anionic bacterial membrane and
for amphipathic pore formation via molecular aggregation.115 While the data supports a
membrane-based mechanism, it does not rule out the possibility of an intracellular target.
Further biological testing (e.g. a membrane depolarization assay) is necessary before any
definite conclusions can be made regarding the mechanism of action of these compounds.
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3.2.5 – Cytotoxicity assay results
The synthesized compounds were screened for any partial cytotoxicity by testing at
the same concentration range that was used for MIC analysis at CO-ADD (≤ 32 μg/mL).
Compounds are normally tested for cytotoxicity at much higher concentrations; this lowconcentration testing allows for the identification of a CC50 value (i.e. the concentration
which is cytotoxic to 50% of cells) through curve-fitting and extrapolation of the lowconcentration cytotoxicity data. Some compounds did not exhibit significant cytotoxicity at
these low concentrations and therefore curve fitting was not possible; a CC50 value could not
be extrapolated from the data – these compounds have CC50 values listed as > 32 μg/mL as
they do not exhibit significant cytotoxicity at the tested concentrations. Cytotoxicity assays
were completed in duplicate and the lower CC50 values are reported in Tables 3.5 and 3.6
(see Tables B2.1 – B2.9 in Appendix B for a set of the cytotoxicity assay data with
corresponding structures).
No definitive observable correlations could be drawn between a compound’s measured
cytotoxicity and its antibacterial efficacy from the data set. The majority of compounds
displayed some level of cytotoxicity; only four scaffold types had no cytotoxic derivatives
(compounds 70a-b, 81a-d, 83a-b and 85a-c). Most notably, the mono-cationic derivatives
(Series A1 and B1) seemed to exhibit the most significant cytotoxicity; compound 64c had
the strongest observed cytotoxicity with a CC50 value of 4.7 μg/mL. Unfortunately, many of
the identified lead compounds exhibited some level of cytotoxicity, for example compound
80b had an observed CC50 value of 16.4 μg/mL. Importantly, some of the identified lead
compounds (e.g. compound 68d) failed to exhibit any cytotoxicity at concentrations up to 32
μg/mL (i.e. well above the compound’s observed MIC value of 4 μg/mL against C. difficile).
118

Although cytotoxicity is not as important for topical or gastrointestinal (i.e. non-systemic)
antibiotic formulations, compounds that exhibited limited or no cytotoxicity were certainly
preferred. Previous research69 has shown a positive correlation between cytotoxicity (as
measured by haemolysis) and antibacterial efficacy in the binaphthyltriazole derivatives;
compounds with reduced antibacterial efficacy exhibited reduced haemolysis. Such a
correlation could be explained if the binaphthylpeptide derivatives exhibit their activity
through a membrane depolarization mechanism, like other antimicrobial peptides.114, 116 In
this study, both highly active and less active antibacterial derivatives were found to exhibit
CC50 values across the range of measured concentrations. While tentative positive
correlations were seen when comparing a few individual compounds, there was no
consistency amongst the wider set of recorded data. Furthermore, different derivatives of a
single scaffold were found to vary in their cytotoxicities; for example, compound set 68a-d
(Series A2) had two derivatives that were non-cytotoxic and two derivatives that exhibited
cytotoxic CC50 values (≤ 32 μg/mL). A compound’s cytotoxicity could not be gauged by the
nature of its termini; a particular terminus might cause cytotoxicity in one scaffold, but be
non-cytotoxic in another scaffold (e.g. the phenethyl terminus occurs in the cytotoxic
compound 69b and in the non-cytotoxic compound 68b – Table 3.5).

3.3 – In vivo assay: murine model of CDI
3.3.1 – General methodology
The murine model of C. difficile infection involved pretreating cohorts of five mice
with an antibiotic cocktail prior to infection via oral gavage with hypervirulent M7404 C.
difficile spores; this helped to eliminate the commensal GI microbiota and allowed the C.
difficile infection to flourish. The infection was allowed to incubate for 12 h before the trial
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drugs were administered every 12 h for five days. The mice received a compound dose of 2.5
mg (i.e. 100 mg/kg for an average 25 g mouse) administered in a solvent mixture of
DMSO/H2O (1:9) at each 12 h dosing interval. The mice were weighed daily: if a mouse lost
≥ 10% of its body weight in the first 24 h (or ≥ 15% thereafter), then the infection was
obviously proliferating and the mouse was removed from the trial and culled for ethical
reasons. The overall survival rate for each drug cohort was used as a measure of drug’s
effectiveness. The latest murine trial also incorporated the use of physiological parameter
scores (like faecal consistency scores and cage appearance scores) as other measures of the
drug’s efficacy. The full experimental methodology and relevant data for the in vivo CDI
model can be found in Section 6.4.

3.3.2 – Preliminary trials
Lead compound 2 had been previously synthesized on larger scale69 (~700 mg) and
subjected to an in vivo mouse model of CDI at Monash University (with four other
binaphthylpeptide derivatives, including lead compound 1).71 This initial trial attempted to
administer the compounds via the drinking water; unfortunately, the mice refused to drink
the adulterated water, which ruined the trial results (as the mice were not consuming enough
drug and they also became dehydrated and lost weight).
Two compounds were selected (including lead compound 2) and then subjected to a second
CDI mouse model trial wherein oral gavage was utilized for compound administration (via a
10% v/v DMSO/H2O vehicle). These preliminary trials saw a 60% survival rate (three out of
five mice) for lead compound 2 compared with a 100% survival rate for the control drug
(vancomycin).71 These results were promising but a new problem was observed; the other
tested compound was quite difficult to administer by oral gavage, as it precipitated and
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flocculated out of solution almost immediately upon dilution of the compound/DMSO stock
solution with water. Despite the initial promising results, it was decided to revisit the CDI
murine model after addressing this poor solubility issue (see Section 3.4.1).

3.3.3 – Secondary trial
Four of the synthesized compounds (68c-d, 77c and 87a – Figure 3.5) were selected
for a CDI mouse model trial due to their promising antibacterial activities against C. difficile
and their varying solubility profiles (see Section 3.4.1).

Figure 3.5 – Structures of the four compounds selected for testing in the murine model of
CDI. Their MIC values against C. difficile and their solubilities (relative to prototypical
compound 1) are displayed.
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Due to solubility issues and administration difficulties during previous trials, Andrew Tague
attended Monash University to ensure the complete solubilization, proper dilution and
administration of the drugs during the CDI murine model.
Unfortunately, none of the compounds fully protected the mice and all mice in the secondary
trial had to be culled by 42 h due to disease weight loss (see Figure 3.6). Twenty-four hours
after infection with C. difficile spores, only one of the four tested compounds (i.e. compound
77c) displayed signs that it was protecting the mice from disease. The mice that were given
compound 77c lost the least amount of weight by 24 h (Figure 3.7) and they also had the least
diarrhoea (as shown by the faecal consistency and cage appearance scores – see Figures 3.8
and 3.9). Furthermore, these mice looked physically healthier than the other three cohorts (as
shown by physiological appearance scores – see Figure 3.10). The mice that were given drug
77c (red line in Figure 3.6) exhibited an 80% (four out of five) survival rate until 42 h,
compared with a 40% survival rate in the DMSO control cage group (blue line) until 42 h.
Despite being the most active derivative against C. difficile in vitro, compound 87a appeared
to make the disease worse; these mice had to be culled by 24 h due to weight loss and disease
progression.
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Figure 3.6 – Kaplan-Meier survival curve for the in vivo CDI mouse trial. Compound 90
(orange) was made by a current PhD student (Muni Kumar Mahadari) who is continuing the
biarylpeptide research.

Figure 3.7 – Percentage weight loss for the various compound cohorts in the in vivo CDI
mouse model.
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Figure 3.8 – Faecal consistency scores for the various
compound cohorts in the in vivo CDI mouse model.

Score
0

Faecal Consistency
Normal stool: solid stool that is firm when subjected to pressure with forceps.
Mouse has no sign of soiling around the anus and passes the stool quickly and
easily.

1

Mildly soft stool: formed stools that appear moist on the outside and have a
slightly sticky consistency. Stools will easily submit to pressure applied with
forceps. Mouse has no sign of soiling around the anus, but passes faeces quickly
and easily.

2

Moderately soft stool: irregularly formed stools that do not hold a normal shape.
Stool appears very moist and is difficult to pick up with forceps. Mouse has some
signs of soiling around anus and takes a longer than normal time to pass the stool.

3

Diarrhoea: stool has no form and/or has a mucous-like liquid appearance with
minimal solid present. Considerable soiling around the anus and the fur around
tail. Mouse takes a long time to pass stool if at all.
Table 3.7 – Faecal consistency (stool) scoring system.
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Figure 3.9 – Cage condition scores for the various
compound cohorts in the in vivo CDI mouse model.

Score

Cage Condition (Diarrhoea)

0

Normal cage

1

Faeces stuck to the side of cage, but clean
nest and sawdust.

2

Mildly soiled nest.

3

Moderately soiled nest.

4

Severely soiled nest
Table 3.8 – Cage condition scoring system.
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Figure 3.10 – Physiological appearance scores for the
various compound cohorts in the in vivo CDI mouse
model.

Score

Physiological Appearance

0

Normal activity, alertness, breathing and movement/gait.

1

Mouse shows signs of reduced grooming with coat starting to appear
rough/scruffy with slight piloerection.

2

Mouse appears slightly hunched with mildly scruffy coat, but moves
when the cage is disturbed. Possible diminished alertness, squinted
eyes or lethargy.

3

Mouse has isolated itself from cage mates, displays hunched posture
and unkempt coat. Mouse does not move when cage is disrupted and
has little response to external environment or handling. Possible
laboured breathing or eye discharge.
Table 3.9 – Physiological appearance scoring system.
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Compound 77c displayed some promising activity, despite not completely protecting the
mice from disease as per the control drug (e.g. vancomycin exhibits a 100% survival rate
until trial completion). The compound (77c) obviously delayed the onset and severity of the
C. difficile infection, as measured by multiple physiological parameters. As predicted by their
measured solubility parameters, compounds 77c and 87a exhibited the least solubility during
the in vivo CDI mouse trial, rapidly precipitating out of solution after dilution of the DMSO
stock solution with water. The insoluble nature of compound 77c meant that the mice were
not receiving the full target dosage (i.e. 100 mg/kg); therefore, compound 77c will likely be
re-trialed with a different drug administration method (possibly in food). By administering
the drug in food to each mouse separately, we can ensure the mice will receive a full dose of
the drug.

3.4 – Pharmacology experiments
3.4.1 – Comparative solubility assay
Some of the previous binaphthylpeptide derivatives were mostly insoluble in the 10%
DMSO/H2O mixture used in the mouse model of CDI; therefore, a comparative solubility
assay was developed to ascertain the relative solubilities of the synthesized compounds.
Knowledge of their solubilities was helpful for selecting compounds that would work well in
the mouse model of CDI.
Lead compound 1 was used as the prototype molecule and all other compounds were
compared to this compound. The compound of interest (5.0 mg) was fully dissolved in
DMSO (50 μL) and then H2O aliquots (5 μL) were added with adequate manual agitation in
between additions. Addition of H2O was continued until a persistent turbidity and cloudiness
was apparent that did not fade after agitation. Compound 1 precipitated after the addition of
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15 μL H2O; compounds that required twice as much water (i.e. 30 μL) than compound 1 to
precipitate from solution are effectively two times more soluble than compound 1 (i.e.
solubility ratio = 2). This comparative solubility ratio was utilized to measure a compound’s
relative solubility and it thus allowed for comparison between multiple similar compounds.
The solubility assay was performed on a varied sample of the synthesized compounds to
ascertain which structural elements are beneficial for solubility (Table 3.10).

Solubility Assay Data
Compound

H2O ppt. vol
(µL)

1
2
64a
65c
66c
68b
68c
68d
69c
70a
73
76d
77c
80c
81d
83b
87a

15
45
>300 (NP)
65
20
35
60
45
30
30
15
>200 (NP)
30
30
55
15
15

Solubility Ratio
(Compound :
compound 1)
1
3
>20 (NP)
4.33
1.33
2.33
4
3
2
2
1
>13.3 (NP)
2
2
3.67
1
1

CLogP
7.47
5.76
4.97
4.26
6.61
3.89
4.07
4.6
4.07
6.24
3.02
5.81
3.77
4.07
4.60
6.94
5.82

Table 3.10 – Comparative solubility assay data and CLogP values for selected
compounds. NP = No precipitation observed.

See Tables B3.1 – B3.6 in Appendix B for a set of the solubility assay data with the
corresponding compound structures. The CLogP values for the tested compounds are also
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included in the solubility tables; unfortunately, no correlation between a compound’s CLogP
value and its measured solubility was observed.
As expected, the biphenyl derivatives were much more soluble than their corresponding
binaphthyl analogues – for example, the Series A1 biphenyl derivative 65c is over three times
more soluble than its binaphthyl analogue 66c (Table 3.10). This effect is further exemplified
by the binaphthyl derivative 83b from Series B2 – the corresponding biphenyl analogue 81d
is almost four times more soluble (Table 3.10). Compounds that contained a single lysine
amino acid side-chain were found to be substantially more soluble than the corresponding
arginine containing analogues. Both of the single lysine derivatives (compounds 64a and
76d) tested in the solubility assay were so soluble that they failed to precipitate during the
experiment. They were shown to be at least five to ten times more soluble than similar monoarginine derivatives (e.g. compounds 65c and 77c). Furthermore, changing the order of the
amino acid residues for dicationic derivatives did have an impact on solubility; for example,
compound 68c (Series A2 – Lys-Arg orientation) was two times more soluble than the
corresponding Arg-Lys isomer 69c – see Table 3.10. When this same swap in amino acid
order was performed in Series B2, the opposite result occurred; swapping a Lys-Arg
orientation for an Arg-Lys pattern resulted in an increase in solubility (see Table B3.5 in
Appendix B). Therefore, no one particular orientation of amino acid residues was always
found to give rise to more soluble compounds than another; this is likely because the
solubility was reliant on multiple complex factors (e.g. scaffold shape, internal hydrogen
bonding, solvent effects and conformation).
Additionally, the more flexible hydrocarbon termini (i.e. Cy and CH2Cy) were generally
found to be more soluble than the aromatic termini (Bn and PhEt) – as seen in Table 3.10;
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the more flexible hydrocarbon derivatives may be able to adopt more soluble conformations
than the aromatic derivatives. There was no observable difference in solubility between the
Series A and Series B peptide orientations. Both Series A and B derivatives were found to
exhibit a range of various solubilities; neither series was generally more soluble than the
other.
The solubility ratio data allowed for the selection of compounds for the in vivo mouse model
of CDI with varying solubilities; compounds with a range of solubilities (Figure 3.5 in
Section 3.3.3 and Table 3.11) were chosen so that the effect of solubility on the drug’s
administration, efficacy and pharmacokinetic parameters could be observed. There was a
direct correlation between a compound’s solubility ratio and the compound’s propensity to
precipitate during dilution with H2O (Table 3.11).

(Compound / Compound 1)

Solubility in DMSO/H2O
(9:1)

1

1

-

87a

1

Precipitated

77c

2

Precipitated

68d

3

Homogenous suspension

68c

4

Homogenous solution

Compound

Solubility Ratio

Table 3.11 – The selected compounds for the in vivo CDI mouse model are displayed
with their corresponding solubility ratio and observed solubility in 10% DMSO/H2O.

The compound with the worst solubility ratio (i.e. 87a) was also the compound that exhibited
the most precipitation and flocculation (making administration by oral gavage difficult); the
compound produced a thick precipitate that stuck to the sides of the vial after dilution with
H2O. Compound 68c (which had the largest solubility ratio) remained as a homogenous,
lightly opaque suspension for the entire 30 min prior to dosing. Compounds required a
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solubility ratio of three or greater to prevent immediate precipitation and flocculation of the
compound after dilution of the DMSO stock solution with H2O (Table 3.11).
There did not appear to be a correlation between solubility and compound efficacy in the in
vivo model; compound 77c was the second least soluble derivative but it displayed the best
efficacy of the compounds tested in the recent in vivo model. Mouse blood and faeces from
the recent in vivo CDI mouse model will be analyzed for the presence of drug (study yet to
be performed); by comparing this data to the solubility data, the optimum solubility to avoid
systemic absorption may be identified.

3.4.2 – Pharmacokinetics assay
Since CDI chemotherapeutics are required to stay in the GI tract to treat the infection,
systemic absorption of the antibiotic is not desirable. Therefore, pharmacokinetic analysis
was performed on the blood and faeces of mice that were infected with C. difficile and treated
with lead compound 2 in the preliminary CDI mouse model trials (see Section 3.3.2).
To ascertain the presence of compound 2 in the blood and faeces, an extraction/analysis
procedure employing LRMS was developed and utilized (see Section 6.4.3 for the
experimental methodology). The mouse blood was diluted with PBS and then extracted with
CH2Cl2 (× 2); the faeces was extracted with CH2Cl2 (× 1). Concentration of the extracts and
LRMS analysis of the residues revealed the presence of the drug (i.e. the doubly-protonated
molecular ion, m/2 = 421 = [M + 2H]2+) in the faeces; whereas no drug could be found in the
blood. To ensure the procedure was viable, mouse blood from an untreated cohort was doped
to achieve a final concentration of compound 2 equivalent to an average 25 g mouse
absorbing 1% of the total dose into its bloodstream – the drug was readily detected in the
doped mouse blood, verifying the validity of the extraction protocol.
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These findings confirm that compound 2 was not absorbed systemically into the bloodstream
by the mice; following oral administration, the drug clearly stayed in the GI tract (i.e. faeces),
as was intended.

3.4.3 – HPLC purity assay
To ensure high sample purity for the in vivo CDI murine model, selected compounds
68c-d, 77c and 87a (Figure 3.5, Section 3.3.3) were subjected to reverse-phase HPLC
analysis with H2O and acetonitrile (both with 0.1% v/v TFA) as the polar and non-polar
solvents, respectively. A gradient elution from 0:100  100:0 (acetonitrile/H2O) over 30 min
was employed and compounds typically eluted between 20 – 25 min. The resultant purities
for the four compounds are displayed in Table 3.12; all compounds were shown to be > 95%
pure by HPLC (detected at 215 nm). The HPLC traces for compounds 68c-d, 77c and 87a
can be found in Section B4 of Appendix B.

Compound

Purity by HPLC
(215 nm)

87a

98.3%

77c

99.9%

63c

99.0%

63d

97.3%

Table 3.12 – Purity of the compounds selected for the
in vivo CDI mouse model (as measured by HPLC).

132

4.0 – NMR spectroscopy analysis: regioselectivity, rotamers and
anomalies
4.1 – Background information
This chapter contains elaboration on the 1-D and 2-D NMR experiments that were
conducted to verify the molecular structures of the synthesized compounds through NMR
assignments and [1H – 1H] and [1H – 13C] correlations. During the characterization process,
numerous unexpected NMR spectroscopy results (i.e. anomalies) were observed. Due to the
volume of spectroscopic data and analysis required for NMR assignment, only the
challenging and novel aspects of complete 1H and

13

C NMR assignment confirmation and

the associated spectroscopic anomalies will be discussed. Protons and carbons will be notated
using the same assignment numbers that are given in the Experimental section (Section 6.0).
In particular, this chapter explores the 1,4-disubstitution regioselectivity of the 1,2,3-triazole
formation via CuAAC and the following anomalous NMR spectroscopy findings: synrotamers of amides/carbamates/guanidines, guanidine tautomerization, missing

13

C NMR

resonances (especially in the case of the 1,2,3-triazole-acid systems) and anomalous
resonances in the 13C and 2-D NMR spectra of alkynes 20 and 21.

4.2 - Triazole orientation: proof of 1,4-regioselectivity
The
1,2,3-triazole

regiochemistry
moieties

of

were

the

installed

unambiguously

established via analysis of the gHMBC spectrum of
compound 63a (Figure C1.3 in Appendix C). The
key observed [1H – 13C] correlations are depicted in
Figure 4.1. Importantly, the 1H NMR resonances

Figure 4.1 – Relevant portion of
compound 63a: significant gHMBC
correlations are shown that prove the
1,4-regiochemistry of the 1,2,3triazole moiety.
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assigned to H6A and H6B displayed 3-bond gHMBC correlations with the

13

C NMR

resonance assigned to C5 (Figure 4.1 – blue arrow) but not with the resonance assigned to
C4. This indicated the orientation of the C(4)=C(5) double bond, relative to the H6 proton
pair; the 1,4-regioisomer had been selectively formed. If the 1,5-regioisomer had been
produced, a correlation between the H6 diastereotopic proton pair and the quaternary triazole
carbon (C4) would have been observed. These findings were congruent with the gHMBC
correlations observed between the 1H NMR resonance at δ 5.17 (-OCH2-C4′)) and the

13

C

NMR resonances assigned to both triazole carbons (C4′ and C5′). This evidence conclusively
established the expected 1,4-regiochemistry of the 1,2,3-triazole ring.

4.3 – Rotamers
Single C–N bonds that are attached to an adjacent carbon–heteroatom double bond
(e.g. C=O or C=N) are known to exhibit partial double bond characteristic due to the
delocalization of the nitrogen’s lone pair of electrons; this leads to restricted rotation of the
C–N bond. If the energy barrier to rotation is high, two distinct rotameric conformations will
be generated (i.e. anti- and syn-rotamers – Figure 4.2), with the anti-rotamer generally being
preferred in secondary amides, carbamates, and guanidines due to steric considerations.78, 117

Figure 4.2 – a) Generic anti- and syn-rotamers b) anti- and syn-rotamers of the Boccarbamate on the lysine side chain

The existence of amide, carbamate and guanidine rotamers (i.e. anti and syn) was evident by
the presence of smaller, additional resonances in the 1H and 13C NMR spectra of various Nprotected scaffolds and derivatives. These resonances were observed as additional resonance
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“shoulders” or small satellite resonances. For example, compound 64c displayed some
anomalous 1H NMR resonance shouldering and 13C NMR resonance splitting (Figures C1.4
and C1.5 – Appendix C) due to the presence of anti and syn N-Cbz carbamate rotamers.
While an accurate rotamer ratio could not be inferred from this example, one rotamer was
most definitely dominant over the other (observed ratio ca. 9:1 – presumably anti : syn).

Figure 4.3 – Rotameric forms of compounds 64c (rotameric carbamate) and 76d
(rotameric amide): carbons assigned to 13C NMR resonances that exhibited splitting or
shouldering are marked with red dots (·) on the syn-rotamers.

The presence of syn-rotamers in compound 64c (Figure 4.3) was confirmed by utilizing
DMSO-d6 (known to disrupt hydrogen bonding117) and variable temperature (VT) NMR
experiments (to increase the rate of bond rotation); compound 64c was dissolved in DMSOd6 and subjected to 1H and

13

C NMR spectroscopic analysis at both rt and 90 °C. The

rotameric shoulder resonances present in the

13

C NMR spectrum of compound 64c (when

obtained in CD3OD – Figure 4.4 – top blue spectrum) were notably reduced when the
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spectrum was recorded in DMSO-d6 at rt (Figure 4.4, middle green spectrum) – the minor
syn-rotamer resonances became smaller, less apparent and they began to coalesce with the
major anti-rotamer resonances. When the temperature was raised to 90 °C, the syn-rotamer
resonances became virtually non-existent (Figure 4.4, bottom red spectrum).

Figure 4.4 – 13C/DEPT Q NMR spectra of compound 64c recorded in CD3OD at rt (blue), DMSOd6 at rt (green) and DMSO-d6 at 90 °C (red). Visible rotameric shoulder peaks are marked with a
red asterisk (*).

Reduction of the syn-rotamer resonances in the 13C NMR spectra of compound 64c is further
exemplified by Figure C1.6 in Appendix C; the use of DMSO-d6 and VT-NMR can be seen
to decrease and almost eliminate the resonances attributed to the syn-rotamer. The use of
hydrogen bond disruption by DMSO and increased temperature allowed for the positive
identification of rotameric entities in the spectra of compound 64c and various other
biarylpeptide derivatives. In another example, compound 76d was found to exhibit
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shouldering and splitting of resonances in the 1H and 13C NMR spectra due to anti- and synamide rotamers (Figures C1.7 and C1.8, Appendix C). The three carbons comprising and
adjacent to the terminal amide moiety (see Figure 4.3 – red dots) were assigned to resonances
at 170.1 (C=O), 65.0 (-CH-C=O) and 47.2 (-CH2Cy); these resonances all exhibited a
rotameric partner (i.e. the resonance was split into two resonances) due to the presence of a
stable syn-rotamer (Figure C1.8 in Appendix C).
In a few of the dicationic compounds, the appearance of rotameric resonances in the 1H and
13

C NMR spectra was exacerbated by the presence of multiple moieties (e.g. amides,

carbamates, guanidines and carboxylic acids) capable of forming or stabilizing rotameric
forms. For example, 1H NMR spectrum of scaffold acid 84 showed resonances for multiple
rotamers due to the stabilizing influence of a terminal carboxylic acid group117 – this moiety
served to stabilize the syn-rotamer forms of the various rotamer-capable functionalities that
were present in the molecule (i.e. amides, carbamates and guanidines). At least two different
forms of rotameric splitting were observed; resonances at δ 8.71 (amide NH) and 7.49
(triazole CH) in the 1H NMR spectra of compound 84 exhibited splitting due to anti- and synrotamers at a molar ratio of 54:46 (determined by 1H NMR integration) as seen in Figure
C1.9, Appendix C. This splitting pattern (primary rotameric splitting) was also observed in
the five resonances assigned to the N-Pbf protons (found between δ 3.00 – 1.40); they
appeared as apparent doublets in the 1H NMR spectrum of compound 84 (Figure C1.10 in
Appendix C). A secondary rotameric splitting of the resonances assigned to the N-Pbf protons
was also observed in the 1H NMR spectrum of compound 84; a molar ratio of 86:14 was
determined by 1H NMR integration for this secondary rotamer pattern. Interestingly, the
small secondary rotameric resonances also exhibited the primary splitting at the molar ratio
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of 54:46 (e.g. the secondary rotameric N-Pbf resonances appeared as small apparent doublets
– see Figure C1.10 in Appendix C). Furthermore, the 13C NMR spectrum of scaffold acid 84
displayed primary rotameric splitting for the majority of resonances observed with some
secondary rotameric splitting evident as well (Figures C1.11 and C1.12 in Appendix C).
DMSO-d6 and VT-NMR were utilized to disrupt the rotamer stabilization but the rotameric
resonances failed to disappear completely – resonances began to coalesce and move closer
together with DMSO-d6 and increased temperature, but rotamer-free 1H or 13C NMR spectra
were not obtained due the strong stabilizing effect of the carboxylic acid moiety. The
rotameric nature of compound 84 was proven by the resolution of split resonances in the 13C
NMR spectrum by the application of higher temperature; when compound 84 was placed in
DMSO-d6 and then heated to 90 °C, split resonances at approximately δ 157.5 (Pbf CAr),
153.5 (CAr2), and 18.5 (Pbf ArCH3) were found to coalesce into three individual resonances
(Figures C1.13 and C1.14 in Appendix C). Additionally, some of the secondary rotameric
resonances in the

13

C NMR spectrum of compound 84 were found to resolve and even

disappear after the utilization of DMSO-d6 and VT-NMR (Figure C1.13 in Appendix C).
Futhermore, the split resonance at δ 7.5 (triazole CH) in the 1H NMR spectrum of compound
84 was also found to change splitting pattern with the application of DMSO-d6 and VT-NMR
(Figure C1.15 in Appendix C). These spectroscopic experiments were able to show the
solvent and temperature dependence of the various 1H and 13C NMR resonances assigned to
the rotameric syn-conformers in the spectra of the biarylpeptide derivatives.
The stabilization of syn-amide and syn-carbamate rotamers by carboxylic acids is a well
understood phenomenon.117 Rotamer stabilization can occur through either inter- or
intra-molecular hydrogen bonding to any dual hydrogen bond donor-acceptor (e.g. a
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carboxylic acid, carbamate or guanidine – see Figure 4.5); the biarylpeptide derivatives
exhibit a predilection for such rotameric stabilization due to their flexible scaffold and
numerous heteroatoms capable of accepting and donating hydrogen bonds. The ability of a
molecule to simultaneously accept and donate hydrogen bonds has been shown to aid
stabilization of the normally non-existent syn-rotamer in carbamates.117-118 Therefore, the
possible hydrogen bonding arrangements (Figure 4.5) were studied and found to exhibit the
correct potential orientation for rotamer stabilization.

Figure 4.5 – Potential inter- or intra-molecular hydrogen
bonding arrangements between the different rotamers
(anti or syn) of the carbamate and guanidine groups.

In summary, the presence of syn-rotamers were evident in both the 1H and 13C NMR spectra
of various biarylpeptide derivatives. These anomalies were investigated by extensive NMR
experiments utilizing DMSO-d6 and VT-NMR. The results of these experiments indicated
the likely stabilization of syn-rotamers by hydrogen bonding.
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4.4 – Guanidine tautomerization
In the previous published

1

H NMR assignments

for N-Pbf

protected

binaphthylpeptides,63-67 the three guanidino protons were always assigned to a single broad
resonance around δ 6.50. Analysis of the 1H NMR spectra of N-Pbf protected biarylpeptide
derivatives found that although a single broad resonance for the guanidine protons (3H) was
sometimes observed, it often contained a ‘shoulder’ adjacent to the main peak. Furthermore,
depending on compound concentration (which affects the chemical shifts of exchangeable
nitrogen protons119) and/or the utilized NMR solvent, the ‘shoulder’ would resolve
completely, resulting in two distinct resonances (i.e. a 1H and 2H resonance – see Figure
C1.16 in Appendix C). Reports on the tautomerization of guanidine compounds revealed that
guanidine moieties are subject to different tautomeric forms depending on the attached
substituents.120 In the presence of a strongly electron-withdrawing substituent (e.g. a N-Pbf
group), disubstituted guanidines will tautomerize such that the double-bond is located on the
nitrogen to which the electron-withdrawing group is attached (Figure 4.6 – structure A).120

Figure 4.6 – (Left) Tautomerization of disubstituted guanidines: if R = electron withdrawing
group, then tautomer A is preferred.120 (Right) Potential E and Z isomers of the guanidine
double bond.

The electronic preference for structure A (Figure 4.6 – left) readily explains the observed 2:1
split seen in the resonances assigned to the guanidino protons. The two resonances are often
degenerate, hence the previous published assignments as a single resonance. Additionally,
the presence of the N-Pbf imine allowed for the possibility of two isomers (E or Z) as seen in
Figure 4.6 (right); it is currently unknown whether the compound exists as one isomer or a
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mixture. Steric considerations dictate that the E-isomer would be energetically favoured, but
there is yet no experimental evidence to support this statement.

4.5 – Missing 13C NMR resonances
4.5.1 – Resonances assigned to the 1,2,3 triazole carbons
Previous research59, 69 has shown that the final mono- or dihydrochloride salt products
do not give adequate NMR spectra (i.e. broad resonances are observed) when CDCl3 is used
as the solvent; therefore, the final hydrochloride salts were dissolved in CD3OD for NMR
spectroscopic analysis. Unfortunately, a large number of the synthesized biaryltriazole
derivatives exhibited anomalous or missing

13

C NMR resonances for the 1,2,3-triazole

carbons. Many quaternary triazole carbons were not observed in the 13C NMR spectrum and
their presence could only be ascertained by positive gHMBC correlations. The methine
triazole carbons were also occasionally afflicted, exhibiting a weak, broad resonance or no
observable resonance at all; gHSQC and gHMBC correlations were utilized to detect the
presence of the methine triazole carbons.
For example, bis-triazole 68a failed to display resonances in the

13

C NMR spectrum that

could be assigned to any of the four triazole carbons (both quaternary and methine) – see
Figure C1.17 in Appendix C. A resonance at δ 7.86 (2H) was assigned as the two degenerate
triazole proton resonances (H5′ and Hα in Figure 4.8); this resonance exhibited gHSQC
correlations with two missing 13C NMR resonances at δ 126.4 (C5′) and 124.5 (Cα) – these
correlations allowed for assignment of the triazole methine carbons (Figure C1.18 in
Appendix C). 1H NMR resonances at δ 5.11 (-OCH2-C4') and 4.07 (-CH2Ph) were assigned
to the two pairs of methylene protons directly attached to the quaternary triazole carbons.
gHMBC correlations were observed between these methylene resonances at δ 5.11 and 4.07
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and the other two missing 13C NMR resonances at δ 145.7 (C4′) and 148.4 (Cβ), respectively;
these correlations allowed for the positive identification of the quaternary triazole carbons
(Figure C1.19 in Appendix C). The different gHMBC correlations that allowed for the
identification and assignment of the missing 13C NMR triazole resonances are displayed on
compounds 68a and 68b in Figure 4.8.

Figure 4.8 - Structures of compounds 68a, 68b and 64c: carbons that could not be assigned
to a visible 13C NMR resonance are marked with red dots (·). The key gHMBC correlations
that allowed for assignment are displayed with blue arrows. 2-D NMR spectroscopy could
not be utilized to assign the triazole carbons in compound 64c and DMSO-d6 was ultimately
required.

In another example, bis-triazole compound 68b failed to display any resonances in the 13C
NMR spectrum that could be assigned to the two quaternary triazole carbons. Resonances at
δ 7.94 and 7.88 in the 1H NMR spectrum of compound 68b were assigned to the two triazole
protons (H5′ and Hα); these resonances displayed gHMBC correlations (Figure C1.20 in
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Appendix C) with the two missing 13C NMR resonances at δ 147.2 (Cβ) and 145.6 (C4′) –
this evidence allowed for the positive assignment of the two quaternary triazole carbons,
despite the lack of visible resonances in the 13C NMR spectrum. Notably, the two methine
triazole carbons were positively assigned to two weak, broadened resonances at δ 126.3 (C5′)
and 125.0 (Cα) in the

13

C NMR spectrum; these assignments were confirmed by gHSQC

correlations with the appropriate 1H NMR resonances (Figure C1.21 in Appendix C).
In some derivatives lacking the appropriate

13

C NMR triazole resonances, prolonged

gHMBC experiments (> 1 h) were not sufficient to detect the desired heterocorrelations. For
example, N-Cbz analogue 64c failed to exhibit 13C NMR resonances that could be assigned
to either of the triazole carbons (Figure 4.8). Furthermore, no gHMBC or gHSQC
correlations could be observed that allowed for the assignment of these triazole carbons; the
resonances for these carbons could not be observed when the spectrum was acquired in
CD3OD. When compound 64c was subjected to

13

C NMR experiments in DMSO-d6, the

triazole carbons were easily assigned to resonances that appeared in the expected regions.
Figure C1.22 in Appendix C shows how the two distinct 13C NMR resonances assigned to
the triazole carbons were not present in the spectrum acquired in CD3OD, but they can be
clearly seen in the spectrum acquired in DMSO-d6. The use of DMSO-d6 as an NMR solvent
obviated the need for extensive 2-D NMR experiments to determine triazole carbon
assignments. Compounds 64c, 65c and 66a all required the use of DMSO-d6 as a solvent for
complete 13C NMR characterization due to missing resonances in other solvents.
It is proposed that hydrogen bonding between the triazole moieties and other capable
functionalities was the primary cause of the observed lack of key NMR resonances; for more
information regarding this phenomenon, see Section 4.6.
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4.5.2 – Trifluoromethyl (CF3) derivatives
Two final Series B1 derivatives (compounds 76e and 77e) contained a terminal
4-CF3-benzylamide moiety; in both molecules, the strong JCF coupling (caused by the -CF3
substituent) obscured the

13

C NMR resonances attributed to the ipso aromatic carbon and

the -CF3 carbon itself. In the 13C NMR spectrum of compound 76e, the two expected quartet
resonances (assigned as the carbons closest to the fluorine atoms, i.e. -CF3 and C-CF3) were
each missing one of the outer quartet peaks. The strong JCF coupling spread the weak
quaternary 13C NMR resonances over multiple lines (as quartets); thus, the resonance became
even weaker and buried amongst the background noise. Furthermore, quaternary carbons do
not experience the large Overhauser enhancement by proton decoupling that is experienced
by protonated carbons, so they exhibit a notably weaker 13C NMR resonance.119
Furthermore, the related and expected 13C NMR quartet resonances (assigned to the -CF3 and
C-CF3 carbons) in the spectrum of compound 77e could not be observed at all; the already
weak quaternary carbon resonances were distributed across a quartet resonance by the strong
JCF coupling – this created extremely weak resonances that were buried amongst the
background noise. The presence of these two carbons could not be inferred from relevant 2-D
NMR correlations because the quartet splitting and lack of Overhauser enhancement by
proton decoupling resulted in correlations that were diffuse and non-observable. The
presence of the attached trifluoromethyl moiety was clear from MS analysis and was inferred
from the other observed aromatic resonances which displayed distinct JCF coupling constants,
multiplicity patterns and chemical shifts.
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4.6 – Weak and non-observable NMR resonances in the 1,2,3-triazole-acid
system
The triazole acid scaffolds synthesized for Series B1 (i.e. compounds 75a-d)
exhibited a lack of expected NMR resonances normally assigned to the triazole ring and the
adjacent methine and carboxylic acid functionalities (Figure 4.9). The 1H and

13

C NMR

resonances associated with these moieties were observed as broad, weak resonances or not
observed when the spectra were acquired in CDCl3 or CD3OD. The effect was most
prominent in the

13

C NMR spectra, although some molecules exhibited anomalous

resonances in the 1H NMR spectra as well.

Figure 4.9 – General structure of scaffolds that
exhibited weak or non-observable NMR
resonances: the affected carbons and protons are
marked with red (· or H).

For example, compound 75a failed to exhibit 13C NMR resonances that could be assigned to
the affected carbons (red dots in Figure 4.9) when the spectrum was acquired in CD3OD. The
utilization of DMSO-d6 and/or 2-D NMR was required for observation of these carbon
resonances; when DMSO-d6 was employed, three resonances appeared in the

13

C NMR

spectrum of compound 75a that were assigned to both triazole carbons (C4′ and C5′) and the
carboxyl carbon (C1) (Figure C1.23 in Appendix C). The methine carbon (C2) could not be
assigned to a resonance in the 13C NMR spectrum of compound 75a; however, the gHSQC
spectrum (acquired in DMSO-d6) displayed a correlation with a broad 1H NMR resonance
assigned as the methine proton (H2) – this allowed for assignment of the methine carbon
145

(C2). Interestingly, the downfield resonances assigned to the triazole proton (H5′) and
methine proton (H2) were substantially broad when the spectrum was acquired in CD3OD;
swapping the solvent to DMSO-d6 resulted in a sharper resonance that was assigned to the
triazole proton (Figure C1.24 in Appendix C).
Additionally, compounds 75b-d exhibited a similar lack of characteristic NMR resonances
for the same moieties as compound 75a (Figure 4.10); a combination of DMSO-d6 and 2-D
NMR spectroscopy was required for assignment of the missing carbon resonances in these
compounds.

Figure 4.10 – Weak and non-observable NMR resonance assignments for compounds 75a-d.
Carbons that are marked with red (·) could not be assigned to a 13C or 2-D NMR resonance.
Carbons that are marked with blue (·) required DMSO-d6 and/or 2-D NMR for assignment.
Protons that are marked with blue (H) exhibited significant NMR resonance broadening.

For the binaphthyl analogues (75b and 75d), the carboxyl (C1) and methine (C2) carbons
could not be assigned to any resonances in the 13C NMR spectra of these compounds, despite
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the use of DMSO-d6. Furthermore, these carbons could not be assigned via 2-D NMR
correlations either.
The weak and non-observable NMR resonances assigned to the triazole-acid systems display
parallels with the missing triazole

13

C NMR resonances (Section 4.5.1); both anomalies

occurred most prominently in the hydrogen bonding solvent CD3OD and the use of DMSOd6 ameliorated or eliminated any observed NMR deactivation phenomena. Therefore, it is
proposed that the NMR effects were a result of hydrogen bonding involving the triazole
moieties. In the case of missing resonances in simple 1,2,3-triazole systems (i.e. Section
4.5.1), it is likely that the triazole rings were hydrogen bonding to the solvent (or inter-/intramolecularly with other hydrogen bonding moieties, e.g. amines or guanidines); this bonding
resulted in electronic disturbances that influenced the magnetic spin relaxation of the triazole
carbons (resulting in weak or non-observable resonances). In the case of the triazole-acid
scaffolds 75a-d, it is theorized that the carboxylic acid was intra-molecularly hydrogen
bonding with the triazole moiety (Figure 4.11); this cyclic bonding would also likely result
in electronic disturbances that could affect the NMR resonances of the triazole carbons (C4′
and C5′) and the adjacent carbons (C1 and C2). This proposed intramolecular hydrogen
bonding could explain the weak and non-observable NMR resonances for scaffolds 75a-d.
The increase in weak/non-observable NMR resonances observed for the binaphthyl
analogues 75c and 75d could be due to the binaphthyl group having a more extreme
electronic effect on the triazole ring than the biphenyl ring system; this could allow for
increased hydrogen bonding between the triazole and the carboxylic acid moieties – allowing
for the observed increase in weak/non-observable NMR resonances (relative to the biphenyl
analogues 75a and 75b).
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Figure 4.11 – Potential intramolecular hydrogen
bonding (----) between the 1,2,3-triazole and the
adjacent carboxylic acid moiety.

4.7 – Anomalous gHSQC correlations for alkynes
Precursor alkynes 20 and 21 both displayed anomalous DEPT Q resonances and
gHSQC correlations that were assigned to the two alkyne carbons. For alkyne 21, the DEPT
Q 13C NMR resonance and the gHSQC correlation assigned to the methine carbon (-C≡C-H)
both exhibited polarities that corresponded to a methylene (CH2) or quaternary carbon
(Figure C1.25 in Appendix C). This unexpected anomalous occurrence was a result of the
defined DEPT Q one-bond [1H – 13C] coupling constant frequency (usually set at 145 Hz).119
Since the methine alkyne carbon exhibited a non-traditional one-bond [1H –

13

C] coupling

constant (approximately 250 Hz),119 the parameter values utilized for determining carbon
saturation (i.e. the number of C–H bonds) did not apply in this unique case. Furthermore,
quaternary alkyne carbons (-C≡C-H) exhibit a two-bond [1H –

13

C] coupling constant

frequency around 50 Hz; this was sufficiently large to show as a weak correlation in the
gHSQC spectrum (Figure C1.25 in Appendix C) but substantially different from the 145 Hz
(leading to anomalous resonance/correlation polarities in the DEPT Q and gHSQC spectra).
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5.0 – Conclusions and future directions
A diverse set of 62 novel antibacterial biaryl-peptidomimetic derivatives were
designed and synthesized as part of an ongoing project into the development of novel
antibiotic drugs and C. difficile chemotherapeutics. This array of compounds was realized
through derivatization of 17 novel scaffolds via the installation of various hydrophobic
termini. The scaffolds were achieved through implementation of a novel, modular multi-step
synthesis that utilized 11 key building block precursors. The modular approach allowed for
easy diversification and manipulation of the target scaffolds based upon the resultant SAR
data.
The targeted compounds were designed to incorporate additional peptidomimetic 1,2,3triazole moieties into the peptide backbone of the lead binaphthylpeptide compounds 2 and
6; this potentially allowed for increased metabolic resistance to the peptidases and acidic
conditions found in the GI tract, which is ideal for a CDI chemotherapeutic. Additionally, the
binaphthyl aromatic core was replaced with a biphenyl core to attain increased solubility and
antibacterial activity. Following synthesis and spectroscopic characterization, the compounds
were subjected to antimicrobial and toxicity assays to screen for potential lead or hit
compounds. The results of these assays were used to explore the SAR trends of the
compounds and thus, to identify pharmacophore elements or other vital structural
components necessary for both C. difficile antibacterial activity as well as broad-spectrum
antibacterial activity.
All of the synthesized compounds exhibited some level of antibacterial activity; the least
potent MIC value observed against S. aureus was 16 μg/mL, with the majority of compounds
having MIC values ranging from 2 – 8 μg/mL. There was a general reduction in the
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antibacterial efficacy (2 – 4 times less active) that was observed amongst the monocationic
derivatives, relative to the dicationic compounds; this result was in agreement with previous
findings.59, 69 Despite this finding, the simple monocationic compound 77c (Figure 5.1) was
identified as having strong Gram-positive antibacterial potency, especially against C.
difficile. Interestingly, the biphenyl bis-triazole derivatives (e.g. compound 80b) were the
only compounds that exhibited substantial broad-spectrum antibacterial activity against both
Gram-positive and Gram-negative bacteria.

Figure 5.1 – Development of potential hit compounds 80b and 77c from lead compound 2.
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The biphenyl bis-triazole compound 80b exhibited the strongest broad-spectrum antibacterial
efficacy, but it did not exhibit strong activity against C. difficile – these two spectrums of
action were not mutually inclusive. The addition of a biphenyl aromatic moiety led to
increased compound solubility which often translated to a decrease in Gram-positive
antibacterial activity, but an increase in antibacterial efficacy against Gram-negative bacteria.
This increase in solubility and decrease in molecular size may allow the drugs to permeate
the extra external membrane exhibited by Gram-negative bacteria.
As seen in Figure 5.1, the pursuit of novel antibacterial molecules from compound 2 led to
the development of two distinct structural scaffolds (i.e. 80b and 77c) that both exhibited an
increase in desirable traits for an antibacterial chemotherapeutic. Compound 80b exhibited a
notable increase in the overall Gram-negative antibacterial efficacy; this could allow the
biarylpeptides to be investigated for use in the treatment of Gram-negative bacterial
infections. Furthermore, compound 77c exhibited an increase in selectivity for C. difficile;
the molecule was also structurally simple and therefore, easier to synthesize.
Four compounds (68b, 68d, 77c and 87a) were selected as potential hit compounds based
upon their in vitro activities against C. difficile; they were synthesized on larger scale and
used in an in vivo CDI mouse model at Monash University. Compound 77c was identified as
the best performer in the in vivo CDI mouse model; both mouse weight loss and disease
progression were significantly slowed by compound 77c during the administration of the
trial. Compound 77c has been selected for testing in a further in vivo CDI mouse model.
Compound 77c exhibited selectivity for Gram-positive bacteria – it was inactive against all
of the Gram-negative bacteria that were tested. This selectivity could be reason for the drug’s
positive performance in the CDI mouse model; by not eliminating the commensal, Gram151

negative Bacteroides spp. and E. coli, compound 77c was likely quite effective at selectively
killing C. difficile without destroying the entire enteric microflora. The monocationic
compound 77c is a structurally simple molecule; large scale synthesis would be very cost
effective, relative to the more complex CDI treatments available (e.g. vancomycin or
fidaxomicin). If successful in further trials, the potential hit compound 77c will be studied
and possibly developed as a potential CDI chemotherapeutic. Larger cohort (i.e. sample)
sizes are needed to confirm the observed in vivo CDI model results; a cohort size of five mice
is indicative, but not conclusive. Larger sample sizes are needed to be statistically confident
in the in vivo CDI model results; unfortunately, the administration of large in vivo CDI model
is extremely labour intensive and costly, so more preliminary in vivo work needs to be done
before such a trial could be conducted.
Furthermore, associated pharmacokinetic studies were performed as part of the in vivo CDI
mouse model; the results confirmed the lack of systemic drug absorption by the mice, as was
intended. A solubility assay was also developed and performed on selected compounds to
ascertain the role of solubility in the efficacy and administration of the biarylpeptide
derivatives. Future pharmacokinetic analysis will be performed on the recently tested
derivatives (68c-d, 77c, and 87a) – i.e. blood and faeces analysis; the relationship between a
compound’s solubility and its systemic absorption will be investigated.
Numerous anomalies were observed during the analysis of the 1H and 13C NMR spectra of
the various biarylpeptide derivatives (e.g. rotamers and some unique NMR properties); these
anomalies were investigated in depth so as to ensure the correct characterization (and
therefore structures and purities) of the compounds being synthesized. HPLC analysis was
also utilized to further ensure compound purity and the lack of any diastereomer formation.
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Further experiments are planned that will determine the mechanism of action for the
biarylpeptide antibiotics; membrane depolarization assays utilizing permeable and nonpermeable fluorescent dyes will be conducted at Monash University to ascertain whether the
molecules exhibit bacterial membrane disruption as their mode of action. Determination of
the mechanism of the action will allow for a more complete understanding of the antibiotic
properties of the biarylpeptides; such knowledge could allow for mechanism-based
molecular design. The lack of a formal target is a current limitation in regard to the molecular
design. Future drug design and development will likely involve two target streams. One
stream will focus on optimizing compound 77c and other compounds that exhibit selectivity
for Gram-positive bacteria, in hopes of achieving a novel CDI chemotherapeutic. The other
research stream will likely focus on increasing compound solubility and Gram-negative
antibacterial efficacy – this avenue will be pursued because there is a large, unmet medical
need for novel medications that work against drug-resistant Gram-negative bacteria.5, 13
In summation, a total of 62 novel antibacterial compounds were synthesized and fully
characterized as part of this project. The synthesis of these derivatives involved the synthesis
of 104 compounds in total, i.e. 88 novel compounds and 16 known compounds A modular
synthetic route to various novel biarylpeptide scaffolds was realized and the resultant
synthetic derivatives represent a potential new direction for developing novel antibiotics for
the treatment of CDI and other bacterial infections. The compounds synthesized and
identified in this project are the subject of ongoing studies into the development of a novel
CDI treatment. Therefore, the current and future chemical and biological research focused
on these biarylpeptide derivatives will aim towards the advancement of an effective and
potent CDI chemotherapeutic.
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6.0 – Experimental
6.1 – General information
Synthesis
Unless stated otherwise, all solvents and chemicals were laboratory or reagent grade
and were purchased from commercial sources. All chemicals were used as received. Water
was purified via Millipore filtration prior to use. HOBt and propargyl bromide were
purchased with added stabilizers (10% w/w H2O and 20% w/w toluene, respectively);
therefore, the quantities required for reactions were adjusted accordingly and are reflected in
the reagent masses reported in the experimental (whereas the reported mmol quantities reflect
the true quantity of chemical). All reactions were conducted under normal atmosphere and
cold reaction temperatures were obtained by an ice bath (0 ºC) or ice/salt bath (–10 ºC).
Heating of reactions was performed with a paraffin oil bath. Small quantities of liquid
reagents were measured and added to reactions via syringe or autopipette. Unless otherwise
noted, all filtrations were conducted as vacuum filtration through a sintered glass funnel
(medium porosity). Vacuum filtration was achieved with the aid of a water aspirator. Solvent
removal via concentration was performed on a rotary evaporator under reduced pressure. All
solvent mixtures are expressed in terms of volume ratio (i.e. v/v). Thin layer chromatography
(TLC) was performed on aluminium-backed SiO2 gel plates (F254 grade - 0.20 mm thickness).
Visualization was achieved with UV light, ninhydrin stain or cerium ammonium molybdate
stain. Flash chromatography was performed on SiO2 gel 60 with a positive air pressure. All
synthesized compounds were dried under high vacuum (< 1 mbar) before determination of
chemical yields and spectroscopic characterization.
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Characterization and analysis
All novel precursors, scaffold intermediates and scaffolds were subjected to full
spectroscopic characterization and assignment. All final derivatives were subjected to full
spectroscopic characterization, but due to the sheer number of final scaffold derivatives, only
one example derivative from each scaffold type was fully assigned. 1H NMR spectra were
recorded on a Bruker Avance 400 (400 MHz), a Varian VNMRS PS54 500 (500 MHz), a
Varian Inova 500 (500 MHz) or a Varian Mercury 300 (300 MHz) NMR spectrometer.
Chemical shifts are reported in ppm and were measured relative to the internal standard.
Samples were dissolved in CDCl3 (with TMS as the internal standard – 0.00 ppm), CD3OD
(solvent resonance as internal standard – 3.31 ppm) or DMSO-d6 (solvent resonance as
internal standard – 2.50 ppm). The 1H NMR data is reported as follows: chemical shift,
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, dt = doublet of triplets, m =
multiplet, br = broad), coupling constants (Hz) and integration.

13

C NMR spectra were

recorded on a Bruker Avance 400 (101 MHz), a Varian VNMRS PS54 500 (126 MHz), a
Varian Inova 500 (126 MHz) or a Varian Mercury 300 (75 MHz) NMR spectrometer with
complete 1H decoupling. Chemical shifts are reported in ppm and were measured relative to
the internal standard. Samples were dissolved in CDCl3 (solvent resonance as the internal
standard – 77.16 ppm), CD3OD (solvent resonance as the internal standard – 49.20 ppm) or
DMSO-d6 (solvent resonance as internal standard – 39.50 ppm). Variable temperature NMR
experiments were performed at 90 C on the Bruker Avance 400 NMR spectrometer. 1H and
13

C NMR signal assignments were confirmed by analysis of NMR experiments: APT,

gCOSY, gHSQC, gHMBC, zTOCSY, NOESY and/or gHSQC-TOCSY. The abbreviations
section defines all NMR experiment acronyms. Ambiguous degenerate carbon resonances
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are marked with a single asterisk * (representing two carbons) or a double asterisk **
(representing three or more carbons) for clarity. Carbon resonances that required 2-D NMR
analysis for assignment (i.e. not observed via 1-D 13C NMR analysis) are marked with the
label “observed by gHMBC” or “observed by gHSQC”. Compounds that exhibited nonobservable carbon resonances in both 1-D and 2-D NMR analysis are denoted and explained
with footnotes. Unassigned aromatic hydrogens are labelled as “ArH”, whereas
specific/assigned aromatic hydrogens are labelled with the normal nomenclature (i.e. HAr3
= hydrogen atom attached to aromatic carbon #3). NMR spectra were processed, analysed
and prepared with MestReNova (version 6.0) NMR software. Low resolution mass spectra
(LRMS) were obtained via electrospray ionization (ESI) on a Shimadzu LC-2010 mass
spectrometer. LRMS data was recorded as the ion mass/charge ratio (m/z) with the
corresponding relative abundance as a percentage. High resolution mass spectrometry
(HRMS) was performed on a Waters Quadrupole-Time of Flight (QTOF) Xevo spectrometer
via ESI and with Leucine-Enkephalin as an internal standard. All mass spectrometry samples
were dissolved in high performance liquid chromatography (HPLC) grade MeOH
(containing <1% formic acid for ionization). Optical rotations were measured on a Jasco
P-2000 polarimeter with a 10 cm path length; rotation values (α) are expressed in units of
“deg cm3 g-1 dm-1” with concentration (c) expressed in units of “g/100 mL”. Solid-state
infrared spectroscopy was performed on a Shimadzu IRAffinity-1 FTIR spectrometer in
combination with a MIRacle 10 Single Reflection Attenuated Total Reflectance accessory
outfitted with a 1.5 mm round diamond crystal. IR peaks are reported as the wavenumber
(ν̄max in cm-1) of the maximum absorption.
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Notes and other considerations
All known compounds are marked with a reference after the compound title; all
compounds without a reference are novel. Unless otherwise noted, all rotameric NMR data
was expressed with relevant footnotes for clarity. Synthesized compounds that contain the
(S)-isopentyloxybinaphthalene fragment and some chiral compounds that contain the
isopentyloxybiphenyl fragment exhibit a pair of diastereotopic methyl (-CH3) groups on the
terminus of the isopentyl substituent; these carbons are consistently referred to as C4 and
C5. Importantly, these two carbons (and associated protons) will sometimes exhibit distinct
chemical shifts due to the chiral environment imposed by the amino acid residue(s) (for all
derivatives) and/or the adjacent (S)-BINOL moiety (for binaphthyl derivatives only).

6.2 – General synthetic procedures
General Procedure A: Copper catalyzed azide-alkyne cycloaddition
To a reaction vessel charged with the azide (1.0 eq), alkyne (2.0 – 3.0 eq),
Cu(OAc)2∙H2O (0.2 eq), and sodium ascorbate (0.4 eq) was added t-BuOH (20 mL/mmol
azide) and H2O (5 mL/mmol azide). The mixture was initially sonicated for < 1 min followed
by vigorous stirring at rt (unless noted otherwise) for the specified time. The reaction mixture
was diluted with EtOAc (20 mL for reactions that contained ≤ 1.0 mmol azide or 20
mL/mmol azide for larger scale reactions) and washed with an equivalent volume of saturated
aqueous NH4Cl solution (e.g. 20 mL). The organic phase was dried (MgSO4), filtered,
concentrated and the residue was subjected to flash chromatography over SiO2 gel to afford
the desired 1,4-disubstituted 1,2,3-triazole product.
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General Procedure B: Amide coupling
The amine (1.0 eq), carboxylic acid (1.0 eq), EDCI (1.2 eq) and HOBt (1.1 eq) were
combined in an acetonitrile solution (10 mL/mmol amine) and stirred at rt for the specified
time. The solvent was removed (not required for ≤ 5.0 mL acetonitrile) and the residue was
dissolved in EtOAc (25 mL for reactions that contained ≤ 1.0 mmol amine or 25 mL/mmol
amine for larger scale reactions). The organic solution was washed successively with aqueous
HCl (1.0 M – 2 × 25 mL), saturated aqueous NaHCO3 (3 × 25 mL) and brine (1 × 25 mL).
The EtOAc solution was dried (MgSO4), filtered and concentrated. If necessary, the residue
was subjected to further purification via flash chromatography over SiO2 gel to furnish the
targeted amide product.

General Procedure C: Amine deprotection (N-Boc and/or N-Pbf removal)
The N-protected amine (1.0 eq) was dissolved in a CH2Cl2 (30 mL/mmol substrate)
with magnetic stirring. If the substrate molecule contained an N-Pbf moiety then H2O (20.0
eq) was also added to the solution. TFA (30.0 mL/mmol substrate) was then added and the
reaction mixture was stirred at rt overnight (> 16 h) followed by removal of the solvent. The
residue was dissolved in CH2Cl2 (30 mL/mmol substrate), an excess amount of anhydrous
HCl (2.0 M in Et2O, 15 mL/mmol substrate, 30.0 eq) was added and the solvent was then
removed. The resulting residue was dissolved in a minimal volume of CH2Cl2 (or MeOH)
and excess Et2O (25 mL for ≤ 0.1 mmol substrate) was added to precipitate the hydrochloride
salt of the amine. The solvent was removed by filtration and the product (both in the filter
funnel and in the flask) was triturated with Et2O (3 × 20 mL). The product was collected by
dissolution in MeOH; concentration followed by drying in vacuo gave the final mono- or
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di-hydrochloride salt as a thin, translucent film that was routinely scratched with a spatula
into a fine hygroscopic powder or amorphous gum.

General Procedure D: Modified amine deprotection (N-Boc removal)
For the monocationic lysine derivatives, General Procedure C was followed with
the following modifications: Et2O (instead of CH2Cl2 or MeOH) was utilized to dissolve the
residue for final precipitation and petroleum spirits (P.S. – instead of Et2O) was utilized as
the antisolvent for precipitation.

6.3 – Synthesis
6.3.1 – Precursor Building Blocks
Aromatic Cores
(S)-2-(Isopentyloxy)-[1,1-binaphthalen]-2-ol (46)63
1-Bromo-3-methylbutane (264 mg, 1.75 mmol) was added
dropwise to a stirred solution of (S)-[1,1-binaphthalene]-2,2diol (45) (500 mg, 1.75 mmol) and K2CO3 (1.00 g, 7.27 mmol)
in acetone (10 mL). The reaction mixture was heated at reflux for 24 h, cooled to rt and
filtered. The solid residue was rinsed with acetone (2 × 20 mL), the combined filtrates were
concentrated and the resultant residue was subjected to flash chromatography over SiO2 gel
(EtOAc/P.S. – 10:90) to give compound 46 (508 mg, 81%) as a translucent, yellow oil. The
spectroscopic data was found to be in agreement with those previously reported.63 TLC
(EtOAc/P.S. – 10:90): Rf = 0.34; 1H NMR (300 MHz, CDCl3) δ 7.80 – 8.01 (m, 4H, H4, H4,
H5, and H5), 7.01 – 7.44 (m, 8H, H3, H3, H6, H6, H7, H7, H8, and H8), 4.96 (br s,
1H, -OH), 3.92 – 4.05 (m, 2H, H1), 1.21 – 1.37 (m, 3H, H2 and H3), 0.65 (d, J = 5.6 Hz,
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3H, H4 or H5), 0.61 (d, J = 5.6 Hz, 3H, H5 or H4); 13C NMR (75 MHz, CDCl3) δ 155.8
(C2), 151.5 (C2), 134.3 (C8a), 134.0 (C8a), 131.0 (C4), 129.8 (C4), 129.7 (C4a), 129.3
(C4a), 128.3 (C5), 128.2 (C5), 127.4 (C7), 126.4 (C7), 125.3 (C8), 125.2 (C8), 124.4 (C6),
123.4 (C6), 117.6 (C3), 116.5 (C1), 115.8 (C3′), 115.4 (C1), 68.4 (C1), 38.1 (C2), 24.9
(C3), 22.54 (C4 or C5), 22.48 (C5 or C4); MS (ESI +ve) m/z 413 ([M + HCOOH +
H]+, 100%), 357 ([M+H]+, 58%).

(S)-2-(Isopentyloxy)-2-(propargyloxy)-1,1-binaphthalene (20)
Propargyl bromide (80% w/w in toluene – 750 mg, 6.31 mmol)
was added dropwise to a stirred solution of 46 (1.50 g, 4.21
mmol) and K2CO3 (1.17 g, 8.40 mmol) in acetonitrile (30 mL).
The mixture was heated at reflux for 40 h, cooled to rt and
filtered. The solid residue was washed with acetonitrile (2 × 50 mL), the filtrate was
concentrated and the resulting residue was subjected to flash chromatography over SiO2 gel
(EtOAc/P.S. – 10:90) to give alkyne 20 (1.65 g, 99%) as a translucent, yellow oil. TLC
23

(EtOAc/P.S. – 10:90): Rf = 0.62; [α] D –25.7 (c 3.06, MeOH); 1H NMR (500 MHz, CDCl3)
δ 7.91 – 7.98 (m, 2H, H4 and H4), 7.83 – 7.88 (m, 2H, H5 and H5), 7.56 (d, J = 9.0 Hz,
1H, H3), 7.42 (d, J = 9.0 Hz, 1H, H3), 7.28 – 7.35 (m, 2H, H6 and H6), 7.17 – 7.23 (m, 2H,
H7 and H7), 7.15 (d, J = 8.5 Hz, 1H, H8), 7.12 (d, J = 8.5 Hz, 1H, H8), 4.54 and 4.58 (ABq,
2H, J = 8.5 Hz, -CHAHB-CC-), 4.01 (dt, J = 9.4, 6.1 Hz, 1H, H1A or H1′′B), 3.91 (dt, J =
9.4, 6.1 Hz, 1H, H1B or H1A), 2.37 (s, 1H, -CCH), 1.22 – 1.36 (m, 3H, H2 and H3),
0.63 (d, J = 5.7 Hz, 3H, H4 or H5), 0.58 (d, J = 5.7 Hz, 3H, H5 or H4); 13C NMR (126
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MHz; CDCl3) δ 154.8 (C2), 153.4 (C2), 134.3 (C8a), 134.2 (C8a), 130.0 (C4a), 129.6 (C4),
129.4 (C4a), 129.2 (C4), 128.1 (C5), 128.0 (C5), 126.4 (C7), 126.3 (C7), 125.8 (C8), 125.7
(C8), 124.1 (C6), 123.8 (C6), 121.5 (C1), 120.1 (C1), 116.3 (C3), 116.0 (C3), 79.6
(-CCH), 75.3 (-CCH), 68.4 (C1), 57.4 (-CH2-CCH), 38.3 (C2), 24.8 (C3), 22.6 (C4
or C5), 22.4 (C5 or C4); IR (neat) ν̄max 3288, 3058, 2954, 2868, 2363, 1620, 1590, 1507,
1460, 1429, 1355, 1329, 1270, 1243, 1217, 1146, 1133, 1084, 1050, 1017, 934, 804, 746,
668 cm-1; MS (ESI +ve) m/z 417 ([M + Na]+, 100%), 395 ([M + H]+, 40%); HRMS (ESI +ve
TOF) calcd for C28H26O2Na 417.1831, found 417.1841 ([M + Na]+).

2'-(Isopentyloxy)-[1,1'-biphenyl]-2-ol (48)66
1-Bromo-3-methylbutane (2.43 g, 16.11 mmol) was added dropwise to a
stirred solution of 2,2-biphenol (47) (3.00 g, 16.11 mmol) and K2CO3
(9.24 g, 66.86 mmol) in acetone (97 mL). The mixture was heated at
reflux for 24 h, cooled to rt and filtered. The solid residue was extracted
with acetone (2 × 50 mL), the combined filtrates were concentrated and the resulting residue
was subjected to flash chromatography over SiO2 gel (Et2O/hexanes – 10:90) to give the
product ether 48 (3.68 g, 89%) as a translucent, viscous oil that eventually crystallized into a
white solid. The spectroscopic data was found to be in agreement with those previously
reported.66 TLC (Et2O/hexanes – 10:90): Rf = 0.50, (EtOAc/P.S. – 5:95): Rf = 0.34; 1H NMR
(300 MHz, CDCl3) δ 7.41 – 7.23 (m, 4H, ArH), 7.16 – 6.96 (m, 4H, ArH), 6.62 (s, 1H, -OH),
4.09 (t, J = 6.6 Hz, 2H, H1''), 1.78 – 1.58 (m, 3H, H2'' and H3''), 0.88 (d, J = 6.2 Hz, 6H, H4''
and H5''); 13C NMR (101 MHz, CDCl3) δ 155.0 (C2'), 154.0 (C2), 132.7 (C6'), 131.4 (C6),
129.2 (C4 and C4'), 128.1 (C1'), 126.7 (C1), 122.5 (C5'), 121.0 (C5), 117.8 (C3), 113.4 (C3'),
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68.5 (C1''), 37.9 (C2''), 25.1 (C3''), 22.6 (C4'' and C5''); MS (ESI +ve) m/z 279 ([M + Na]+,
100%), 257 ([M + H]+, 16%).

2-(Isopentyloxy)-2'-(prop-2-yn-1-yloxy)-1,1'-biphenyl (21)
Propargyl bromide (80% w/w in toluene – 1.31 g, 8.78 mmol) was added
dropwise to a stirred solution of the ether 48 (1.50 g, 5.85 mmol) and
K2CO3 (1.62 g, 11.70 mmol) in acetonitrile (41 mL). The mixture was
then heated at reflux for 48 h, cooled to rt and filtered. The solid residue
was washed with acetonitrile (2 × 50 mL), the combined filtrates were concentrated and the
resulting residue was subjected to flash chromatography over SiO2 gel (EtOAc/P.S. – 5:95)
to give alkyne 21 (1.70 g, 99%) as a translucent, yellow oil. TLC (EtOAc/P.S. – 5:95): Rf =
0.46; 1H NMR (400 MHz, CDCl3) δ 7.37 – 7.21 (m, 4H, ArH), 7.10 (d, J = 8.1 Hz, 1H, ArH),
7.07 – 6.91 (m, 3H, ArH), 4.60 (d, J = 2.3 Hz, 2H, -CH2C≡C-), 3.95 (t, J = 6.7 Hz, 2H, H1''),
2.43 (t, J = 2.3 Hz, 1H, -C≡CH), 1.71 – 1.44 (m, 3H, H2'' and H3''), 0.83 (d, J = 6.5 Hz, 6H,
H4'' and H5''); 13C NMR (101 MHz, CDCl3) δ 156.7 (C2), 155.3 (C2'), 131.9 (C6 or C6'),
131.7 (C6 or C6'), 128.9 (C1'), 128.7 (C4 or C4'), 128.4 (C4 or C4'), 128.0 (C1), 121.3 (C5'),
120.3 (C5), 113.0 (C3'), 112.4 (C3), 79.3 (-C≡CH), 75.2 (-C≡CH), 67.1 (C1''), 56.4
(-CH2C≡C-), 38.1 (C2''), 25.1 (C3''), 22.7 (C4'' and C5''); IR (neat) ν̄max 3292, 2955, 2870,
2362, 2328, 1594, 1502, 1473, 1441, 1384, 1367, 1251, 1212, 1162, 1123, 1110, 1054, 909,
749, 731, 668 cm-1; MS (ESI +ve) m/z 317 ([M + Na]+, 100%), 295 ([M + H]+, 22%); HRMS
(ESI +ve TOF) calcd for C20H23O2 295.1698, found 295.1692 ([M + H]+).
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Lysine Building Blocks
(R)-N2-(Benzyloxycarbonyl)-N6-(tert-butoxycarbonyl)-2,6-diaminohexanoic acid (50)69
H-(D)-Lys(Boc)-OH (49) (4.00 g, 16.24 mmol) was dissolved
in 4.0 M NaOH (4.06 mL, 16.24 mmol) and the solution was
cooled to 0 ºC in an ice bath. With vigorous stirring at 0 ºC,
benzyl chloroformate (2.84 g, 16.65 mmol) and 4.0 M NaOH
(4.06 mL, 16.24 mmol) were added portion-wise and
alternately over a 15 min period. The mixture was then removed from the ice bath and stirred
at rt for 90 min. The reaction mixture was diluted with H2O (5 mL) and extracted with EtOAc
(3 × 20 mL). The combined organic layers were extracted with H2O (3 × 30 mL); the
combined aqueous extracts were then acidified to pH 2-3 with concentrated aqueous HCl
(36% w/w) followed by extraction with Et2O (3 × 40 mL). The combined ethereal extracts
were dried (MgSO4), filtered and concentrated to give the acid 50 (5.86 g, 95%) as a light
yellow, viscous oil. The spectroscopic data was found to be in agreement those previously
reported.69 TLC (MeOH/CH2Cl2 - 10:90): Rf = 0.43; 1H NMR (500 MHz, CDCl3) δ 7.27 –
7.38 (m, 5H, ArH), 5.68 (s, 1H, N2-H), 5.01 – 5.20 (m, 2H, -CH2Ph), 4.86 (br s, 1H, -OH),
4.70 (s, 1H, N6-H), 4.34 (s, 1H, H2), 3.08 (br s, 2H, H6), 1.62 – 1.95 (m, 2H, H3), 1.21 –
1.56 (m, 13H, H4, H5 and -C(CH3)3); 13C NMR (126 MHz; CDCl3) δ 175.8 (C1), 156.6 (Cα),
156.5 (Cβ), 136.5 (CAr1), 128.7 (CAr3 and CAr5), 128.34 (CAr2 and CAr6), 128.27 (CAr4),
79.7 (-C(CH3)3), 67.2 (-CH2Ph), 54.1 (C2), 40.2 (C6), 32.0 (C3), 29.7 (C5), 28.6 (-C(CH3)3),
22.5 (C4); MS (ESI +ve) m/z 403 ([M + Na]+, 100%), 281 ([M – Boc + 2H]+, 28%).
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Benzyl ((R)-N6-(tert-butoxycarbonyl)-6-amino-1-hydroxyhexan-2-yl)carbamate (51)82
To a stirred solution of the acid 50 (804 mg, 2.11 mmol) in THF
(4.3 mL) at −10 ºC was added dropwise N-methylmorpholine
(243 mg, 2.11 mmol) followed by isobutyl chloroformate (288
mg, 2.11 mmol). The mixture was stirred at –10 ºC for 30 min
and then filtered. To the cold filtrate (ice/salt bath) was added a
solution of NaBH4 (120 mg, 3.16 mmol) in H2O (1.1 mL) and then the reaction mixture was
manually agitated for 15 s followed by quenching of the reaction with excess H2O (~65 mL).
The reaction mixture was then extracted with EtOAc (3 × 30 mL) and the combined extracts
were then washed with H2O (3 × 30 mL). The organic phase was dried (Na2SO4), filtered and
concentrated to give alcohol 51 (762 mg, 98%) as a clear, viscous oil. The spectroscopic data
was found to be in agreement with those previously reported.82 TLC (MeOH/CH2Cl2 –
10:90): Rf = 0.41; 1H NMR (500 MHz, CDCl3) δ 7.29 – 7.41 (m, 5H, ArH), 5.11 (br s,
3H, -CH2Ph and N2-H), 4.61 (s, 1H, N6-H), 3.54 – 3.73 (m, 3H, H1 and H2), 2.98 – 3.23 (m,
2H, H6), 2.64 (br s, 1H, -OH), 1.75 (br s, 1H, H3A or H3B), 1.60 (br s, 1H, H3B or H3A), 1.20
– 1.55 (m, 13H, -C(CH3)3, H4 and H5); 13C NMR (126 MHz, CDCl3) δ 156.9 (Cα), 156.5
(Cβ), 136.7 (CAr1), 128.7 (CAr3 and CAr5), 128.31 (CAr2 and CAr6), 128.29 (CAr4), 79.5
(-C(CH3)3), 67.0 (-CH2Ph), 65.2 (C1), 53.3 (C2), 40.0 (C6), 30.8 (C3), 30.2 (C5), 28.6
(-C(CH3)3), 22.9 (C4); MS (ESI +ve) m/z 389 ([M + Na]+, 100%), 267 ([M – Boc + 2H]+,
15%).
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Benzyl ((R)-N6-(tert-butoxycarbonyl)-6-amino-1-azidohexan-2-yl)carbamate (23)82
To a stirred solution of the alcohol 51 (6.56 g, 17.90 mmol) in
CH2Cl2 (54 mL) at 0 ºC was added dropwise triethylamine (2.36
g, 23.27 mmol) followed by the slow, dropwise addition of
methanesulfonyl chloride (2.67 g, 23.27 mmol). The reaction
mixture was allowed to warm to rt and then stirring was
continued for 1 h. Toluene (58 mL) was added and the reaction
mixture was concentrated under vacuum (600 mbar) to selectively remove the CH2Cl2. To
the resulting solution was added sodium azide (5.82 g, 89.50 mmol), tetrabutylammonium
bromide (693 mg, 2.15 mmol) and H2O (5.8 mL) and the mixture was heated at 70 ºC for 18
h with vigorous stirring. A further portion of H2O (4.0 mL) was added and stirring was
continued at 70 ºC for 6 h before the mixture was cooled to rt and partitioned between Et2O
(150 mL) and H2O (150 mL). The aqueous phase was separated and re-extracted with fresh
Et2O (2 × 75 mL). The combined ethereal extracts were washed with brine (2 × 75 mL), dried
(MgSO4), filtered and concentrated. The residue was subjected to flash chromatography over
SiO2 gel (EtOAc/P.S. - 5:95  20:80) which gave the azide 23 (5.80 g, 83%) as a clear,
viscous oil. The spectroscopic data was found to be in agreement with those previously
reported.82 TLC (EtOAc/P.S. - 40:60): Rf = 0.61; 1H NMR (500 MHz, CDCl3) δ 7.28 – 7.40
(m, 5H, ArH), 5.03 – 5.18 (m, 2H, -CH2Ph), 4.94 (br s, 1H, N2-H), 4.57 (br s, 1H, N6-H),
3.77 (br s, 1H, H2), 3.32 – 3.49 (m, 2H, H1), 3.10 (br s, 2H, H6), 1.29 – 1.59 (m, 15H, H3,
H4, H5 and -C(CH3)3); 13C NMR (126 MHz; CDCl3) δ 156.1 (Cα), 156.0 (Cβ), 136.3 (CAr1),
128.5 (CAr3 and CAr5), 128.14 (CAr2 and CAr6), 128.06 (CAr4), 79.1 (-C(CH3)3), 66.8
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(-CH2Ph), 54.7 (C1), 50.8 (C2), 40.0 (C6), 31.6 (C3), 29.7 (C5), 28.4 (-C(CH3)3), 22.8 (C4);
MS (ESI +ve) m/z 414 ([M + Na]+, 100%), 292 ([M – Boc + 2H]+, 28%).

(9H-Fluoren-9-yl)methyl ((R)-N6-(tert-butoxycarbonyl)-6-amino-1-hydroxyhexan-2yl)carbamate (53)121
Fmoc-(D)-Lys(Boc)-OH (52) (4.00 g, 8.54 mmol) was
dissolved in THF (17.1 mL) with magnetic stirring. The
solution was brought to −10 °C (ice/salt bath) followed by
sequential dropwise addition of isobutyl chloroformate (1.12
g, 8.54 mmol) and then N-methylmorpholine (983 mg, 8.54
mmol). The mixture was stirred at −10 °C for 30 min and
filtered through a small pad of Celite – the Celite pad was rinsed with fresh, cold THF (5 ×
5 mL) and the combined filtrates were kept cold (ice bath). The cold filtrate was added
dropwise to a cold aqueous solution of NaBH4 (647 mg, 17.07 mmol in 12.8 mL H2O) with
vigorous stirring. The mixture was stirred for 5 min before being added directly to H2O (213
mL) with vigorous stirring. The reaction was stirred for 10 min and then the aqueous mixture
was extracted with EtOAc (3 × 150 mL). The combined organic extracts were washed with
H2O (2 × 200 mL) and brine (1 × 200 mL). The organic phase was dried (MgSO4), filtered,
concentrated and subjected to flash chromatography over SiO2 gel (EtOAc/P.S. – 50:50) to
afford the alcohol 53 (3.57 g, 92%) as a white, amorphous solid. The spectroscopic data was
found to be in agreement with those previously reported.121 TLC (EtOAc/P.S. – 50:50): Rf =
0.35; 1H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 7.5 Hz, 2H, HAr5), 7.59 (d, J = 7.4 Hz, 2H,
HAr2), 7.39 (t, J = 7.4 Hz, 2H, HAr3), 7.31 (t, J = 7.4 Hz, 2H, HAr4), 5.12 (br s, 1H, N2-H),
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4.61 (br s, 1H, N6-H), 4.41 (d, J = 6.5 Hz, 2H, H1'), 4.20 (t, J = 6.7 Hz, 1H, H2'), 3.73 – 3.50
(m, 3H, H1 and H2), 3.24 – 2.97 (m, 2H, H6), 1.68 – 1.19 (m, 15H, H3, H4, H5
and -C(CH3)3); 13C NMR (101 MHz, CDCl3) δ 156.8 (Cα), 156.5 (Cβ), 144.1 (CAr1), 141.5
(CAr6), 127.8 (CAr4), 127.2 (CAr3), 125.2 (CAr2), 120.1 (CAr5), 79.4 (-C(CH3)3), 66.7
(C1'), 64.8 (C1), 53.1 (C2), 47.4 (C2'), 39.8 (C6), 30.6 (C3), 30.1 (C5), 28.6 (-C(CH3)3), 22.7
(C4); MS (ESI +ve) m/z 477 ([M + Na]+, 100%).

Tert-butyl (R)-(5-amino-6-azidohexyl)carbamate (22)59
A stirred solution of the alcohol 53 (100 mg, 0.22 mmol) in anhydrous
CH2Cl2 (2.2 mL) was brought to 0 °C (ice bath). Triethylamine (33 mg,
0.33 mmol) was added followed by the dropwise addition of
methanesulfonyl chloride (38 mg, 0.33 mmol). The solution was
stirred at 0 °C for 15 min followed by stirring at rt for 60 min. The
mixture was diluted with CH2Cl2 (30 mL) and washed successively with 1.0 M aqueous citric
acid solution (2 × 20 mL) and brine (1 × 20 mL). The organic phase was dried (MgSO4),
filtered and concentrated to give the intermediate mesylate as a yellow, translucent gum. The
mesylate was dissolved in DMF (1.1 mL) with magnetic stirring. NaN3 (72 mg, 1.10 mmol)
was added and the reaction mixture was stirred vigorously and heated at 45-50 °C for 18 h.
After the reaction was complete (as verified by MS/TLC analysis), the DMF was removed
from the reaction mixture via a rotary evaporator by utilizing the DMF-toluene azeotrope.
The residue was subjected to flash chromatography over SiO2 gel (EtOAc  MeOH/CH2Cl2
– 10:90) which afforded the target amine 22 (26 mg, 46%) as a yellow, translucent oil. The
spectroscopic data was found to be in agreement with those previously reported.59 TLC
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(MeOH/CH2Cl2 – 10:90): Rf = 0.13, (NEt3/MeOH/CH2Cl2 – 2:10:88): Rf = 0.41; 1H NMR
(400 MHz, CDCl3) δ 4.85 (br s, 1H, N1-H), 3.35 (dd, J = 9.3, 4.7 Hz, 1H, H6A or H6B), 3.18
– 3.04 (m, 3H, H6B or H6A and H1), 2.89 (br s, 1H, H5), 1.64 – 1.23 (m, 17H, H2, H3,
H4, -C(CH3)3 and -NH2); 13C NMR (101 MHz, CDCl3) δ 156.0 (C=O), 78.9 (-C(CH3)3), 58.2
(C6), 50.9 (C5), 40.2 (C1), 34.5 (C4), 30.0 (C2), 28.3 (-C(CH3)3), 23.1 (C3); MS (ESI +ve)
m/z 258 ([M + H]+, 100%), 280 ([M + Na]+, 10%).

(R)-2-Azido-6-((tert-butoxycarbonyl)amino)hexanoic acid (24)90
The methyl triflate salt of sulfuryl-diimidazole87-88 (4.85g, 13.40 mmol)
was added to cold (≤ 5 °C) H2O (16 mL) and the mixture was
magnetically stirred over an ice bath until the salt fully dissolved.
EtOAc (16 mL) was added to the solution, followed by NaN3 (1.16 g,
17.86 mmol); the mixture was stirred vigorously at 0 °C for 60 min. The
EtOAc layer was separated, dried (Na2SO4), filtered and the Na2SO4 solids were rinsed with
minimal fresh EtOAc. The combined EtOAc filtrate (containing the newly formed
diazotransfer reagent) was then added to a reaction vessel containing a solution of H-(D)Lys(Boc)-OH (54) (2.20 g, 8.93 mmol) in MeOH (36 mL), CuSO4∙5H2O (22 mg, 0.09 mmol)
and K2CO3 (1.85 g, 13.40 mmol). The reaction was stirred vigorously at rt for 24 h, at which
point the reaction was shown to be complete by MS analysis. The mixture was diluted with
H2O (50 mL) and a few drops of aqueous NaOH solution (10% w/w) were added to ensure
an alkaline mixture (pH > 10). The volatile solvents (EtOAc and MeOH) were removed under
reduced pressure at 40 °C. The aqueous reaction mixture was then washed with Et2O (2 × 50
mL) and made acidic (pH < 3) with concentrated aqueous HCl (36% w/w). The aqueous
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phase was extracted with Et2O (3 × 50 mL) and the combined ethereal extracts were washed
with H2O (3 × 100 mL), brine (1 × 50 mL), dried (MgSO4), filtered and concentrated to afford
a residue which was further purified by flash chromatography over SiO2 gel (EtOAc/P.S. –
0:100  40:60) to yield the target α-azido-acid 24 (2.39g, 98%) as a translucent, viscous
faint tan oil. The spectroscopic data was found to be in agreement with those previously
reported.90 TLC (EtOAc/P.S. – 40:60): Rf = 0.58; 1H NMR (400 MHz, CD3OD) δ 4.00 – 3.89
(m, 1H, H2), 3.04 (t, J = 6.6 Hz, 2H, H6), 1.90 – 1.79 (m, 1H, H3A or H3B), 1.79 – 1.67 (m,
1H, H3B or H3A), 1.56 – 1.35 (m, 14H, H4, H5 and -C(CH3)3); 13C NMR (101 MHz, CD3OD)
δ 174.0 (C1), 158.7 (Cα), 80.1 (-C(CH3)3), 63.3 (C2), 41.2 (C6), 32.3 (C3), 30.6 (C5), 29.0
(-C(CH3)3), 24.3 (C4); MS (ESI −ve) m/z 271 ([M − H]−, 100%), (ESI +ve) m/z 295 ([M +
Na]+, 100%).

Arginine Derivatives
Benzyl (R)-(1-hydroxy-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5yl)sulfonyl)guanidino)pentan-2-yl)carbamate (56)
Cbz-(D)-Arg(Pbf)-OH (55) (5.00 g, 8.92 mmol) was
dissolved in THF (17.8 mL) with magnetic stirring. The
solution was brought to −10 °C (ice/salt bath) followed by
sequential dropwise addition of isobutyl chloroformate
(1.22 g, 8.92 mmol) and N-methylmorpholine (1.03 g, 8.92
mmol). The mixture was stirred at −10 °C for 30 min and then filtered through a small pad
of Celite – the Celite pad was rinsed with fresh, cold THF (5 × 5 mL) and the combined
filtrates were kept cold (ice bath). The cold filtrate was added dropwise to a cold aqueous
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solution of NaBH4 (676 mg, 17.84 mmol in 13.4 mL H2O) with vigorous magnetic stirring.
After the addition was complete, the reaction was allowed to react for 5 min and was added
to excess H2O (223 mL) with vigorous stirring. The reaction was stirred for 10 min and the
aqueous mixture was extracted with EtOAc (3 × 150 mL). The combined organic extracts
were washed with H2O (2 × 200 mL), brine (1 × 200 mL), dried (MgSO4), filtered and
concentrated. The residue was subjected to flash chromatography over SiO2 gel (EtOAc/P.S.
– 80:20  100:0) to afford the alcohol 56 (3.82 g, 78%) as a white foam that collapsed into
23

a translucent gum. TLC (EtOAc/P.S. – 80:20): Rf = 0.31; [α] D –3.5 (c 0.77, MeOH); 1H
NMR (400 MHz, CDCl3) δ 7.28 (br s, 5H, ArH), 6.10 – 6.32 (m, 3H, N5-H/NH2), 5.62 (d, J
= 8.5 Hz, 1H, N2-H), 5.03 (s, 2H, -CH2Ph), 3.50 – 3.69 (m, 3H, H1 and H2), 3.17 (br s, 2H,
H5), 2.91 (s, 2H, ArCH2-), 2.53 (s, 3H, ArCH3), 2.46 (s, 3H, ArCH3), 2.06 (s, 3H, ArCH3),
1.40 – 1.61 (m, 10H, H3, H4 and -C(CH3)2); 13C NMR (101 MHz, CDCl3) δ 159.0 (Pbf CAr),
157.1 (C=O), 156.5 (C=N), 138.5 (Pbf CAr), 136.6 (Cbz CAr), 132.7 (Pbf CAr), 132.4 (Pbf
CAr), 128.6 (Cbz CAr)*, 128.2 (Cbz CAr), 128.0 (Cbz CAr)*, 124.8 (Pbf CAr), 117.7 (Pbf CAr),
86.6 (-C(CH3)2), 66.9 (-CH2Ph), 64.8 (C1), 52.8 (C2), 43.3 (ArCH2-), 41.1 (C5), 28.7
(-C(CH3)2), 28.7 (C3), 25.8 (C4), 19.4 (ArCH3), 18.1 (ArCH3), 12.6 (ArCH3); IR (neat) ν̄max
3431, 3328, 2934, 1696, 1617, 1545, 1454, 1243, 1153, 1088, 1028, 903, 806, 781, 733, 658
cm-1; MS (ESI +ve) m/z 569 ([M + Na]+, 100%), 547 ([M + H]+, 56%); HRMS (ESI +ve
TOF) calcd for C27H39N4O6S 547.2590, found 547.2589 ([M + H]+).
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Benzyl (R)-(1-azido-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran5-yl)sulfonyl)guanidino)pentan-2-yl)carbamate (26)
To a stirred solution of the alcohol 56 (3.79 g, 6.94 mmol)
in CH2Cl2 (21 mL) at 0 ºC was added triethylamine (912
mg, 9.02 mmol) followed by slow, dropwise addition of
methanesulfonyl chloride (1.03 g, 9.02 mmol). The
reaction was allowed to warm to rt and stirring was
continued for 1 h. Toluene (22.5 mL) was added and the mixture was concentrated under
vacuum (600 mbar) to selectively remove the CH2Cl2. Sodium azide (2.26 g, 34.68 mmol),
tetrabutylammonium bromide (268 mg, 0.83 mmol) and H2O (4.9 mL) were added and the
mixture was heated at 80 ºC for 36 h with vigorous stirring before being cooled to rt and
partitioned between EtOAc (150 mL) and H2O (150 mL). The aqueous phase was separated
and extracted with EtOAc (2 × 75 mL). The combined organic extracts were washed with
H2O (1 × 100 mL), brine (1 × 100 mL), dried (MgSO4), filtered and concentrated. The residue
was subjected to flash chromatography over SiO2 gel (EtOAc/P.S. – 20:80  60:40) which
gave the target azide 26 (2.82 g, 71% over two steps) as an off-white foam that collapsed into
23

a translucent gum. TLC (EtOAc/P.S. – 80:20): Rf = 0.69; [α] D +4.5 (c 13.96, MeOH); 1H
NMR (400 MHz, CDCl3) δ 7.31 (br s, 5H, ArH), 6.10 (br s, 3H, N5-H/NH2), 5.29 (d, J = 9.0
Hz, 1H, N2-H), 5.13 – 4.99 (m, 2H, -CH2Ph), 3.73 (br s, 1H, H2), 3.42 – 3.26 (m, 2H, H1),
3.17 (br s, 2H, H5), 2.93 (s, 2H, ArCH2-), 2.55 (s, 3H, ArCH3), 2.48 (s, 3H, ArCH3), 2.08 (s,
3H, ArCH3), 1.62 – 1.39 (m, 10H, H3, H4 and -C(CH3)2);

13

C NMR (101 MHz, CDCl3)

δ 158.8 (Pbf CAr), 156.4 (C=O), 156.2 (C=N), 138.3 (Pbf CAr), 136.2 (Cbz CAr), 132.7 (Pbf
CAr), 132.3 (Pbf CAr), 128.6 (Cbz CAr)*, 128.2 (Cbz CAr), 128.0 (Cbz CAr)*, 124.7 (Pbf CAr),
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117.6 (Pbf CAr), 86.5 (-C(CH3)2), 67.0 (-CH2Ph), 54.9 (C1), 50.5 (C2), 43.2 (ArCH2-), 40.8
(C5), 29.6 (C3), 28.6 (-C(CH3)2), 25.5 (C4), 19.3 (ArCH3), 17.9 (ArCH3), 12.5 (ArCH3); IR
(neat) ν̄max 3431, 3332, 2930, 2098, 1700, 1616, 1540, 1456, 1242, 1153, 1088, 1028, 908,
807, 781, 732, 658 cm-1; MS (ESI +ve) m/z 594 ([M + Na]+, 100%), 572 ([M + H]+, 52%);
HRMS (ESI +ve TOF) calcd for C27H38N7O5S 572.2655, found 572.2677 ([M + H]+).

(9H-Fluoren-9-yl)methyl (R)-(1-hydroxy-5-(2-((2,2,4,6,7-pentamethyl-2,3dihydrobenzofuran-5-yl)sulfonyl)guanidino)pentan-2-yl)carbamate (58)121
Fmoc-(D)-Arg(Pbf)-OH (57) (4.00 g, 6.17 mmol) was
dissolved in THF (12.3 mL) with magnetic stirring.
The solution was brought to −10 °C (ice/salt bath)
followed by sequential dropwise addition of isobutyl
chloroformate

(842

mg,

6.17

mmol)

and

N-methylmorpholine (710 mg, 6.17 mmol). The mixture was stirred at −10 °C for 30 min
and filtered through a small pad of Celite – the Celite pad was rinsed with fresh, cold THF
(5 × 5 mL) and the combined filtrates were kept cold (ice bath). The cold filtrate was added
dropwise to a cold aqueous solution of NaBH4 (467 mg, 12.33 mmol in 9.3 mL H2O) with
vigorous magnetic stirring. After the addition was complete, the mixture was stirred for 5
min and added to H2O (154 mL) with vigorous stirring. The reaction was stirred for 10 min
and then the aqueous mixture was extracted with EtOAc (3 × 150 mL). The combined organic
extracts were washed with H2O (2 × 200 mL), brine (1 × 200 mL), dried (MgSO4), filtered
and concentrated. The residue was subjected to flash chromatography over SiO2 gel (EtOAc)
to afford the alcohol 58 (3.12 g, 80%) as a translucent gum. The spectroscopic data was found
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to be in agreement with those previously reported.121 TLC (EtOAc/P.S. – 60:40): Rf = 0.36;
1

H NMR (400 MHz, CDCl3) δ 7.69 (d, J = 7.5 Hz, 2H, HAr5), 7.52 (d, J = 7.4 Hz, 2H, HAr2),

7.32 (t, J = 7.4 Hz, 2H, HAr3), 7.20 (t, J = 7.3 Hz, 2H, HAr4), 6.38 – 6.18 (m, 3H, N5-H/NH2),
5.72 (d, J = 7.9 Hz, 1H, N2-H), 4.30 (d, J = 6.8 Hz, 2H, H1'), 4.09 (t, J = 6.7 Hz, 1H, H2'),
3.67 – 3.48 (m, 3H, H1 and H2), 3.18 (s, 2H, H5), 2.86 (s, 2H, ArCH2-), 2.55 (s, 3H, ArCH3),
2.47 (s, 3H, ArCH3), 2.04 (s, 3H, ArCH3), 1.63 – 1.41 (m, 4H, H3 and H4), 1.39 (s,
6H, -C(CH3)2); 13C NMR (101 MHz, CDCl3) δ 159.0 (Pbf CAr), 157.1 (C=N), 156.5 (C=O),
144.0 (CAr1 or CAr1') 143.9 (CAr1' or CAr1), 141.3 (CAr6), 138.4 (Pbf CAr), 132.7 (Pbf
CAr), 132.3 (Pbf CAr), 127.8 (C4), 127.2 (C3), 125.3 (C2), 124.9 (Pbf CAr), 120.0 (C5), 117.7
(Pbf CAr), 86.6 (-C(CH3)2), 66.8 (C1'), 64.8 (C1), 52.8 (C2), 47.3 (C2'), 43.3 (ArCH2-), 41.1
(C5), 28.7 (-C(CH3)2), 28.6 (C3), 25.8 (C4), 19.4 (ArCH3), 18.1 (ArCH3), 12.6 (ArCH3); MS
(ESI +ve) m/z 657 ([M + Na]+, 100%), 635 ([M + H]+, 86%).

(R)-1-Azido-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5yl)sulfonyl)guanidino)pentan-2-amine (25)59
A reaction vessel charged with triphenylphosphine (1.41 g, 5.37
mmol), iodine (1.36 g, 5.37 mmol), imidazole (399 mg, 5.86
mmol) and CH2Cl2 (7.0 mL) was stirred at rt for 10 min followed
by the addition a solution of the alcohol 58 (3.10g, 4.88 mmol) in
CH2Cl2 (3.0 mL). The reaction was stirred at rt for 20 h, diluted with CH2Cl2 (30 mL) and
filtered to remove the white precipitate. The filtrate was concentrated and the residue was
subjected to flash chromatography over SiO2 gel (EtOAc/Et2O – 50:50) to give a mixture of
the intermediate iodide and triphenylphosphine oxide. The mixture was dissolved in DMF
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(24.5 mL) and NaN3 (1.59g, 24.42 mmol) was added to the solution followed by vigorous
stirring at rt for 4 h. After the azidation reaction was shown to be complete by TLC analysis
(EtOAc/P.S. – 80:20), the reaction was heated to 50 °C (oil bath) overnight (18 h) to remove
the N-Fmoc protecting group. The reaction mixture was cooled to rt and then partitioned
between EtOAc (200 mL) and aqueous HCl (0.5 M – 200 mL) with magnetic stirring for 5
min. The acidic aqueous phase was separated and washed with EtOAc (3 × 100 mL). The
aqueous phase was made alkaline (pH > 10) with aqueous NaOH solution (10% w/w) and
was extracted with EtOAc (3 × 100 mL). The organic extracts were combined and washed
with H2O (1 × 150 mL), brine (1 × 100 mL), dried (Na2SO4), filtered and concentrated to
afford the amine 25 (1.71 g, 80% over two steps) as an off-white foam that eventually
collapsed into a translucent, pale yellow gum. The spectroscopic data was found to be in
agreement with those previously reported.59 TLC (MeOH/CH2Cl2 – 10:90): Rf = 0.21;
1

H NMR (400 MHz, CDCl3) δ 6.55 – 6.31 (m, 3H, N5-H/NH2 (guanidine)), 3.27 (dd, J = 12.0,

4.1 Hz, 1H, H1A or H1B ), 3.22 – 3.11 (m, 2H, H5), 3.07 (dd, J = 12.0, 7.4 Hz, 1H, H1B or
H1A), 2.95 (s, 2H, ArCH2-), 2.86 – 2.76 (m, 1H, H2), 2.56 (s, 3H, ArCH3), 2.49 (s, 3H,
ArCH3), 2.09 (s, 3H, ArCH3), 1.73 (s, 2H, -NH2), 1.61 – 1.34 (m, 9H, H3A or H3B, H4
and -C(CH3)2), 1.31 – 1.19 (m, 1H, H3B or H3A); 13C NMR (101 MHz, CDCl3) δ 158.8 (Pbf
CAr), 156.4 (C=N), 138.2 (Pbf CAr), 132.9 (Pbf CAr), 132.1 (Pbf CAr), 124.7 (Pbf CAr), 117.6
(Pbf CAr), 86.5 (-C(CH3)2), 58.3 (C1), 50.8 (C2), 43.3 (ArCH2-), 40.9 (C5), 31.7 (C3), 28.6
(-C(CH3)2), 25.9 (C4), 19.3 (ArCH3), 18.0 (ArCH3), 12.5 (ArCH3); MS (ESI +ve) m/z 438
([M + H]+, 100%), 460 ([M + Na]+, 53%).
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Tert-butyl (R)-(1-azido-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5yl)sulfonyl)guanidino)pentan-2-yl)carbamate (27)
To a stirred solution of amine 25 (100 mg, 0.23 mmol) in CH2Cl2
(2.0 mL) was slowly added a solution of Boc2O (60 mg, 0.27
mmol) in CH2Cl2 (0.5 mL) and the resulting mixture was stirred
at rt for 2 h. The reaction was then diluted with EtOAc (100 mL)
and washed successively with 1.0 M HCl (2 × 50 mL), saturated aqueous NaHCO3 (1 × 50
mL), H2O (1 × 50 mL) and brine (1 × 50 mL). The organic phase was dried (MgSO4), filtered,
concentrated and the resultant residue was subjected to flash chromatography over SiO2 gel
(EtOAc/P.S. – 20:80  100:0) to afford the azide 27 (121 mg, 98%) as a light tan, translucent
23

gum. TLC (EtOAc): Rf = 0.67, (MeOH/CH2Cl2 – 5:95): Rf = 0.42; [α] D –3.3 (c 0.70, MeOH);
1

H NMR (400 MHz, CDCl3) δ 6.22 (br s, 3H, N5-H/NH2), 4.89 (d, J = 8.5 Hz, 1H, N2-H),

3.69 (br s, 1H, H2), 3.38 – 3.12 (m, 4H, H1 and H5), 2.96 (s, 2H, ArCH2-), 2.57 (s, 3H,
ArCH3), 2.51 (s, 3H, ArCH3), 2.10 (s, 3H, ArCH3), 1.61 – 1.37 (m, 19H, H3, H4. -C(CH3)3
and -C(CH3)2); 13C NMR (101 MHz, CDCl3) δ 158.9 (Pbf CAr), 156.4 (C=N), 156.1 (C=O),
138.5 (Pbf CAr), 133.0 (Pbf CAr), 132.4 (Pbf CAr), 124.8 (Pbf CAr), 117.7 (Pbf CAr), 86.6
(-C(CH3)2), 80.1 (-C(CH3)3), 55.2 (C1), 50.0 (C2), 43.4 (ArCH2-), 41.1 (C5), 30.0 (C3), 28.7
(-C(CH3)2), 28.5 (-C(CH3)3), 25.6 (C4), 19.4 (ArCH3), 18.1 (ArCH3), 12.6 (ArCH3); IR (neat)
ν̄max 3452, 3333, 2975, 2934, 2098, 1684, 1617, 1545, 1456, 1367, 1248, 1163, 1089, 1028,
901, 851, 808, 783, 660 cm-1; MS (ESI +ve) m/z 560 ([M + Na]+, 100%), 538 ([M + H]+,
30%); HRMS (ESI +ve TOF) calcd for C24H40N7O5S 538.2812, found 538.2811 ([M + H]+).
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(R)-2-Azido-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran5-yl)sulfonyl)guanidino)pentanoic acid (28)89
The methyl triflate salt of sulfuryl-diimidazole87-88 (2.55g, 7.03
mmol) was added to cold (≤ 5 °C) H2O (8.5 mL) and was stirred
over an ice bath until the salt fully dissolved. EtOAc (8.5 mL) was
added to the solution, followed by NaN3 (549 mg, 8.44 mmol) and
the mixture was then stirred vigorously at 0 °C for 60 min. The EtOAc layer was separated,
dried (Na2SO4), filtered and the Na2SO4 solids were rinsed with minimal fresh EtOAc. The
EtOAc filtrate (containing the newly formed diazotransfer reagent) was then added to
reaction vessel charged with a solution of H-(D)-Arg(Pbf)-OH (60) (2.00 g, 4.69 mmol) in
MeOH (12.7 mL), CuSO4∙5H2O (12 mg, 0.05 mmol) and K2CO3 (972 mg, 7.03 mmol). The
mixture was stirred vigorously at rt for 24 h, at which point the reaction was shown to be
complete by MS analysis; the reaction was diluted with H2O (50 mL) and a few drops of
aqueous NaOH solution (10% w/w) were added to ensure an alkaline mixture (pH > 10). The
volatile solvents (EtOAc and MeOH) were removed under reduced pressure at 40 °C. The
aqueous reaction mixture was washed with Et2O (2 × 50 mL) and then made acidic (pH < 3)
with concentrated aqueous HCl. The aqueous phase was extracted with Et2O (3 × 50 mL)
and the combined ethereal extracts were washed with H2O (3 × 100 mL) and brine (1 × 50
mL). The organic phase was dried (MgSO4), filtered and concentrated to afford the α-azidoacid 28 (1.76 g, 83%) as a white foam that collapsed into a translucent gum. The
spectroscopic data was found to be in agreement with those previously reported.89 TLC
(EtOAc/P.S. – 80:20): Rf = 0.44, (MeOH/CH2Cl2 – 10:90): Rf = 0.37; 1H NMR (400 MHz,
CDCl3) δ 6.35 (br s, 4H, N5-H/NH2 and -OH), 3.97 (t, J = 6.5 Hz, 1H, H2), 3.25 (s, 2H, H5),
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2.95 (s, 2H, ArCH2-), 2.53 (s, 3H, ArCH3), 2.47 (s, 3H, ArCH3), 2.08 (s, 3H, ArCH3), 1.60 –
1.98 (m, 4H, H3 and H4), 1.46 (s, 6H, -C(CH3)2); 13C NMR (101 MHz, CD3OD) δ 173.7
(C1), 160.0 (Pbf CAr), 158.1 (C=N), 139.5 (Pbf CAr), 134.4 (Pbf CAr), 133.6 (Pbf CAr), 126.2
(Pbf CAr), 118.6 (Pbf CAr), 87.8 (-C(CH3)2), 63.0 (C2), 44.1 (ArCH2-), 41.4 (C5), 29.7 (C3),
28.9 (-C(CH3)2), 27.1 (C4), 19.7 (ArCH3), 18.6 (ArCH3), 12.7 (ArCH3); MS (ESI −ve) m/z
451 ([M − H]−, 100%), MS (ESI +ve) m/z 453 ([M + H]+, 100%).

Methyl (R)-2-amino-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5yl)sulfonyl)guanidinyl)pentanoate (29)59
Fmoc-(D)-Arg(Pbf)-OH (61) (1.00 g, 1.54 mmol) was dissolved
in MeOH (9.3 mL) and the solution was brought to 0 °C (ice bath)
with magnetic stirring. Thionyl chloride (312 mg, 2.62 mmol) was
added dropwise, the ice bath removed and the reaction solution
stirred at rt for 24 h. The solvent was removed and the residue was dissolved in EtOAc (100
mL); the organic phase was washed with aqueous NaHCO3 (5% w/w – 1 × 50 mL), brine (1
× 50 mL), dried (MgSO4), filtered and concentrated to afford the intermediate methyl ester
as a translucent gum. The ester was dissolved in MeOH (15.7 mL) with magnetic stirring and
piperidine (668 mg, 7.85 mmol) was then added and the mixture was stirred at rt for 24 h.
The reaction was diluted with MeOH (80 mL), washed with hexane (5 × 100 mL) and
concentrated to afford the target amine 29 (551 mg, 80% over two steps) as a translucent,
colourless gum. The spectroscopic data was found to be in agreement with those previously
reported.59 TLC (MeOH/CH2Cl2 – 10:90): Rf = 0.09, (NEt3/MeOH/CH2Cl2 – 2:10:88): Rf =
0.33; 1H NMR (400 MHz, CDCl3) δ 6.57 (br s, 1H, N5-H), 6.47 (br s, 2H, -NH2 (guanidine)),
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3.66 (s, 3H, -OCH3), 3.40 (br s, 1H, H2), 3.15 (br s, 2H, H5), 2.95 (s, 2H, ArCH2-), 2.55 (s,
3H, ArCH3), 2.48 (s, 3H, ArCH3), 2.06 (s, 3H, ArCH3), 1.74 – 1.63 (m, 1H, H3A or H3B),
1.61 – 1.39 (m, 9H, H3B or H3A, H4 and -C(CH3)2); 13C NMR (101 MHz, CDCl3) δ 176.0
(C1), 158.6 (Pbf CAr), 156.4 (C=N), 138.1 (Pbf CAr), 132.9 (Pbf CAr), 132.0 (Pbf CAr), 124.6
(Pbf CAr), 117.4 (Pbf CAr), 86.3 (-C(CH3)2), 53.8 (C2), 51.9 (-OCH3), 43.1 (ArCH2-), 40.6
(C5), 31.8 (C3), 28.5 (-C(CH3)2), 25.5 (C4), 19.2 (ArCH3), 17.9 (ArCH3), 12.4 (ArCH3); MS
(ESI +ve) m/z 441 ([M + H]+, 100%), 463 ([M + Na]+, 95%).

6.3.2 – Series A1
Benzyl ((R)-N6-(tert-butoxycarbonyl)-6-amino-1-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]2-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)hexan-2-yl)carbamate (62a)
Following General Procedure A, azide 23 (1.50 g,
3.83 mmol), alkyne 21 (2.26 g, 7.66 mmol),
Cu(OAc)2∙H2O (153 mg, 0.77 mmol) and sodium
ascorbate (304 mg, 1.53 mmol) were stirred in
t-BuOH (77 mL) and H2O (19 mL) for 48 h to give
the triazole 62a (1.97 g, 75%) as a white foam after flash chromatography over SiO2 gel
23

(EtOAc/P.S. – 20:80  50:50). TLC (EtOAc/P.S. – 50:50): Rf = 0.48; [α] D +31.3 (c 0.83,
MeOH); 1H NMR (400 MHz, CDCl3) δ 7.38 – 7.21 (m, 9H, ArH), 7.17 (s, 1H, H5'), 7.07 –
6.99 (m, 2H, ArH), 6.99 – 6.91 (m, 2H, ArH), 5.14 (s, 2H, -OCH2-C4'), 5.06 (s, 3H, -CH2Ph
and N2-H), 4.55 (br s, 1H, N6-H), 4.39 (d, J = 5.1 Hz, 2H, H1), 3.92 (br s, 1H, H2), 3.88 (t, J
= 6.6 Hz, 2H, H1''), 3.06 (br s, 2H, H6), 1.62 – 1.52 (m, 1H, H3''), 1.52 – 1.23 (m, 17H, H3,
H4, H5, H2'' and -C(CH3)3), 0.79 (d, J = 6.6 Hz, 6H, H4'' and H5'');

13

C NMR (101 MHz,
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CDCl3) δ 156.6 (CAr2'), 156.2 (Cβ), 155.9 (Cα), 155.8 (CAr2), 145.2 (C4'), 136.2 (Phenyl
CAr), 131.7 (CAr6 or CAr6'), 131.5 (CAr6' or CAr6), 128.7 (CAr1), 128.54 (Phenyl CAr* and
CAr4 or CAr4'), 128.46 (CAr4′ or CAr4), 128.2 (Phenyl CAr), 128.1 (Phenyl CAr* and CAr1'),
123.3 (C5'), 121.1 (CAr5), 120.1 (CAr5'), 113.3 (CAr3), 112.3 (CAr3'), 79.2 (-C(CH3)3),
67.0 (C1''), 66.9 (-CH2Ph), 63.4 (-OCH2-C4'), 53.1 (C1), 51.2 (C2), 39.8 (C6), 37.9 (C2''),
31.0 (C3), 29.7 (C5), 28.4 (-C(CH3)3), 25.0 (C3''), 22.7 (C4), 22.5 (C4'' and C5''); IR (neat)
ν̄max 3323, 2952, 2930, 2869, 2358, 2342, 1696, 1506, 1437, 1394, 1364, 1242, 1166, 1052,
1011, 856, 750, 697 cm-1; MS (ESI +ve) m/z 708 ([M + Na]+, 100%), 686 ([M + H]+, 22%);
HRMS (ESI +ve TOF) calcd for C39H51N5O6Na 708.3737, found 708.3755 ([M + Na]+).

Tert-butyl (R)-(5-amino-6-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H1,2,3-triazol-1-yl)hexyl)carbamate (63a)
To a reaction vessel charged with carbamate 62a (1.90 g,
2.77 mmol), acetic acid (3.17 mL, 55.40 mmol) and
palladium on charcoal (10% w/w – 442 mg, 0.42 mmol)
was added MeOH (27.7 mL) under a flow of N2 gas. The
reaction vessel was then sealed and degassed under high
vacuum with magnetic stirring. N2 gas was allowed into the reaction vessel and the vessel
was again degassed; this step was done twice. After the third degassing, the vacuum was
maintained and a 2.0 L balloon of H2 gas was attached and allowed into the reaction vessel.
The reaction mixture was then stirred vigorously at rt for 24 h under an atmosphere of H2
gas. After the reaction was shown to be complete by TLC analysis (EtOAc/P.S. – 50:50), the
H2 source was removed, the reaction vessel was purged with N2 gas and Celite was added to
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the reaction mixture with vigorous magnetic stirring. The mixture was then vacuum filtered
through a pad of fresh Celite atop a PTFE membrane, the solids were rinsed thoroughly with
MeOH (5 × 20 mL) and the combined filtrates were concentrated until nearly dry. The residue
was dissolved in EtOAc (200 mL) and washed successively with saturated aqueous NaHCO3
(3 × 100 mL), H2O (1 × 100 mL) and finally brine (1 × 100 mL). The organic phase was
dried (Na2SO4), filtered and concentrated to afford the amine 63a (1.52 g, 99%) as
23

translucent, light tan gum. TLC (NEt3/MeOH/CH2Cl2 – 2:10:88): Rf = 0.46; [α] D +16.5 (c
1.67, MeOH); 1H NMR (400 MHz, CDCl3) δ 7.34 – 7.22 (m, 5H, ArH and H5'), 7.08 – 6.92
(m, 4H, ArH), 5.17 (d, J = 0.8 Hz, 2H, -OCH2-C4'), 4.57 (br s, 1H, N1-H), 4.28 (dd, J = 13.6,
4.2 Hz, 1H, H6A or H6B), 4.07 (dd, J = 13.6, 7.9 Hz, 1H, H6B or H6A), 3.90 (t, J = 6.6 Hz,
2H, H1''), 3.21 – 3.02 (m, 3H, H1 and H5), 1.68 – 1.21 (m, 18H, H2, H3, H4, H2'', H3''
and -C(CH3)3), 0.80 (d, J = 6.6 Hz, 6H, H4'' and H5''); 13C NMR (101 MHz, CDCl3) δ 156.6
(CAr2'), 156.0 (C=O), 155.8 (CAr2), 145.2 (C4'), 131.62 (CAr6 or CAr6'), 131.56 (CAr6' or
CAr6), 128.7 (CAr1), 128.50 (CAr4 or CAr4'), 128.49 (CAr4' or CAr4), 128.2 (CAr1'), 123.1
(C5'), 121.1 (CAr5), 120.1(CAr5'), 113.2 (CAr3), 112.3 (CAr3'), 79.2 (-C(CH3)3), 67.1 (C1''),
63.54 (-OCH2-C4'), 57.0 (C6), 51.5 (C5), 40.2 (C1), 38.0 (C2''), 34.5 (C4), 30.0 (C2), 28.5
(-C(CH3)3), 25.0 (C3), 23.0 (C3''), 22.5 (C4'' and C5''); IR (neat) ν̄max 3345, 2955, 2930, 2869,
2362, 2327, 1700, 1506, 1437, 1388, 1364, 1241, 1166, 1125, 1051, 1002, 852, 750, 615
cm-1; MS (ESI +ve) m/z 574 ([M + Na]+, 100%), 552 ([M + H]+, 80%); HRMS (ESI +ve
TOF) calcd for C31H46N5O4 552.3550, found 552.3564 ([M + H]+).
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(R)-N-(6-Amino-1-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H-1,2,3triazol-1-yl)hexan-2-yl)-2-phenylacetamide hydrochloride (64a)
Following General Procedure B, amine 63a (50 mg,
0.09 mmol), phenylacetic acid (15 mg, 0.11 mmol),
EDCI (21 mg, 0.11 mmol) and HOBt (15 mg, 0.10
mmol) were stirred in acetonitrile (0.9 mL) for 24 h to
give the intermediate amide as a translucent tan gum. Following General Procedure D, the
amide was dissolved in CH2Cl2 (2.7 mL) and treated with CF3CO2H (2.7 mL) followed by
work-up with ethereal HCl to give the amine salt 64a (53 mg, 96% over two steps) as a light
23

tan powder that rapidly transitioned to a sticky gum. [α] D +22.7 (c 1.30, MeOH); 1H NMR
(400 MHz, CD3OD) δ 7.50 (s, 1H, H5'), 7.36 – 7.10 (m, 10H, ArH), 7.06 – 6.91 (m, 3H,
ArH), 5.02 (s, 2H, -OCH2-C4'), 4.51 (dd, J = 13.8, 4.3 Hz, 1H, H1A or H1B), 4.37 (dd, J =
13.8, 8.0 Hz, 1H, H1B or H1A), 4.25 (br s, 1H, H2), 3.90 (t, J = 6.4 Hz, 2H, H1''), 3.38 (br s,
2H, -CH2Ph), 2.92 – 2.77 (m, 2H, H6), 1.79 – 1.22 (m, 9H, H3, H4, H5, H2'' and H3''), 0.81
(d, J = 6.6 Hz, 6H, H4'' and H5'');

13

C NMR (101 MHz, CD3OD) δ 174.3 (C=O), 158.2

(CAr2'), 157.4 (CAr2), 145.4 (C4'), 136.9 (Phenyl CAr), 133.0 (CAr6 or CAr6'), 132.6 (CAr6'
or CAr6), 130.5 (CAr1), 130.3 (Phenyl CAr*), 129.9 (CAr4 or CAr4'), 129.77 (Phenyl CAr*),
129.75 (CAr1' and CAr4' or CAr4), 128.2 (Phenyl C Ar), 126.0 (C5'), 122.4 (CAr5), 121.5
(CAr5'), 114.8 (CAr3), 113.9 (CAr3'), 68.2 (C1''), 63.6 (-OCH2-C4'), 54.6 (C1), 50.8 (C2),
44.1 (-CH2Ph), 40.7 (C6), 39.4 (C2''), 32.3 (C3), 28.2 (C5), 26.2 (C3''), 23.9 (C4), 23.1 (C4''
and C5''); IR (neat) ν̄max 3242, 2955, 2873, 2363, 2337, 1653, 1559, 1539, 1506, 1437, 1261,
1223, 1162, 1124, 1109, 1050, 1003, 876, 849 cm-1; MS (ESI +ve) m/z 570 ([M + H]+, 100%),
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592 ([M + Na]+, 15%); HRMS (ESI +ve TOF) calcd for C34H44N5O3 570.3444, found
570.3451 ([M + H]+).

(R)-N-(6-Amino-1-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H-1,2,3triazol-1-yl)hexan-2-yl)-3-phenylpropanamide hydrochloride (64b)
Following General Procedure B, amine 63a (50
mg, 0.09 mmol), 3-phenylpropanoic acid (16 mg,
0.11 mmol), EDCI (21 mg, 0.11 mmol) and HOBt
(15 mg, 0.10 mmol) were stirred in acetonitrile (0.9
mL) for 24 h to give the intermediate amide as a translucent tan gum. Following General
Procedure D, the amide was dissolved in CH2Cl2 (2.7 mL) and treated with CF3CO2H (2.7
mL) followed by work-up with ethereal HCl to give the amine salt 64b (52 mg, 93% over
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two steps) as a light tan powder that rapidly transitioned to a sticky gum. [α] D +21.7 (c 1.37,
MeOH); 1H NMR (400 MHz, CD3OD) δ 7.53 (s, 1H), 7.36 – 7.08 (m, 10H), 7.06 – 6.89 (m,
3H), 5.09 (s, 2H), 4.45 (dd, J = 14.0, 4.4 Hz, 1H), 4.33 (dd, J = 13.8, 7.2 Hz, 1H), 4.20 (s,
1H), 3.90 (t, J = 6.2 Hz, 2H), 3.00 – 2.75 (m, 4H), 2.50 – 2.29 (m, 2H), 1.80 – 1.18 (m, 9H),
0.81 (d, J = 6.5 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 175.3, 158.1, 157.4, 145.4, 142.2,
133.0, 132.6, 130.5, 129.9, 129.72, 129.68*, 129.67*, 127.5, 126.1, 122.4, 121.5, 114.8,
113.9, 68.2, 63.6, 54.8, 50.7, 40.7, 39.4, 38.8, 32.8, 32.1, 28.2, 26.2, 23.8, 23.1*; IR (neat)
ν̄max 3242, 2954, 2869, 2358, 2329, 1653, 1559, 1539, 1506, 1437, 1387, 1261, 1225, 1161,
1124, 1109, 1052, 1002, 847, 749, 699 cm-1; MS (ESI +ve) m/z 584 ([M + H]+, 100%), 606
([M + Na]+, 11%); HRMS (ESI +ve TOF) calcd for C35H46N5O3 584.3601, found 584.3609
([M + H]+).
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Benzyl (R)-(6-amino-1-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H1,2,3-triazol-1-yl)hexan-2-yl)carbamate hydrochloride (64c)
Following General Procedure D, carbamate 62a
(50 mg, 0.07 mmol) was dissolved in CH2Cl2 (2.1
mL) and treated with CF3CO2H (2.1 mL) followed
by work-up with ethereal HCl to give the amine salt
23

64c (42 mg, 93%) as a light tan powder that rapidly transitioned to a sticky gum. [α] D +8.8
(c 1.20, MeOH); 1H NMR (400 MHz, DMSO) δ 7.83 (s, 1H), 7.39 – 7.18 (m, 8H), 7.18 –
7.09 (m, 2H), 7.05 – 6.87 (m, 4H), 5.06 (s, 2H), 4.93 (s, 2H), 4.41 (dd, J = 13.7, 4.9 Hz, 1H),
4.30 (dd, J = 13.6, 7.7 Hz, 1H), 3.94 – 3.77 (m, 3H), 2.78 – 2.66 (m, 2H), 1.60 – 1.24 (m,
9H), 0.78 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, DMSO) δ 156.0, 155.7, 155.6, 142.8,
137.0, 131.3, 131.1, 128.5*, 128.4, 128.3*, 127.8, 127.7, 127.5, 127.4, 124.4, 120.4, 119.9,
112.9, 112.3, 66.2, 65.2, 61.8, 52.7, 51.0, 38.4, 37.4, 30.9, 26.6, 24.4, 22.3, 22.2*; IR (neat)
ν̄max 2956, 2926, 2873, 2357, 2337, 1700, 1680, 1559, 1539, 1506, 1437, 1339, 1261, 1204,
1125, 1052, 1002, 833, 799, 750, 698 cm-1; MS (ESI +ve) m/z 608 ([M + Na]+, 100%), 586
([M + H]+, 42%); HRMS (ESI +ve TOF) calcd for C34H44N5O4 586.3393, found 586.3400
([M + H]+).
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Benzyl (R)-(1-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H-1,2,3-triazol1-yl)-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5yl)sulfonyl)guanidino)pentan-2-yl)carbamate (62b)
Following General Procedure A, azide 26 (1.00 g,
1.75 mmol), alkyne 21 (1.03 g, 3.50 mmol),
Cu(OAc)2∙H2O (70 mg, 0.35 mmol) and sodium
ascorbate (139 mg, 0.70 mmol) were stirred in
t-BuOH (35 mL) and H2O (8.8 mL) for 20 h to give
the product triazole 62b (1.24 g, 82%) as a white
foam after flash chromatography over SiO2 gel
23

(EtOAc/P.S. – 10:90  80:20). TLC (EtOAc/P.S. – 80:20): Rf = 0.44; [α] D +18.3 (c 1.53,
MeOH); 1H NMR (400 MHz, CDCl3) δ 7.32 – 7.15 (m, 10H, H5' and ArH), 7.04 – 6.96 (m,
2H, ArH), 6.93 – 6.86 (m, 2H, ArH), 6.10 (br s, 2H, -NH2), 5.92 (br s, 1H, N5-H), 5.81 (d, J
= 8.2 Hz, 1H, N2-H), 5.04 (s, 2H, -OCH2-C4'), 4.99 (s, 2H, -CH2Ph), 4.30 (br s, 2H, H1),
3.97 – 3.88 (m, 1H, H2), 3.84 (t, J = 6.6 Hz, 2H, H1''), 3.16 – 3.06 (m, 2H, H5), 2.90 (s, 2H,
ArCH2-), 2.54 (s, 3H, ArCH3), 2.46 (s, 3H, ArCH3), 2.06 (s, 3H, ArCH3), 1.60 – 1.33 (m,
13H, H3, H4, H2'', H3'' and -C(CH3)2), 0.77 (d, J = 6.6 Hz, 6H, H4'' and H5''); 13C NMR (101
MHz, CDCl3) δ 158.9 (Pbf CAr), 156.7 (CAr2'), 156.4 (C=O), 156.3 (C=N), 155.9 (CAr2),
144.8 (C4'), 138.5 (Pbf CAr), 136.4 (Phenyl CAr), 132.9 (Pbf CAr), 132.4 (Pbf CAr), 131.9
(CAr6 or CAr6'), 131.7 (CAr6 or CAr6'), 128.74 (CAr4 or CAr4'), 128.73 (CAr1), 128.66
(Phenyl CAr)*, 128.6 (CAr1'), 128.3 (Phenyl CAr), 128.12 (CAr4 or CAr4'), 128.06 (Phenyl
CAr)*, 124.8 (Pbf CAr), 124.1 (C5'), 121.33 (CAr5), 120.30 (CAr5'), 117.7 (Pbf CAr), 113.6
(CAr3), 112.6 (CAr3'), 86.6 (-C(CH3)2), 67.2 (C1''), 66.9 (-CH2Ph), 63.3 (-OCH2-C4'), 53.2
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(C1), 51.2 (C2), 43.3 (ArCH2-), 40.8 (C5), 38.0 (C2''), 28.9 (C3), 28.7 (-C(CH3)2), 25.5 (C4),
25.1 (C3''), 22.6 (C4'' and C5''), 19.4 (ArCH3), 18.1 (ArCH3), 12.6 (ArCH3); IR (neat) ν̄max
3336, 2955, 2927, 2873, 2312, 1715, 1700, 1617, 1559, 1540, 1507, 1457, 1340, 1241, 1154,
1107, 1090, 1052, 1000, 902, 851, 806, 751, 734, 664, 642, 617 cm-1; MS (ESI +ve) m/z 888
([M + Na]+, 100%), 866 ([M + H]+, 9%); HRMS (ESI +ve TOF) calcd for C47H59N7O7SNa
888.4094, found 888.4136 ([M + Na]+).

(R)-(1-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-5(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino)pentan-2yl)amine (63b)
To a reaction vessel charged with carbamate 62b (1.11 g,
1.29 mmol), acetic acid (1.5 mL, 25.70 mmol) and
palladium on charcoal (10% w/w – 205 mg, 0.19 mmol)
was added MeOH (13.0 mL) under a flow of N2 gas. The
reaction vessel was then sealed and degassed under high
vacuum with magnetic stirring. N2 gas was allowed into the
reaction vessel and the vessel was again degassed; this step was done twice. After the third
degassing, the vacuum was maintained and a 2.0 L balloon of H2 gas was attached and
allowed into reaction vessel. The reaction mixture was stirred vigorously at rt for 18 h under
an atmosphere of H2 gas. After the reaction was shown to be complete by TLC analysis
(EtOAc), the H2 source was removed, the reaction vessel was purged with N2 gas and Celite
was added to the reaction mixture with vigorous magnetic stirring. The reaction mixture was
vacuum filtered through a pad of fresh Celite atop a PTFE membrane, the solids were rinsed
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thoroughly with MeOH (5 × 20 mL) and the combined filtrates were concentrated until nearly
dry. The residue was dissolved in CH2Cl2 (100 mL) and washed successively with saturated
aqueous NaHCO3 (3 × 50 mL), H2O (1 × 50 mL) and brine (1 × 50 mL). The organic phase
was dried (Na2SO4), filtered and concentrated to afford the amine 63b (864 mg, 92%) as
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translucent, light tan gum. TLC (NEt3/MeOH/CH2Cl2 – 2:10:88): Rf = 0.47; [α] D +7.0
(c 4.27, MeOH); 1H NMR (400 MHz, CDCl3) δ 7.33 – 7.19 (m, 5H, H5' and ArH), 7.08 –
6.97 (m, 2H, ArH), 6.96 – 6.89 (m, 2H, ArH), 6.29 – 6.13 (m, 3H, -NH/NH2 (guanidine)), 5.10
(s, 2H, -OCH2-C4'), 4.22 (dd, J = 13.8, 4.2 Hz, 1H, H1A or H1B), 4.09 (dd, J = 13.8, 7.4 Hz,
1H, H1B or H1A), 3.88 (t, J = 6.6 Hz, 2H, H1''), 3.14 (br s, 3H, H2 and H5), 2.92 (s, 2H,
ArCH2-), 2.56 (s, 3H, ArCH3), 2.47 (s, 3H, ArCH3), 2.06 (s, 3H, ArCH3), 1.66 – 1.18 (m,
13H, H3, H4, H2'', H3'' and -C(CH3)2), 0.78 (d, J = 6.6 Hz, 6H, H4'' and H5''); 13C NMR (101
MHz, CDCl3) δ 158.9 (Pbf CAr), 156.7 (CAr2'), 156.3 (C=N), 155.9 (CAr2), 145.0 (C4'),
138.4 (Pbf CAr), 133.1 (Pbf CAr), 132.3 (Pbf CAr), 131.9 (CAr6 or CAr6'), 131.7 (CAr6' or
CAr6), 128.8 (CAr1), 128.70 (CAr4 or CAr4'), 128.67 (CAr4' or CAr4), 128.2 (CAr1'), 124.8
(Pbf CAr), 123.9 (C5'), 121.4 (CAr5), 120.3 (CAr5'), 117.6 (Pbf CAr), 113.5 (CAr3), 112.6
(CAr3'), 86.5 (-C(CH3)2), 67.2 (C1''), 63.4 (-OCH2-C4'), 56.6 (C1), 51.3 (C2), 43.4 (ArCH2), 40.9 (C5), 38.1 (C2''), 31.4 (C3), 28.7 (-C(CH3)2), 25.6 (C4), 25.1 (C3'') 22.6 (C4'' and
C5''), 19.4 (ArCH3), 18.1 (ArCH3), 12.6 (ArCH3); IR (neat) ν̄max 3337, 2956, 2870, 2358,
2321, 1715, 1700, 1559, 1539, 1507, 1457, 1340, 1240, 1156, 1106, 1090, 1048, 906, 852,
804, 783, 751, 734, 668, 639, 614 cm-1; MS (ESI +ve) m/z 754 ([M + Na]+, 100%), 732 ([M
+ H]+, 38%); HRMS (ESI +ve TOF) calcd for C39H54N7O5S 732.3907, found 732.3931 ([M
+ H]+).
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(R)-N-(5-Guanidino-1-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H1,2,3-triazol-1-yl)pentan-2-yl)-2-phenylacetamide hydrochloride (65a)
Following General Procedure B, amine 63b (50 mg,
0.07 mmol), phenylacetic acid (11 mg, 0.08 mmol),
EDCI (16 mg, 0.08 mmol) and HOBt (11 mg, 0.07
mmol) were stirred in acetonitrile (0.7 mL) for 18 h to
give the intermediate amide as a translucent tan gum. Following General Procedure C, the
amide was dissolved in CH2Cl2 (2.0 mL) and treated with H2O (25 mg, 1.37 mmol) and
CF3CO2H (2.0 mL) followed by work-up with ethereal HCl to give the amine salt 65a (36
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mg, 84% over two steps) as a light tan powder that rapidly transitioned to a sticky gum. [α] D

+28.2 (c 1.03, MeOH); 1H NMR (400 MHz, CD3OD) δ 7.48 (d, J = 8.0 Hz, 1H, H5'), 7.35 –
7.08 (m, 10H, ArH), 7.05 – 6.86 (m, 3H, ArH), 5.01 (d, J = 4.0 Hz, 2H, -OCH2-C4'), 4.55 –
4.14 (m, 3H, H1 and H2), 3.94 – 3.84 (m, 2H, H1''), 3.33 (s, 2H, -CH2Ph), 3.15 (br s, 2H,
H6), 1.69 – 1.27 (m, 7H, H3, H4, H2'' and H3''), 0.80 (d, J = 6.6 Hz, 6H, H4'' and H5''); 13C
NMR (101 MHz, CD3OD) δ 174.4 (C=O), 158.7 (C=N), 158.1 (CAr2'), 157.4 (CAr2), 144.1
(C4' – observed by gHMBC), 136.8 (Phenyl CAr), 133.0 (CAr6 or CAr6'), 132.6 (CAr6 or
CAr6'), 130.5 (CAr1), 130.3 (Phenyl CAr)*, 129.84 (CAr4 or CAr4'), 129.78 (Phenyl CAr)*,
129.7 (CAr4 or CAr4' and CAr1'), 128.2 (Phenyl CAr), 125.9 (C5'), 122.4 (CAr5), 121.5
(CAr5'), 114.7 (CAr3), 113.8 (CAr3'), 68.2 (C1''), 63.7 (-OCH2-C4'), 54.5 (C1), 50.7 (C2),
44.1 (-CH2Ph), 42.1 (C5), 39.4 (C2''), 30.1 (C3), 26.4 (C4), 26.2 (C3''), 23.1 (C4'' and C5'');
IR (neat) ν̄max 3336, 2957, 2873, 2362, 2327, 1715, 1700, 1653, 1559, 1540, 1507, 1457,
1437, 1340, 1218, 1162, 1109, 1051, 1003, 914, 852, 751, 729, 668 cm-1; MS (ESI +ve) m/z
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598 ([M + H]+, 100%), 620 ([M + Na]+, 21%); HRMS (ESI +ve TOF) calcd for C34H44N7O3
598.3506, found 598.3510 ([M + H]+).

(R)-N-(5-Guanidino-1-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H1,2,3-triazol-1-yl)pentan-2-yl)-3-phenylpropanamide hydrochloride (65b)
Following General Procedure B, amine 63b (50 mg,
0.07 mmol), 3-phenylpropanoic acid (12 mg, 0.08
mmol), EDCI (16 mg, 0.08 mmol) and HOBt (11 mg,
0.07 mmol) were stirred in acetonitrile (0.7 mL) for
18 h to give the intermediate amide as a translucent tan gum. Following General Procedure
C, the amide was dissolved in CH2Cl2 (2.0 mL) and treated with H2O (25 mg, 1.37 mmol)
and CF3CO2H (2.0 mL) followed by work-up with ethereal HCl to give the amine salt 65b
(42 mg, 95% over two steps) as a light tan powder that rapidly transitioned to a sticky gum.
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[α] D +55.1 (c 0.53, MeOH); 1H NMR (400 MHz, CD3OD) δ 7.47 (d, J = 3.7 Hz, 1H), 7.34 –
7.05 (m, 10H), 7.03 – 6.84 (m, 3H), 5.07 (d, J = 3.8 Hz, 2H), 4.45 – 4.08 (m, 3H), 3.93 –
3.82 (m, 2H), 3.08 (br s, 2H), 2.84 – 2.74 (m, 2H), 2.44 – 2.28 (m, 2H), 1.63 – 1.22 (m, 7H),
0.78 (d, J = 6.5 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 175.5, 158.7, 158.1, 157.5, 145.5,
142.1, 133.0, 132.6, 130.5, 129.9, 129.74, 129.68*, 129.66**, 127.5, 125.9, 122.4, 121.5,
114.7, 113.9, 113.8, 68.2, 63.7, 54.6, 50.5, 42.1, 39.4, 38.8, 32.8, 29.8, 26.3, 26.2, 23.1*; IR
(neat) ν̄max 3330, 2955, 2873, 2331, 1684, 1653, 1559, 1539, 1507, 1457, 1219, 1162, 1109,
1043, 1003, 913, 880, 852, 750, 698, 668 cm-1; MS (ESI +ve) m/z 612 ([M + H]+, 100%),
634 ([M + Na]+, 14%); HRMS (ESI +ve TOF) calcd for C35H46N7O3 612.3662, found
612.3676 ([M + H]+).
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Benzyl (R)-(5-guanidino-1-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H1,2,3-triazol-1-yl)pentan-2-yl)carbamate hydrochloride (65c)
Following General Procedure C, carbamate 62b
(50 mg, 0.06 mmol) was dissolved in CH2Cl2 (1.9
mL) and treated with H2O (18 mg, 1.00 mmol) and
CF3CO2H (1.9 mL) followed by work-up with
ethereal HCl to give the amine salt 65c (33 mg, 87%) as a light tan powder that rapidly
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transitioned to a sticky gum. [α] D +82.0 (c 0.37, MeOH); 1H NMR (500 MHz, DMSO) δ 7.83
(s, 1H), 7.53 (br s, 1H), 7.42 – 7.18 (m, 9H), 7.17 – 7.09 (m, 2H), 7.06 – 6.81 (m, 5H), 5.06
(s, 2H), 4.95 (s, 2H), 4.41 (dd, J = 13.5, 4.3 Hz, 1H), 4.31 (dd, J = 13.5, 8.1 Hz, 1H), 3.92 –
3.80 (m, 3H), 3.05 (br s, 2H), 1.61 – 1.21 (m, 7H), 0.78 (d, J = 6.6 Hz, 6H); 13C NMR (126
MHz, DMSO) δ 156.6, 156.1, 155.8, 155.6, 142.9, 137.0, 131.3, 131.1, 128.5, 128.4, 128.3*,
127.8, 127.5*, 127.4*, 124.4, 120.4, 119.9, 112.9, 112.3, 66.2, 65.2, 61.8, 52.6, 50.9, 40.4,
37.5, 28.7, 25.0, 24.5, 22.4*; IR (neat) ν̄max 3337 3198, 2956, 2930, 2873, 2362, 2323, 1683,
1653, 1559, 1539, 1507, 1457, 1340, 1212, 1162, 1109, 1040, 1003, 913, 852, 749, 697, 668
cm-1; MS (ESI +ve) m/z 614 ([M + H]+, 100%), 636 ([M + Na]+, 8%); HRMS (ESI +ve TOF)
calcd for C34H44N7O4 614.3455, found 614.3438 ([M + H]+).

189

Tert-butyl ((R)-1-(4-((((S)-2'-(isopentyloxy)-[1,1'-binaphthalen]-2-yl)oxy)methyl)-1H1,2,3-triazol-1-yl)-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5yl)sulfonyl)guanidino)pentan-2-yl)carbamate (62d)
Following General Procedure A, azide 27 (94
mg, 0.17 mmol), alkyne 20 (138 mg, 0.35 mmol),
Cu(OAc)2∙H2O (7 mg, 0.035 mmol) and sodium
ascorbate (14 mg, 0.07 mmol) were stirred in
t-BuOH (3.5 mL) and H2O (0.9 mL) at 45 °C for
20 h to give the triazole 62d (153 mg, 94%) as a
light tan gum after flash chromatography over
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SiO2 gel (EtOAc/P.S. – 10:90  100:0). TLC (EtOAc): Rf = 0.74; [α] D −6.5 (c 0.50, MeOH);
1

H NMR (400 MHz, CDCl3) δ 7.94 – 7.87 (m, 2H, ArH), 7.87 – 7.79 (m, 2H, ArH), 7.49 (d,

J = 9.0 Hz, 1H, ArH), 7.39 (d, J = 9.0 Hz, 1H, ArH), 7.32 (t, J = 7.4 Hz, 1H, ArH), 7.29 –
7.18 (m, 2H, ArH), 7.18 – 7.06 (m, 3H, ArH), 6.66 (s, 1H, H5'), 6.11 (br s, 2H, -NH2), 5.88
(br s, 1H, N5-H), 5.16 (d, J = 8.5 Hz, 1H, N2-H), 5.08 (s, 2H, -OCH2-C4'), 4.23 – 4.06 (m,
2H, H1), 4.01 – 3.92 (m, 1H, H1''A or H1''B), 3.90 – 3.82 (m, 1H, H1''B or H1''A), 3.77 (br s,
1H, H2), 3.14 – 3.03 (m, 2H, H5), 2.91 (s, 2H, ArCH2-), 2.57 (s, 3H, ArCH3), 2.49 (s, 3H,
ArCH3), 2.07 (s, 3H, ArCH3), 1.59 – 1.10 (m, 22H, H3, H4, H2'', H3'', -C(CH3)2
and -C(CH3)3), 0.57 (d, J = 6.3 Hz, 3H, H4'' or H5''), 0.52 (d, J = 6.3 Hz, 3H, H5'' or H4'');
C NMR (101 MHz, CDCl3) δ 158.9 (Pbf CAr), 156.2 (C=N), 155.8 (C=O), 154.7 (CAr2'),
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153.9 (CAr2), 144.9 (C4'), 138.5 (Pbf CAr), 134.1 (CAr8a and CAr8a'), 133.1 (Pbf CAr), 132.4
(Pbf CAr), 129.9 (CAr4a), 129.6 (CAr4), 129.5 (CAr4'), 129.3 (CAr4a'), 128.1 (CAr5), 128.0
(CAr5'), 126.43 (CAr7), 126.39 (CAr7'), 125.7 (CAr8), 125.5 (CAr8'), 124.7 (Pbf CAr), 124.1
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(CAr6), 124.0 (C5'), 123.7 (CAr6'), 121.5 (CAr1), 120.4 (CAr1'), 117.6 (Pbf C Ar), 116.5
(CAr3), 116.0 (CAr3'), 86.5 (-C(CH3)2), 80.0 (-C(CH3)3), 68.4 (C1''), 64.4 (-OCH2-C4'), 53.3
(C1), 50.2 (C2), 43.4 (ArCH2-), 40.8 (C5), 38.2 (C2''), 29.1 (C3), 28.7 (-C(CH3)2), 28.4
(-C(CH3)3), 25.4 (C4), 24.7 (C3''), 22.5 (C4'' or C5''), 22.2 (C5'' or C4''), 19.4 (ArCH3), 18.1
(ArCH3), 12.6 (ArCH3); IR (neat) ν̄max 3345, 2967, 2930, 2873, 2537, 2331, 1700, 1683,
1653, 1559, 1539, 1507, 1457, 1362, 1244, 1163, 1088, 1047, 1015, 904, 852, 807, 782, 748,
668, 640, 618 cm-1; MS (ESI +ve) m/z 932 ([M + H]+, 100%), 954 ([M + Na]+, 90%); HRMS
(ESI +ve TOF) calcd for C52H66N7O7S 932.4744, found 932.4790 ([M + H]+).

(R)-(1-(4-((((S)-2'-(Isopentyloxy)-[1,1'-binaphthalen]-2-yl)oxy)methyl)-1H-1,2,3triazol-1-yl)-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5yl)sulfonyl)guanidino)pentan-2-yl)amine (63d)
To a stirred solution of carbamate 62d (113 mg,
0.12 mmol) in MeOH (1.2 mL) was added HCl (2.0
M in Et2O – 1.2 mL, 2.40 mmol) and the resulting
reaction mixture was stirred at room temperature
for 18 h. The reaction mixture was concentrated, the
residue was dissolved in CH2Cl2 (100 mL) and the
organic solution was washed with saturated
aqueous NaHCO3 (3 × 50 mL) and brine (1 × 50 mL). The organic phase was dried (Na2SO4),
filtered and concentrated to afford the amine 63d (104 mg, 95%) as a light tan gum. TLC
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(NEt3/MeOH/CH2Cl2 – 2:10:88): Rf = 0.46; [α] D +64.2 (c 0.37, MeOH); 1H NMR (400 MHz,
CDCl3) δ 7.95 – 7.87 (m, 2H, ArH), 7.87 – 7.79 (m, 2H, ArH), 7.48 (d, J = 9.0 Hz, 1H,
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HAr3), 7.39 (d, J = 9.0 Hz, 1H, HAr3'), 7.36 – 7.30 (m, 1H, ArH), 7.30 – 7.09 (m, 5H, ArH),
6.58 (s, 1H, H5'), 6.24 (br s, 2H, -NH2), 6.18 (br s, 1H, N5-H), 5.12 (s, 2H, -OCH2-C4'), 4.05
– 3.82 (m, 4H, H1 and H1''), 3.10 (br s, 2H, H5), 2.94 (br s, 1H, H2), 2.89 (s, 2H, ArCH2-),
2.57 (s, 3H, ArCH3), 2.48 (s, 3H, ArCH3), 2.07 (s, 3H, ArCH3), 1.61 – 1.46 (m, 2H, H3),
1.41 (s, 6H, -C(CH3)2), 1.31 – 1.08 (m, 5H, H4, H2'' and H3''), 0.57 (d, J = 6.3 Hz, 3H, H4''
or H5''), 0.52 (d, J = 6.3 Hz, 3H, H5'' or H4'');
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C NMR (101 MHz, CDCl3) δ 158.9 (Pbf

CAr), 156.3 (C=N), 154.8 (CAr2'), 153.9 (CAr2), 145.0 (C4'), 138.4 (Pbf CAr), 134.2 (CAr8a
or CAr8a'), 134.1 (CAr8a' or CAr8a), 133.2 (Pbf CAr), 132.3 (Pbf CAr), 129.9 (CAr4a), 129.6
(CAr4), 129.4 (CAr4'), 129.3 (CAr4a'), 128.0 (CAr5 and CAr5'), 126.4 (CAr7 and CAr7'),
125.7 (CAr8), 125.5 (CAr8'), 124.8 (Pbf CAr), 124.1 (CAr6), 123.7 (CAr6' and C5'), 121.3
(CAr1), 120.4 (CAr1'), 117.6 (Pbf CAr), 116.3 (CAr3), 116.0 (CAr3'), 86.5 (-C(CH3)2), 68.4
(C1''), 64.5 (-OCH2-C4'), 56.5 (C1), 51.2 (C2), 43.3 (ArCH2-), 40.9 (C5), 38.2 (C2''), 31.3
(C3), 28.7 (-C(CH3)2), 25.6 (C4), 24.7 (C3''), 22.5 (C4'' or C5''), 22.3 (C5'' or C4''), 19.4
(ArCH3), 18.1 (ArCH3), 12.6 (ArCH3); IR (neat) ν̄max 3336, 2966, 2927, 2871, 2356, 2331,
1700, 1653, 1617, 1559, 1539, 1507, 1457, 1340, 1261, 1243, 1146, 1087, 1046, 1016, 906,
880, 852, 808, 783, 748, 668, 640 cm-1; MS (ESI +ve) m/z 854 ([M + Na]+, 100%), 832 ([M
+ H]+, 64%); HRMS (ESI +ve TOF) calcd for C47H58N7O5S 832.4220, found 832.4261 ([M
+ H]+).
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N-((R)-5-Guanidino-1-(4-((((S)-2'-(isopentyloxy)-[1,1'-binaphthalen]-2-yl)oxy)methyl)1H-1,2,3-triazol-1-yl)pentan-2-yl)-2-phenylacetamide hydrochloride (66a)
Following General Procedure B, amine 63d
(40 mg, 0.05 mmol), phenylacetic acid (8 mg,
0.06 mmol), EDCI (11 mg, 0.06 mmol) and
HOBt (8 mg, 0.06 mmol) were stirred in
acetonitrile (1.0 mL) for 18 h to give the
intermediate amide as a translucent tan gum. Following General Procedure C, the amide
was dissolved in CH2Cl2 (1.5 mL) and treated with H2O (17 mg, 0.96 mmol) and CF3CO2H
(1.5 mL) followed by work-up with ethereal HCl to give the amine salt 66a (30 mg, 86%
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over two steps) as a light tan powder that rapidly transitioned to a sticky gum. [α] D +38.0 (c
0.77, MeOH); 1H NMR (400 MHz, DMSO) δ 8.11 (d, J = 8.4 Hz, 1H, N2-H), 8.07 – 7.99 (m,
2H, ArH), 7.96 – 7.89 (m, 2H, ArH), 7.73 (d, J = 9.1 Hz, 1H, HAr3), 7.66 (t, J = 5.3 Hz, 1H,
N5-H), 7.57 (d, J = 9.1 Hz, 1H, HAr3'), 7.41 (s, 1H, H5'), 7.36 – 7.27 (m, 2H, ArH), 7.24 –
7.08 (m, 7H, ArH), 6.94 – 6.86 (m, 2H, ArH), 5.02 and 5.09 (ABq, 2H, J = 12.7
Hz, -OCH2-C4'), 4.33 (dd, J = 13.8, 5.1 Hz, 1H, H1A or H1B), 4.24 (dd, J = 13.8, 7.5 Hz, 1H,
H1B or H1A), 4.06 – 3.88 (m, 3H, H2 and H1''), 3.37 – 3.21 (m, 2H, -CH2Ph), 3.11 – 2.93 (m,
2H, H5), 1.53 – 1.13 (m, 7H, H3, H4, H2'' and H3''), 0.57 (d, J = 6.3 Hz, 3H, H4'' or H5''),
0.54 (d, J = 6.3 Hz, 3H, H5'' or H4''); 13C NMR (101 MHz, DMSO) δ 170.2 (C=O), 156.8
(C=N), 154.2 (CAr2'), 153.7 (CAr2), 142.9 (C4'), 136.1 (Phenyl C Ar), 133.42 (CAr8a or
CAr8a'), 133.37 (CAr8a' or CAr8a), 129.3 (CAr4), 129.1 (CAr4'), 129.0 (CAr4a), 128.8
(Phenyl CAr)*, 128.7 (CAr4a'), 128.1 (Phenyl CAr)*, 127.93 (CAr5 or CAr5'), 127.89 (CAr5'
or CAr5), 126.24 (Phenyl CAr), 126.17 (CAr7 or CAr7'), 126.1 (CAr7' or CAr7), 124.7
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(CAr8), 124.6 (CAr8'), 124.2 (C5'), 123.5 (CAr6), 123.3 (CAr6'), 119.8 (CAr1), 119.2
(CAr1'), 116.2 (CAr3), 115.7 (CAr3'), 67.3 (C1''), 62.7 (-OCH2-C4'), 52.4 (C1), 48.6 (C2),
42.3 (-CH2Ph), 40.1 (C5 – observed by gHMBC), 37.6 (C2''), 28.4 (C3), 24.9 (C4), 24.1
(C3''), 22.2 (C4'' and C5''), 22.1 (C4'' and C5''); IR (neat) ν̄max 3172, 2954, 2873, 2363, 2331,
1683, 1647, 1636, 1559, 1539, 1507, 1457, 1340, 1261, 1241, 1212, 1146, 1083, 1046, 1013,
908, 865, 808, 746, 727, 694, 668, 625, 615, 609 cm-1; MS (ESI +ve) m/z 698 ([M + H]+,
100%), 720 ([M + Na]+, 23%); HRMS (ESI +ve TOF) calcd for C42H48N7O3 698.3819, found
698.3806 ([M + H]+).

N-((R)-5-Guanidino-1-(4-((((S)-2'-(isopentyloxy)-[1,1'-binaphthalen]-2-yl)oxy)methyl)1H-1,2,3-triazol-1-yl)pentan-2-yl)-3-phenylpropanamide hydrochloride (66b)
Following General Procedure B, amine 63d
(40 mg, 0.05 mmol), 3-phenylpropanoic acid (9
mg, 0.06 mmol), EDCI (11 mg, 0.06 mmol) and
HOBt (8 mg, 0.06 mmol) were stirred in
acetonitrile (1.0 mL) for 18 h to give the intermediate amide as a translucent tan gum.
Following General Procedure C, the amide was dissolved in CH2Cl2 (1.5 mL) and treated
with H2O (17 mg, 0.96 mmol) and CF3CO2H (1.5 mL) followed by work-up with ethereal
HCl to give the amine salt 66b (32 mg, 89% over two steps) as a light tan powder that rapidly
23

transitioned to a sticky gum. [α] D +43.0 (c 0.67, MeOH); 1H NMR (400 MHz, CD3OD)
δ 8.00 – 7.94 (m, 2H), 7.89 – 7.84 (m, 2H), 7.58 (d, J = 9.0 Hz, 1H), 7.48 (d, J = 9.0 Hz, 1H),
7.33 – 7.25 (m, 2H), 7.21 – 7.06 (m, 7H), 7.03 (d, J = 8.5 Hz, 1H), 6.98 (d, J = 8.9 Hz, 1H),
6.96 (s, 1H), 5.15 – 5.01 (m, 2H), 4.27 – 4.14 (m, 2H), 4.07 (br s, 1H), 4.03 – 3.96 (m, 1H),
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3.93 – 3.85 (m, 1H), 3.11 – 2.97 (m, 2H), 2.77 (t, J = 7.5 Hz, 2H), 2.41 – 2.24 (m, 2H), 1.48
– 1.11 (m, 7H), 0.56 (d, J = 6.4 Hz, 3H), 0.51 (d, J = 6.3 Hz, 3H);

13

C NMR (101 MHz,

CD3OD) δ 175.4, 158.7, 156.2, 155.5, 146.0 (observed by gHMBC), 142.1, 135.60, 135.58,
131.5, 130.9, 130.8, 130.7, 129.7**, 129.3, 129.2, 127.5, 127.42, 127.39, 126.7, 126.4, 125.6,
125.2, 124.8, 122.9, 121.5, 117.9, 117.0, 69.2, 64.9, 54.4, 50.4, 42.1, 39.5, 38.8, 32.8, 29.7,
26.2, 25.8, 23.0, 22.7; IR (neat) ν̄max 3297, 2954, 2869, 2362, 2320, 1683, 1668, 1647, 1636,
1559, 1539, 1507, 1457, 1340, 1269, 1213, 1150, 1084, 1044, 1016, 990, 953, 867, 807, 776,
747, 703, 668 cm-1; MS (ESI +ve) m/z 712 ([M + H]+, 100%), 734 ([M + Na]+, 12%); HRMS
(ESI +ve TOF) calcd for C43H50N7O3 712.3975, found 712.3991 ([M + H]+).

Benzyl ((R)-5-guanidino-1-(4-((((S)-2'-(isopentyloxy)-[1,1'-binaphthalen]-2yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)pentan-2-yl)carbamate hydrochloride (66c)
Following General Procedure A, azide 26
(310 mg, 0.54 mmol), alkyne 20 (428 mg, 1.08
mmol), Cu(OAc)2∙H2O (22 mg, 0.11 mmol) and
sodium ascorbate (43 mg, 0.22 mmol) were
stirred in t-BuOH (10.8 mL) and H2O (2.7 mL) at 45 °C for 48 h to give the intermediate
triazole (524 mg, 96%) as a light tan gum after flash chromatography over SiO2 gel
(EtOAc/P.S. – 10:90  100:0). Following General Procedure C, the intermediate triazole
(45 mg, 0.05 mmol) was dissolved in CH2Cl2 (1.4 mL) and treated with H2O (17 mg, 0.93
mmol) and CF3CO2H (1.4 mL) followed by work-up with ethereal HCl to give the amine salt
23

66c (33 mg, 94%) as a light tan powder that rapidly transitioned to a sticky gum. [α] D +37.5
(c 0.70, MeOH); 1H NMR (400 MHz, CD3OD) δ 8.00 – 7.91 (m, 2H), 7.90 – 7.81 (m, 2H),
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7.55 (d, J = 9.0 Hz, 1H), 7.45 (d, J = 9.0 Hz, 1H), 7.34 – 6.96 (m, 12H), 5.04 (s, 2H), 4.90
(s, 2H), 4.31 (dd, J = 13.9, 4.9 Hz, 1H), 4.20 (dd, J = 13.9, 7.8 Hz, 1H), 4.03 – 3.92 (m, 1H),
3.92 – 3.81 (m, 2H), 3.21 – 3.02 (m, 2H), 1.75 – 1.35 (m, 4H), 1.34 – 1.08 (m, 3H), 0.55 (d,
J = 6.3 Hz, 3H), 0.51 (d, J = 6.3 Hz, 3H);

13

C NMR (101 MHz, CD3OD) δ 158.7, 158.5,

156.1, 155.4, 146.0 (observed by gHMBC) 138.3, 135.6, 135.5, 131.5, 130.9, 130.8, 130.7,
129.7*, 129.3, 129.21, 129.17, 128.8*, 127.5, 127.4, 126.7, 126.4, 125.6, 125.2, 124.8, 122.9,
121.5, 117.8, 117.0, 69.2, 67.6, 64.9, 54.8, 52.6, 42.1, 39.5, 30.1, 26.4, 25.8, 23.0, 22.7; IR
(neat) ν̄max 3191, 2953, 2873, 2362, 2331, 1700, 1684, 1669, 1653, 1559, 1539, 1507, 1457,
1340, 1260, 1212, 1146, 1083, 1044, 1016, 903, 860, 807, 774, 746, 697, 668 cm-1; MS (ESI
+ve) m/z 714 ([M + H]+, 100%), 736 ([M + Na]+, 23%); HRMS (ESI +ve TOF) calcd for
C42H48N7O4 714.3768, found 714.3799 ([M + H]+).

6.3.3 – Series A2
Tert-butyl ((R)-5-((R)-2-azido-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5yl)sulfonyl)guanidino)pentanamido)-6-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)hexyl)carbamate (67a)
Following General Procedure B, amine 63a (300
mg, 0.54 mmol), acid 28 (271 mg, 0.60 mmol),
EDCI (125 mg, 0.65 mmol) and HOBt (88 mg, 0.60
mmol) were stirred in acetonitrile (5.4 mL) for 48 h
to give the amide 67a (479 mg, 89%) as a
translucent tan gum after flash chromatography
over SiO2 gel (EtOAc/P.S. – 30:70  80:20). TLC
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(EtOAc/P.S. – 80:20): Rf = 0.53; [α] D −14.7 (c 2.97, MeOH); 1H NMR (400 MHz, CDCl3)
δ 7.48 (br s, 2H, H5' and N5-H), 7.33 – 7.19 (m, 4H, ArH), 7.09 (d, J = 8.0 Hz, 1H, ArH),
7.05 – 6.92 (m, 3H, ArH), 6.26 (br s, 2H, -NH2

(guanidine)),

5.90 (br s, 1H, N5'''-H), 5.11 (s,

2H, -OCH2-C4'), 4.70 (br s, 1H, N1-H), 4.49 – 4.32 (m, 3H, H5 and H6), 3.97 – 3.82 (m, 3H,
H1'' and H2'''), 3.35 (br s, 1H, H5'''A or H5'''B), 3.06 (br s, 2H, H1), 2.95 (s, 2H, ArCH2-), 2.89
(br s, 1H, H5'''B or H5'''A), 2.58 (s, 3H, ArCH3), 2.51 (s, 3H, ArCH3), 2.09 (s, 3H, ArCH3),
1.63 – 1.19 (m, 28H, H2, H3, H4, H2'', H3'', H3''', H4''', -C(CH3)2, and -C(CH3)3), 0.80 (d, J
= 6.5 Hz, 6H, H4'' and H5''); 13C NMR (101 MHz, CDCl3) δ 170.9 (C1'''), 159.0 (Pbf CAr),
156.5 (C=N), 156.4 (CAr2'), 156.3 (C=O), 156.1 (CAr2), 144.6 (C4'), 138.4 (Pbf CAr), 132.7
(Pbf CAr), 132.3 (Pbf CAr), 131.9 (CAr6 or CAr6'), 131.8 (CAr6' or CAr6), 128.9 (CAr4 and
CAr4'), 128.4 (CAr1), 128.0 (CAr1'), 124.8 (Pbf CAr), 124.0 (C5'), 121.5 (CAr5), 120.5
(CAr5'), 117.7 (Pbf CAr), 114.2 (CAr3), 112.8 (CAr3'), 86.6 (-C(CH3)2), 79.2 (-C(CH3)3),
67.3 (C1''), 63.7 (-OCH2-C4'), 61.0 (C2'''), 53.7 (C6), 49.4 (C5), 43.4 (ArCH2-), 40.3 (C1),
38.5 (C5'''), 38.0 (C2''), 31.6 (C4), 29.6 (C3'''), 28.7 (-C(CH3)2), 28.5 (-C(CH3)3), 27.6 (C2),
25.6 (C4'''), 25.1 (C3''), 23.1 (C3), 22.6 (C4'' or C5''), 22.5 (C5'' or C4''), 19.5 (ArCH3), 18.1
(ArCH3), 12.6 (ArCH3); IR (neat) ν̄max 3455, 3335, 2954, 2933, 2875, 2375, 2331, 2104,
1689, 1653, 1559, 1540, 1512, 1457, 1437, 1368, 1243, 1162, 1107, 1091, 1053, 1031, 1003,
903, 853, 807, 784, 751, 734, 663, 641, 617 cm-1; MS (ESI +ve) m/z 1009 ([M + Na]+, 100%),
987 ([M + H]+, 17%); HRMS (ESI +ve TOF) calcd for C50H72N11O8S 986.5286, found
986.5305 ([M + H]+).
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(R)-N-((R)-6-Amino-1-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H1,2,3-triazol-1-yl)hexan-2-yl)-2-(4-benzyl-1H-1,2,3-triazol-1-yl)-5guanidinopentanamide dihydrochloride (68a)

Following General Procedure A, azide 67a (50 mg, 0.05 mmol), 3-phenyl-1-propyne (18
mg, 0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol)
were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 20 h to give the intermediate triazole
as a light tan gum after flash chromatography over SiO2 gel (EtOAc/P.S. – 10:90  100:0).
Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) and treated
with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with ethereal
HCl to give the amine salt 68a (36 mg, 86% over two steps) as a light tan powder that rapidly
23

transitioned to a sticky gum. [α] D −44.2 (c 1.07, MeOH); 1H NMR (400 MHz, CD3OD)
δ 7.86 (br s, 2H, H5' and Hα), 7.34 – 7.10 (m, 10H, ArH), 7.04 – 6.87 (m, 3H, ArH), 5.27 (br
s, 1H, H2'''), 5.11 (s, 2H, -OCH2-C4'), 4.62 – 4.51 (m, 1H, H1A or H1B), 4.50 – 4.36 (m, 1H,
H1B or H1A), 4.28 (br s, 1H, H2), 4.07 (s, 2H, -CH2Ph), 3.90 (t, J = 6.1 Hz, 2H, H1''), 3.07
(br s, 2H, H5'''), 2.89 (br s, 2H, H6), 2.08 – 1.81 (m, 2H, H3'''), 1.74 – 1.17 (m, 11H, H3, H4,
H5, H2'', H3'' and H4'''), 0.80 (d, J = 6.5 Hz, 6H, H4'' and H5''); 13C NMR (101 MHz, CD3OD)
δ 169.8 (C1'''), 158.7 (C=N), 158.1 (CAr2'), 157.5 (CAr2), 148.4 (Cβ – observed by
gHMBC), 145.7 (C4' – observed by gHMBC), 139.8 (Phenyl CAr), 133.1 (CAr6 or CAr6'),
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132.6 (CAr6' or CAr6), 130.4 (CAr1), 130.0 (Phenyl CAr)*, 129.9 (Phenyl CAr* and CAr4 or
CAr4'), 129.8 (CAr4' or CAr4), 129.7 (CAr1'), 128.0 (Phenyl CAr), 126.4 (C5' – observed by
gHSQC/gHMBC), 124.5 (Cα – observed by gHSQC/gHMBC), 122.5 (CAr5), 121.5 (CAr5'),
115.0 (CAr3), 113.9 (CAr3'), 68.3 (C1''), 65.1 (C2'''), 63.7 (-OCH2-C4'), 54.8 (C1), 51.4 (C2),
41.6 (C5'''), 40.7 (C6), 39.4 (C2''), 32.4 (-CH2Ph), 32.3 (C3), 30.4 (C3'''), 28.2 (C5), 26.3
(C3''), 26.1 (C4'''), 23.9 (C4), 23.1 (C4'' and C5''); IR (neat) ν̄max 3159, 3065, 2954, 2926,
2868, 2379, 2314, 1734, 1700, 1684, 1653, 1636, 1559, 1540, 1521, 1507, 1473, 1457, 1437,
1419, 1340, 1212, 1161, 1125, 1049, 1002, 853, 752, 731, 698, 668, 610 cm-1; MS (ESI +ve)
m/2 376 ([M + 2H]2+, 100%), m/z 772 ([M + Na]+, 16%), 750 ([M + H]+, 14%); HRMS (ESI
+ve TOF) calcd for C41H56N11O3 750.4568, found 750.4587 ([M + H]+).

(R)-N-((R)-6-Amino-1-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H1,2,3-triazol-1-yl)hexan-2-yl)-5-guanidino-2-(4-phenethyl-1H-1,2,3-triazol-1yl)pentanamide dihydrochloride (68b)

Following General Procedure A, azide 67a (50 mg, 0.05 mmol), 4-phenyl-1-butyne (20 mg,
0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol)
were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 20 h to give the intermediate triazole
as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2. – 0:100 
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10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) and
treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with
ethereal HCl to give the amine salt 68b (40 mg, 94% over two steps) as a light tan powder
23

that rapidly transitioned to a sticky gum. [α] D −37.3 (c 1.03, MeOH); 1H NMR (400 MHz,
CD3OD) δ 7.91 (s, 1H), 7.84 (s, 1H), 7.36 – 7.08 (m, 10H), 7.06 – 6.88 (m, 3H), 5.36 – 5.24
(m, 1H), 5.12 (s, 2H), 4.62 – 4.54 (m, 1H), 4.44 (dd, J = 13.6, 8.9 Hz, 1H), 4.28 (br s, 1H),
3.91 (t, J = 6.4 Hz, 2H), 3.15 – 2.93 (m, 6H), 2.89 (t, J = 7.1 Hz, 2H), 2.10 – 1.86 (m, 2H),
1.73 – 1.19 (m, 11H), 0.80 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 169.5, 158.7,
158.1, 157.5, 147.2 (observed by gHMBC), 145.6 (observed by gHMBC), 141.9, 133.1,
132.6, 130.5, 129.9, 129.8, 129.74, 129.72**, 127.6, 126.3, 125.0, 122.5, 121.5, 115.0, 113.9,
68.3, 65.4, 63.7, 54.7, 51.4, 41.6, 40.7, 39.4, 36.3, 32.2, 30.4, 28.2, 27.9, 26.3, 26.0, 23.9,
23.1*; IR (neat) ν̄max 3159, 3065, 2954, 2928, 2868, 2379, 2350, 2314, 1734, 1718, 1700,
1684, 1653, 1636, 1559, 1540, 1521, 1507, 1473, 1457, 1437, 1419, 1363, 1340, 1260, 1212,
1161, 1124, 1109, 1049, 1002, 854, 751, 732, 700, 669, 609 cm-1; MS (ESI +ve) m/2 383 ([M
+ 2H]2+, 100%), m/z 764 ([M + H]+, 12%), 786 ([M + Na]+, 9%); HRMS (ESI +ve TOF)
calcd for C42H58N11O3 764.4724, found 764.4761 ([M + H]+).
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(R)-N-((R)-6-Amino-1-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H1,2,3-triazol-1-yl)hexan-2-yl)-5-guanidino-2-(4-cyclohexyl-1H-1,2,3-triazol-1yl)pentanamide dihydrochloride (68c)

Following General Procedure A, azide 67a (50 mg, 0.05 mmol), cyclohexylacetylene (18
mg, 0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol)
were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 20 h to give the intermediate triazole
as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2. – 0:100 
10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) and
treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with
ethereal HCl to give the amine salt 68c (38 mg, 92% over two steps) as a light tan powder
23

that rapidly transitioned to a sticky gum. [α] D −27.2 (c 1.03, MeOH); 1H NMR (400 MHz,
CD3OD) δ 8.11 (s, 1H), 7.85 (s, 1H), 7.37 – 7.23 (m, 2H), 7.23 – 7.12 (m, 3H), 7.07 – 6.88
(m, 3H), 5.36 (t, J = 7.2 Hz, 1H), 5.13 (s, 2H), 4.59 (dd, J = 13.7, 3.3 Hz, 1H), 4.45 (dd, J =
13.6, 8.8 Hz, 1H), 4.28 (br s, 1H), 3.92 (t, J = 6.3 Hz, 2H), 3.12 (t, J = 6.5 Hz, 2H), 2.90 (t, J
= 6.8 Hz, 2H), 2.85 – 2.76 (m, 1H), 2.14 – 1.93 (m, 4H), 1.90 – 1.23 (m, 19H), 0.81 (d, J =
6.6 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 169.3, 158.7, 158.2, 157.5, 153.0 (observed by
gHMBC), 145.6 (observed by gHMBC), 133.1, 132.7, 130.5, 129.9, 129.8, 129.7, 126.3,
124.1, 122.5, 121.5, 115.0, 113.9, 68.3, 65.8, 63.7, 54.7, 51.5, 41.7, 40.7, 39.4, 35.9, 33.70,
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33.67, 32.2, 30.3, 28.2, 27.1*, 27.0, 26.3, 26.1, 23.9, 23.1*; IR (neat) ν̄max 3158, 3065, 2950,
2928, 2870, 2380, 2349, 2312, 1734, 1718, 1700, 1684, 1653, 1636, 1559, 1540, 1521, 1507,
1473, 1457, 1437, 1419, 1363, 1340, 1260, 1212, 1162, 1123, 1109, 1040, 1003, 855, 750,
735, 701, 669, 608 cm-1; MS (ESI +ve) m/2 372 ([M + 2H]2+, 100%), m/z 742 ([M + H]+,
11%), 764 ([M + Na]+, 8%); HRMS (ESI +ve TOF) calcd for C40H60N11O3 742.4881, found
742.4911 ([M + H]+).

(R)-N-((R)-6-Amino-1-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H1,2,3-triazol-1-yl)hexan-2-yl)-5-guanidino-2-(4-(cyclohexylmethyl)-1H-1,2,3-triazol-1yl)pentanamide dihydrochloride (68d)

Following General Procedure A, azide 67a (50 mg, 0.05 mmol), 3-cyclohexyl-1-propyne
(19 mg, 0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02
mmol) were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 20 h to give the intermediate
triazole as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2. – 0:100
 10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL)
and treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with
ethereal HCl to give the amine salt 68d (33 mg, 79% over two steps) as a light tan powder
23

that rapidly transitioned to a sticky gum. [α] D −23.4 (c 0.80, MeOH); 1H NMR (400 MHz,
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CD3OD) δ 7.93 (s, 1H), 7.84 (s, 1H), 7.36 – 7.24 (m, 2H), 7.23 – 7.13 (m, 3H), 7.06 – 6.91
(m, 3H), 5.34 – 5.26 (m, 1H), 5.13 (s, 2H), 4.59 (dd, J = 13.9, 3.8 Hz, 1H), 4.44 (dd, J = 13.9,
8.9 Hz, 1H), 4.27 (br s, 1H), 3.92 (t, J = 6.2 Hz, 2H), 3.10 (t, J = 6.8 Hz, 2H), 2.89 (t, J = 7.1
Hz, 2H), 2.61 (d, J = 6.8 Hz, 2H), 2.11 – 1.89 (m, 2H), 1.77 – 1.13 (m, 20H), 1.04 – 0.91 (m,
2H), 0.81 (d, J = 6.2 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 169.7, 158.7, 158.2, 157.5,
147.0 (observed by gHMBC), 145.5 (observed by gHMBC), 133.1, 132.7, 130.5, 129.9,
129.82, 129.76, 126.2, 124.8, 122.5, 121.5, 115.0, 113.9, 68.3, 65.2, 63.7, 54.7, 51.4, 41.7,
40.7, 39.44, 39.41, 34.2*, 33.7, 32.3, 30.4, 28.2, 27.6, 27.4*, 26.3, 26.1, 23.9, 23.1*; IR (neat)
ν̄max 3158, 3065, 2950, 2926, 2869, 2380, 2350, 2312, 1734, 1718, 1700, 1684, 1653, 1636,
1559, 1540, 1521, 1507, 1473, 1457, 1437, 1419, 1363, 1340, 1260, 1213, 1161, 1125, 1109,
1040, 1003, 855, 750, 735, 701, 669, 608 cm-1; MS (ESI +ve) m/2 379 ([M + 2H]2+, 100%),
m/z 756 ([M + H]+, 19%), 778 ([M + Na]+, 16%); HRMS (ESI +ve TOF) calcd for
C41H62N11O3 756.5037, found 756.5072 ([M + H]+).
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Tert-butyl ((R)-5-azido-6-(((R)-1-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-5-(2-((2,2,4,6,7-pentamethyl-2,3dihydrobenzofuran-5-yl)sulfonyl)guanidino)pentan-2-yl)amino)-6oxohexyl)carbamate (67b)
Following General Procedure B, amine 63b
(200 mg, 0.27 mmol), acid 24 (82 mg, 0.30
mmol), EDCI (63 mg, 0.33 mmol) and HOBt (44
mg, 0.30 mmol) were stirred in acetonitrile (2.7
mL) for 18 h to give the product amide 67b (207
mg, 77%) as a translucent tan gum after flash
chromatography over SiO2 gel (MeOH/EtOAc –
0.5:99.5). TLC (MeOH/EtOAc. – 0.5:99.5): Rf =
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0.51, (EtOAc/P.S. – 80:20): Rf = 0.38; [α] D −5.9
(c 0.70, MeOH); 1H NMR (400 MHz, CDCl3) δ 7.34 – 7.19 (m, 5H, H5' and ArH), 7.11 –
6.97 (m, 3H, N2-H and ArH ), 6.98 – 6.90 (m, 2H, ArH), 6.20 (br s, 2H, -NH2), 5.94 (br s,
1H, N5-H), 5.13 (s, 2H, -CH2-C4'), 4.72 (br s, 1H, N1'''-H), 4.44 – 4.25 (m, 3H, H1 and H2),
3.88 (t, J = 6.6 Hz, 2H, H1''), 3.83 (br s, 1H, H5'''), 3.27 – 2.99 (m, 4H, H5 and H1'''), 2.94
(s, 2H, ArCH2-), 2.58 (s, 3H, ArCH3), 2.50 (s, 3H, ArCH3), 2.09 (s, 3H, ArCH3), 1.83 – 1.67
(m, 2H, H4'''), 1.61 – 1.20 (m, 26H, H3, H4, H2'', H3'', H2''', H3''', -C(CH3)3 and -C(CH3)2),
0.79 (d, J = 6.6 Hz, 6H, H4'' and H5''); 13C NMR (101 MHz, CDCl3) δ 170.0 (C6'''), 158.9
(Pbf CAr), 156.7 (CAr2'), 156.5 (C=O), 156.3 (C=N), 155.9 (CAr2), 145.1 (C4'), 138.5 (Pbf
CAr), 133.1 (Pbf CAr), 132.4 (Pbf CAr), 131.9 (CAr6 or CAr6'), 131.7 (CAr6' or CAr6), 128.8
(CAr1), 128.7 (CAr4 or CAr4'), 128.6 (CAr4' or CAr4), 128.2 (CAr1'), 124.8 (Pbf C Ar), 124.0
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(C5'), 121.3 (CAr5), 120.3 (CAr5'), 117.7 (Pbf CAr), 113.5 (CAr3), 112.6 (CAr3'), 86.5
(-C(CH3)2), 79.6 (-C(CH3)3), 67.2 (C1''), 63.4 (C5'''), 63.3 (-OCH2-C4'), 53.2 (C1), 49.0 (C2),
43.4 (ArCH2-), 40.6 (C5), 40.4 (C1'''), 38.1 (C2''), 31.3 (C4'''), 29.8 (C3), 29.0 (C2'''), 28.7
(-C(CH3)2), 28.6 (-C(CH3)3), 25.8 (C4), 25.1 (C3''), 22.6 (C4'' and C5''), 22.4 (C3'''), 19.4
(ArCH3), 18.1 (ArCH3), 12.6 (ArCH3); IR (neat) ν̄max 3328, 2955, 2931, 2876, 2375, 2323,
2104, 1700, 1684, 1653, 1559, 1540, 1507, 1457, 1437, 1419, 1340, 1241, 1164, 1106, 1091,
1052, 1002, 854, 810, 782, 752, 734, 668, 640, 621 cm-1; MS (ESI +ve) m/z 1008 ([M + Na]+,
100%), 986 ([M + H]+, 21%); HRMS (ESI +ve TOF) calcd for C50H72N11O8S 986.5286,
found 986.5313 ([M + H]+).

(R)-6-Amino-2-(4-benzyl-1H-1,2,3-triazol-1-yl)-N-((R)-5-guanidino-1-(4-(((2'(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)pentan-2yl)hexanamide dihydrochloride (69a)

Following General Procedure A, azide 67b (45 mg, 0.05 mmol), 3-phenyl-1-propyne (18
mg, 0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol)
were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 18 h to give the intermediate triazole
as a light tan gum after flash chromatography over SiO2 gel (EtOAc/P.S. – 10:90  100:0).
Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) and treated
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with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with ethereal
HCl to give the amine salt 69a (37 mg, 97% over two steps) as a light tan powder that rapidly
23

transitioned to a sticky gum. [α] D +18.1 (c 1.00, MeOH); 1H NMR (400 MHz, CD3OD) δ
7.82 (s, 1H, H5'), 7.80 (s, 1H, Hα), 7.34 – 7.11 (m, 10H, ArH), 7.03 – 6.89 (m, 3H, ArH),
5.21 (br s, 1H, H2'''), 5.10 (s, 2H, -OCH2-C4'), 4.61 – 4.51 (m, 1H, H1A or H1B), 4.49 – 4.39
(m, 1H, H1B or H1A), 4.30 (br s, 1H, H2), 4.05 (s, 2H, -CH2Ph), 3.90 (t, J = 6.0 Hz, 2H, H1''),
3.14 (s, 2H, H5), 2.85 (s, 2H, H6'''), 2.02 – 1.77 (m, 2H, H3'''), 1.76 – 1.26 (m, 9H, H3, H4,
H2'', H3'' and H5'''), 1.07 (s, 2H, H4'''), 0.80 (d, J = 6.5 Hz, 6H, H4'' and H5''); 13C NMR (101
MHz, CD3OD) δ 170.1 (C1'''), 158.7 (C=N), 158.1 (CAr2'), 157.5 (CAr2), 148.4 (Cβ –
observed by gHMBC), 145.7 (C4' – observed by gHMBC), 140.1 (Phenyl CAr), 133.1 (CAr6
or CAr6'), 132.7 (CAr6' or CAr6), 130.4 (CAr1), 129.92 (Phenyl C Ar)*, 129.89 (CAr4 or
CAr4'), 129.86 (Phenyl CAr)*, 129.8 (CAr4' or CAr4), 129.7 (CAr1'), 127.9 (Phenyl CAr),
126.2 (C5'), 124.0 (Cα), 122.4 (CAr5), 121.5 (CAr5'), 114.7 (CAr3), 113.9 (CAr3'), 68.2
(C1''), 65.0 (C2'''), 63.6 (-CH2-C4'), 54.7 (C1), 51.1 (C2), 42.1 (C6'''), 40.5 (C5), 39.4 (C2''),
32.61 (C3'''), 32.57 (-CH2Ph), 30.1 (C3), 27.8 (C5'''), 26.3 (C4), 26.2 (C3''), 23.5 (C4'''), 23.1
(C4'' and C5''); IR (neat) ν̄max 3064, 2954, 2928, 2874, 2376, 2350, 2321, 1734, 1700, 1684,
1653, 1623, 1559, 1540, 1507, 1490, 1457, 1437, 1419, 1340, 1218, 1164, 1109, 1087, 1049,
1003, 855, 752, 729, 669, 621 cm-1; MS (ESI +ve) m/2 376 ([M + 2H]2+, 100%), m/z 750 ([M
+ H]+, 32%), 772 ([M + Na]+, 8%); HRMS (ESI +ve TOF) calcd for C41H56N11O3 750.4568,
found 750.4581 ([M + H]+).
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(R)-6-Amino-N-((R)-5-guanidino-1-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)pentan-2-yl)-2-(4-phenethyl-1H-1,2,3-triazol-1yl)hexanamide dihydrochloride (69b)

Following General Procedure A, azide 67b (45 mg, 0.05 mmol), 4-phenyl-1-butyne (20
mg, 0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol)
were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 18 h to give the intermediate triazole
as a light tan gum after flash chromatography over SiO2 gel (EtOAc/P.S. – 10:90  100:0).
Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) and treated
with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with ethereal
HCl to give the amine salt 69b (36 mg, 95% over two steps) as a light tan powder that rapidly
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transitioned to a sticky gum. [α] D +19.4 (c 0.40, MeOH); 1H NMR (400 MHz, CD3OD) δ
7.80 (s, 1H), 7.67 (s, 1H), 7.36 – 7.10 (m, 10H), 7.05 – 6.98 (m, 2H), 6.95 (t, J = 7.4 Hz, 1H),
5.17 (t, J = 7.4 Hz, 1H), 5.12 (s, 2H), 4.57 (dd, J = 13.9, 3.7 Hz, 1H), 4.49 – 4.39 (m, 1H),
4.30 (br s, 1H), 3.92 (t, J = 6.3 Hz, 2H), 3.23 – 3.07 (m, 2H), 3.04 – 2.91 (m, 4H), 2.90 –
2.76 (m, 2H), 2.00 – 1.88 (m, 1H), 1.85 – 1.75 (m, 1H), 1.73 – 1.40 (m, 9H), 1.11 – 0.95 (m,
2H), 0.81 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 170.2, 158.8, 158.2, 157.5,
148.5 (observed by gHMBC), 145.9 (observed by gHMBC), 142.3, 133.1, 132.7, 130.4,
129.9, 129.81, 129.76, 129.7*, 129.6*, 127.4, 126.1, 123.4, 122.4, 121.5, 114.8, 113.9, 68.2,
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64.8, 63.6, 54.7, 51.1, 42.1, 40.5, 39.4, 36.6, 32.7, 30.1, 28.4, 27.8, 26.4, 26.3, 23.5, 23.1*;
IR (neat) ν̄max 3164, 3065, 2953, 2927, 2874, 2375, 2322, 1734, 1700, 1684, 1653, 1623,
1559, 1540, 1507, 1490, 1457, 1437, 1419, 1340, 1218, 1161, 1110, 1085, 1050, 1002, 855,
750, 700, 668, 621 cm-1; MS (ESI +ve) m/2 383 ([M + 2H]2+, 100%), m/z 764 ([M + H]+,
28%), 786 ([M + Na]+, 13%); HRMS (ESI +ve TOF) calcd for C42H58N11O3 764.4724, found
764.4708 ([M + H]+).

(R)-6-Amino-2-(4-cyclohexyl-1H-1,2,3-triazol-1-yl)-N-((R)-5-guanidino-1-(4-(((2'(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)pentan-2yl)hexanamide dihydrochloride (69c)

Following General Procedure A, azide 67b (45 mg, 0.05 mmol), cyclohexylacetylene (18
mg, 0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol)
were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 18 h to give the intermediate triazole
as a light tan gum after flash chromatography over SiO2 gel (EtOAc/P.S. – 10:90  100:0).
Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) and treated
with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with ethereal
HCl to give the amine salt 69c (31 mg, 84% over two steps) as a light tan powder that rapidly
23

transitioned to a sticky gum. [α] D +19.3 (c 0.60, MeOH); 1H NMR (400 MHz, CD3OD)
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δ 7.94 (s, 1H), 7.82 (s, 1H), 7.36 – 7.24 (m, 2H), 7.24 – 7.12 (m, 3H), 7.07 – 6.91 (m, 3H),
5.25 (t, J = 7.3 Hz, 1H), 5.12 (s, 2H), 4.63 – 4.52 (m, 1H), 4.51 – 4.40 (m, 1H), 4.31 (br s,
1H), 3.99 – 3.84 (m, 2H), 3.24 – 3.07 (m, 2H), 2.87 (br s, 2H), 2.73 (br s, 1H), 2.09 – 1.21
(m, 23H), 1.11 (br s, 2H), 0.81 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 169.9,
158.8, 158.2, 157.5, 153.6 (observed by gHMBC), 145.7 (observed by gHMBC), 133.1,
132.7, 130.4, 129.9, 129.8, 129.7, 126.2, 122.8, 122.4, 121.5, 114.8, 113.9, 68.2, 65.4, 63.6,
54.7, 51.2, 42.1, 40.5, 39.4, 36.3, 33.94*, 33.91, 32.5, 30.1, 27.8, 27.3, 27.1, 26.4, 26.3, 23.6,
23.1*; IR (neat) ν̄max 3329, 3164, 3065, 2954, 2928, 2874, 2375, 2322, 1734, 1700, 1684,
1653, 1623, 1559, 1540, 1507, 1490, 1457, 1437, 1419, 1340, 1212, 1162, 1109, 1087, 1050,
1003, 854, 750, 668, 622 cm-1; MS (ESI +ve) m/2 372 ([M + 2H]2+, 100%), m/z 742 ([M +
H]+, 37%), 764 ([M + Na]+, 11%); HRMS (ESI +ve TOF) calcd for C40H59N11O3Na
764.4700, found 764.4723 ([M + Na]+).

(R)-6-Amino-2-azido-N-((R)-5-guanidino-1-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)pentan-2-yl)hexanamide dihydrochloride (69d)

Following General Procedure C, azide 67b (45 mg, 0.05 mmol) was dissolved in CH2Cl2
(1.5 mL) and treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by
work-up with ethereal HCl to give the amine salt 69d (30 mg, 97%) as a light tan powder
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that rapidly transitioned to a sticky gum. [α] D +43.4 (c 0.50, MeOH); 1H NMR (400 MHz,
CDCl3) δ 7.75 (s, 1H), 7.34 – 7.23 (m, 2H), 7.22 – 7.12 (m, 3H), 7.05 – 6.90 (m, 3H), 5.10
(s, 2H), 4.55 – 4.41 (m, 2H), 4.31 (br s, 1H), 3.91 (t, J = 6.4 Hz, 2H), 3.81 (t, J = 6.5 Hz, 1H),
3.28 – 3.07 (m, 2H), 2.89 (br s, 2H), 1.77 – 1.50 (m, 9H), 1.50 – 1.41 (m, 2H), 1.27 (br s,
2H), 0.80 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 172.9, 158.9, 158.2, 157.5,
145.8 (observed by gHMBC), 133.0, 132.6, 130.5, 129.9, 129.8, 129.8, 126.0, 122.3, 121.5,
114.8, 113.9, 68.2, 63.7, 63.4, 54.7, 51.1, 42.2, 40.5, 39.4, 31.9, 29.9, 27.7, 26.3, 26.3, 23.3,
23.1*; IR (neat) ν̄max 3165, 3065, 2955, 2928, 2874, 2368, 2322, 2106, 1734, 1700, 1684,
1653, 1623, 1559, 1540, 1507, 1490, 1457, 1437, 1419, 1340, 1216, 1161, 1106, 1088, 1051,
1003, 855, 750, 668, 611 cm-1; MS (ESI +ve) m/2 318 ([M + 2H]2+, 100%), m/z 634 ([M +
H]+, 64%), 656 ([M + Na]+, 23%); HRMS (ESI +ve TOF) calcd for C32H48N11O3 634.3942,
found 634.3966 ([M + H]+).

Tert-butyl ((R)-5-((R)-2-azido-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5yl)sulfonyl)guanidino)pentanamido)-6-(4-((((S)-2'-(isopentyloxy)-[1,1'-binaphthalen]2-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)hexyl)carbamate (67c)
Following General Procedure B, amine
63c (65 mg, 0.10 mmol), acid 28 (54 mg,
0.12 mmol), EDCI (23 mg, 0.12 mmol) and
HOBt (18 mg, 0.11 mmol) were stirred in
acetonitrile (1.0 mL) for 24 h to give the
amide 67c (105 mg, 96%) as a translucent
tan gum. TLC (MeOH/CH2Cl2 – 5:95): Rf =
210
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0.55; [α] D −18.0 (c 0.40, MeOH); 1H NMR (400 MHz, CDCl3) δ 7.99 – 7.92 (m, 2H, ArH),
7.90 – 7.84 (m, 2H, ArH), 7.53 (d, J = 9.0 Hz, 1H, HAr3), 7.45 (d, J = 9.0 Hz, 1H, HAr3'),
7.38 – 7.29 (m, 2H, ArH), 7.25 – 7.16 (m, 3H, N5-H and ArH), 7.15 – 7.09 (m, 2H, ArH),
7.06 (br s, 1H, H5'), 5.99 (br s, 2H, -NH2 (guanidine)), 5.08 (s, 2H, -OCH2-C4'), 4.63 (br s, 1H,
N1-H), 4.37 – 4.23 (m, 3H, H5 and H6), 4.06 – 3.96 (m, 1H, H1''A or H1''B), 3.92 – 3.82 (m,
1H, H1''B or H1''A), 3.81 – 3.74 (m, 1H, H2'''), 3.32 (br s, 1H, H5'''A or H5'''B), 3.09 (br s, 2H,
H1), 2.95 (s, 2H, ArCH2-), 2.72 (br s, 1H, H5'''B or H5'''A), 2.55 (s, 3H, ArCH3), 2.49 (s, 3H,
ArCH3), 2.08 (s, 3H, ArCH3), 1.57 – 1.03 (m, 28H, H2, H3, H4, H2'', H3'', H3''',
H4''', -C(CH3)2 and -C(CH3)3), 0.58 (d, J = 6.4 Hz, 3H, H4'' or H5''), 0.51 (d, J = 6.3 Hz, 3H,
H5'' or H4'');
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C NMR (101 MHz, CDCl3) δ 170.9 (C1'''), 159.0 (Pbf CAr), 156.2 (C=N),

155.0 (Cα), 154.7 (CAr2'), 154.5 (CAr2), 144.5 (C4'), 138.4 (Pbf CAr), 134.1 (CAr8a or
CAr8a'), 134.0 (CAr8a' or CAr8a), 132.8 (Pbf CAr), 132.4 (Pbf CAr), 130.2 (CAr4a), 130.0
(CAr4), 129.7 (CAr4'), 129.3 (CAr4a'), 128.2 (CAr5), 128.1 (CAr5'), 126.7 (CAr7), 126.6
(CAr7'), 125.7 (CAr8), 125.4 (CAr8'), 124.8 (Pbf CAr), 124.4 (CAr6), 124.0 (CAr6'), 123.8
(C5' – observed by gHSQC), 121.5 (CAr1), 120.6 (CAr1'), 117.7 (Pbf CAr), 117.6 (CAr3),
116.3 (CAr3'), 86.6 (-C(CH3)2), 79.0 (-C(CH3)3 – observed by gHMBC), 68.8 (C1''), 65.3
(-OCH2-C4'), 60.8 (C2'''), 53.5 (C6), 49.3 (C5), 43.4 (C1), 40.3 (C5'''), 38.2 (C2''), 31.7 (C4),
29.6 (C3'''), 28.7 (-C(CH3)2), 28.6 (-C(CH3)3), 27.3 (C2), 25.3 (C4'''), 24.7 (C3''), 23.1 (C3),
22.5 (C4'' or C5''), 22.2 (C5'' or C4''), 19.5 (ArCH3), 18.1 (ArCH3), 12.6 (ArCH3); IR (neat)
ν̄max 3320, 2955, 2927, 2868, 2108, 1688, 1617, 1559, 1540, 1507, 1458, 1366, 1244, 1164,
1147, 1105, 1089, 1051, 1013, 903, 854, 808, 783, 748, 663, 640, 614 cm-1; MS (ESI +ve)
m/z 413 (100%), 1108 ([M + Na]+, 20%), 1086 ([M + H]+, 13%); HRMS (ESI +ve TOF)
calcd for C58H75N11O8SNa 1108.5419, found 1108.5476 ([M + Na]+).
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(R)-N-((R)-6-Amino-1-(4-((((S)-2'-(isopentyloxy)-[1,1'-binaphthalen]-2-yl)oxy)methyl)1H-1,2,3-triazol-1-yl)hexan-2-yl)-2-(4-benzyl-1H-1,2,3-triazol-1-yl)-5guanidinopentanamide dihydrochloride (70a)

Following General Procedure A, azide 67c (50 mg, 0.05 mmol), 4-phenyl-1-butyne (18 mg,
0.14 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol)
were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 18 h to give the intermediate triazole
as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 
10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) and
treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with
ethereal HCl to give the amine salt 70a (25 mg, 58% over two steps) as a light tan powder
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that rapidly transitioned to a sticky gum. [α] D −65.4 (c 0.37, MeOH); 1H NMR (400 MHz,
CD3OD) δ 8.05 – 7.96 (m, 2H, ArH), 7.93 – 7.86 (m, 2H, ArH), 7.66 – 7.60 (m, 2H, HAr3
and Hα), 7.53 (d, J = 9.0 Hz, 1H, HAr3'), 7.39 (s, 1H, H5'), 7.37 – 7.27 (m, 2H, ArH), 7.27
– 7.10 (m, 7H, ArH), 7.07 – 6.97 (m, 2H, ArH), 5.18 – 5.08 (m, 3H, H2''' and -OCH2-C4'),
4.48 – 4.40 (m, 1H, H1A or H1B), 4.35 – 4.26 (m, 1H, H1B or H1A), 4.25 – 4.16 (m, 1H, H2),
4.09 – 4.00 (m, 1H, H1''A or H1''B), 3.96 – 3.87 (m, 1H, H1''B or H1''A), 3.00 – 2.90 (m, 6H,
H5''', Hγ and -CH2Ph ), 2.85 (t, J = 7.0 Hz, 2H, H6), 1.97 – 1.87 (m, 1H, H3A or H3B), 1.85
– 1.03 (m, 12H, H3B or H3A, H4, H5, H3''', H4''', H2'' and H3''), 0.58 (d, J = 6.4 Hz, 3H, H4''
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or H5''), 0.52 (d, J = 6.4 Hz, 3H, H5'' or H4''); 13C NMR (101 MHz, CD3OD) δ 170.1 (C=O),
158.7 (C=N), 156.2 (CAr2'), 155.7 (CAr2), 148.5 (Cβ), 145.9 (C4' - observed by gHMBC),
142.4 (Phenyl CAr), 135.62 (CAr8a or CAr8a'), 135.57 (CAr8a' or CAr8a), 131.7 (CAr4a),
131.0 (CAr4a'), 130.8 (CAr4 and CAr4'), 129.7 (Phenyl C Ar)*, 129.6 (Phenyl CAr)*, 129.4
(CAr5 or CAr5'), 129.2 (CAr5' or CAr5), 127.50 (CAr7), 127.46 (Phenyl CAr), 127.4 (CAr7'),
126.7 (CAr8), 126.4 (CAr8'), 125.9 (Cα), 125.3 (CAr6), 124.8 (CAr6'), 123.2 (CAr1), 123.0
(C5'), 121.5 (CAr1'), 118.3 (CAr3), 117.1 (CAr3'), 69.3 (C1''), 65.2 (-OCH2-C4'), 64.4 (C2'''),
54.6 (C1), 51.1 (C2), 41.6 (C5'''), 40.6 (C6), 39.6 (C2''), 36.7 (Cγ), 32.2 (C3), 30.5 (C3'''),
28.6 (-CH2Ph), 28.2 (C5), 26.0 (C4'''), 25.9 (C3''), 23.8 (C4), 23.0 (C4'' or C5''), 22.7 (C5'' or
C4''); IR (neat) ν̄max 3318, 3155, 3061, 2952, 2928, 2868, 1669, 1653, 1617, 1591, 1559,
1540, 1507, 1458, 1328, 1242, 1215, 1147, 1133, 1106, 1084, 1040, 1006, 905, 861, 808,
748, 701, 680, 614 cm-1; MS (ESI +ve) m/2 433 ([M + 2H]2+, 100%), m/z 864 ([M + H]+,
12%); HRMS (ESI +ve TOF) calcd for C50H62N11O3 864.5037, found 864.5074 ([M + H]+).
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(R)-N-((R)-6-Amino-1-(4-((((S)-2'-(isopentyloxy)-[1,1'-binaphthalen]-2-yl)oxy)methyl)1H-1,2,3-triazol-1-yl)hexan-2-yl)-2-(4-(cyclohexylmethyl)-1H-1,2,3-triazol-1-yl)-5guanidinopentanamide dihydrochloride (70b)

Following General Procedure A, azide 67c (50 mg, 0.05 mmol), 3-cyclohexyl-1-propyne
(17 mg, 0.14 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02
mmol) were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 18 h to give the intermediate
triazole as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100
 10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL)
and treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with
ethereal HCl to give the amine salt 70b (32 mg, 74% over two steps) as a light tan powder
that rapidly transitioned to a sticky gum. [α]2D3 −42.1 (c 0.37, MeOH); 1H NMR (400 MHz,
CD3OD) δ 8.05 – 7.98 (m, 2H), 7.93 – 7.86 (m, 3H), 7.64 (d, J = 9.0 Hz, 1H), 7.53 (d, J =
9.0 Hz, 1H), 7.44 (s, 1H), 7.38 – 7.27 (m, 2H), 7.24 – 7.12 (m, 2H), 7.04 (d, J = 8.5 Hz, 1H),
7.00 (d, J = 8.5 Hz, 1H), 5.27 – 5.19 (m, 1H), 5.19 – 5.07 (m, 2H), 4.46 (dd, J = 13.8, 3.9 Hz,
1H), 4.33 (dd, J = 13.6, 8.8 Hz, 1H), 4.28 – 4.17 (m, 1H), 4.11 – 4.00 (m, 1H), 3.97 – 3.85
(m, 1H), 2.98 (t, J = 6.7 Hz, 2H), 2.87 (t, J = 6.8 Hz, 2H), 2.56 (d, J = 6.9 Hz, 2H), 2.03 –
1.83 (m, 2H), 1.77 – 1.09 (m, 20H), 1.03 – 0.86 (m, 2H), 0.58 (d, J = 6.4 Hz, 3H), 0.52 (d, J
= 6.4 Hz, 3H); 13C NMR (101 MHz, CD3OD) δ 169.7, 158.6, 156.2, 155.7, 147.1 (observed
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by gHMBC), 145.9 (observed by gHMBC), 135.6, 135.6, 131.7, 130.9, 130.8*, 129.4, 129.2,
127.5, 127.4, 126.7, 126.4, 126.1, 125.4, 124.8, 124.6, 123.2, 121.5, 118.4, 117.1, 69.3, 65.2,
65.1, 54.6, 51.2, 41.6, 40.6, 39.6, 39.4, 34.2*, 33.7, 32.2, 30.5, 28.2, 27.6, 27.4*, 26.0, 25.9,
23.8, 23.0, 22.7; IR (neat) ν̄max 3319, 3158, 3059, 2950, 2926, 2855, 1669, 1653, 1623, 1591,
1559, 1540, 1507, 1458, 1328, 1242, 1213, 1147, 1133, 1106, 1084, 1040, 1007, 903, 861,
808, 746, 613 cm-1; MS (ESI +ve) m/2 429 ([M + 2H]2+, 100%), m/z 856 ([M + H]+, 31%);
HRMS (ESI +ve TOF) calcd for C49H66N11O3 856.5350, found 856.5313 ([M + H]+).

(R)-N-((R)-6-Amino-1-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H1,2,3-triazol-1-yl)hexan-2-yl)-5-guanidino-2-(2-phenylacetamido)pentanamide
dihydrochloride (73)

Following General Procedure B, amine 63a (400 mg, 0.73 mmol), Fmoc-(D)-Arg(Pbf)-OH
(61) (564 mg, 0.87 mmol), EDCI (166 mg, 0.87 mmol) and HOBt (118 mg, 0.79 mmol) were
stirred in acetonitrile (7.2 mL) for 24 h to give the intermediate amide 72 (665 mg, 78%) as
a translucent tan gum after flash chromatography over SiO2 gel (MeOH/EtOAc/P.S. –
0:40:60  0.5:80:19.5). To a solution of the amide (250 mg, 0.21 mmol) in acetonitrile (2.1
mL) was added tris-(2-aminoethyl)amine (155 mg, 1.06 mmol) and the reaction was stirred
vigorously at rt for 90 min. The reaction mixture was diluted with CH2Cl2 (100 mL) and
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washed successively with phosphate buffer (pH = 5.5) – (3 × 50 mL) and brine (1 × 50 mL).
The organic phase was dried (Na2SO4), filtered, concentrated and the residue was subjected
to flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 5:95  10:90) to afford the
intermediate amine 71 (151 mg, 74%). Following General Procedure B, the intermediate
amine (53 mg, 0.06 mmol), phenylacetic acid (9 mg, 0.07 mmol), EDCI (13 mg, 0.07 mmol)
and HOBt (9 mg, 0.06 mmol) were stirred in acetonitrile (0.6 mL) for 18 h to give the
intermediate amide as a translucent tan gum. Following General Procedure C, the amide
was dissolved in CH2Cl2 (1.7 mL) and treated with H2O (20 mg, 1.10 mmol) and CF3CO2H
(1.7 mL) followed by work-up with ethereal HCl to give the amine salt 73 (27 mg, 61% over
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two steps) as a light tan powder that rapidly transitioned to a sticky gum. [α] D −6.2 (c 0.57,
MeOH); 1H NMR (400 MHz, CD3OD) δ 7.69 (s, 1H, H5'), 7.35 – 7.08 (m, 10H, ArH), 7.02
– 6.86 (m, 3H, ArH), 5.05 (s, 2H, -OCH2-C4'), 4.48 – 4.30 (m, 2H, H1), 4.23 (s, 1H, H2),
4.15 (br s, 1H, H2'''), 3.93 – 3.84 (m, 2H, H1''), 3.66 – 3.51 (m, 2H, -CH2Ph), 3.11 (br s, 2H,
H6), 2.85 (br s, 2H, H5'''), 1.75 – 1.27 (m, 13H, H3, H4, H5, H2'', H3'', H3''' and H4'''), 0.79
(d, J = 6.6 Hz, 6H, H4'' and H5''); 13C NMR (101 MHz, CD3OD) δ 174.9 (C1'''), 174.6 (Cα),
158.8 (C=N), 158.1 (CAr2'), 157.5 (CAr2), 145.4 (C4'), 137.3 (Phenyl CAr), 133.0 (CAr6 or
CAr6'), 132.7 (CAr6' or CAr6), 130.6 (Phenyl CAr)*, 130.4 (CAr1 and CAr1'), 129.83 (CAr4
or CAr4'), 129.78 (Phenyl CAr)*, 129.7 (CAr4' or CAr4), 128.1 (Phenyl CAr), 126.3 (C5'),
122.3 (CAr5), 121.5 (CAr5'), 114.8 (CAr3), 113.8 (CAr3'), 68.2 (C1''), 63.6 (-OCH2-C4'),
55.2 (C2'''), 54.7 (C1), 51.1 (C2), 43.7 (-CH2Ph), 41.7 (C6), 40.5 (C5'''), 39.4 (C2''), 31.9
(C3), 29.9 (C3'''), 28.1 (C5), 26.3 (C3''), 26.2 (C4'''), 23.6 (C4), 23.1 (C4'' and C5''); IR (neat)
ν̄max 3069, 2955, 2931, 2869, 1663, 1540, 1506, 1473, 1438, 1386, 1260, 1203, 1089, 1053,
1022, 800, 751, 721, 696, 616 cm-1; MS (ESI +ve) m/z 726 ([M + H]+, 100%), 748 ([M +
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Na]+, 22%); HRMS (ESI +ve TOF) calcd for C40H55N9O4Na 748.4275, found 748.4288 ([M
+ Na]+).

(9H-Fluoren-9-yl)methyl ((R)-1-(((R)-6-amino-1-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]2-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)hexan-2-yl)amino)-5-guanidino-1-oxopentan-2yl)carbamate dihydrochloride (74)

Following General Procedure C, the intermediate amide 72 (50 mg, 0.04 mmol) was
dissolved in CH2Cl2 (1.3 mL) and treated with H2O (15 mg, 0.85 mmol) and CF3CO2H (1.3
mL) followed by work-up with ethereal HCl to give the amine salt 74 (36 mg, 95%) as a light
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tan powder that rapidly transitioned to a sticky gum. [α] D −4.4 (c 1.03, MeOH); 1H NMR
(400 MHz, CD3OD) δ 7.82 – 7.51 (m, 5H), 7.42 – 7.08 (m, 9H), 7.04 – 6.83 (m, 3H), 5.05
(s, 2H), 4.53 – 4.22 (m, 6H), 4.00 – 3.83 (m, 3H), 3.15 – 3.04 (m, 2H), 2.98 – 2.84 (m, 2H),
1.75 – 1.25 (m, 13H), 0.79 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 175.0, 158.8,
158.4, 158.1, 157.5, 147.7, 145.4, 141.3, 136.5*, 133.0, 132.7, 130.6, 130.5, 130.4, 129.84,
129.76, 129.7, 126.0, 125.2*, 122.3, 122.0, 121.5*, 114.8, 113.8, 71.0, 68.2, 63.7, 56.2, 54.7,
50.9, 48.5, 41.9, 40.7, 39.4, 32.1, 30.2, 28.1, 26.3, 26.2, 23.7, 23.1*; IR (neat) ν̄max 3168,
3067, 2956, 2932, 2871, 1714, 1664, 1526, 1506, 1473, 1438, 1386, 1227, 1150, 1091, 1052,
976, 917, 859, 737, 615 cm-1; MS (ESI +ve) m/2 416 ([M + 2H]2+, 100%), m/z 852 ([M +
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Na]+, 8%); HRMS (ESI +ve TOF) calcd for C47H60N9O5 830.4717, found 830.4747 ([M +
H]+).

6.3.4 – Series B1
(R)-6-((Tert-butoxycarbonyl)amino)-2-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)hexanoic acid (75a)
Following General Procedure A, azide 24 (400 mg, 1.47
mmol), alkyne 21 (865 mg, 2.94 mmol), Cu(OAc)2∙H2O (59
mg, 0.29 mmol) and sodium ascorbate (116 mg, 0.59 mmol)
were stirred in t-BuOH (29.4 mL) and H2O (7.4 mL) for 26
h to give the product triazole 75a (703 mg, 85%) as a
translucent tan gum after flash chromatography over SiO2
gel (EtOAc/P.S. – 10:90  MeOH/CH2Cl2 – 10:90). TLC
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(MeOH/CH2Cl2 – 10:90): Rf = 0.44; [α] D +5.0 (c 1.27, MeOH); 1H NMR (400 MHz, DMSO)
δ 7.89 (s, 1H, H5'), 7.35 – 7.20 (m, 3H, ArH), 7.20 – 7.11 (m, 2H, ArH), 7.05 – 6.88 (m, 3H,
ArH), 6.73 (br s, 1H, N6-H), 5.19 (br s, 1H, H2), 5.09 (s, 2H, -OCH2-C4'), 3.94 – 3.83 (m,
2H, H1''), 2.89 – 2.77 (m, 2H, H6), 2.19 – 1.92 (m, 2H, H3), 1.61 – 1.50 (m, 1H, H3''), 1.47
– 1.26 (m, 13H, H5, H2'' and -C(CH3)3), 1.19 – 1.07 (m, 1H, H4A or H4B), 1.01 – 0.88 (m,
1H, H4B or H4A), 0.78 (d, J = 6.6 Hz, 6H, H4'' and H5'');

13

C NMR (101 MHz, DMSO)

δ 156.1 (CAr2'), 155.7 (CAr2), 155.6 (C1), 155.5 (Cα), 142.9 (C4'), 131.13 (CAr6 or CAr6'),
131.07 (CAr6' or CAr6), 128.4 (CAr4 or CAr4'), 128.3 (CAr4' or CAr4), 127.9 (CAr1), 127.4
(CAr1'), 123.3 (C5'), 120.4 (CAr5), 119.8 (CAr5'), 113.0 (CAr3), 112.2 (CAr3'), 77.3
(-C(CH3)3), 66.2 (C1''), 63.0 (C2 – observed by gHSQC), 62.2 (-OCH2-C4'), 39.4 (C6 –
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observed by gHSQC), 37.4 (C2''), 31.4 (C3), 28.8 (C5), 28.2 (-C(CH3)3), 24.4 (C3''), 22.8
(C4), 22.3 (C4'' and C5''); IR (neat) ν̄max 3345, 2956, 2932, 2869, 2362, 2341, 1734, 1718,
1700, 1684, 1653, 1636, 1594, 1577, 1559, 1540, 1507, 1473, 1457, 1437, 1395, 1367, 1340,
1260, 1238, 1165, 1124, 1109, 1052, 1003, 982, 931, 855, 810, 751, 734 cm-1; MS (ESI −ve)
m/z 565 ([M − H]−, 100%); HRMS (ESI +ve TOF) calcd for C31H42N4O6Na 589.3002, found
589.2993 ([M + Na]+).

(R)-6-Amino-N-benzyl-2-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H1,2,3-triazol-1-yl)hexanamide hydrochloride (76a)
Following General Procedure B, acid 75a (50 mg, 0.09
mmol), benzylamine (11 mg, 0.11 mmol), EDCI (20 mg,
0.11 mmol) and HOBt (14 mg, 0.11 mmol) were stirred
in acetonitrile (0.9 mL) for 24 h to give the intermediate
amide as a translucent tan gum. Following General
Procedure D, the amide was dissolved in CH2Cl2 (2.7 mL) and treated with CF3CO2H (2.7
mL) followed by work-up with ethereal HCl to give the amine salt 76a (56 mg, 95% over
23

two steps) as a light tan powder that rapidly transitioned to a sticky gum. [α] D +7.0 (c 1.33,
MeOH); 1H NMR (400 MHz, CD3OD) δ 7.75 (s, 1H, H5'), 7.34 – 7.10 (m, 10H, ArH), 7.05
– 6.97 (m, 2H, ArH), 6.94 (t, J = 7.1 Hz, 1H, ArH), 5.29 (t, J = 7.6 Hz, 1H, H2), 5.15 – 5.04
(m, 2H, -OCH2-C4'), 4.37 (s, 2H, -CH2Ph), 3.95 – 3.83 (m, 2H, H1''), 2.83 (t, J = 6.8 Hz, 2H,
H6), 2.23 – 2.01 (m, 2H, H3), 1.72 – 1.50 (m, 3H, H5 and H3''), 1.46 – 1.38 (m, 2H, H2''),
1.34 – 1.11 (m, 2H, H4), 0.77 (d, J = 6.6 Hz, 6H, H4'' and H5''); 13C NMR (101 MHz, CD3OD)
δ 169.8 (C1), 158.2 (CAr2'), 157.6 (CAr2), 146.3 (C4'), 139.5 (Phenyl C Ar), 132.8 (CAr6 or
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CAr6'), 132.5 (CAr6' or CAr6), 130.7 (CAr1 and CAr1'), 129.9 (CAr4 or CAr4'), 129.84
(Phenyl CAr)*, 129.76 (CAr4' or CAr4), 128.8 (Phenyl CAr)*, 128.7 (Phenyl CAr), 124.1 (C5'),
122.5 (CAr5), 121.5 (CAr5'), 114.7 (CAr3), 113.7 (CAr3'), 68.2 (C1''), 64.9 (C2), 64.1
(-OCH2-C4'), 44.6 (-CH2Ph), 40.5 (C6), 39.4 (C2''), 33.3 (C3), 28.0 (C5), 26.2 (C3''), 23.8
(C4), 23.10 (C4'' or C5''), 23.07 (C5'' or C4''); IR (neat) ν̄max 3276, 3065, 2954, 2934, 2870,
2364, 2318, 1718, 1684, 1669, 1653, 1636, 1594, 1576, 1559, 1540, 1507, 1473, 1457, 1437,
1395, 1340, 1260, 1202, 1180, 1130, 1110, 1052, 1003, 982, 932, 836, 799, 751, 721, 698,
615 cm-1; MS (ESI +ve) m/z 578 ([M + Na]+, 100%), 556 ([M + H]+, 91%); HRMS (ESI +ve
TOF) calcd for C33H42N5O3 556.3288, found 556.3302 ([M + H]+).

(R)-6-Amino-2-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H-1,2,3triazol-1-yl)-N-phenethylhexanamide hydrochloride (76b)
Following General Procedure B, acid 75a (50 mg,
0.09 mmol), β-phenylethylamine (13 mg, 0.11 mmol),
EDCI (20 mg, 0.11 mmol) and HOBt (14 mg, 0.11
mmol) were stirred in acetonitrile (0.9 mL) for 24 h to
give the intermediate amide as a translucent tan gum.
Following General Procedure D, the amide was dissolved in CH2Cl2 (2.7 mL) and treated
with CF3CO2H (2.7 mL) followed by work-up with ethereal HCl to give the amine salt 76b
(51 mg, 94% over two steps) as a light tan powder that rapidly transitioned to a sticky gum.
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[α] D +7.9 (c 1.20, MeOH); 1H NMR (400 MHz, CD3OD) δ 7.72 (s, 1H), 7.35 – 7.08 (m,
10H), 7.01 (t, J = 7.5 Hz, 2H), 6.94 (t, J = 7.4 Hz, 1H), 5.21 (t, J = 7.6 Hz, 1H), 5.14 – 5.06
(m, 2H), 3.95 – 3.84 (m, 2H), 3.45 (t, J = 7.0 Hz, 2H), 2.83 (t, J = 7.2 Hz, 2H), 2.78 (t, J =
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7.1 Hz, 2H), 2.15 – 1.94 (m, 2H), 1.70 – 1.50 (m, 3H), 1.47 – 1.38 (m, 2H), 1.29 – 1.10 (m,
2H), 0.78 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 169.7, 158.2, 157.5, 146.1,
140.3, 132.8, 132.6, 130.6, 130.0*, 129.9, 129.82, 129.76, 129.7*, 127.6, 124.2, 122.5, 121.5,
114.7, 113.7, 68.2, 65.0, 64.0, 42.2, 40.5, 39.4, 36.3, 33.2, 28.0, 26.2, 23.7, 23.11, 23.09; IR
(neat) ν̄max 3242, 3065, 2954, 2934, 2869, 2363, 1684, 1670, 1594, 1555, 1502, 1474, 1438,
1385, 1367, 1261, 1219, 1161, 1123, 1110, 1052, 1002, 933, 852, 799, 749, 700, 616 cm-1;
MS (ESI +ve) m/z 570 ([M + H]+, 100%), 592 ([M + Na]+, 82%); HRMS (ESI +ve TOF)
calcd for C34H44N5O3 570.3444, found 570.3448 ([M + H]+).

(R)-6-Amino-N-cyclohexyl-2-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)1H-1,2,3-triazol-1-yl)hexanamide hydrochloride (76c)
Following General Procedure B, acid 75a (50 mg, 0.09
mmol), cyclohexylamine (11 mg, 0.11 mmol), EDCI (20
mg, 0.11 mmol) and HOBt (14 mg, 0.11 mmol) were stirred
in acetonitrile (0.9 mL) for 24 h to give the intermediate
amide as a translucent tan gum. Following General
Procedure D, the amide was dissolved in CH2Cl2 (2.7 mL) and treated with CF3CO2H (2.7
mL) followed by work-up with ethereal HCl to give the amine salt 76c (48 mg, 94% over
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two steps) as a light tan powder that rapidly transitioned to a sticky gum. [α] D +5.7 (c 1.37,
MeOH); 1H NMR (400 MHz, CD3OD) δ 7.75 (s, 1H), 7.34 – 7.25 (m, 2H), 7.21 – 7.10 (m,
3H), 7.06 – 6.98 (m, 2H), 6.95 (t, J = 7.4 Hz, 1H), 5.26 (t, J = 7.6 Hz, 1H), 5.14 – 5.04 (m,
2H), 3.98 – 3.84 (m, 2H), 3.68 – 3.56 (m, 1H), 2.87 (t, J = 6.6 Hz, 2H), 2.19 – 1.98 (m, 2H),
1.92 – 1.50 (m, 7H), 1.47 – 1.11 (m, 10H), 0.78 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz,
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CD3OD) δ 168.9, 158.2, 157.5, 146.2, 132.7, 132.5, 130.6*, 129.8, 129.7, 123.9, 122.4,
121.5, 114.7, 113.7, 68.2, 64.9, 64.1, 50.4, 40.5, 39.4, 33.8, 33.6, 33.5, 28.1, 26.7, 26.24,
26.20, 26.17, 23.8, 23.11, 23.08; IR (neat) ν̄max 3265, 3065, 2934, 2855, 2371, 1680, 1665,
1545, 1507, 1472, 1441, 1339, 1261, 1219, 1160, 1023, 892, 854, 805, 750, 616 cm-1; MS
(ESI +ve) m/z 548 ([M + H]+, 100%), 570 ([M + Na]+, 73%); HRMS (ESI +ve TOF) calcd
for C32H46N5O3 548.3601, found 548.3602 ([M + H]+).

(R)-6-Amino-N-(cyclohexylmethyl)-2-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)hexanamide hydrochloride (76d)
Following General Procedure B, acid 75a (50 mg, 0.09
mmol), cyclohexylmethylamine (12 mg, 0.11 mmol),
EDCI (20 mg, 0.11 mmol) and HOBt (14 mg, 0.11
mmol) were stirred in acetonitrile (0.9 mL) for 24 h to
give the intermediate amide as a translucent tan gum.
Following General Procedure D, the amide was dissolved in CH2Cl2 (2.7 mL) and treated
with CF3CO2H (2.7 mL) followed by work-up with ethereal HCl to give the amine salt 76d
(49 mg, 92% over two steps) as a light tan powder that rapidly transitioned to a sticky gum.
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[α] D +4.5 (c 1.00, MeOH); 1H NMR (400 MHz, CD3OD) δ 7.75 (s, 1H), 7.35 – 7.25 (m, 2H),
7.22 – 7.10 (m, 3H), 7.01 (t, J = 7.0 Hz, 2H), 6.95 (t, J = 7.4 Hz, 1H), 5.29 (t, J = 7.6 Hz,
1H), 5.15 – 5.05 (m, 2H), 3.97 – 3.85 (m, 2H), 3.04 (dd, J = 6.7, 2.6 Hz, 2H), 2.93 – 2.79 (m,
2H), 2.21 – 2.00 (m, 2H), 1.76 – 1.40 (m, 10H), 1.35 – 1.10 (m, 6H), 0.97 – 0.83 (m, 2H),
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0.78 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 170.1‡, 158.2, 157.6, 146.2, 132.7,
132.6, 130.7*, 129.9, 129.8, 124.0, 122.5, 121.5, 114.7, 113.7, 68.2, 65.0‡, 64.1, 47.2‡, 40.5,
39.4, 39.2, 33.3, 32.08, 32.05, 28.1, 27.7, 27.1*, 26.3, 23.9, 23.12, 23.08; IR (neat) ν̄max 3241,
3068, 2954, 2925, 2868, 2856, 2362, 1684, 1669, 1594, 1555, 1503, 1474, 1441, 1386, 1368,
1261, 1223, 1161, 1123, 1109, 1052, 1019, 982, 932, 851, 799, 750, 615 cm-1; MS (ESI +ve)
m/z 584 ([M + Na]+, 100%), 562 ([M + H]+, 81%); HRMS (ESI +ve TOF) calcd for
C33H48N5O3 562.3757, found 562.3759 ([M + H]+).

(R)-6-Amino-2-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H-1,2,3triazol-1-yl)-N-(4-(trifluoromethyl)benzyl)hexanamide hydrochloride (76e)
Following General Procedure B, acid 75a (50 mg,
0.09 mmol), 4-(trifluoromethyl)benzylamine (19
mg, 0.11 mmol), EDCI (20 mg, 0.11 mmol) and
HOBt (14 mg, 0.11 mmol) were stirred in
acetonitrile (0.9 mL) for 24 h to give the
intermediate amide as a translucent tan gum. Following General Procedure D, the amide
was dissolved in CH2Cl2 (2.7 mL) and treated with CF3CO2H (2.7 mL) followed by work-up
with ethereal HCl to give the amine salt 76e (56 mg, 97% over two steps) as a light tan
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powder that rapidly transitioned to a sticky gum. [α] D +14.2 (c 1.50, MeOH); 1H NMR (400

‡ Indicates that the 13C NMR resonance was split into two resonances due to the presence of both amide
rotamers (i.e. the syn- and anti-amide conformations); only the major resonance from each resonance pair is
reported for clarity.
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MHz, CD3OD) δ 7.79 (s, 1H), 7.59 (d, J = 8.0 Hz, 2H), 7.42 (d, J = 8.0 Hz, 2H), 7.34 – 7.22
(m, 2H), 7.21 – 7.10 (m, 3H), 7.04 – 6.97 (m, 2H), 6.93 (t, J = 7.3 Hz, 1H), 5.37 (t, J = 7.4
Hz, 1H), 5.16 – 5.04 (m, 2H), 4.52 – 4.40 (m, 2H), 3.95 – 3.82 (m, 2H), 2.86 (br s, 2H), 2.28
– 2.04 (m, 2H), 1.75 – 1.61 (m, 2H), 1.61 – 1.48 (m, 1H), 1.46 – 1.37 (m, 2H), 1.36 – 1.11
(m, 2H), 0.76 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 170.1, 158.2, 157.5, 146.3,
144.2, 132.8, 132.5, 130.9 (q, 2JCF = 32.2 Hz)†, 130.6, 129.9, 129.82, 129.75, 129.3*, 126.7
(q, 3JCF = 3.8 Hz)*, 126.6, 124.5 (q, 1JCF = 270.5 Hz)†, 124.3, 122.5, 121.5, 114.7, 113.7,
68.2, 64.9, 64.0, 44.0, 40.5, 39.4, 33.2, 28.0, 26.2, 23.8, 23.08, 23.05; IR (neat) ν̄max 3242,
3067, 2955, 2928, 2869, 2361, 1684, 1620, 1594, 1555, 1504, 1474, 1441, 1420, 1387, 1324,
1261, 1223, 1164, 1122, 1112, 1067, 1018, 849, 819, 751, 615 cm-1; MS (ESI +ve) m/z 624
([M + H]+, 100%), 646 ([M + Na]+, 98%); HRMS (ESI +ve TOF) calcd for C34H41N5O3F3
624.3162, found 624.3173 ([M + H]+).

† Incomplete multiplet resonance: the two 13C NMR quartet resonances (assigned to the carbons closest to the
fluorine atoms (i.e. -CF3 and C-CF3)) were each missing one of their outer quartet peaks due to the strong JCF
coupling that spread the weak quaternary signals over multiple lines (as quartets) – thus, the signals became
even weaker and buried amongst the background noise. Furthermore, quaternary carbons do not experience
the large Overhauser enhancement by proton decoupling that is experienced by protonated carbons, hence the
weaker signal.
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(R)-6-Amino-N-(4-fluorophenethyl)-2-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)hexanamide hydrochloride (76f)
Following General Procedure B, acid 75a (50 mg,
0.09 mmol), 2-(4-fluorophenyl)ethylamine (15 mg,
0.11 mmol), EDCI (20 mg, 0.11 mmol) and HOBt
(14 mg, 0.11 mmol) were stirred in acetonitrile (0.9
mL) for 24 h to give the intermediate amide as a
translucent tan gum. Following General Procedure D, the amide was dissolved in CH2Cl2
(2.7 mL) and treated with CF3CO2H (2.7 mL) followed by work-up with ethereal HCl to give
the amine salt 76f (51 mg, 93% over two steps) as a light tan powder that rapidly transitioned
23

to a sticky gum. [α] D +10.8 (c 1.23, MeOH); 1H NMR (400 MHz, CD3OD) δ 7.70 (s, 1H),
7.34 – 7.23 (m, 2H), 7.21 – 7.06 (m, 5H), 7.05 – 6.88 (m, 5H), 5.20 (t, J = 7.6 Hz, 1H), 5.14
– 5.05 (m, 2H), 3.95 – 3.84 (m, 2H), 3.50 – 3.33 (m, 2H), 2.84 (t, J = 6.6 Hz, 2H), 2.76 (t, J
= 6.9 Hz, 2H), 2.14 – 1.94 (m, 2H), 1.71 – 1.50 (m, 3H), 1.47 – 1.39 (m, 2H), 1.28 – 1.09
(m, 2H), 0.78 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 169.8, 163.2 (d, 1JCF =
242.8 Hz), 158.2, 157.5, 146.2, 136.2 (d, 4JCF = 3.2 Hz), 132.8, 132.6, 131.7 (d, 3JCF = 7.9
Hz), 130.6*, 129.9, 129.8, 124.0, 122.4, 121.5, 116.2 (d, 2JCF = 21.4 Hz), 114.7, 113.7, 68.2,
64.9, 64.0, 42.1, 40.5, 39.4, 35.4, 33.2, 28.0, 26.2, 23.8, 23.10, 23.08; IR (neat) ν̄max 3241,
3068, 2954, 2925, 2868, 2362, 1684, 1594, 1555, 1503, 1474, 1441, 1386, 1368, 1261, 1223,
1161, 1123, 1109, 1052, 1019, 982, 932, 851, 805, 750, 615 cm-1; MS (ESI +ve) m/z 610 ([M
+ Na]+, 100%), 588 ([M + H]+, 86%); HRMS (ESI +ve TOF) calcd for C34H43N5O3F
588.3350, found 588.3358 ([M + H]+).
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(R)-2-(4-(((2'-(Isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-5(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino)pentanoic
acid (75b)
Following General Procedure A, azide 28 (1.20 g, 2.65
mmol), alkyne 21 (1.56 g, 5.30 mmol), Cu(OAc)2∙H2O (106
mg, 0.53 mmol) and sodium ascorbate (210 mg, 1.06 mmol)
were stirred in t-BuOH (53 mL) and H2O (13.3 mL) for 18 h
to give the product triazole 75b (1.63 g, 82%) as a translucent
tan gum after flash chromatography over SiO2 gel
(EtOAc/P.S. – 10:90  MeOH/CH2Cl2 – 10:90). TLC (MeOH/CH2Cl2 – 10:90): Rf = 0.40,
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(EtOAc/P.S. – 80:20): Rf = 0.42; [α] D −28.1 (c 1.03, MeOH); 1H NMR (400 MHz, DMSO)
δ 7.84 (s, 1H, H5'), 7.60 (br s, 1H, N5-H), 7.33 – 7.18 (m, 3H, ArH), 7.18 – 7.10 (m, 2H,
ArH), 7.01 – 6.94 (m, 2H, ArH), 6.88 (t, J = 7.3 Hz, 1H, ArH), 6.80 (br s, 2H, -NH2), 5.06
(s, 2H, -OCH2-C4'), 4.91 (br s, 1H, H2), 3.93 – 3.81 (m, 2H, H1''), 3.07 – 2.96 (m, 2H, H5),
2.94 (s, 2H, ArCH2-), 2.47 (s, 3H, ArCH3), 2.41 (s, 3H, ArCH3), 2.22 – 2.07 (m, 1H, H3A or
H3B), 1.99 (s, 3H, ArCH3), 1.91 – 1.77 (m, 1H, H3B or H3A), 1.54 (td, J = 13.2, 6.6 Hz, 1H,
H3''), 1.45 – 1.33 (m, 8H, H2'' and -C(CH3)2), 1.23 (br s, 1H, H4A or H4B), 1.07 (br s, 1H,
H4B or H4A), 0.76 (d, J = 6.6 Hz, 6H, H4'' and H5''); 13C NMR (101 MHz, DMSO) δ 157.4
(Pbf CAr), 156.32 (C=N), 156.27 (C1), 156.1 (CAr2'), 155.7 (CAr2), 142.6 (C4'), 137.2 (Pbf
CAr), 134.3 (Pbf CAr), 131.4 (Pbf CAr), 131.2 (CAr6 or CAr6'), 131.1 (CAr6' or CAr6), 128.5
(CAr4 or CAr4'), 128.4 (CAr4' or CAr4), 127.9 (CAr1), 127.4 (CAr1'), 124.3 (Pbf C Ar), 123.1
(C5'), 120.4 (CAr5), 119.9 (CAr5'), 116.2 (Pbf CAr), 113.0 (CAr3), 112.2 (CAr3'), 86.2
(-C(CH3)2), 66.2 (C1''), 64.9 (C2), 62.2 (-OCH2-C4'), 42.5 (ArCH2-), 39.5 (C5 – observed by
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gHSQC), 37.5 (C2''), 30.2 (C3), 28.3 (-C(CH3)2), 25.9 (C4), 24.5 (C3''), 22.4 (C4'' and C5''),
18.9 (ArCH3), 17.6 (ArCH3), 12.3 (ArCH3); IR (neat) ν̄max 3327, 2946, 2873, 2831, 2363,
2167, 2027, 1617, 1559, 1506, 1442, 1405, 1238, 1108, 1023, 804, 751, 668 cm-1; MS (ESI
+ve) m/z 747 ([M + H]+, 100%), MS (ESI −ve) m/z 745 ([M − H]−, 100%); HRMS (ESI +ve
TOF) calcd for C39H51N6O7S 747.3540, found 747.3572 ([M + H]+).

(R)-N-Benzyl-5-guanidino-2-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)1H-1,2,3-triazol-1-yl)pentanamide hydrochloride (77a)
Following General Procedure B, acid 75b (50 mg, 0.07
mmol), benzylamine (9 mg, 0.08 mmol), EDCI (15 mg,
0.08 mmol) and HOBt (11 mg, 0.07 mmol) were stirred
in acetonitrile (0.7 mL) for 22 h to give the intermediate
amide as a translucent tan gum. Following General
Procedure C, the amide was dissolved in CH2Cl2 (2.0 mL) and treated with H2O (24 mg,
1.34 mmol) and CF3CO2H (2.0 mL) followed by work-up with ethereal HCl to give the amine
salt 77a (39 mg, 94% over two steps) as a light tan powder that rapidly transitioned to a sticky
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gum. [α] D +17.8 (c 0.93, MeOH); 1H NMR (400 MHz, CD3OD) δ 7.77 (s, 1H, H5'), 7.33 –
7.11 (m, 10H, ArH), 7.05 – 6.91 (m, 3H, ArH), 5.34 – 5.27 (m, 1H, H2), 5.13 – 5.06 (m,
2H, -OCH2-C4'), 4.44 – 4.32 (m, 2H, -CH2Ph), 3.95 – 3.82 (m, 2H, H1''), 3.20 – 3.12 (m, 2H,
H5), 2.27 – 2.03 (m, 2H, H3), 1.60 – 1.33 (m, 5H, H4, H2'' and H3''), 0.77 (d, J = 6.9 Hz, 6H,
H4'' and H5'');
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C NMR (101 MHz, CD3OD) δ 169.7 (C1), 158.7 (C=N), 158.2 (CAr2'),

157.6 (CAr2), 146.3 (C4'), 139.5 (Phenyl CAr), 132.8 (CAr6 or CAr6'), 132.5 (CAr6' or
CAr6), 130.7 (CAr1), 129.9 (CAr4 or CAr4'), 129.84 (Phenyl CAr)*, 129.82 (CAr1'), 129.76
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(CAr4' or CAr4), 128.8 (Phenyl CAr)*, 128.6 (Phenyl CAr), 124.2 (C5'), 122.5 (CAr5), 121.5
(CAr5'), 114.8 (CAr3), 113.7 (CAr3'), 68.2 (C1''), 64.8 (C2), 64.1 (-OCH2-C4'), 44.6 (CH2Ph), 41.8 (C5), 39.4 (C2''), 31.0 (C3), 26.4 (C4), 26.2 (C3''), 23.09 (C4'' or C5''), 23.07
(C5'' or C4''); IR (neat) ν̄max 3328, 3183, 3065, 2955, 2932, 2871, 2364, 2323, 1669, 1653,
1617, 1559, 1540, 1507, 1473, 1457, 1437, 1387, 1363, 1340, 1213, 1123, 1107, 1082, 1040,
1003, 855, 801, 749, 698, 669 cm-1; MS (ESI +ve) m/z 584 ([M + H]+, 100%), 606 ([M +
Na]+, 5%); HRMS (ESI +ve TOF) calcd for C33H42N7O3 584.3349, found 584.3373 ([M +
H]+).

(R)-5-Guanidino-2-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H-1,2,3triazol-1-yl)-N-phenethylpentanamide hydrochloride (77b)
Following General Procedure B, acid 75b (50 mg,
0.07 mmol), β-phenylethylamine (10 mg, 0.08 mmol),
EDCI (15 mg, 0.08 mmol) and HOBt (11 mg, 0.07
mmol) were stirred in acetonitrile (0.7 mL) for 22 h to
give the intermediate amide as a translucent tan gum.
Following General Procedure C, the amide was dissolved in CH2Cl2 (2.0 mL) and treated
with H2O (24 mg, 1.34 mmol) and CF3CO2H (2.0 mL) followed by work-up with ethereal
HCl to give the amine salt 77b (37 mg, 87% over two steps) as a light tan powder that rapidly
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transitioned to a sticky gum. [α] D +33.8 (c 0.97, MeOH); 1H NMR (400 MHz, CD3OD)
δ 7.71 (s, 1H), 7.34 – 7.08 (m, 10H), 7.04 – 6.91 (m, 3H), 5.21 (t, J = 7.7 Hz, 1H), 5.12 –
5.06 (m, 2H), 3.95 – 3.83 (m, 2H), 3.48 – 3.41 (m, 2H), 3.14 (t, J = 7.0 Hz, 2H), 2.78 (t, J =
7.1 Hz, 2H), 2.18 – 1.95 (m, 2H), 1.61 – 1.50 (m, 1H), 1.48 – 1.29 (m, 4H), 0.77 (d, J = 6.6
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Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 169.6, 158.7, 158.2, 157.5, 146.1, 140.2, 132.8,
132.6, 130.6, 130.0*, 129.9, 129.81, 129.77, 129.7*, 127.6, 124.2, 122.5, 121.5, 114.7, 113.8,
68.2, 64.9, 64.0, 42.2, 41.9, 39.4, 36.3, 30.8, 26.2, 26.2, 23.09, 23.08; IR (neat) ν̄max 3330,
3185, 3065, 2953, 2930, 2870, 2364, 2322, 1684, 1669, 1653, 1617, 1559, 1540, 1507, 1473,
1457, 1437, 1387, 1363, 1340, 1212, 1123, 1109, 1087, 1040, 1003, 936, 855, 801, 748, 700,
668 cm-1; MS (ESI +ve) m/z 598 ([M + H]+, 100%), 620 ([M + Na]+, 22%); HRMS (ESI +ve
TOF) calcd for C34H44N7O3 598.3506, found 598.3523 ([M + H]+).

(R)-N-Cyclohexyl-5-guanidino-2-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)pentanamide hydrochloride (77c)
Following General Procedure B, acid 75b (50 mg, 0.07
mmol), cyclohexylamine (8 mg, 0.08 mmol), EDCI (15
mg, 0.08 mmol) and HOBt (11 mg, 0.07 mmol) were
stirred in acetonitrile (0.7 mL) for 21 h to give the
intermediate amide as a translucent tan gum. Following
General Procedure C, the amide was dissolved in CH2Cl2 (2.0 mL) and treated with H2O
(24 mg, 1.34 mmol) and CF3CO2H (2.0 mL) followed by work-up with ethereal HCl to give
the amine salt 77c (39 mg, 95% over two steps) as a light tan powder that rapidly transitioned
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to a sticky gum. [α] D +15.9 (c 0.83, MeOH); 1H NMR (400 MHz, CD3OD) δ 7.77 (s, 1H),
7.34 – 7.24 (m, 2H), 7.23 – 7.09 (m, 3H), 7.05 – 6.98 (m, 2H), 6.95 (t, J = 7.4 Hz, 1H), 5.24
(t, J = 7.7 Hz, 1H), 5.14 – 5.05 (m, 2H), 3.96 – 3.85 (m, 2H), 3.68 – 3.57 (m, 1H), 3.18 (t, J
= 7.0 Hz, 2H), 2.22 – 2.00 (m, 2H), 1.92 – 1.12 (m, 15H), 0.77 (d, J = 6.6 Hz, 6H); 13C NMR
(101 MHz, CD3OD) δ 168.7, 158.8, 158.2, 157.5, 146.2, 132.7, 132.5, 130.7*, 129.9, 129.7,
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124.0, 122.5, 121.5, 114.7, 113.8, 68.2, 64.8, 64.1, 50.4, 41.9, 39.4, 33.7, 33.6, 31.1, 26.7,
26.4, 26.3, 26.20, 26.16, 23.1*; IR (neat) ν̄max 3329, 3185, 3067, 2953, 2929, 2868, 2364,
2323, 1684, 1669, 1653, 1617, 1559, 1540, 1507, 1473, 1457, 1437, 1387, 1363, 1340, 1213,
1123, 1108, 1088, 1040, 1003, 941, 855, 802, 749, 668 cm-1; MS (ESI +ve) m/z 576 ([M +
H]+, 100%), 598 ([M + Na]+, 19%); HRMS (ESI +ve TOF) calcd for C32H46N7O3 576.3662,
found 576.3688 ([M + H]+).

(R)-N-(Cyclohexylmethyl)-5-guanidino-2-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)pentanamide hydrochloride (77d)
Following General Procedure B, acid 75b (50 mg, 0.07
mmol), cyclohexylmethylamine (9 mg, 0.08 mmol),
EDCI (15 mg, 0.08 mmol) and HOBt (11 mg, 0.07 mmol)
were stirred in acetonitrile (0.7 mL) for 24 h to give the
intermediate amide as a translucent tan gum. Following
General Procedure C, the amide was dissolved in CH2Cl2 (2.0 mL) and treated with H2O
(24 mg, 1.34 mmol) and CF3CO2H (2.0 mL) followed by work-up with ethereal HCl to give
the amine salt 77d (25 mg, 60% over two steps) as a light tan powder that rapidly transitioned
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to a sticky gum. [α] D −5.6 (c 0.63, MeOH); 1H NMR (400 MHz, CD3OD) δ 7.76 (s, 1H),
7.34 – 7.24 (m, 2H), 7.22 – 7.10 (m, 3H), 7.05 – 6.98 (m, 2H), 6.95 (t, J = 7.4 Hz, 1H), 5.31
(t, J = 7.6 Hz, 1H), 5.13 – 5.04 (m, 2H), 3.96 – 3.85 (m, 2H), 3.17 (t, J = 6.7 Hz, 2H), 3.07 –
2.99 (m, 2H), 2.26 – 2.01 (m, 2H), 1.77 – 1.36 (m, 11H), 1.33 – 1.12 (m, 3H), 0.96 – 0.82
(m, 2H), 0.78 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 169.9, 158.8, 158.2, 157.6,
146.4, 132.8, 132.6, 130.7, 129.9, 129.84, 129.76, 124.2, 122.5, 121.5, 114.8, 113.8, 68.2,
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64.8, 64.1, 47.2, 41.8, 39.4, 39.2, 32.08, 32.06, 31.0, 27.7, 27.1*, 26.31, 26.25, 23.11, 23.08;
IR (neat) ν̄max 3330, 3185, 2954, 2926, 2869, 2364, 2322, 1684, 1669, 1653, 1617, 1559,
1540, 1507, 1473, 1457, 1437, 1387, 1363, 1340, 1213, 1123, 1108, 1088, 1049, 854, 801,
749, 668 cm-1; MS (ESI +ve) m/z 590 ([M + H]+, 100%), 612 ([M + Na]+, 28%); HRMS (ESI
+ve TOF) calcd for C33H48N7O3 590.3819, found 590.3829 ([M + H]+).

(R)-5-Guanidino-2-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H-1,2,3triazol-1-yl)-N-(4-(trifluoromethyl)benzyl)pentanamide hydrochloride (77e)
Following General Procedure B, acid 75b (50 mg,
0.07 mmol), 4-(trifluoromethyl)benzylamine (14
mg, 0.08 mmol), EDCI (15 mg, 0.08 mmol) and
HOBt (11 mg, 0.07 mmol) were stirred in
acetonitrile (0.7 mL) for 24 h to give the
intermediate amide as a translucent tan gum. Following General Procedure C, the amide
was dissolved in CH2Cl2 (2.0 mL) and treated with H2O (24 mg, 1.34 mmol) and CF3CO2H
(2.0 mL) followed by work-up with ethereal HCl to give the amine salt 77e (30 mg, 65%
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over two steps) as a light tan powder that rapidly transitioned to a sticky gum. [α] D +17.8 (c
1.23, MeOH); 1H NMR (400 MHz, CD3OD) δ 7.77 (s, 1H), 7.62 – 7.52 (m, 2H), 7.45 – 7.36
(m, 2H), 7.33 – 7.07 (m, 5H), 7.05 – 6.84 (m, 3H), 5.40 – 5.30 (m, 1H), 5.14 – 5.04 (m, 2H),
4.49 – 4.40 (m, 2H), 3.93 – 3.79 (m, 2H), 3.23 – 3.08 (m, 2H), 2.25 – 1.97 (m, 2H), 1.62 –
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1.18 (m, 5H), 0.77 – 0.71 (m, 6H);
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C NMR (101 MHz, CD3OD)† δ 169.9, 158.8, 158.2,

157.6, 149.6, 144.2, 132.8, 132.5, 130.6, 129.9, 129.83, 129.76, 129.3*, 126.7 (q, 3JCF = 3.6
Hz)*, 124.3, 122.5, 121.5, 114.7, 113.7, 68.2, 64.8, 64.1, 44.0, 41.9, 39.4, 30.9, 26.4, 26.2,
23.09, 23.07; IR (neat) ν̄max 2954, 2926, 2869, 2371, 2349, 2322, 1700, 1684, 1669, 1653,
1617, 1559, 1540, 1507, 1473, 1457, 1437, 1387, 1363, 1340, 1324, 1260, 1223, 1164, 1110,
1067, 1052, 1017, 917, 818, 751, 669 cm-1; MS (ESI +ve) m/z 652 ([M + H]+, 100%), 674
([M + Na]+, 18%); HRMS (ESI +ve TOF) calcd for C34H41N7O3F3 652.3223, found 652.3243
([M + H]+).

(R)-N-(4-Fluorophenethyl)-5-guanidino-2-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)pentanamide hydrochloride (77f)
Following General Procedure B, acid 75b (50 mg,
0.07 mmol), 2-(4-fluorophenyl)ethylamine (11 mg,
0.08 mmol), EDCI (15 mg, 0.08 mmol) and HOBt
(11 mg, 0.07 mmol) were stirred in acetonitrile (0.7
mL) for 24 h to give the intermediate amide as a
translucent tan gum. Following General Procedure C, the amide was dissolved in CH2Cl2

† Missing resonances: the two carbons closest to the fluorine atoms (i.e. -CF3 and C-CF3) could not be
assigned to resonances in the 13C NMR spectrum due to the strong JCF coupling that spread the weak
quaternary resonances over multiple lines (as quartets) – thus, the resonances became even weaker and buried
amongst the background noise. Furthermore, quaternary carbons do not experience the large Overhauser
enhancement by proton decoupling that is experienced by protonated carbons, thus making the resonances
even weaker and more difficult to observe..
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(2.0 mL) and treated with H2O (24 mg, 1.34 mmol) and CF3CO2H (2.0 mL) followed by
work-up with ethereal HCl to give the amine salt 77f (37 mg, 84% over two steps) as a light
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tan powder that rapidly transitioned to a sticky gum. [α] D +12.6 (c 1.00, MeOH); 1H NMR
(400 MHz, CD3OD) δ 7.72 (s, 1H), 7.34 – 7.05 (m, 7H), 7.04 – 6.85 (m, 5H), 5.20 (t, J = 7.6
Hz, 1H), 5.10 (s, 2H), 3.94 – 3.81 (m, 2H), 3.50 – 3.34 (m, 2H), 3.15 (t, J = 6.9 Hz, 2H), 2.79
– 2.68 (m, 2H), 2.18 – 1.96 (m, 2H), 1.60 – 1.26 (m, 5H), 0.77 (d, J = 6.5 Hz, 6H); 13C NMR
(101 MHz, CD3OD) δ 169.6, 163.2 (d, 1JCF = 242.8 Hz), 158.7, 158.2, 157.5, 146.0 (observed
by gHMBC), 136.2 (d, 4JCF = 3.2 Hz), 132.8, 132.6, 131.7 (d, 3JCF = 7.9 Hz)*, 130.6, 129.9,
129.80, 129.76, 124.1, 122.5, 121.5, 116.2 (d, 2JCF = 21.4 Hz)*, 114.7, 113.7, 68.2, 64.8,
64.0, 42.2, 41.9, 39.4, 35.5, 30.8, 26.3, 26.2, 23.09, 23.08; IR (neat) ν̄max 3330, 3194, 3072,
2954, 2931, 2869, 2370, 2323, 1671, 1669, 1625, 1603, 1573, 1551, 1509, 1473, 1441, 1385,
1364, 1220, 1158, 1108, 1040, 1005, 914, 823, 750, 668 cm-1; MS (ESI +ve) m/z 616 ([M +
H]+, 100%), 638 ([M + Na]+, 25%); HRMS (ESI +ve TOF) calcd for C34H43N7O3F 616.3411,
found 616.3428 ([M + H]+).

(R)-N-(3,5-Difluorobenzyl)-5-guanidino-2-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)pentanamide (77g)
Following General Procedure B, acid 75b (50 mg,
0.07 mmol), 3,5-difluorobenzylamine (12 mg, 0.08
mmol), EDCI (15 mg, 0.08 mmol) and HOBt (11 mg,
0.07 mmol) were stirred in acetonitrile (0.7 mL) for 24
h to give the intermediate amide as a translucent tan
gum. Following General Procedure C, the amide was dissolved in CH2Cl2 (2.0 mL) and
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treated with H2O (24 mg, 1.34 mmol) and CF3CO2H (2.0 mL) followed by work-up with
ethereal HCl to give the amine salt 77g (23 mg, 53% over two steps) as a light tan powder
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that rapidly transitioned to a sticky gum. [α] D −13.9 (c 0.50, MeOH); 1H NMR (400 MHz,
CD3OD) δ 7.76 (s, 1H), 7.33 – 7.09 (m, 5H), 7.05 – 6.77 (m, 6H), 5.33 (dd, J = 8.6, 6.6 Hz,
1H), 5.13 – 5.06 (m, 2H), 4.37 (m, 2H), 3.93 – 3.81 (m, 2H), 3.17 (t, J = 7.1 Hz, 2H), 2.21 –
1.98 (m, 2H), 1.59 – 1.25 (m, 5H), 0.79 – 0.71 (m, 6H);
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C NMR (101 MHz, CD3OD)

δ 169.9, 164.8 (dd, 1,3JCF = 248.6, 12.0 Hz)*, 158.8, 158.2, 157.6, 146.4, 144.3 (t, 3JCF = 9.1
Hz), 132.8, 132.5, 130.7*, 129.9, 129.8, 124.2, 122.5, 121.5, 114.8, 113.7, 111.5 (d, 2JCF =
25.7 Hz)*, 103.7 (t, 2JCF = 25.8 Hz), 68.2, 64.8, 64.2, 43.7, 41.9, 39.4, 30.9, 26.4, 26.2, 23.1,
23.0; IR (neat) ν̄max 3329, 3196, 3070, 2955, 2931, 2869, 2369, 2323, 1671, 1625, 1597, 1573,
1550, 1503, 1462, 1441, 1384, 1364, 1317, 1222, 1163, 1117, 1041, 1004, 914, 847, 750,
733, 668 cm-1; MS (ESI +ve) m/z 620 ([M + H]+, 100%), 642 ([M + Na]+, 34%); HRMS (ESI
+ve TOF) calcd for C33H40N7O3F2 620.3161, found 620.3152 ([M + H]+).

(R)-N-(3-Fluorophenyl)-5-guanidino-2-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)pentanamide hydrochloride (77h)
Following General Procedure B, acid 75b (50 mg, 0.07
mmol), 3-fluoroaniline (9 mg, 0.08 mmol), EDCI (15
mg, 0.08 mmol) and HOBt (11 mg, 0.07 mmol) were
stirred in acetonitrile (0.7 mL) for 24 h to give the
intermediate amide as a translucent tan gum. Following
General Procedure C, the amide was dissolved in CH2Cl2 (2.0 mL) and treated with H2O
(24 mg, 1.34 mmol) and CF3CO2H (2.0 mL) followed by work-up with ethereal HCl to give
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the amine salt 77h (33 mg, 79% over two steps) as a light tan powder that rapidly transitioned
23

to a sticky gum. [α] D +3.5 (c 0.93, MeOH); 1H NMR (400 MHz, CD3OD) δ 7.70 (s, 1H),
7.65 (d, J = 11.3 Hz, 1H), 7.43 – 7.39 (m, 1H), 7.35 – 7.08 (m, 6H), 7.06 – 6.88 (m, 3H),
6.88 – 6.79 (m, 1H), 5.34 (dd, J = 9.6, 5.0 Hz, 1H), 5.14 – 5.05 (m, 2H), 3.94 – 3.82 (m, 2H),
3.15 (t, J = 7.3 Hz, 2H), 2.41 – 2.24 (m, 1H), 2.21 – 2.06 (m, 1H), 1.65 – 1.24 (m, 5H), 0.80
– 0.72 (m, 6H); 13C NMR (101 MHz, CD3OD) δ 168.4, 164.4 (d, 1JCF = 242.6 Hz), 158.8,
158.2, 157.6, 146.5, 141.4 (d, 3JCF = 10.8 Hz), 132.8, 132.6, 131.5 (d, 3JCF = 9.4 Hz), 130.7,
129.9, 129.81, 129.76, 124.9, 122.5, 121.5, 117.1 (d, 4JCF = 2.9 Hz), 114.8, 113.7, 112.2 (d,
2

JCF = 21.8 Hz), 108.6 (d, 2JCF = 26.7 Hz), 68.1, 65.1, 64.1, 41.7, 39.4, 30.5, 26.6, 26.2, 23.10,

23.08; IR (neat) ν̄max 3329, 3171, 2955, 2931, 2871, 2369, 2323, 2107, 1672, 1626, 1555,
1503, 1474, 1443, 1387, 1368, 1260, 1223, 1160, 1087, 1049, 1024, 875, 799, 750, 669, 611
cm-1; MS (ESI +ve) m/z 588 ([M + H]+, 100%), 610 ([M + Na]+, 9%); HRMS (ESI +ve TOF)
calcd for C32H39N7O3F 588.3098, found 588.3081 ([M + H]+).

(R)-5-Guanidino-2-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H-1,2,3triazol-1-yl)-N-phenylpentanamide hydrochloride (77i)
Following General Procedure B, acid 75b (50 mg, 0.07
mmol), aniline (8 mg, 0.08 mmol), EDCI (15 mg, 0.08
mmol) and HOBt (11 mg, 0.07 mmol) were stirred in
acetonitrile (0.7 mL) for 24 h to give the intermediate
amide as a translucent tan gum. Following General
Procedure C, the amide was dissolved in CH2Cl2 (2.0 mL) and treated with H2O (24 mg,
1.34 mmol) and CF3CO2H (2.0 mL) followed by work-up with ethereal HCl to give the amine
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salt 77i (36 mg, 89% over two steps) as a light tan powder that rapidly transitioned to a sticky
23

gum. [α] D +18.3 (c 0.83, MeOH); 1H NMR (400 MHz, CD3OD) δ 7.79 (s, 1H), 7.62 (d, J =
7.7 Hz, 2H), 7.38 – 7.09 (m, 8H), 7.04 – 6.89 (m, 3H), 5.48 (dd, J = 8.4, 6.8 Hz, 1H), 5.15 –
5.06 (m, 2H), 3.93 – 3.77 (m, 2H), 3.20 (t, J = 7.0 Hz, 2H), 2.37 – 2.10 (m, 2H), 1.64 – 1.29
(m, 5H), 0.73 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 167.9, 158.8, 158.2, 157.6,
146.5, 139.3, 132.7, 132.5, 130.7, 130.2*, 129.9, 129.82, 129.77, 126.1, 124.0, 122.5,
121.5**, 114.7, 113.7, 68.1, 65.3, 64.2, 41.9, 39.4, 31.1, 26.4, 26.2, 23.1, 23.0; IR (neat) ν̄max
3346, 3277, 3201, 2954, 2931, 2871, 2370, 2323, 1671, 1625, 1602, 1555, 1501, 1474, 1445,
1386, 1368, 1254, 1215, 1163, 1123, 1109, 1048, 1019, 873, 810, 750, 692 cm-1; MS (ESI
+ve) m/z 570 ([M + H]+, 100%), 592 ([M + Na]+, 20%); HRMS (ESI +ve TOF) calcd for
C32H40N7O3 570.3193, found 570.3207 ([M + H]+).

(R)-N-(3,5-Dimethoxyphenyl)-5-guanidino-2-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)pentanamide hydrochloride (77j)
Following General Procedure B, acid 75b (50 mg,
0.07 mmol), 3,5-dimethoxyaniline (12 mg, 0.08
mmol), EDCI (15 mg, 0.08 mmol) and HOBt (11 mg,
0.07 mmol) were stirred in acetonitrile (0.7 mL) for
22 h to give the intermediate amide as a translucent
tan gum. Following General Procedure C, the amide was dissolved in CH2Cl2 (2.0 mL) and
treated with H2O (24 mg, 1.34 mmol) and CF3CO2H (2.0 mL) followed by work-up with
ethereal HCl to give the amine salt 77j (36 mg, 81% over two steps) as a light tan powder
23

that rapidly transitioned to a sticky gum. [α] D +10.5 (c 0.90, MeOH); 1H NMR (400 MHz,
236

CD3OD) δ 7.77 (s, 1H), 7.34 – 7.09 (m, 5H), 7.05 – 6.86 (m, 5H), 6.27 (s, 1H), 5.53 – 5.45
(m, 1H), 5.14 – 5.05 (m, 2H), 3.92 – 3.80 (m, 2H), 3.75 (s, 6H), 3.19 (t, J = 6.9 Hz, 2H), 2.37
– 2.24 (m, 1H), 2.22 – 2.09 (m, 1H), 1.62 – 1.29 (m, 5H), 0.73 (d, J = 6.6 Hz, 6H); 13C NMR
(101 MHz, CD3OD) δ 168.0, 162.7*, 158.8, 158.2, 157.6, 146.4, 141.0, 132.6, 132.5, 130.7,
129.9, 129.79, 129.77, 124.1, 122.5, 121.5, 114.7, 113.7, 99.8*, 98.0, 68.1, 65.3, 64.2, 56.0,
41.8, 39.4, 31.0, 26.3, 26.2, 23.1, 23.0; IR (neat) ν̄max 3345, 3278, 3199, 2955, 2931, 2870,
2370, 2323, 1672, 1619, 1595, 1555, 1502, 1446, 1386, 1260, 1205, 1154, 1110, 1049, 1019,
844, 750, 669 cm-1; MS (ESI +ve) m/z 630 ([M + H]+, 100%), 652 ([M + Na]+, 34%); HRMS
(ESI +ve TOF) calcd for C34H44N7O5 630.3404, found 630.3404 ([M + H]+).

(R)-N-Cyclopropyl-5-guanidino-2-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)pentanamide hydrochloride (77k)
Following General Procedure B, acid 75b (50 mg, 0.07
mmol), cyclopropylamine (5 mg, 0.08 mmol), EDCI (15
mg, 0.08 mmol) and HOBt (11 mg, 0.07 mmol) were
stirred in acetonitrile (0.7 mL) for 23 h to give the
intermediate amide as a translucent tan gum. Following
General Procedure C, the amide was dissolved in CH2Cl2 (2.0 mL) and treated with H2O
(24 mg, 1.34 mmol) and CF3CO2H (2.0 mL) followed by work-up with ethereal HCl to give
the amine salt 77k (34 mg, 89% over two steps) as a light tan powder that rapidly transitioned
23

to a sticky gum. [α] D +5.1 (c 0.80, MeOH); 1H NMR (400 MHz, CD3OD) δ 7.77 (s, 1H),
7.36 – 7.25 (m, 2H), 7.23 – 7.10 (m, 3H), 7.04 – 6.99 (m, 2H), 6.96 (td, J = 7.4, 0.9 Hz, 1H),
5.20 (dd, J = 8.5, 6.9 Hz, 1H), 5.14 – 5.05 (m, 2H), 3.96 – 3.84 (m, 2H), 3.17 (t, J = 7.0 Hz,
237

2H), 2.73 – 2.65 (m, 1H), 2.22 – 2.01 (m, 2H), 1.61 – 1.31 (m, 5H), 0.82 – 0.65 (m, 8H), 0.57
– 0.45 (m, 2H); 13C NMR (101 MHz, CD3OD) δ 171.1, 158.8, 158.2, 157.5, 146.2, 132.8,
132.5, 130.7, 129.9, 129.83, 129.76, 124.0, 122.5, 121.5, 114.7, 113.7, 68.2, 64.6, 64.0, 41.8,
39.4, 31.0, 26.3, 26.2, 23.8, 23.09, 23.07, 6.7, 6.6; IR (neat) ν̄max 3344, 3278, 3200, 2955,
2931, 2871, 2369, 2323, 1666, 1626, 1594, 1555, 1503, 1474, 1440, 1387, 1367, 1253, 1212,
1163, 1123, 1109, 1049, 1004, 854, 750, 668 cm-1; MS (ESI +ve) m/z 534 ([M + H]+, 100%),
556 ([M + Na]+, 41%); HRMS (ESI +ve TOF) calcd for C29H40N7O3 534.3193, found
534.3204 ([M + H]+).

(R)-N-(Cyclopropylmethyl)-5-guanidino-2-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-N-propylpentanamide hydrochloride (77l)
Following General Procedure B, acid 75b (50 mg, 0.07
mmol), N-propyl-cyclopropylmethylamine (9 mg, 0.08
mmol), EDCI (15 mg, 0.08 mmol) and HOBt (11 mg, 0.07
mmol) were stirred in acetonitrile (0.7 mL) for 24 h to give
the intermediate amide as a translucent tan gum.
Following General Procedure C, the amide was dissolved in CH2Cl2 (2.0 mL) and treated
with H2O (24 mg, 1.34 mmol) and CF3CO2H (2.0 mL) followed by work-up with ethereal
HCl to give the amine salt 77l (36 mg, 86% over two steps) as a light tan powder that rapidly
23

transitioned to a sticky gum. [α] D +5.2 (c 0.70, MeOH); 1H NMR (400 MHz, CD3OD) :
(mixture of rotamers) ‡ δ 7.74 (s, 1H), 7.34 – 7.25 (m, 2H), 7.21 – 7.10 (m, 3H), 7.05 – 6.91

‡ All rotamer resonances are reported.
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(m, 3H), 5.86 – 5.73 (m, 1H), 5.18 – 5.02 (m, 2H), 3.98 – 3.83 (m, 2H), 3.54 – 3.24 (m, 4H),
3.23 – 3.11 (m, 2H), 2.22 – 1.99 (m, 2H), 1.66 – 1.28 (m, 7H), 1.06 – 0.93 (m, 1H), 0.92 –
0.80 (m, 3H), 0.78 (d, J = 6.6 Hz, 6H), 0.59 – 0.39 (m, 2H), 0.35 – 0.13 (m, 2H); 13C NMR
(101 MHz, CD3OD) : (mixture of rotamers)‡ δ 169.2, 168.8, 158.8, 158.2, 157.49, 157.45,
146.6, 146.5, 132.8, 132.5, 130.6, 129.88, 129.86, 129.7, 123.74, 123.66, 122.5, 121.5, 114.6,
113.7, 68.2, 64.0, 63.9, 60.9, 53.7, 51.9, 51.0, 49.9, 42.0, 39.4, 31.6, 31.5, 26.3, 26.1, 23.6,
23.10, 23.07, 21.7, 11.8, 11.6, 11.5, 10.6, 5.1, 4.4, 4.2, 4.0; IR (neat) ν̄max 3345, 3189, 2955,
2931, 2871, 2370, 2323, 1650, 1594, 1503, 1474, 1438, 1385, 1367, 1254, 1214, 1162, 1122,
1109, 1047, 1020, 934, 855, 801, 749, 669 cm-1; MS (ESI +ve) m/z 590 ([M + H]+, 100%),
612 ([M + Na]+, 16%); HRMS (ESI +ve TOF) calcd for C33H48N7O3 590.3819, found
590.3834 ([M + H]+).

(R)-6-((Tert-butoxycarbonyl)amino)-2-(4-((((S)-2'-(isopentyloxy)-[1,1'-binaphthalen]2-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)hexanoic acid (75c)
Following General Procedure A, azide 24 (253
mg, 0.93 mmol), alkyne 20 (733 mg, 1.86 mmol),
Cu(OAc)2∙H2O (37 mg, 0.19 mmol) and sodium
ascorbate (74 mg, 0.37 mmol) were stirred in
t-BuOH (18.6 mL) and H2O (4.7 mL) at 40 °C for
72 h to give the product triazole 75c (386 mg, 64%)
as a translucent tan gum after flash chromatography over SiO2 gel (EtOAc/P.S. – 10:90 

‡ All rotamer resonances are reported.
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23

50:50). TLC (EtOAc/P.S. – 40:60): Rf = 0.50; [α] D −11.3 (c 0.76, MeOH); 1H NMR (400
MHz, DMSO) δ 8.04 (app. t, J = 8.6 Hz, 2H, ArH), 7.93 (app. t, J = 8.0 Hz, 2H, ArH), 7.74
(d, J = 9.0 Hz, 1H, ArH), 7.57 (d, J = 9.0 Hz, 1H, ArH), 7.47 – 7.37 (br s, 1H, H5'), 7.37 –
7.26 (m, 2H, ArH), 7.26 – 7.13 (m, 2H, ArH), 7.00 – 6.89 (m, 2H, ArH), 6.74 (br s, 1H,
N6-H), 5.22 – 5.06 (m, 3H, H2 and -OCH2-C4'), 4.05 – 3.90 (m, 2H, H1''), 2.87 – 2.74 (m,
2H, H6), 2.04 (br s, 1H, H3A or H3B), 1.91 (br s, 1H, H3B or H3A), 1.39 – 1.13 (m, 14H, H5,
H2'', H3'' and -C(CH3)3), 1.08 (br s, 1H, H4A or H4B), 0.86 (br s, 1H, H4B or H4A), 0.57 (d, J
= 6.3 Hz, 3H, H4'' or H5''), 0.55 (d, J = 6.2 Hz, 3H, H5'' or H4'');

13

C NMR (101 MHz,

DMSO)† δ 155.5 (Cα), 154.1 (CAr2'), 153.7 (CAr2), 143.5 (C4' – observed by gHMBC),
133.4 (CAr8a or CAr8a'), 133.3 (CAr8a' or CAr8a), 129.2 (CAr4), 129.1 (CAr4'), 129.0
(CAr4a), 128.7 (CAr4a'), 127.9 (CAr5 and CAr5'), 126.2 (CAr7), 126.1 (CAr7'), 124.7
(CAr8), 124.5 (CAr8'), 123.5 (CAr6), 123.3 (CAr6'), 123.0 (C5'), 119.8 (CAr1), 119.1
(CAr1'), 116.2 (CAr3), 115.6 (CAr3'), 77.3 (-C(CH3)3), 67.2 (C1''), 63.0 (-OCH2-C4'), 39.4
(C6), 37.6 (C2''), 31.0 (C3), 28.7 (C5), 28.2 (-C(CH3)3), 24.1 (C3''), 22.6 (C4), 22.2 (C4'' or
C5''), 22.1 (C5'' or C4''); IR (neat) ν̄max 3342, 3061, 2954, 2932, 2869, 2366, 2345, 1734,
1718, 1700, 1684, 1653, 1623, 1591, 1559, 1540, 1507, 1458, 1430, 1395, 1366, 1329, 1263,
1243, 1165, 1147, 1083, 1046, 1015, 915, 862, 809, 747, 668, 610 cm-1; MS (ESI −ve) m/z
665 ([M − H]−, 100%); HRMS (ESI −ve TOF) calcd for C39H45N4O6 665.3339, found
665.3353 ([M − H]−).

† Missing resonances: two carbons (the carboxyl carbon (C1) and the adjacent methine carbon (C2)) could not
be assigned to resonances in the 13C NMR spectrum; the corresponding methine proton (H2) was assigned to a
very broad signal in the 1H NMR spectrum (by gCOSY correlation with H3). This 1H NMR signal showed no
heterocorrelations in 2-D NMR (i.e. gHSQC and gHMBC).
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(R)-2-(4-((((S)-2'-(Isopentyloxy)-[1,1'-binaphthalen]-2-yl)oxy)methyl)-1H-1,2,3-triazol1-yl)-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5yl)sulfonyl)guanidino)pentanoic acid (75d)
Following General Procedure A, azide 28 (152 mg,
0.34 mmol), alkyne 20 (265 mg, 0.67 mmol),
Cu(OAc)2∙H2O (13 mg, 0.07 mmol) and sodium
ascorbate (27 mg, 0.13 mmol) were stirred in
t-BuOH (6.7 mL) and H2O (1.7 mL) for 24 h to give
the product triazole 75d (236 mg, 83%) as a
translucent tan gum after flash chromatography over
SiO2 gel (EtOAc/P.S. – 10:90  MeOH/CH2Cl2 – 10:90). TLC (EtOAc/P.S. – 80:20): Rf =
23

0.34; [α] D −25.8 (c 0.43, MeOH); 1H NMR (400 MHz, DMSO) δ 8.03 (d, J = 9.0 Hz, 1H,
ArH), 7.98 – 7.88 (m, 2H, ArH), 7.84 (d, J = 8.0 Hz, 1H, ArH), 7.73 (d, J = 9.1 Hz, 1H, ArH),
7.54 (br s, 1H, N5-H), 7.52 (d, J = 9.0 Hz, 1H, ArH), 7.39 (br s, 1H, H5'), 7.32 (t, J = 7.0 Hz,
1H, ArH), 7.28 – 7.18 (m, 2H, ArH), 7.14 (t, J = 7.4 Hz, 1H, ArH), 6.94 (d, J = 8.5 Hz, 1H,
ArH), 6.90 (d, J = 8.4 Hz, 1H, ArH), 6.82 (br s, 2H, -NH2), 5.13 and 5.06 (ABq, J = 12.4 Hz,
2H, -OCH2-C4'), 4.81 (br s, 1H, H2), 4.05 – 3.88 (m, 2H, H1''), 2.96 (br s, 2H, H5), 2.92 (s,
2H, ArCH2-), 2.48 (s, 3H, ArCH3), 2.42 (s, 3H, ArCH3), 2.08 (br s, 1H, H3A or H3B), 1.98
(s, 3H, ArCH3), 1.73 (br s, 1H, H3B or H3A), 1.36 (s, 6H, -C(CH3)2), 1.29 – 0.87 (m, 5H, H4,
H2'', H3''), 0.56 (d, J = 6.2 Hz, 3H, H4'' or H5''), 0.54 (d, J = 6.2 Hz, 3H, H5'' or H4''); 13C
NMR (101 MHz, DMSO)† δ 157.4 (Pbf CAr), 156.3 (C=N), 154.1 (CAr2'), 153.8 (CAr2),

† Missing resonances: two carbons (the carboxyl carbon (C1) and the adjacent methine carbon (C2)) could not
be assigned to resonances in the 13C NMR spectrum; the corresponding methine proton (H2) was assigned to a
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142.7 (C4'), 137.2 (Pbf CAr), 134.3 (Pbf CAr), 133.4 (CAr8a or CAr8a'), 133.3 (CAr8a' or
CAr8a), 131.3 (Pbf CAr), 129.2 (CAr4), 129.1 (CAr4'), 129.0 (CAr4a), 128.6 (CAr4a'), 127.9
(CAr5 and CAr5'), 126.1 (CAr7), 126.0 (CAr7'), 124.7 (CAr8), 124.5 (CAr8'), 124.3 (Pbf
CAr), 123.4 (CAr6), 123.2 (CAr6'), 122.7 (C5'), 119.8 (CAr1), 119.1 (CAr1'), 116.23 (Pbf
CAr), 116.20 (CAr3), 115.5 (CAr3'), 86.2 (-C(CH3)2), 67.2 (C1''), 63.2 (-OCH2-C4'), 42.4
(ArCH2-), 39.6 (C5 – observed by gHSQC), 37.6 (C2''), 30.0 (C3), 28.2 (-C(CH3)2), 25.8
(C4), 24.1 (C3''), 22.2 (C4'' or C5''), 22.1 (C5'' or C4''), 18.9 (ArCH3), 17.6 (ArCH3), 12.2
(ArCH3); IR (neat) ν̄max 2961, 2932, 2873, 2362, 2342, 1734, 1700, 1684, 1653, 1623, 1559,
1540, 1507, 1473, 1457, 1437, 1419, 1399, 1260, 1243, 1147, 1109, 1087, 1059, 1016, 907,
852, 808, 784, 746, 734, 668, 641 cm-1; MS (ESI −ve) m/z 845 ([M − H]−, 100%); HRMS
(ESI −ve TOF) calcd for C47H53N6O7S 845.3696, found 845.3710 ([M − H]−).

(R)-N-Benzyl-5-guanidino-2-(4-((((S)-2'-(isopentyloxy)-[1,1'-binaphthalen]-2yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)pentanamide hydrochloride (78a)
Following General Procedure B, acid 75d (50
mg, 0.06 mmol), benzylamine (8 mg, 0.07 mmol),
EDCI (14 mg, 0.07 mmol) and HOBt (10 mg,
0.06 mmol) were stirred in acetonitrile (0.6 mL)
for 21 h to give the intermediate amide as a
translucent tan gum. Following General Procedure C, the amide was dissolved in CH2Cl2
(1.8 mL) and treated with H2O (21 mg, 1.18 mmol) and CF3CO2H (1.8 mL) followed by

very broad signal in the 1H NMR spectrum (by gCOSY correlation with H3). This 1H NMR signal showed no
heterocorrelations in 2-D NMR (i.e. gHSQC and gHMBC).
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work-up with ethereal HCl to give the amine salt 78a (37 mg, 87% over two steps) as a light
23

tan powder that rapidly transitioned to a sticky gum. [α] D −15.0 (c 0.90, MeOH); 1H NMR
(400 MHz, CD3OD) δ 8.02 – 7.96 (m, 2H, ArH), 7.91 – 7.85 (m, 2H, ArH), 7.58 (d, J = 9.0
Hz, 1H, ArH), 7.51 (d, J = 9.0 Hz, 1H, ArH), 7.36 – 7.11 (m, 10H, ArH and H5'), 7.08 (d, J
= 8.6 Hz, 1H, ArH), 7.02 (d, J = 8.6 Hz, 1H, ArH), 5.20 (dd, J = 8.7, 6.7 Hz, 1H, H2), 5.14
and 5.09 (ABq, J = 12.4 Hz, 2H, -OCH2-C4'), 4.35 (s, 2H, -CH2Ph), 4.02 (dt, J = 9.6, 6.0 Hz,
1H, H1''A or H1''B), 3.91 (dt, J = 9.6, 6.3 Hz, 1H, H1''B or H1''A), 3.17 – 3.04 (m, 2H, H5),
2.18 – 2.05 (m, 1H, H3A or H3B), 2.02 – 1.84 (m, 1H, H3B or H3A), 1.49 – 1.11 (m, 5H, H4,
H2'', H3''), 0.55 (d, J = 6.4 Hz, 3H, H4'' or H5''), 0.52 (d, J = 6.3 Hz, 3H, H5'' or H4''); 13C
NMR (101 MHz, CD3OD) δ 169.6 (C1), 158.7 (C=N), 156.1 (CAr2'), 155.5 (CAr2), 146.3
(C4' – observed by gHMBC), 139.5 (Phenyl CAr), 135.6 (CAr8a or CAr8a'), 135.5 (CAr8a'
or CAr8a), 131.6 (CAr4a), 130.9 (CAr4a'), 130.8 (CAr4), 130.7 (CAr4'), 129.8 (Phenyl
CAr)*, 129.3 (CAr5 or CAr5'), 129.2 (CAr5' or CAr5), 128.8 (Phenyl C Ar)*, 128.6 (Phenyl
CAr), 127.5 (CAr7 or CAr7'), 127.4 (CAr7' or CAr7), 126.7 (CAr8), 126.4 (CAr8'), 125.2
(CAr6), 124.8 (CAr6'), 124.0 (C5'), 122.9 (CAr1), 121.4 (CAr1'), 117.7 (CAr3), 117.0
(CAr3'), 69.2 (C1''), 65.1 (-OCH2-C4'), 64.7 (C2), 44.5 (-CH2Ph), 41.8 (C5), 39.5 (C2''), 30.8
(C3), 26.2 (C4), 25.8 (C3''), 23.0 (C4'' or C5''), 22.8 (C5'' or C4''); IR (neat) ν̄max 3335, 3190,
3059, 2959, 2931, 2875, 2364, 2325, 1734, 1700, 1684, 1669, 1653, 1636, 1623, 1590, 1559,
1540, 1507, 1473, 1457, 1437, 1419, 1399, 1340, 1261, 1241, 1212, 1147, 1083, 1040, 1007,
908, 861, 808, 775, 745, 699, 668, 601 cm-1; MS (ESI +ve) m/z 684 ([M + H]+, 100%), 706
([M + Na]+, 8%); HRMS (ESI +ve TOF) calcd for C41H46N7O3 684.3662, found 684.3669
([M + H]+).
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(R)-5-Guanidino-2-(4-((((S)-2'-(isopentyloxy)-[1,1'-binaphthalen]-2-yl)oxy)methyl)1H-1,2,3-triazol-1-yl)-N-phenethylpentanamide hydrochloride (78b)
Following General Procedure B, acid 75d (50
mg, 0.06 mmol), β-phenylethylamine (9 mg, 0.07
mmol), EDCI (14 mg, 0.07 mmol) and HOBt (10
mg, 0.06 mmol) were stirred in acetonitrile (0.6
mL) for 21 h to give the intermediate amide as a
translucent tan gum. Following General Procedure C, the amide was dissolved in CH2Cl2
(1.8 mL) and treated with H2O (21 mg, 1.18 mmol) and CF3CO2H (1.8 mL) followed by
work-up with ethereal HCl to give the amine salt 78b (21 mg, 49% over two steps) as a light
23

tan powder that rapidly transitioned to a sticky gum. [α] D −20.3 (c 0.33, MeOH); 1H NMR
(400 MHz, CD3OD) δ 8.01 (s, 1H), 7.99 (s, 1H), 7.92 – 7.85 (m, 2H), 7.60 (d, J = 9.0 Hz,
1H), 7.52 (d, J = 9.1 Hz, 1H), 7.37 – 7.00 (m, 12H), 5.16 – 5.06 (m, 3H), 4.07 – 3.98 (m,
1H), 3.96 – 3.88 (m, 1H), 3.49 – 3.34 (m, 2H), 3.08 (t, J = 7.1 Hz, 2H), 2.75 (t, J = 7.1 Hz,
2H), 2.09 – 1.98 (m, 1H), 1.91 – 1.79 (m, 1H), 1.36 – 1.12 (m, 5H), 0.56 (d, J = 6.4 Hz, 3H),
0.52 (d, J = 6.3 Hz, 3H); 13C NMR (101 MHz, CD3OD) δ 169.6, 158.8, 156.2, 155.5, 146.4
(observed by gHMBC), 140.3, 135.61, 135.57, 131.6, 130.9, 130.8, 130.7, 130.0*, 129.7*,
129.3, 129.2, 127.6, 127.5, 127.4, 126.7, 126.4, 125.2, 124.8, 123.9, 122.9, 121.5, 117.7,
117.0, 69.2, 65.2, 64.6, 42.2, 41.8, 39.5, 36.3, 30.7, 26.1, 25.9, 23.0, 22.8; IR (neat) ν̄max 3335,
3189, 3061, 2960, 2932, 2874, 2364, 2325, 1734, 1700, 1684, 1669, 1653, 1636, 1623, 1591,
1559, 1540, 1507, 1473, 1457, 1437, 1419, 1363, 1340, 1261, 1241, 1213, 1147, 1132, 1083,
1045, 1016, 908, 878, 864, 808, 775, 747, 699, 668, 601 cm-1; MS (ESI +ve) m/z 698 ([M +
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H]+, 100%), 720 ([M + Na]+, 7%); HRMS (ESI +ve TOF) calcd for C42H48N7O3 698.3819,
found 698.3837 ([M + H]+).

6.3.5 – Series B2
Tert-butyl ((R)-6-(((R)-1-azido-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5yl)sulfonyl)guanidino)pentan-2-yl)amino)-5-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-6-oxohexyl)carbamate (79a)
Following General Procedure B, acid 75a (176 mg,
0.31 mmol), amine 25 (143 mg, 0.33 mmol), EDCI (72
mg, 0.37 mmol) and HOBt (50 mg, 0.33 mmol) were
stirred in acetonitrile (3.1 mL) for 48 h to give the
product amide 79a (251 mg, 82%) as a translucent tan
gum after flash chromatography over SiO2 gel
(EtOAc/P.S. – 60:40  80:20). TLC (EtOAc/P.S. –
23

80:20): Rf = 0.44; [α] D −8.0 (c 1.23, MeOH); 1H NMR
(400 MHz, CDCl3) δ 7.54 (br s, 2H, H5′ and N2′′′-H), 7.32 – 7.17 (m, 4H, ArH), 7.09 – 6.99
(m, 2H, ArH), 6.99 – 6.90 (m, 2H, ArH), 6.11 (br s, 3H, N5′′′-H and -NH2), 5.34 – 5.25 (m,
1H, H5), 5.09 (s, 2H, -OCH2-C4′), 4.71 (br s, 1H, N1-H), 3.96 (br s, 1H, H2′′′), 3.90 (t, J =
6.1 Hz, 2H, H1′′), 3.30 (br s, 2H, H1′′′), 3.08 – 2.95 (m, 4H, H1 and H5′′′), 2.94 (s, 2H,
ArCH2-), 2.54 (s, 3H, ArCH3), 2.49 (s, 3H, ArCH3), 2.21 – 2.12 (m, 1H, H4A or H4B), 2.08
(s, 3H, ArCH3), 2.02 – 1.88 (m, 1H, H4B or H4A), 1.64 – 1.09 (m, 26H, H2, H3, H2′′, H3′′,
H3′′′, H4′′′, -C(CH3)2 and -C(CH3)3), 0.78 (d, J = 6.3 Hz, 6H, H4′′ and H5′′); 13C NMR (101
MHz, CDCl3) δ 168.5 (C6), 158.9 (Pbf CAr), 156.6 (CAr2′), 156.3 (CAr2 and C=N), 155.9
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(Cα), 145.0 (C4′), 138.4 (Pbf CAr), 132.9 (Pbf CAr), 132.3 (Pbf CAr), 131.8 (CAr6 or CAr6′),
131.6 (CAr6′ or CAr6), 128.9 (CAr1), 128.8 (CAr4), 128.7 (CAr4′), 128.1 (CAr1′), 124.8
(Pbf CAr), 122.6 (C5′), 121.5 (CAr5), 120.4 (CAr5′), 117.7 (Pbf C Ar), 113.7 (CAr3), 112.6
(CAr3′), 86.6 (-C(CH3)2), 79.4 (-C(CH3)3), 67.2 (C1′′), 63.8 (C5), 63.5 (-OCH2-C4′), 54.6
(C1′′′), 49.6 (C2′′′), 43.4 (ArCH2-), 40.8 (C1 or C5′′′), 40.1 (C5′′′ or C1), 38.1 (C2′′), 32.3
(C4), 29.3 (C3′′′), 29.0 (C2), 28.7 (-C(CH3)2), 28.5 (-C(CH3)3), 25.6 (C4′′′), 25.1 (C3′′), 22.8
(C3), 22.63 (C4′′ or C5′′), 22.61 (C5′′ or C4′′), 19.4 (ArCH3), 18.1 (ArCH3), 12.6 (ArCH3);
IR (neat) ν̄max 3443, 3339, 2958, 2926, 2870, 2101, 1700, 1684, 1617, 1559, 1545, 1507,
1457, 1442, 1395, 1368, 1241, 1163, 1106, 1091, 1052, 1028, 905, 853, 808, 784, 751, 734,
668, 659, 640, 620, 615 cm-1; MS (ESI +ve) m/z 1009 ([M + Na]+, 100%), 987 ([M + H]+,
21%); HRMS (ESI +ve TOF) calcd for C50H72N11O8S 986.5286, found 986.5335 ([M + H]+).

(R)-6-Amino-N-((R)-1-(4-benzyl-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2-(4(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)hexanamide
dihydrochloride (80a)

Following General Procedure A, azide 79a (50 mg, 0.05 mmol), 3-phenyl-1-propyne (18
mg, 0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol)
were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 24 h to give the intermediate triazole
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as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 
10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) and
treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with
ethereal HCl to give the amine salt 80a (40 mg, 95% over two steps) as a light tan powder
23

that rapidly transitioned to a sticky gum. [α] D +6.2 (c 1.07, MeOH); 1H NMR (400 MHz,
CD3OD) δ 7.92 (s, 1H, Hα), 7.69 (s, 1H, H5′), 7.36 – 7.09 (m, 10H, ArH), 7.05 – 6.97 (m,
2H, ArH), 6.94 (t, J = 7.3 Hz, 1H, ArH), 5.25 (t, J = 7.0 Hz, 1H, H2), 5.09 (s, 2H, -OCH2-C4′),
4.66 – 4.56 (m, 1H, H1′′′A or H1′′′B), 4.51 – 4.40 (m, 1H, H1′′′B or H1′′′A), 4.32 (br s, 1H,
H2′′′), 4.14 – 4.02 (m, 2H, -CH2Ph), 3.95 – 3.86 (m, 2H, H1′′), 3.12 (br s, 2H, H5′′′), 2.83 (br
s, 2H, H6), 1.98 – 1.25 (m, 11H, H3, H5, H2′′, H3′′, H3′′′ and H4′′′), 1.16 – 0.99 (m, 2H, H4),
0.78 (d, J = 6.6 Hz, 6H, H4′′ and H5′′); 13C NMR (101 MHz, CD3OD) δ 170.2 (C1), 158.7
(C=N), 158.2 (CAr2′), 157.5 (CAr2), 148.3 (Cβ – observed by gHMBC), 145.9 (C4′ –
observed by gHMBC), 140.2 (Phenyl CAr), 132.9 (CAr6 or CAr6′), 132.6 (CAr6′ or CAr6),
130.5 (CAr1), 129.97 (Phenyl CAr)*, 129.95 (Phenyl CAr)*, 129.9 (CAr4), 129.79 (CAr4′),
129.76 (CAr1′), 127.9 (Phenyl CAr), 125.7 (Cα), 124.5 (C5′), 122.5 (CAr5), 121.5 (CAr5′),
114.8 (CAr3), 113.8 (CAr3′), 68.2 (C1′′), 64.6 (C2), 64.0 (-OCH2-C4′), 55.2 (C1′′′), 51.2
(C2′′′), 42.0 (C5′′′), 40.5 (C6), 39.4 (C2′′), 32.9 (C3), 32.4 (-CH2Ph), 30.0 (C3′′′), 27.7 (C5),
26.3 (C4′′′), 26.2 (C3′′), 23.6 (C4), 23.11 (C4′′ or C5′′), 23.10 (C5′′ or C4′′); IR (neat) ν̄max
3333, 3166, 3061, 2958, 2934, 2872, 2377, 2324, 1684, 1669, 1653, 1559, 1540, 1507, 1473,
1457, 1437, 1395, 1363, 1340, 1260, 1219, 1162, 1124, 1109, 1049, 1002, 855, 808, 751,
726, 698, 697, 668, 616 cm-1; MS (ESI +ve) m/2 376 ([M + 2H]2+, 100%), m/z 750 ([M +
H]+, 27%), 772 ([M + Na]+, 8%); HRMS (ESI +ve TOF) calcd for C41H56N11O3 750.4568,
found 750.4570 ([M + H]+).
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(R)-6-Amino-N-((R)-5-guanidino-1-(4-phenethyl-1H-1,2,3-triazol-1-yl)pentan-2-yl)-2(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H-1,2,3-triazol-1yl)hexanamide dihydrochloride (80b)

Following General Procedure A, azide 79a (50 mg, 0.05 mmol), 4-phenyl-1-butyne (20 mg,
0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol)
were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 20 h to give the intermediate triazole
as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 
10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) and
treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with
ethereal HCl to give the amine salt 80b (36 mg, 85% over two steps) as a light tan powder
23

that rapidly transitioned to a sticky gum. [α] D +3.1 (c 0.97, MeOH); 1H NMR (400 MHz,
CD3OD) δ 8.07 (s, 1H), 7.79 (s, 1H), 7.35 – 7.07 (m, 10H), 7.05 – 6.96 (m, 2H), 6.93 (t, J =
7.4 Hz, 1H), 5.38 – 5.28 (m, 1H), 5.13 – 5.03 (m, 2H), 4.76 – 4.64 (m, 1H), 4.61 – 4.49 (m,
1H), 4.28 (br s, 1H), 3.96 – 3.81 (m, 2H), 3.21 – 3.06 (m, 4H), 3.06 – 2.95 (m, 2H), 2.95 –
2.81 (m, 2H), 2.15 – 1.89 (m, 2H), 1.81 – 1.09 (m, 11H), 0.77 (d, J = 6.6 Hz, 6H); 13C NMR
(101 MHz, CD3OD) δ 170.3, 158.7, 158.2, 157.5, 146.1 (observed by gHMBC), 144.2
(observed by gHMBC), 141.7, 132.8, 132.6, 130.5*, 129.9**, 129.8, 129.7*, 127.7, 127.0,
124.7, 122.5, 121.5, 114.8, 113.8, 68.2, 64.7, 64.0, 56.0, 51.3, 42.0, 40.5, 39.4, 36.1, 32.9,
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29.7, 27.8, 27.5, 26.4, 26.2, 23.7, 23.1*; IR (neat) ν̄max 3334, 3165, 3059, 2959, 2934, 2872,
2378, 2324, 1684, 1669, 1653, 1559, 1540, 1507, 1473, 1457, 1437, 1395, 1363, 1340, 1260,
1218, 1162, 1124, 1109, 1048, 1021, 856, 751, 702, 668, 616 cm-1; MS (ESI +ve) m/2 383
([M + 2H]2+, 100%), m/z 764 ([M + H]+, 24%), 786 ([M + Na]+, 8%); HRMS (ESI +ve TOF)
calcd for C42H58N11O3 764.4724, found 764.4731 ([M + H]+).

(R)-6-Amino-N-((R)-1-(4-cyclohexyl-1H-1,2,3-triazol-1-yl)-5-guanidinopentan-2-yl)-2(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H-1,2,3-triazol-1yl)hexanamide dihydrochloride (80c)

Following General Procedure A, azide 79a (50 mg, 0.05 mmol), cyclohexylacetylene (18
mg, 0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol)
were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 20 h to give the intermediate triazole
as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 
10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) and
treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with
ethereal HCl to give the amine salt 80c (39 mg, 94% over two steps) as a light tan powder
23

that rapidly transitioned to a sticky gum. [α] D +2.9 (c 0.97, MeOH); 1H NMR (400 MHz,
CD3OD) δ 8.16 (br s, 1H), 7.78 (br s, 1H), 7.36 – 7.23 (m, 2H), 7.22 – 7.09 (m, 3H), 7.05 –
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6.90 (m, 3H), 5.31 (br s, 1H), 5.09 (s, 2H), 4.77 – 4.62 (m, 1H), 4.62 – 4.45 (m, 1H), 4.32 (br
s, 1H), 3.98 – 3.84 (m, 2H), 3.14 (br s, 2H), 2.90 (br s, 3H), 2.14 – 1.05 (m, 23H), 0.78 (d, J
= 6.4 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 170.3, 158.7, 158.2, 157.5, 152.9 (observed
by gHMBC), 146.5 (observed by gHMBC), 132.8, 132.6, 130.5, 129.9, 129.82, 129.77,
126.4, 124.9, 122.5, 121.5, 114.8, 113.8, 68.2, 64.7, 64.0, 56.2, 51.3, 42.1, 40.6, 39.4, 35.8,
33.8*, 33.0, 29.9, 27.9, 27.1*, 27.0, 26.4, 26.2, 23.7, 23.1*; IR (neat) ν̄max 3338, 3168, 3059,
2953, 2931, 2870, 2371, 2323, 1684, 1669, 1653, 1559, 1540, 1507, 1473, 1457, 1437, 1395,
1363, 1340, 1260, 1218, 1164, 1123, 1108, 1048, 1017, 853, 818, 750, 668, 616 cm-1; MS
(ESI +ve) m/2 372 ([M + 2H]2+, 100%), m/z 742 ([M + H]+, 52%), 764 ([M + Na]+, 38%);
HRMS (ESI +ve TOF) calcd for C40H60N11O3 742.4881, found 742.4903 ([M + H]+).

(R)-6-Amino-N-((R)-1-(4-(cyclohexylmethyl)-1H-1,2,3-triazol-1-yl)-5guanidinopentan-2-yl)-2-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H1,2,3-triazol-1-yl)hexanamide dihydrochloride (80d)

Following General Procedure A, azide 79a (50 mg, 0.05 mmol), 3-cyclohexyl-1-propyne
(19 mg, 0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02
mmol) were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 20 h to give the intermediate
triazole as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100
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 10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL)
and treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with
ethereal HCl to give the amine salt 80d (38 mg, 90% over two steps) as a light tan powder
23

that rapidly transitioned to a sticky gum. [α] D +5.2 (c 1.00, MeOH); 1H NMR (400 MHz,
CD3OD) δ 8.21 (s, 1H), 7.76 (s, 1H), 7.35 – 7.23 (m, 2H), 7.22 – 7.10 (m, 3H), 7.05 – 6.97
(m, 2H), 6.94 (t, J = 7.3 Hz, 1H), 5.37 – 5.27 (m, 1H), 5.11 (s, 2H), 4.79 – 4.68 (m, 1H), 4.61
– 4.50 (m, 1H), 4.29 (br s, 1H), 3.95 – 3.85 (m, 2H), 3.21 – 3.07 (m, 2H), 2.98 – 2.83 (m,
2H), 2.70 (d, J = 5.4 Hz, 2H), 2.13 – 1.90 (m, 2H), 1.85 – 0.94 (m, 22H), 0.79 (d, J = 6.6 Hz,
6H);

13

C NMR (101 MHz, CD3OD) δ 170.3, 158.7, 158.2, 157.5, 146.2 (observed by

gHMBC), 146.0 (observed by gHMBC), 132.9, 132.6, 130.5, 129.9, 129.82, 129.77, 127.5,
124.5, 122.5, 121.5, 114.8, 113.8, 68.2, 64.7, 64.0, 56.5, 51.3, 42.0, 40.6, 39.4, 39.3, 34.02,
33.97, 32.90, 32.87, 29.7, 27.8, 27.5, 27.34, 27.32, 26.4, 26.3, 23.7, 23.1*; IR (neat) ν̄max
3338, 3169, 3060, 2953, 2925, 2867, 2370, 2323, 1684, 1669, 1653, 1559, 1540, 1507, 1473,
1457, 1437, 1387, 1363, 1340, 1261, 1217, 1162, 1136, 1124, 1109, 1049, 1002, 936, 853,
749, 668, 616 cm-1; MS (ESI +ve) m/2 379 ([M + 2H]2+, 100%), m/z 756 ([M + H]+, 41%),
778 ([M + Na]+, 17%); HRMS (ESI +ve TOF) calcd for C41H62N11O3 756.5037, found
756.5038 ([M + H]+).
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Tert-butyl ((R)-6-azido-5-((R)-2-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-5-(2-((2,2,4,6,7-pentamethyl-2,3dihydrobenzofuran-5-yl)sulfonyl)guanidino)pentanamido)hexyl)carbamate (79b)
Following General Procedure B, acid 75b (200
mg, 0.27 mmol), amine 22 (69 mg, 0.27 mmol),
EDCI (62 mg, 0.32 mmol) and HOBt (43 mg, 0.32
mmol) were stirred in acetonitrile (2.7 mL) for 48 h
to give the product amide 79b (241 mg, 91%) as a
translucent tan gum. TLC (EtOAc/P.S. – 60:40): Rf
23

= 0.30, (MeOH/CH2Cl2 – 10:90): Rf = 0.38; [α] D

−9.1 (c 1.03, MeOH); 1H NMR (400 MHz, CDCl3) δ 7.89 (br s, 1H, N5′′′-H), 7.69 (s, 1H,
H5′), 7.32 – 7.17 (m, 4H, ArH), 7.10 – 6.97 (m, 2H, ArH), 6.97 – 6.87 (m, 2H, ArH), 6.31
(br s, 2H, -NH2), 6.03 (br s, 1H, N5-H), 5.65 (br s, 1H, H2), 5.12 and 5.08 (ABq, J = 12.3 Hz,
2H), 4.66 (br s, 1H, N1′′′-H), 4.04 – 3.93 (m, 1H, H5′′′), 3.93 – 3.84 (m, 2H, H1′′), 3.46 – 3.27
(m, 3H, H5A or H5B and H6′′′), 3.03 – 2.90 (m, 5H, H5B or H5A, H1′′′ and ArCH2-), 2.60 (s,
3H, ArCH3), 2.52 (s, 3H, ArCH3), 2.21 – 1.98 (m, 5H, H3 and ArCH3), 1.63 – 1.02 (m, 26H,
H4, H2′′, H3′′, H2′′′, H3′′′, H4′′′, -C(CH3)2 and –C(CH3)3), 0.78 (d, J = 6.6 Hz, 6H, H4′′ and
H5′′);
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C NMR (101 MHz, CDCl3) δ 168.7 (C1), 159.0 (Pbf CAr), 156.7 (C=N), 156.6

(CAr2′), 156.2 (Cα), 156.0 (CAr2), 145.0 (C4′), 138.5 (Pbf CAr), 132.7 (Pbf CAr), 132.4 (Pbf
CAr), 131.8 (CAr6 or CAr6′), 131.6 (CAr6′ or CAr6), 128.9 (CAr1), 128.7 (CAr4), 128.6
(CAr4′), 128.0 (CAr1′), 124.9 (Pbf CAr), 122.7 (C5′), 121.4 (CAr5), 120.2 (CAr5′), 117.8
(Pbf CAr), 113.8 (CAr3), 112.5 (CAr3′), 86.6 (-C(CH3)2), 79.2 (-C(CH3)3), 67.1 (C1′′), 63.6
(-OCH2-C4′), 62.7 (C2), 54.4 (C6′′′), 50.0 (C5′′′), 43.4 (ArCH2-), 40.3 (C1′′′), 38.8 (C5), 38.0
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(C2′′), 31.4 (C4′′′), 29.8 (C3), 29.7 (C2′′′), 28.7 (-C(CH3)2), 28.5 (-C(CH3)3), 25.6 (C4), 25.1
(C3′′), 23.1 (C3′′′), 22.63 (C4′′ or C5′′), 22.61 (C5′′ or C4′′), 19.5 (ArCH3), 18.2 (ArCH3),
12.6 (ArCH3); IR (neat) ν̄max 3338, 2956, 2932, 2873, 2356, 2323, 2100, 1718, 1700, 1684,
1653, 1636, 1617, 1559, 1540, 1507, 1457, 1441, 1419, 1395, 1363, 1340, 1250, 1163, 1107,
1091, 1051, 1005, 933, 853, 806, 782, 752, 733, 668, 642, 621 cm-1; MS (ESI +ve) m/z 1009
([M + Na]+, 100%), 987 ([M + H]+, 8%); HRMS (ESI +ve TOF) calcd for C50H72N11O8S
986.5286, found 986.5322 ([M + H]+).

(R)-N-((R)-6-Amino-1-(4-benzyl-1H-1,2,3-triazol-1-yl)hexan-2-yl)-5-guanidino-2-(4(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H-1,2,3-triazol-1yl)pentanamide dihydrochloride (81a)

Following General Procedure A, azide 79b (50 mg, 0.05 mmol), 3-phenyl-1-propyne (18
mg, 0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol)
were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 24 h to give the intermediate triazole
as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 
10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) and
treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with
ethereal HCl to give the amine salt 81a (35 mg, 84% over two steps) as a light tan powder
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that rapidly transitioned to a sticky gum. [α] D +5.1 (c 1.00, MeOH); 1H NMR (400 MHz,
CD3OD) δ 7.94 (s, 1H, Hα), 7.70 (s, 1H, H5′), 7.36 – 7.10 (m, 10H, ArH), 7.05 – 6.98 (m,
2H, ArH), 6.95 (t, J = 7.1 Hz, 1H, ArH), 5.26 (dd, J = 8.9, 6.2 Hz, 1H, H2), 5.09 (s,
2H, -OCH2-C4′), 4.62 (dd, J = 13.8, 3.6 Hz, 1H, H1′′′A or H1′′′B), 4.45 (dd, J = 13.7, 9.5 Hz,
1H, H1′′′B or H1′′′A), 4.35 – 4.23 (m, 1H, H2′′′), 4.14 – 4.02 (m, 2H, -CH2Ph), 3.96 – 3.85
(m, 2H, H1′′), 3.06 (t, J = 6.8 Hz, 2H, H5), 2.83 (t, J = 7.0 Hz, 2H, H6′′′), 2.04 – 1.91 (m,
1H, H3A or H3B), 1.84 – 1.14 (m, 12H, H3B or H3A, H4, H2′′, H3′′, H3′′′, H4′′′, H5′′′), 0.78
(d, J = 6.6 Hz, 6H, H4′′ and H5′′); 13C NMR (101 MHz, CD3OD) δ 170.0 (C1), 158.7 (C=N),
158.2 (CAr2′), 157.6 (CAr2), 148.2 (Cβ – observed by gHMBC), 146.0 (C4′ – observed by
gHMBC), 140.0 (Phenyl CAr), 132.9 (CAr6 or CAr6′), 132.6 (CAr6′ or CAr6), 130.5 (CAr1),
129.98 (Phenyl CAr)*, 129.96 (Phenyl CAr)*, 129.9 (CAr4), 129.8 (CAr1′), 129.8 (CAr4′),
128.0 (Phenyl CAr), 125.8 (Cα), 124.4 (C5′), 122.5 (CAr5), 121.5 (CAr5′), 114.8 (CAr3),
113.8 (CAr3′), 68.2 (C1′′), 64.4 (C2), 64.0 (-OCH2-C4′), 55.2 (C1′′′), 51.4 (C2′′′), 41.6 (C5),
40.6 (C6′′′), 39.4 (C2′′), 32.3 (-CH2Ph), 32.2 (C3′′′), 30.6 (C3), 28.2 (C5′′′), 26.3 (C3′′), 26.0
(C4), 23.8 (C4′′′), 23.1 (C4′′ and C5′′); IR (neat) ν̄max 3338, 3186, 3064, 2953, 2935, 2870,
2358, 2323, 1734, 1718, 1700, 1684, 1653, 1636, 1617, 1595, 1559, 1540, 1507, 1473, 1457,
1437, 1419, 1395, 1363, 1340, 1219, 1162, 1108, 1091, 1050, 1021, 937, 853, 751, 721, 697,
669, 620 cm-1; MS (ESI +ve) m/2 376 ([M + 2H]2+, 100%), m/z 750 ([M + H]+, 18%), 772
([M + Na]+, 7%); HRMS (ESI +ve TOF) calcd for C41H56N11O3 750.4568, found 750.4572
([M + H]+).
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(R)-N-((R)-6-Amino-1-(4-phenethyl-1H-1,2,3-triazol-1-yl)hexan-2-yl)-5-guanidino-2(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H-1,2,3-triazol-1yl)pentanamide dihydrochloride (81b)

Following General Procedure A, azide 79b (50 mg, 0.05 mmol), 4-phenyl-1-butyne (20
mg, 0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol)
were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 24 h to give the intermediate triazole
as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 
10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) and
treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with
ethereal HCl to give the amine salt 81b (40 mg, 94% over two steps) as a light tan powder
23

that rapidly transitioned to a sticky gum. [α] D +9.5 (c 0.83, MeOH); 1H NMR (400 MHz,
CD3OD) δ 7.96 (s, 1H), 7.78 (s, 1H), 7.34 – 7.09 (m, 10H), 7.06 – 6.96 (m, 2H), 6.93 (t, J =
7.4 Hz, 1H), 5.32 (dd, J = 9.1, 6.0 Hz, 1H), 5.11 (s, 2H), 4.65 (dd, J = 13.8, 3.6 Hz, 1H), 4.49
(dd, J = 13.8, 8.9 Hz, 1H), 4.31 – 4.20 (m, 1H), 3.94 – 3.85 (m, 2H), 3.19 (t, J = 6.9 Hz, 2H),
3.11 – 2.96 (m, 4H), 2.84 (t, J = 7.2 Hz, 2H), 2.20 – 1.92 (m, 2H), 1.75 – 1.23 (m, 11H), 0.78
(d, J = 6.6 Hz, 6H);

13

C NMR (101 MHz, CD3OD) δ 170.0, 158.8, 158.2, 157.5, 147.9

(observed by gHMBC), 146.1 (observed by gHMBC), 141.9, 132.9, 132.6, 130.5*, 129.9,
129.82*, 129.79, 129.7*, 127.6, 126.3, 124.5, 122.5, 121.5, 114.8, 113.8, 68.2, 64.5, 64.0,
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55.6, 51.5, 41.8, 40.6, 39.4, 36.3, 32.0, 30.6, 28.2, 27.8, 26.2, 26.1, 23.8, 23.1*; IR (neat) ν̄max
3338, 3140, 3065, 2953, 2925, 2871, 2378, 2324, 1734, 1718, 1700, 1684, 1669, 1653, 1636,
1617, 1559, 1540, 1507, 1473, 1457, 1437, 1419, 1395, 1363, 1340, 1213, 1160, 1136, 1109,
1049, 1003, 937, 853, 751, 699, 669, 620 cm-1; MS (ESI +ve) m/2 383 ([M + 2H]2+, 100%),
m/z 786 ([M + Na]+, 28%), 764 ([M + H]+, 22%); HRMS (ESI +ve TOF) calcd for
C42H58N11O3 764.4724, found 764.4754 ([M + H]+).

(R)-N-((R)-6-Amino-1-(4-cyclohexyl-1H-1,2,3-triazol-1-yl)hexan-2-yl)-5-guanidino-2(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H-1,2,3-triazol-1yl)pentanamide dihydrochloride (81c)

Following General Procedure A, azide 79b (50 mg, 0.05 mmol), cyclohexylacetylene (18
mg, 0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol)
were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 24 h to give the intermediate triazole
as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 
10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL) and
treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with
ethereal HCl to give the amine salt 81c (40 mg, 97% over two steps) as a light tan powder
23

that rapidly transitioned to a sticky gum. [α] D +2.6 (c 0.97, MeOH); 1H NMR (400 MHz,
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CD3OD) δ 7.82 (s, 1H), 7.73 (s, 1H), 7.34 – 7.24 (m, 2H), 7.17 (mp, 3H), 7.05 – 6.97 (m,
2H), 6.94 (t, J = 7.2 Hz, 1H), 5.37 – 5.29 (m, 1H), 5.10 (s, 2H), 4.60 – 4.41 (m, 2H), 4.30 (br
s, 1H), 3.97 – 3.84 (m, 2H), 3.18 (t, J = 6.2 Hz, 2H), 2.89 – 2.79 (m, 2H), 2.79 – 2.67 (m,
1H), 2.13 – 1.21 (m, 23H), 0.78 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, CD3OD) δ 170.0,
158.8, 158.2, 157.6, 154.6 (observed by gHMBC), 146.1 (observed by gHMBC), 132.8,
132.6, 130.6*, 129.9, 129.8, 124.4, 123.3, 122.5, 121.5, 114.8, 113.8, 68.2, 64.3, 64.1, 54.5,
51.5, 41.5, 40.6, 39.4, 36.7, 34.40, 34.35, 32.3, 30.8, 28.2, 27.4*, 27.3, 26.3, 25.9, 23.8,
23.1*; IR (neat) ν̄max 3337, 3139, 3064, 2954, 2927, 2864, 2378, 2324, 1734, 1718, 1700,
1684, 1669, 1653, 1636, 1617, 1559, 1540, 1507, 1473, 1457, 1437, 1419, 1395, 1363, 1340,
1261, 1213, 1159, 1123, 1109, 1049, 1002, 937, 853, 800, 750, 668, 619 cm-1; MS (ESI +ve)
m/2 372 ([M + 2H]2+, 100%), m/z 742 ([M + H]+, 58%), 764 ([M + Na]+, 52%); HRMS (ESI
+ve TOF) calcd for C40H60N11O3 742.4881, found 742.4908 ([M + H]+).

(R)-N-((R)-6-Amino-1-(4-(cyclohexylmethyl)-1H-1,2,3-triazol-1-yl)hexan-2-yl)-5guanidino-2-(4-(((2'-(isopentyloxy)-[1,1'-biphenyl]-2-yl)oxy)methyl)-1H-1,2,3-triazol1-yl)pentanamide dihydrochloride (81d)

Following General Procedure A, azide 79b (50 mg, 0.05 mmol), 3-cyclohexyl-1-propyne
(19 mg, 0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02
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mmol) were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 24 h to give the intermediate
triazole as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100
 10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.5 mL)
and treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with
ethereal HCl to give the amine salt 81d (38 mg, 90% over two steps) as a light tan powder
23

that rapidly transitioned to a sticky gum. [α] D +3.0 (c 0.70, MeOH); 1H NMR (400 MHz,
CD3OD) δ 7.98 (s, 1H), 7.75 (s, 1H), 7.35 – 7.24 (m, 2H), 7.23 – 7.09 (m, 3H), 7.05 – 6.98
(m, 2H), 6.94 (t, J = 7.4 Hz, 1H), 5.30 (dd, J = 8.9, 6.2 Hz, 1H), 5.09 (s, 2H), 4.64 (dd, J =
13.8, 3.5 Hz, 1H), 4.47 (dd, J = 13.8, 9.3 Hz, 1H), 4.28 (br s, 1H), 3.97 – 3.84 (m, 2H), 3.19
(t, J = 6.8 Hz, 2H), 2.83 (t, J = 7.1 Hz, 2H), 2.63 (d, J = 6.8 Hz, 2H), 2.15 – 1.88 (m, 2H),
1.78 – 1.12 (m, 20H), 1.06 – 0.93 (m, 2H), 0.79 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz,
CD3OD) δ 170.0, 158.8, 158.2, 157.6, 147.1 (observed by gHMBC), 146.2 (observed by
gHMBC), 132.9, 132.6, 130.6, 129.88, 129.85, 129.8, 126.2, 124.4, 122.5, 121.5, 114.8,
113.8, 68.2, 64.5, 64.0, 55.4, 51.5, 41.8, 40.6, 39.5, 39.4, 34.2, 34.1, 33.6, 32.2, 30.7, 28.2,
27.6, 27.4*, 26.3, 26.1, 23.8, 23.1*; IR (neat) ν̄max 3337, 3140, 3064, 2953, 2926, 2866, 2376,
2323, 1734, 1718, 1700, 1684, 1669, 1653, 1636, 1617, 1559, 1540, 1507, 1473, 1457, 1437,
1419, 1395, 1363, 1340, 1260, 1214, 1159, 1123, 1109, 1049, 1003, 937, 870, 852, 750, 669,
620 cm-1; MS (ESI +ve) m/2 379 ([M + 2H]2+, 100%), m/z 778 ([M + Na]+, 38%), 756 ([M +
H]+, 18%); HRMS (ESI +ve TOF) calcd for C41H62N11O3 756.5037, found 756.5062 ([M +
H]+).

258

Tert-butyl ((R)-6-(((R)-1-azido-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5yl)sulfonyl)guanidino)pentan-2-yl)amino)-5-(4-((((S)-2'-(isopentyloxy)-[1,1'binaphthalen]-2-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-6-oxohexyl)carbamate (79c)
Following General Procedure B, acid 75c
(182 mg, 0.27 mmol), amine 25 (131 mg, 0.30
mmol), EDCI (63 mg, 0.33 mmol) and HOBt
(44 mg, 0.30 mmol) were stirred in acetonitrile
(2.7 mL) for 18 h to give the product amide 79c
(252 mg, 86%) as a translucent tan gum after
flash

chromatography

over

SiO2

gel

(EtOAc/P.S. – 80:20). TLC (EtOAc/P.S. –
23

80:20): Rf = 0.38; [α] D −18.3 (c 0.43, MeOH);
1

H NMR (400 MHz, CDCl3) δ 7.99 – 7.90 (m, 2H, ArH), 7.90 – 7.82 (m, 2H, ArH), 7.45 (d,

J = 9.0 Hz, 1H, ArH), 7.41 (d, J = 9.0 Hz, 1H, ArH), 7.38 – 7.09 (m, 6H, ArH), 6.72 (s, 1H,
H5′), 6.04 (br s, 3H, N5′′′-H and -NH2), 5.17 – 5.02 (m, 3H, H5 and -OCH2-C4′), 4.66 (br s,
1H, N1-H), 4.02 – 3.80 (m, 3H, H5 and H1′′), 3.32 – 3.20 (m, 2H, H1′′′), 3.07 – 2.85 (m, 6H,
H1, H5′′′ and ArCH2-), 2.56 (s, 3H, ArCH3), 2.50 (s, 3H, ArCH3), 2.12 – 1.99 (m, 4H, ArCH3
and H4A or H4B), 1.83 – 1.72 (m, 1H, H4B or H4A), 1.50 – 0.98 (m, 26H, H2, H3, H2′′, H3′′,
H3′′′, H4′′′, -C(CH3)3 and -C(CH3)2), 0.55 (d, J = 6.3 Hz, 3H, H4′′ or H5′′), 0.51 (d, J = 6.2
Hz, 3H, H5′′ or H4′′); 13C NMR (101 MHz, CD3OD) δ 168.3 (C6), 158.9 (Pbf CAr), 156.2
(Cα), 156.1 (C=N), 154.6 (CAr2′), 153.8 (CAr2), 145.1 (C4′), 138.4 (Pbf CAr), 134.13
(CAr8a or CAr8a′), 134.10 (CAr8a′ or CAr8a), 133.0 (Pbf CAr), 132.4 (Pbf CAr), 130.0
(CAr4a), 129.71 (CAr4), 129.67 (CAr4′), 129.3 (CAr4a′), 128.2 (CAr5), 128.1 (CAr5′),
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126.6 (CAr7), 126.5 (CAr7′), 125.7 (CAr8), 125.3 (CAr8′), 124.8 (Pbf CAr), 124.3 (CAr6),
123.8 (CAr6′), 122.4 (C5′), 121.6 (CAr1), 120.2 (CAr1′), 117.7 (Pbf CAr), 116.4 (CAr3),
115.9 (CAr3′), 86.5 (-C(CH3)2), 79.3 (-C(CH3)3 – observed by gHMBC), 68.3 (C1′′′), 64.6
(-OCH2-C4′), 63.8 (C5), 54.7 (C1′′′), 49.4 (C2′′′), 43.4 (ArCH2-), 40.8 (C5′′′), 40.1 (C1), 38.1
(C2′′), 31.8 (C4), 29.3 (C3′′′), 29.0 (C2), 28.7 (-C(CH3)2), 28.6 (-C(CH3)3), 25.5 (C4′′′), 24.7
(C3′′), 22.8 (C3), 22.5 (C4′′ or C5′′), 22.2 (C5′′ or C4′′), 19.5 (ArCH3), 18.1 (ArCH3), 12.6
(ArCH3); IR (neat) ν̄max 3320, 2954, 2928, 2870, 2102, 1718, 1700, 1684, 1653, 1617, 1559,
1540, 1507, 1457, 1363, 1243, 1163, 1147, 1089, 1045, 1014, 908, 852, 807, 782, 749, 734,
661, 641, 621 cm-1; MS (ESI +ve) m/z 1109 ([M + Na]+, 100%), 1087 ([M + H]+, 17%);
HRMS (ESI +ve TOF) calcd for C58H76N11O8S 1086.5599, found 1086.5637 ([M + H]+).

(R)-6-Amino-N-((R)-5-guanidino-1-(4-phenethyl-1H-1,2,3-triazol-1-yl)pentan-2-yl)-2(4-((((S)-2'-(isopentyloxy)-[1,1'-binaphthalen]-2-yl)oxy)methyl)-1H-1,2,3-triazol-1yl)hexanamide dihydrochloride (82a)

Following General Procedure A, azide 79c (50 mg, 0.05 mmol), 4-phenyl-1-butyne (18 mg,
0.14 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol)
were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 24 h to give the intermediate triazole
as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 
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10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.4 mL) and
treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.4 mL) followed by work-up with
ethereal HCl to give the amine salt 82a (24 mg, 56% over two steps) as a light tan powder
23

that rapidly transitioned to a sticky gum. [α] D −27.9 (c 0.47, MeOH); 1H NMR (400 MHz,
CD3OD) δ 8.05 – 7.94 (m, 2H, ArH), 7.93 – 7.81 (m, 2H, ArH), 7.73 (s, 1H, H5′), 7.58 (d, J
= 8.9 Hz, 1H, ArH), 7.49 (d, J = 8.9 Hz, 1H, ArH), 7.39 – 7.11 (m, 10H, ArH), 7.09 – 6.99
(m, 2H, ArH), 5.11 (m, 3H, H2 and -OCH2-C4′), 4.61 – 4.50 (m, 1H, H1′′′A or H1′′′B), 4.47
– 4.34 (m, 1H, H1′′′B or H1′′′A), 4.25 (br s, 1H, H2′′′), 4.08 – 3.96 (m, 1H, H1′′A or H1′′B),
3.96 – 3.86 (m, 1H, H1′′B or H1′′A), 3.19 – 2.94 (m, 6H, H5′′′, Hγ and -CH2Ph), 2.86 (br s,
2H, H6), 1.96 – 1.84 (m, 1H, H3A or H3B), 1.76 – 0.79 (m, 12H, H3B or H3A, H4, H5, H2′′,
H3′′, H3′′′ and H4′′′), 0.55 (d, J = 6.4 Hz, 3H, H4′′ or H5′′), 0.51 (d, J = 6.3 Hz, 3H, H5′′ or
H4′′);

13

C NMR (101 MHz, CD3OD) δ 170.1 (C1), 158.7 (C=N), 156.1 (CAr2′), 155.4

(CAr2), 148.4 (Cβ – observed by gHMBC), 145.7 (C4′ – observed by gHMBC), 142.4
(Phenyl CAr), 135.6 (CAr8a or CAr8a′), 135.5 (CAr8a′ or CAr8a), 131.6 (CAr4a), 130.9
(CAr4a′), 130.8 (CAr4), 130.7 (CAr4′), 129.76 (Phenyl CAr)*, 129.75 (Phenyl CAr)*, 129.3
(CAr5), 129.2 (CAr5′), 127.49 (Phenyl CAr), 127.48 (CAr7 and CAr7′), 126.6 (CAr8), 126.4
(CAr8′), 125.3 (CAr6), 124.8 (CAr6′ and Cα), 124.0 (C5′), 122.9 (CAr1), 121.4 (CAr1′),
117.7 (CAr3), 117.0 (CAr3′), 69.2 (C1′′), 65.2 (-OCH2-C4′), 64.6 (C2), 54.7 (C1′′′), 51.2
(C2′′′), 42.1 (C5′′′), 40.6 (C6), 39.5 (C2′′), 36.8 (Cγ), 32.8 (C3), 30.1 (C3′′′), 28.5 (-CH2Ph),
27.9 (C5), 26.3 (C4′′′), 25.8 (C3′′), 23.6 (C4), 23.0 (C4′′ or C5′′), 22.7 (C5′′ or C4′′); IR (neat)
ν̄max 3320, 3178, 2954, 2926, 2869, 2375, 2352, 2322, 1734, 1718, 1700, 1684, 1669, 1653,
1617, 1559, 1540, 1507, 1457, 1437, 1363, 1243, 1212, 1147, 1085, 1055, 1040, 1005, 912,
865, 809, 776, 746, 701, 669, 611 cm-1; MS (ESI +ve) m/2 433 ([M + 2H]2+, 100%), m/z 865
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([M + H]+, 21%); HRMS (ESI +ve TOF) calcd for C50H62N11O3 864.5037, found 864.5078
([M + H]+).

(R)-6-Amino-N-((R)-1-(4-(cyclohexylmethyl)-1H-1,2,3-triazol-1-yl)-5guanidinopentan-2-yl)-2-(4-((((S)-2'-(isopentyloxy)-[1,1'-binaphthalen]-2yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)hexanamide dihydrochloride (82b)

Following General Procedure A, azide 79c (50 mg, 0.05 mmol), 3-cyclohexyl-1-propyne
(17 mg, 0.15 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02
mmol) were stirred in t-BuOH (1.0 mL) and H2O (0.25 mL) for 24 h to give the intermediate
triazole as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100
 10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.4 mL)
and treated with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.4 mL) followed by work-up with
ethereal HCl to give the amine salt 82b (32 mg, 75% over two steps) as a light tan powder
23

that rapidly transitioned to a sticky gum. [α] D −10.2 (c 0.80, MeOH); 1H NMR (400 MHz,
CD3OD) δ 8.04 – 7.96 (m, 2H), 7.94 (s, 1H), 7.92 – 7.86 (m, 2H), 7.59 (d, J = 9.0 Hz, 1H),
7.51 (d, J = 9.0 Hz, 1H), 7.37 – 7.27 (m, 2H), 7.25 – 7.14 (m, 3H), 7.06 (d, J = 8.4 Hz, 1H),
7.02 (d, J = 8.5 Hz, 1H), 5.21 – 5.04 (m, 3H), 4.66 – 4.56 (m, 1H), 4.51 – 4.41 (m, 1H), 4.29
(br s, 1H), 4.08 – 3.99 (m, 1H), 3.97 – 3.87 (m, 1H), 3.16 – 3.03 (m, 2H), 2.95 – 2.81 (m,
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2H), 2.63 (d, J = 6.5 Hz, 2H), 1.97 – 1.86 (m, 1H), 1.80 – 0.79 (m, 23H), 0.56 (d, J = 6.4 Hz,
3H), 0.52 (d, J = 6.3 Hz, 3H); 13C NMR (101 MHz, CD3OD) δ 170.1, 158.7, 156.2, 155.4,
147.5 (observed by gHMBC), 146.0 (observed by gHMBC), 135.6, 135.5, 131.6, 130.9,
130.8, 130.7, 129.3, 129.2, 127.48, 127.46, 126.6, 126.4, 125.8, 125.2, 124.8, 124.2, 122.9,
121.4, 117.8, 117.0, 69.2, 65.1, 64.6, 55.2, 51.2, 42.0, 40.6, 39.6, 39.5, 34.2, 34.2, 33.9, 32.8,
30.0, 27.9, 27.6, 27.5, 27.4, 26.3, 25.8, 23.6, 23.0, 22.8; IR (neat) ν̄max 3320, 3178, 2953,
2923, 2854, 2376, 2351, 2321, 1734, 1718, 1700, 1684, 1669, 1653, 1617, 1559, 1540, 1507,
1457, 1437, 1374, 1363, 1340, 1261, 1244, 1212, 1147, 1083, 1055, 1040, 1006, 915, 864,
809, 774, 744, 669, 614 cm-1; MS (ESI +ve) m/2 429 ([M + 2H]2+, 100%), m/z 857 ([M +
H]+, 22%); HRMS (ESI +ve TOF) calcd for C49H66N11O3 856.5350, found 856.5377 ([M +
H]+).

Tert-butyl ((R)-6-azido-5-((R)-2-(4-((((S)-2'-(isopentyloxy)-[1,1'-binaphthalen]-2yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-5-(2-((2,2,4,6,7-pentamethyl-2,3dihydrobenzofuran-5-yl)sulfonyl)guanidino)pentanamido)hexyl)carbamate (79d)
Following General Procedure B, acid 75d
(120 mg, 0.14 mmol), amine 22 (37 mg, 0.14
mmol), EDCI (33 mg, 0.17 mmol) and HOBt
(23 mg, 0.17 mmol) were stirred in
acetonitrile (1.4 mL) for 48 h to give the
product amide 79d (143 mg, 93%) as a
translucent tan gum. TLC (EtOAc/P.S. –
23

80:20): Rf = 0.72; [α] D −8.7 (c 1.27, MeOH);
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1

H NMR (400 MHz, CDCl3) δ 7.90 (app. t, J = 9.0 Hz, 2H, ArH), 7.85 (d, J = 8.2 Hz, 1H,

ArH), 7.77 (m, 2H, N5′′′-H and ArH), 7.48 (d, J = 9.0 Hz, 1H, ArH), 7.42 (d, J = 9.0 Hz, 1H,
ArH), 7.33 (t, J = 7.3 Hz, 1H, ArH), 7.24 – 7.04 (m, 6H, H5′ and ArH), 6.27 (br s, 2H, -NH2),
5.93 (br s, 1H, N5-H), 5.49 (br s, 1H, H2), 5.11 and 5.07 (ABq, J = 12.3 Hz, 2H, -OCH2-C4′),
4.64 (br s, 1H, N1′′′-H), 4.05 – 3.84 (m, 3H, H1′′ and H5′′′), 3.40 – 3.22 (m, 3H, H5A or H5B
and H6′′′), 2.93 (br s, 5H, H5B or H5A, H1′′′ and ArCH2-), 2.61 (s, 3H, ArCH3), 2.52 (s, 3H,
ArCH3), 2.13 – 2.01 (m, 4H, H3A or H3B and ArCH3), 1.96 – 1.82 (m, 1H, H3B or H3A), 1.53
– 1.07 (m, 25H, H4A or H4B, H2′′, H3′′, H2′′′, H3′′′, H4′′′, -C(CH3)2 and -C(CH3)3), 0.93 –
0.77 (m, 1H, H4B or H4A), 0.57 (d, J = 6.3 Hz, 3H, H4′′ or H5′′), 0.53 (d, J = 6.3 Hz, 3H, H5′′
or H4′′); 13C NMR (101 MHz, CD3OD) δ 168.5 (C1), 159.0 (Pbf CAr), 156.6 (C=N), 156.2
(Cα), 154.7 (CAr2′), 154.1 (CAr2), 145.0 (C4′), 138.5 (Pbf CAr), 134.14 (CAr8a or CAr8a′),
134.10 (CAr8a′ or CAr8a), 132.8 (Pbf CAr), 132.4 (Pbf CAr), 130.0 (CAr4a), 129.52 (CAr4),
129.51 (CAr4′), 129.2 (CAr4a′), 128.04 (CAr5), 127.99 (CAr5′), 126.4 (CAr7), 126.3
(CAr7′), 125.7 (CAr8), 125.4 (CAr8′), 124.9 (Pbf CAr), 124.1 (CAr6), 123.6 (CAr6′), 122.7
(C5′), 121.7 (CAr1), 120.1 (CAr1′), 117.8 (Pbf CAr), 116.9 (CAr3), 115.9 (CAr3′), 86.6
(-C(CH3)2), 79.2 (-C(CH3)3, 68.3 (C1′′), 64.7 (-OCH2-C4′), 62.7 (C2), 54.3 (C6′′′), 50.0
(C5′′′), 43.4 (ArCH2-), 40.3 (C1′′′), 38.9 (C5), 38.2 (C2′′), 31.4 (C4′′′), 29.8 (C3), 29.6 (C5′′′),
28.7 (-C(CH3)2), 28.5 (-C(CH3)3), 25.5 (C4), 24.7 (C3′′), 23.1 (C3′′′), 22.5 (C4′′ or C5′′), 22.3
(C5′′ or C4′′), 19.6 (ArCH3), 18.2 (ArCH3), 12.6 (ArCH3); IR (neat) ν̄max 3334, 2958, 2933,
2878, 2377, 2323, 2099, 1751, 1734, 1718, 1700, 1684, 1653, 1636, 1617, 1559, 1540, 1507,
1490, 1473, 1457, 1437, 1419, 1395, 1363, 1340, 1244, 1166, 1154, 1106, 1090, 1048, 1015,
904, 853, 808, 779, 748, 668, 641, 620, 609 cm-1; MS (ESI +ve) m/z 1109 ([M + Na]+, 100%),
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1087 ([M + H]+, 9%); HRMS (ESI +ve TOF) calcd for C58H75N11O8SNa 1108.5419, found
1108.5433 ([M + Na]+).

(R)-N-((R)-6-Amino-1-(4-phenethyl-1H-1,2,3-triazol-1-yl)hexan-2-yl)-5-guanidino-2(4-((((S)-2'-(isopentyloxy)-[1,1'-binaphthalen]-2-yl)oxy)methyl)-1H-1,2,3-triazol-1yl)pentanamide dihydrochloride (83a)

Following General Procedure A, azide 79d (45 mg, 0.04 mmol), 4-phenyl-1-butyne (16
mg, 0.12 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol)
were stirred in t-BuOH (0.8 mL) and H2O (0.2 mL) for 24 h to give the intermediate triazole
as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100 
10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.2 mL) and
treated with H2O (15 mg, 0.83 mmol) and CF3CO2H (1.2 mL) followed by work-up with
ethereal HCl to give the amine salt 83a (37 mg, 95% over two steps) as a light tan powder
23

that rapidly transitioned to a sticky gum. [α] D −10.3 (c 0.90, MeOH); 1H NMR (400 MHz,
CD3OD) δ 8.19 (s, 1H, Hα), 8.03 – 7.94 (m, 2H, ArH), 7.92 – 7.84 (m, 2H, ArH), 7.60 (d, J
= 9.0 Hz, 1H, ArH), 7.49 (d, J = 9.0 Hz, 1H, ArH), 7.37 – 7.13 (m, 10H, H5′ and ArH), 7.08
– 6.99 (m, 2H, ArH), 5.24 (dd, J = 9.3, 5.6 Hz, 1H, H2), 5.14 and 5.10 (ABq, J = 12.4 Hz,
2H, -OCH2-C4′), 4.77 – 4.69 (m, 1H, H1′′′A or H1′′′B), 4.59 – 4.49 (m, 1H, H1′′′B or H1′′′A),
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4.22 (br s, 1H, H2′′′), 4.07 – 3.97 (m, 1H, H1′′A or H1′′B), 3.94 – 3.85 (m, 1H, H1′′B or H1′′A),
3.22 – 3.10 (m, 4H, H5 and Hγ), 3.08 – 2.98 (m, 2H, -CH2Ph), 2.84 (t, J = 7.2 Hz, 2H, H6′′′),
2.16 – 2.01 (m, 1H, H3A or H3B), 1.93 – 1.81 (m, 1H, H3B or H3A), 1.78 – 1.07 (m, 11H, H4,
H2′′, H3′′, H3′′′, H4′′′ and H5′′′), 0.55 (d, J = 6.4 Hz, 3H, H4′′ or H5′′), 0.51 (d, J = 6.3 Hz,
3H, H5′′ or H4′′); 13C NMR (101 MHz, CD3OD) δ 170.0 (C1), 158.8 (C=N), 156.1 (CAr2′),
155.5 (CAr2), 146.4 (Cβ – observed by gHMBC), 146.2 (C4′ – observed by gHMBC), 141.3
(Phenyl CAr), 135.6 (CAr8a or CAr8a′), 135.5 (CAr8a′ or CAr8a), 131.6 (CAr4a), 130.9
(CAr4a′), 130.80 (CAr4), 130.77 (CAr4′), 129.9 (Phenyl CAr)*, 129.8 (Phenyl CAr)*, 129.3
(CAr5), 129.2 (CAr5′), 128.3 (Cα – observed by gHMBC), 127.9 (Phenyl CAr), 127.51
(CAr7), 127.46 (CAr7′), 126.6 (CAr8), 126.4 (CAr8′), 125.3 (CAr6), 124.8 (CAr6′), 124.5
(C5′ – observed by gHMBC), 122.9 (CAr1), 121.4 (CAr1′), 117.8 (CAr3), 117.0 (CAr3′),
69.2 (C1′′), 65.0 (-OCH2-C4′), 64.5 (C2), 56.6 (C1′′′), 51.5 (C2′′′), 41.7 (C5), 40.6 (C6′′′),
39.5 (C2′′), 35.9 (-CH2Ph), 31.8 (C3′′′), 30.4 (C3), 28.1 (C5′′′), 27.1 (Cγ), 26.0 (C4), 25.8
(C3′′), 23.8 (C4′′′), 23.0 (C4′′ or C5′′), 22.7 (C5′′ or C4′′); IR (neat) ν̄max 3334, 3147, 3060,
2953, 2933, 2874, 2377, 2324, 1751, 1734, 1718, 1700, 1684, 1653, 1636, 1617, 1559, 1540,
1507, 1490, 1473, 1457, 1437, 1419, 1395, 1363, 1340, 1319, 1243, 1215, 1164, 1147, 1108,
1083, 1047, 1009, 903, 861, 810, 747, 702, 668, 620, 608 cm-1; MS (ESI +ve) m/2 433 ([M
+ 2H]2+, 100%), m/z 887 ([M + Na]+, 18%), 865 ([M + H]+, 8%); HRMS (ESI +ve TOF)
calcd for C50H62N11O3 864.5037, found 864.5018 ([M + H]+).
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(R)-N-((R)-6-Amino-1-(4-(cyclohexylmethyl)-1H-1,2,3-triazol-1-yl)hexan-2-yl)-5guanidino-2-(4-((((S)-2'-(isopentyloxy)-[1,1'-binaphthalen]-2-yl)oxy)methyl)-1H-1,2,3triazol-1-yl)pentanamide dihydrochloride (83b)

Following General Procedure A, azide 79d (45 mg, 0.04 mmol), 3-cyclohexyl-1-propyne
(15 mg, 0.12 mmol), Cu(OAc)2∙H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02
mmol) were stirred in t-BuOH (0.8 mL) and H2O (0.2 mL) for 24 h to give the intermediate
triazole as a light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100
 10:90). Following General Procedure C, the triazole was dissolved in CH2Cl2 (1.2 mL)
and treated with H2O (15 mg, 0.83 mmol) and CF3CO2H (1.2 mL) followed by work-up with
ethereal HCl to give the amine salt 83b (26 mg, 68% over two steps) as a light tan powder
23

that rapidly transitioned to a sticky gum. [α] D −25.9 (c 0.30, MeOH); 1H NMR (400 MHz,
CD3OD) δ 8.03 – 7.96 (m, 2H), 7.93 – 7.82 (m, 3H), 7.57 (d, J = 9.0 Hz, 1H), 7.51 (d, J =
9.0 Hz, 1H), 7.38 – 7.25 (m, 2H), 7.25 – 7.13 (m, 3H), 7.07 (d, J = 8.4 Hz, 1H), 7.02 (d, J =
8.4 Hz, 1H), 5.33 – 5.25 (m, 1H), 5.11 and 5.09 (ABq, J = 12.3 Hz, 2H), 4.57 – 4.47 (m, 2H),
4.32 – 4.23 (m, 1H), 4.08 – 4.00 (m, 1H), 3.97 – 3.88 (m, 1H), 3.13 (br s, 2H), 2.84 (br s,
2H), 2.63 – 2.51 (m, 2H), 2.00 (s, 1H), 1.78 – 0.84 (m, 23H), 0.57 (d, J = 6.4 Hz, 3H), 0.53
(d, J = 6.3 Hz, 3H); 13C NMR (101 MHz, CD3OD) δ 170.1, 158.9, 156.2, 147.5 (observed by
gHMBC), 146.3 (observed by gHMBC), 155.5, 135.60, 135.56, 131.6, 130.9, 130.8, 130.7,
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129.3, 129.2, 127.5*, 126.7, 126.4, 125.3, 125.2, 124.8, 124.2, 123.0, 121.5, 117.8, 117.0,
69.2, 65.2, 64.1, 54.4, 51.6, 41.2, 40.5, 39.7, 39.5, 34.4, 34.34, 34.28, 32.2, 30.6, 28.2, 27.7,
27.5*, 25.9, 25.7, 23.5, 23.0, 22.8; IR (neat) ν̄max 3337, 3146, 3059, 2952, 2923, 2853, 2378,
2323, 1751, 1734, 1718, 1700, 1684, 1653, 1636, 1623, 1559, 1540, 1507, 1490, 1473, 1457,
1437, 1419, 1395, 1363, 1340, 1319, 1261, 1244, 1202, 1177, 1131, 1083, 1056, 1017, 916,
862, 808, 775, 748, 721, 669, 620, 609 cm-1; MS (ESI +ve) m/2 429 ([M + 2H]2+, 100%), m/z
857 ([M + H]+, 34%), 879 ([M + Na]+, 16%); HRMS (ESI +ve TOF) calcd for C49H66N11O3
856.5350, found 856.5376 ([M + H]+).

(R)-N2-((R)-6-((Tert-butoxycarbonyl)amino)-2-(4-((((S)-2'-(isopentyloxy)-[1,1'binaphthalen]-2-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)hexanoyl)-2-amino-5-(2((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino)pentanoic acid
(84)
Following General Procedure B, acid 75c
(150 mg, 0.23 mmol), amine 29 (109 mg, 0.25
mmol), EDCI (52 mg, 0.27 mmol) and HOBt
(37 mg, 0.25 mmol) were stirred in acetonitrile
(2.3 mL) for 18 h to give the intermediate ester
as

a

translucent

tan

gum

after

flash

chromatography over SiO2 gel (EtOAc). The
ester was dissolved in THF (3.0 mL) with
stirring, H2O (2.0 mL) and LiOH∙H2O (84 mg,
2.00 mmol) were added and the reaction was stirred vigorously at rt for 24 h. The mixture
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was diluted with 1.0 M aqueous HCl (25 mL), extracted with EtOAc (2 × 50 mL) and the
combined organic extracts were washed with H2O (1 × 50 mL), brine (1 × 50 mL), dried
(MgSO4), filtered and concentrated to give the acid 84 (205 mg, 86% over two steps) as a
23

light tan gum. TLC (MeOH/CH2Cl2 – 5:95): Rf = 0.25; [α] D −4.6 (c 1.53, MeOH); 1H NMR
(400 MHz, CD3OD) : (mixture of rotamers) δ 8.00 – 7.90 (m, 2H, ArH), 7.90 – 7.81 (m, 2H,
ArH), 7.58 – 7.42 (m, 2H, ArH)‡, 7.34 – 7.22 (m, 2H, ArH), 7.22 – 6.98 (m, 5H, H5′ and
ArH), 5.21 (t, J = 7.0 Hz, 1H, H2), 5.15 – 5.03 (m, 2H, -OCH2-C4′), 4.36 – 4.26 (m, 1H,
H2′′′), 4.05 – 3.85 (m, 2H, H1′′), 3.17 (br s, 1H, H5′′′A or H5′′′B), 3.08 (br s, 1H, H5′′′B or
H5′′′A), 3.01 – 2.86 (m, 4H, H6 and ArCH2-), 2.60 – 2.52 (m, 3H, ArCH3)‡, 2.52 – 2.44 (m,
3H, ArCH3)‡, 2.08 – 2.00 (m, 4H, H3A or H3B and ArCH3)‡, 1.93 – 1.75 (m, 2H, H3B or H3A
and H3′′′A or H3′′′B), 1.73 – 0.80 (m, 25H, H4, H5, H2′′, H3′′, H3′′′B or H3′′′A, H4′′′, -C(CH3)2
and -C(CH3)3), 0.59 – 0.46 (m, 6H, H4′′ and H5′′)‡; 13C NMR (101 MHz, CD3OD) : (mixture
of rotamers)† δ 174.8 (C1′′′), 170.2 (C1), 160.0 (Pbf CAr), 158.6 (Cα), 158.2 (C=N), 156.1
(CAr2′), 155.4 (CAr2), 146.1 (C4′), 139.5 (Pbf CAr), 135.6 (CAr8a or CAr8a′), 135.5 (CAr8a′
or CAr8a), 134.5 (Pbf CAr), 133.7 (Pbf CAr)Δ, 131.5 (CAr4a), 130.8 (CAr4a′)Δ, 130.7 (CAr4),
130.6 (CAr4′), 129.3 (CAr5), 129.2 (CAr5′), 127.5 (CAr7), 127.4 (CAr7′), 126.7 (CAr8)∆,
126.3 (CAr8′), 126.2 (Pbf CAr), 125.1 (CAr6), 124.8 (CAr6′), 123.8 (C5′), 122.8 (CAr1),

‡ Indicates that the 1H NMR resonance was split into two or more signals due to the presence of amide and
carbamate rotamers (e.g. the syn- and anti-amide conformations).
† All 13C NMR resonances (except those denoted with a Δ symbol) were split into two resonances due to the
presence of amide and/or carbamate rotamers (e.g. the syn- and anti-amide conformations); only the major
resonance from each resonance pair is reported for clarity.
∆ Indicates that the 13C NMR resonance was not split into multiple resonances due to rotamers.
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121.3 (CAr1′), 118.6 (Pbf CAr), 117.6 (CAr3), 116.9 (CAr3′), 87.8 (-C(CH3)2), 80.1
(-C(CH3)3), 69.1 (C1′′)Δ, 65.1 (-OCH2-C4′), 64.7 (C2), 53.7 (C2′′′)Δ, 44.1 (ArCH2-), 41.6
(C5′′′), 41.1 (C6)Δ, 39.5 (C2′′)Δ, 33.8 (C3), 30.4 (C3′′′), 30.0 (C5), 29.0 (-C(CH3)2
or -C(CH3)3), 28.9 (-C(CH3)3 or -C(CH3)2)Δ, 27.2 (C4′′′), 25.8 (C3′′), 23.9 (C4), 23.0 (C4′′ or
C5′′), 22.8 (C5′′ or C4′′), 19.8 (ArCH3), 18.6 (ArCH3), 12.7 (ArCH3); IR (neat) ν̄max 3336,
2967, 2931, 2870, 2369, 2322, 1700, 1684, 1653, 1559, 1540, 1507, 1473, 1457, 1419, 1363,
1340, 1244, 1163, 1147, 1088, 1049, 1016, 906, 852, 808, 783, 747, 669, 614 cm-1; MS (ESI
−ve) m/z 1074 ([M − H]−, 100%); HRMS (ESI −ve TOF) calcd for C58H73N8O10S 1073.5170,
found 1073.5156 ([M − H]−).

(R)-6-Amino-N-((R)-1-(benzylamino)-5-guanidino-1-oxopentan-2-yl)-2-(4-((((S)-2'(isopentyloxy)-[1,1'-binaphthalen]-2-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)hexanamide
dihydrochloride (85a)

Following General Procedure B, acid 84 (50 mg, 0.05 mmol), benzylamine (6 mg, 0.06
mmol), EDCI (11 mg, 0.06 mmol) and HOBt (8 mg, 0.05 mmol) were stirred in acetonitrile
(0.5 mL) for 24 h to give the intermediate amide as a translucent tan gum. Following General
Procedure C, the amide was dissolved in CH2Cl2 (1.4 mL) and treated with H2O (17 mg,
0.94 mmol) and CF3CO2H (1.4 mL) followed by work-up with ethereal HCl to give the amine
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salt 85a (33 mg, 79% over two steps) as a light tan powder that rapidly transitioned to a sticky
23

gum. [α] D −8.7 (c 0.87, MeOH); 1H NMR (400 MHz, CD3OD) : (mixture of rotamers) δ 8.02
– 7.92 (m, 2H, ArH), 7.91 – 7.81 (m, 2H, ArH), 7.62 – 7.41 (m, 2H, ArH)‡, 7.37 – 6.97 (m,
12H, H5′ and ArH), 5.48 – 5.25 (m, 1H, H2)‡, 5.16 – 5.03 (m, 2H, -OCH2-C4′)‡, 4.40 – 4.19
(m, 3H, H2′′′ and -CH2Ph)‡, 4.07 – 3.85 (m, 2H, H1′′), 3.24 – 3.05 (m, 2H, H5′′′)‡, 2.93 –
2.76 (m, 2H, H6)‡, 2.22 – 2.01 (m, 2H, H3A or H3B), 1.97 – 1.06 (m, 12H, H3B or H3A, H4,
H5, H2′′, H3′′, H3′′′ and H4′′′), 0.60 – 0.46 (m, 6H, H4′′ and H5′′)‡;

13

C NMR (101 MHz,

CD3OD) : (mixture of rotamers)† δ 174.2 (C1′′′), 170.6 (C1), 158.9 (C=N), 156.1 (CAr2′),
155.5 (CAr2), 145.8 (C4′ – observed by gHMBC), 139.8 (Phenyl CAr), 135.6 (CAr8a), 135.5
(CAr8a′), 131.5 (CAr4a), 130.9 (CAr4a′)∆, 130.8 (CAr4), 130.7 (CAr4′), 129.8 (Phenyl
CAr)*, 129.3 (CAr5)Δ, 129.2 (CAr5′)Δ, 128.8 (Phenyl CAr)*, 128.4 (Phenyl CAr), 127.6
(CAr7), 127.4 (CAr7′), 126.7 (CAr8)Δ, 126.4 (CAr8′), 125.2 (CAr6), 124.8 (CAr6′), 124.2
(C5′ – observed by gHMBC), 122.9 (CAr1), 121.4 (CAr1′), 117.7 (CAr3), 116.9 (CAr3′),
69.2 (C1′′), 65.1 (-OCH2-C4′), 64.0 (C2), 55.0 (C2′′′), 44.2 (-CH2Ph), 42.1 (C5′′′), 40.5 (C6),
39.5 (C2′′)Δ, 32.7 (C3), 30.1 (C3′′′), 27.5 (C5), 26.4 (C4′′′), 25.8 (C3′′)Δ, 23.2 (C4), 23.0 (C4′′
or C5′′), 22.8 (C5′′ or C4′′); IR (neat) ν̄max 3060, 2954, 2932, 2869, 2367, 2319, 1734, 1718,
1700, 1684, 1669, 1653, 1623, 1590, 1559, 1540, 1507, 1490, 1457, 1437, 1419, 1395, 1363,

‡ Indicates that the 1H NMR resonance was split into two or more signals due to the presence of amide and
carbamate rotamers (e.g. the syn- and anti-amide conformations).

† All 13C NMR resonances (except those denoted with a Δ symbol) were split into two resonances due to the
presence of amide and/or carbamate rotamers (e.g. the syn- and anti-amide conformations); only the major
resonance from each resonance pair is reported for clarity.
∆ Indicates that the 13C NMR resonance was not split into multiple resonances due to rotamers.
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1340, 1261, 1242, 1223, 1146, 1109, 1084, 1049, 1014, 914, 861, 809, 746, 668, 608 cm-1;
MS (ESI +ve) m/2 407 ([M + 2H]2+, 100%), m/z 812 ([M + H]+, 24%); HRMS (ESI +ve TOF)
calcd for C47H58N9O4 812.4612, found 812.4604 ([M + H]+).

(R)-6-Amino-N-((R)-5-guanidino-1-oxo-1-(phenethylamino)pentan-2-yl)-2-(4-((((S)-2'(isopentyloxy)-[1,1'-binaphthalen]-2-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)hexanamide
dihydrochloride (85b)

Following General Procedure B, acid 84 (50 mg, 0.05 mmol), β-phenylethylamine (7 mg,
0.06 mmol), EDCI (11 mg, 0.06 mmol) and HOBt (8 mg, 0.05 mmol) were stirred in
acetonitrile (0.5 mL) for 24 h to give the intermediate amide as a translucent tan gum.
Following General Procedure C, the amide was dissolved in CH2Cl2 (1.4 mL) and treated
with H2O (17 mg, 0.94 mmol) and CF3CO2H (1.4 mL) followed by work-up with ethereal
HCl to give the amine salt 85b (39 mg, 92% over two steps) as a light tan powder that rapidly
23

transitioned to a sticky gum. [α] D −19.4 (c 0.40, MeOH); 1H NMR (400 MHz, CD3OD) :
(mixture of rotamers) δ 8.04 – 7.91 (m, 2H), 7.91 – 7.80 (m, 2H), 7.60 – 7.41 (m, 2H)‡, 7.36

‡ Indicates that the 1H NMR resonance was split into two or more signals due to the presence of amide and
carbamate rotamers (e.g. the syn- and anti-amide conformations).

272

– 6.97 (m, 12H), 5.50 – 5.24 (m, 1H)‡, 5.16 – 5.03 (m, 2H)‡, 4.26 – 4.10 (m, 1H)‡, 4.07 –
3.83 (m, 2H), 3.57 – 3.31 (m, 2H)‡, 3.24 – 3.02 (m, 2H)‡, 2.97 – 2.74 (m, 4H)‡, 2.22 – 2.02
(m, 1H), 1.97 – 1.02 (m, 12H), 0.55 (d, J = 6.3 Hz, 3H)‡, 0.51 (d, J = 6.3 Hz, 3H)‡; 13C NMR
(101 MHz, CD3OD) : (mixture of rotamers)† δ 174.1, 170.3, 158.8, 156.1, 155.5, 145.8,
140.5, 135.6∆, 135.5Δ, 131.6, 130.9Δ, 130.8, 130.7, 130.1*, 129.6*, 129.3, 129.2, 127.6,
127.5, 127.4, 126.7Δ, 126.4, 125.2, 124.8, 124.2, 122.9, 121.4Δ, 117.7, 117.0, 69.2, 65.1, 64.1,
55.5, 42.2, 42.1, 40.4, 39.5Δ, 36.7, 32.7, 30.3, 27.5, 26.3, 25.8Δ, 23.3, 23.0, 22.8; IR (neat)
ν̄max 2953, 2926, 2869, 2366, 2322, 1734, 1718, 1700, 1684, 1669, 1653, 1623, 1591, 1559,
1540, 1507, 1490, 1457, 1437, 1419, 1395, 1363, 1340, 1261, 1242, 1223, 1085, 1048, 1016,
915, 861, 809, 748, 698, 668, 613 cm-1; MS (ESI +ve) m/2 414 ([M + 2H]2+, 100%), m/z 826
([M + H]+, 28%); HRMS (ESI +ve TOF) calcd for C48H60N9O4 826.4768, found 826.4800
([M + H]+).

† All 13C NMR resonances (except those denoted with a Δ symbol) were split into two resonances due to the
presence of amide and/or carbamate rotamers (e.g. the syn- and anti-amide conformations); only the major
resonance from each resonance pair is reported for clarity.
∆ Indicates that the 13C NMR resonance was not split into multiple resonances due to rotamers.
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(R)-6-Amino-N-((R)-5-guanidino-1-oxo-1-(piperidin-1-yl)pentan-2-yl)-2-(4-((((S)-2'(isopentyloxy)-[1,1'-binaphthalen]-2-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)hexanamide
dihydrochloride (85c)

Following General Procedure B, acid 84 (50 mg, 0.05 mmol), piperidine (5 mg, 0.06 mmol),
EDCI (11 mg, 0.06 mmol) and HOBt (8 mg, 0.05 mmol) were stirred in acetonitrile (0.5 mL)
for 24 h to give the intermediate amide as a translucent tan gum. Following General
Procedure C, the amide was dissolved in CH2Cl2 (1.4 mL) and treated with H2O (17 mg,
0.94 mmol) and CF3CO2H (1.4 mL) followed by work-up with ethereal HCl to give the amine
salt 85c (31 mg, 76% over two steps) as a light tan powder that rapidly transitioned to a sticky
23

gum. [α] D −18.5 (c 0.60, MeOH); 1H NMR (400 MHz, CD3OD) : (mixture of rotamers) δ
8.05 – 7.93 (m, 2H, ArH), 7.92 – 7.83 (m, 2H, ArH), 7.62 – 7.43 (m, 2H, ArH)‡, 7.37 – 7.11
(m, 5H), 7.10 – 6.98 (m, 2H), 5.45 – 5.26 (m, 1H)‡, 5.18 – 5.03 (m, 2H)‡, 4.75 – 4.66 (m,
1H)‡, 4.08 – 3.87 (m, 2H), 3.67 – 3.36 (m, 2H)‡, 3.28 – 3.06 (m, 4H)‡, 2.89 (m, 2H)‡, 2.22 –
2.05 (m, 1H), 1.99 – 1.08 (m, 18H), 0.56 (d, J = 6.4 Hz, 3H)‡, 0.53 (d, J = 5.9 Hz, 3H)‡; 13C

‡ Indicates that the 1H NMR resonance was split into two or more signals due to the presence of amide and
carbamate rotamers (e.g. the syn- and anti-amide conformations).
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NMR (101 MHz, CD3OD) : (mixture of rotamers)† δ 170.9, 170.1, 158.9, 156.2, 155.4, 146.0,
135.6∆, 135.5Δ, 131.6, 130.9, 130.74, 130.71, 129.3, 129.2, 127.5, 127.4, 126.6Δ, 126.4,
125.2, 124.8, 124.2, 122.6, 121.5, 117.7, 117.0, 69.2Δ, 65.1, 64.4, 50.7, 48.1, 44.7, 42.2, 40.6,
39.5, 33.2, 30.2, 27.8, 27.7, 26.8, 26.5, 25.8Δ, 25.6, 23.6, 23.0, 22.8; IR (neat) ν̄max 2950,
2924, 2869, 2367, 2322, 1734, 1718, 1700, 1684, 1669, 1653, 1636, 1623, 1591, 1559, 1540,
1507, 1490, 1457, 1437, 1419, 1395, 1363, 1340, 1261, 1243, 1222, 1107, 1082, 1048, 1015,
912, 865, 808, 747, 669, 613 cm-1; MS (ESI +ve) m/2 396 ([M + 2H]2+, 100%), m/z 790 ([M
+ H]+, 38%); HRMS (ESI +ve TOF) calcd for C45H60N9O4 790.4768, found 790.4802 ([M
+ H]+).

† All 13C NMR resonances (except those denoted with a Δ symbol) were split into two resonances due to the
presence of amide and/or carbamate rotamers (e.g. the syn- and anti-amide conformations); only the major
resonance from each resonance pair is reported for clarity.
∆ Indicates that the 13C NMR resonance was not split into multiple resonances due to rotamers.
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6.3.6 – Series C
(R)-2-(2-(((S)-2'-(Isopentyloxy)-[1,1'-binaphthalen]-2-yl)oxy)acetamido)-5-(2((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino)pentanoic acid
(86)
Following General Procedure B, acid 42 (246 mg,
0.59 mmol), amine 29 (261 mg, 0.59 mmol), EDCI (136
mg, 0.71 mmol) and HOBt (107 mg, 0.64 mmol) were
stirred in acetonitrile (6.0 mL) for 21 h to give the
intermediate amide as a translucent tan gum after flash
chromatography over SiO2 gel (EtOAc). To a solution
of the amide in THF (5.0 mL) was added LiOH·H2O
(210 mg, 5.00 mmol) and H2O (5.0 mL) followed by vigorous stirring at rt for 18 h. The
reaction mixture was diluted with 1.0 M aqueous HCl (50 mL), extracted with EtOAc (3 x
40 mL) and the combined extracts were dried (MgSO4), filtered and concentrated to afford
the acid 86 (398 mg, 82% over two steps) as a translucent tan gum after flash chromatography
23

over SiO2 gel (MeOH/CH2Cl2 – 10:90). TLC (MeOH/CH2Cl2 – 5:95) RF = 0.31; [α] D −4.1
(c 1.87, MeOH); 1H NMR (400 MHz, CD3OD) δ 8.03 – 7.94 (m, 2H, ArH), 7.92 – 7.81 (m,
2H, ArH), 7.75 (br s, 1H, N2-H), 7.50 – 7.39 (m, 2H, ArH), 7.36 – 7.27 (m, 1H, ArH), 7.23
– 7.14 (m, 2H, ArH), 7.12 – 6.95 (m, 3H, ArH), 4.54 and 4.42 (ABq, J = 14.6 Hz,
2H, -OCH2-Cα), 4.16 (br s, 1H, H2), 4.12 – 4.04 (m, 1H, H1′′A or H1′′B), 3.99 – 3.88 (m, 1H,
H1′′B or H1′′A), 3.08 – 2.84 (m, 4H, H5 and ArCH2-), 2.60 (s, 3H, ArCH3), 2.53 (s, 3H,
ArCH3), 2.11 (s, 3H, ArCH3), 1.56 – 1.44 (m, 1H, H3A or H3B), 1.41 – 1.12 (m, 11H, H4,
H2′′, H3′′ and -C(CH3)2), 1.09 – 0.96 (m, 1H, H3B or H3A), 0.58 (d, J = 6.4 Hz, 3H, H4′′ or
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H5′′), 0.52 (d, J = 6.4 Hz, 3H, H5′′ or H4′′); 13C NMR (101 MHz, CD3OD)† δ 173.8 (C1),
170.6 (Cα), 160.4 (Pbf CAr – observed by gHMBC), 156.1 (CAr2′), 154.0 (CAr2), 139.8 (Pbf
CAr – observed by gHMBC), 135.4 (CAr8a or CAr8a′), 135.1 (CAr8a′ or CAr8a), 134.5 (Pbf
CAr – observed by gHMBC), 133.7 (Pbf CAr – observed by gHMBC), 131.5 (CAr4a), 131.10
(CAr4), 131.06 (CAr4′), 130.8 (CAr4a′), 129.5 (CAr5), 129.3 (CAr5′), 127.74 (CAr7),
127.70 (CAr7′), 126.6 (CAr8), 126.4 (Pbf CAr – observed by gHMBC), 126.0 (CAr8′), 125.4
(CAr6), 125.0 (CAr6′), 121.9 (CAr1), 120.6 (CAr1′), 118.7 (Pbf CAr – observed by gHMBC),
117.1 (CAr3), 115.9 (CAr3′), 88.1 (-C(CH3)2 – observed by gHMBC), 69.2 (C1′′), 69.2
(-OCH2-Cα), 52.4 (C2), 44.1 (ArCH2-), 41.6 (C5 – observed by gHSQC), 39.4 (C2′′), 30.9
(C4), 30.1 (C3), 28.9 (-C(CH3)2), 25.8 (C3′′), 22.9 (C4′′ or C5′′), 22.8 (C5′′ or C4′′), 19.9
(ArCH3), 18.6 (ArCH3), 12.8 (ArCH3); IR (neat) ν̄max 2953, 2926, 2372, 2324, 1734, 1718,
1700, 1684, 1653, 1636, 1617, 1577, 1559, 1540, 1521, 1507, 1490, 1473, 1457, 1437, 1419,
1395, 1363, 1340, 1271, 1243, 1147, 1092, 852, 808, 779, 748, 668, 619, 609 cm-1; MS (ESI
−ve) m/z 821 ([M − H]−, 100%); HRMS (ESI +ve TOF) calcd for C46H54N4O8SNa 845.3560,
found 845.3597 ([M + Na]+).

† The guanidine carbon (C=N) could not be assigned to a resonance in the 13C NMR spectrum. This carbon
was easily observed and assigned to resonances in the 13C NMR spectra of the corresponding amide derivatives
(as seen below).
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(R)-N-Benzyl-5-guanidino-2-(2-(((S)-2'-(isopentyloxy)-[1,1'-binaphthalen]-2yl)oxy)acetamido)pentanamide hydrochloride (87a)
Following General Procedure B, acid 86 (50 mg,
0.06 mmol), benzylamine (8 mg, 0.07 mmol),
EDCI (14 mg, 0.07 mmol) and HOBt (10 mg, 0.07
mmol) were stirred in acetonitrile (0.6 mL) for 22
h to give the intermediate amide as a translucent
tan gum. Following General Procedure C, the amide was dissolved in CH2Cl2 (1.8 mL) and
treated with H2O (22 mg, 1.21 mmol) and CF3CO2H (1.8 mL) followed by work-up with
ethereal HCl to give the amine salt 87a (41 mg, 97% over two steps) as a light tan powder
23

that rapidly transitioned to a sticky gum. [α] D −7.5 (c 0.83, MeOH); 1H NMR (400 MHz,
CD3OD) δ 8.06 – 7.97 (m, 2H, ArH), 7.95 – 7.86 (m, 2H, ArH), 7.52 (d, J = 9.0 Hz, 1H,
ArH), 7.46 (d, J = 9.0 Hz, 1H, ArH), 7.39 – 7.15 (m, 9H, ArH), 7.10 – 7.02 (m, 2H, ArH),
4.57 and 4.43 (ABq, J = 14.7 Hz, 2H, -OCH2-Cα), 4.37 – 4.25 (m, 2H, -CH2Ph), 4.23 (t, J =
6.0 Hz, 1H, H2), 4.08 (dt, J = 9.7, 6.1 Hz, 1H, H1′′A or H1′′B), 3.93 (dt, J = 9.6, 6.4 Hz, 1H,
H1′′B or H1′′A), 3.09 – 2.89 (m, 2H, H5), 1.62 – 1.49 (m, 1H, H3A or H3B), 1.31 – 1.02 (m,
6H, H3B or H3A, H4, H2′′ and H3′′), 0.56 (d, J = 6.5 Hz, 3H, H4′′ or H5′′), 0.50 (d, J = 6.4
Hz, 3H, H5′′ or H4′′); 13C NMR (101 MHz, CD3OD) δ 172.9 (C1), 171.0 (Cα), 158.7 (C=N),
156.1 (CAr2′), 154.2 (CAr2), 140.0 (Phenyl CAr), 135.4 (CAr8a or CAr8a′), 135.2 (CAr8a′
or CAr8a), 131.6 (CAr4a), 131.13 (CAr4), 131.09 (CAr4′), 130.9 (CAr4a′), 129.8 (Phenyl
CAr)*, 129.5 (CAr5), 129.3 (CAr5′), 128.7 (Phenyl CAr)*, 128.5 (Phenyl CAr), 127.8 (CAr7),
127.7 (CAr7′), 126.6 (CAr8), 126.1 (CAr8′), 125.4 (CAr6), 125.0 (CAr6′), 122.1 (CAr1),
120.8 (CAr1′), 117.3 (CAr3), 116.3 (CAr3′), 69.6 (C1′′), 69.3 (-OCH2-Cα), 53.3 (C2), 44.2
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(-CH2Ph), 41.9 (C5), 39.5 (C2′′), 30.5 (C3), 25.9 (C4), 25.8 (C3′′), 23.0 (C4′′ or C5′′), 22.8
(C5′′ or C4′′); IR (neat) ν̄max 3334, 3188, 2954, 2926, 2376, 2323, 1734, 1718, 1700, 1684,
1653, 1636, 1617, 1577, 1559, 1540, 1521, 1507, 1490, 1473, 1457, 1437, 1419, 1395, 1363,
1340, 1329, 1271, 1242, 1215, 1147, 1094, 1073, 1047, 920, 862, 807, 775, 747, 696, 669,
621, 608 cm-1; MS (ESI +ve) m/z 660 ([M + H]+, 100%), 682 ([M + Na]+, 16%); HRMS (ESI
+ve TOF) calcd for C40H46N5O4 660.3550, found 660.3553 ([M + H]+).

(R)-5-Guanidino-2-(2-(((S)-2'-(isopentyloxy)-[1,1'-binaphthalen]-2-yl)oxy)acetamido)N-phenethylpentanamide hydrochloride (87b)
Following General Procedure B, acid 86 (50 mg,
0.06 mmol), β-phenylethylamine (9 mg, 0.07
mmol), EDCI (14 mg, 0.07 mmol) and HOBt (10
mg, 0.07 mmol) were stirred in acetonitrile (0.6 mL)
for 22 h to give the intermediate amide as a translucent tan gum. Following General
Procedure C, the amide was dissolved in CH2Cl2 (1.8 mL) and treated with H2O (22 mg,
1.21 mmol) and CF3CO2H (1.8 mL) followed by work-up with ethereal HCl to give the amine
salt 87b (42 mg, 97% over two steps) as a light tan powder that rapidly transitioned to a sticky
23

gum. [α] D −3.7 (c 0.97, MeOH); 1H NMR (400 MHz, CD3OD) δ 8.05 – 7.98 (m, 2H), 7.94
– 7.86 (m, 2H), 7.56 (d, J = 9.1 Hz, 1H), 7.46 (d, J = 9.0 Hz, 1H), 7.38 – 7.12 (m, 9H), 7.10
– 7.02 (m, 2H), 4.52 and 4.44 (ABq, J = 14.8 Hz, 2H), 4.18 – 4.08 (m, 2H), 3.96 (dt, J = 9.5,
6.5 Hz, 1H), 3.42 – 3.32 (m, 2H), 3.02 – 2.89 (m, 2H), 2.79 – 2.67 (m, 2H), 1.53 – 1.41 (m,
1H), 1.34 – 0.96 (m, 6H), 0.57 (d, J = 6.5 Hz, 3H), 0.52 (d, J = 6.4 Hz, 3H); 13C NMR (101
MHz, CD3OD) δ 172.8, 170.9, 158.7, 156.1, 154.3, 140.5, 135.4, 135.2, 131.7, 131.14,
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131.08, 131.0, 130.1*, 129.7*, 129.5, 129.3, 127.8, 127.7, 127.6, 126.6, 126.1, 125.4, 125.0,
122.2, 120.8, 117.2, 116.3, 69.6, 69.3, 53.2, 42.1, 41.9, 39.5, 36.6, 30.5, 25.9, 25.8, 23.0,
22.8; IR (neat) ν̄max 3335, 3185, 2953, 2926, 2874, 2376, 2323, 1734, 1718, 1700, 1684, 1653,
1636, 1617, 1577, 1559, 1540, 1521, 1507, 1490, 1473, 1457, 1437, 1419, 1395, 1363, 1340,
1319, 1271, 1244, 1215, 1147, 1094, 1072, 1048, 920, 861, 808, 775, 747, 698, 668, 620,
609 cm-1; MS (ESI +ve) m/z 674 ([M + H]+, 100%), 696 ([M + Na]+, 14%); HRMS (ESI +ve
TOF) calcd for C41H48N5O4 674.3706, found 674.3722 ([M + H]+).

(R)-N-(4-Fluorophenethyl)-5-guanidino-2-(2-(((S)-2'-(isopentyloxy)-[1,1'binaphthalen]-2-yl)oxy)acetamido)pentanamide hydrochloride (87c)
Following General Procedure B, acid 86 (40
mg, 0.05 mmol), 2-(4-fluorophenyl)ethylamine
(8 mg, 0.06 mmol), EDCI (11 mg, 0.06 mmol)
and HOBt (8 mg, 0.06 mmol) were stirred in
acetonitrile (0.5 mL) for 22 h to give the intermediate amide as a translucent tan gum.
Following General Procedure C, the amide was dissolved in CH2Cl2 (1.5 mL) and treated
with H2O (18 mg, 1.00 mmol) and CF3CO2H (1.5 mL) followed by work-up with ethereal
HCl to give the amine salt 87c (26 mg, 74% over two steps) as a light tan powder that rapidly
23

transitioned to a sticky gum. [α] D −9.2 (c 0.50, MeOH); 1H NMR (400 MHz, CD3OD) δ 8.06
– 8.00 (m, 2H), 7.93 – 7.88 (m, 2H), 7.56 (d, J = 9.1 Hz, 1H), 7.48 (d, J = 9.0 Hz, 1H), 7.39
– 7.29 (m, 2H), 7.26 – 7.14 (m, 4H), 7.10 – 7.03 (m, 2H), 6.98 (app. t, J = 8.8 Hz, 2H), 4.49
(ABq, J = 14.8 Hz, 2H), 4.18 – 4.08 (m, 2H), 3.97 (dt, J = 9.5, 6.6 Hz, 1H), 3.40 – 3.32 (m,
2H), 3.03 – 2.91 (m, 2H), 2.73 (t, J = 7.2 Hz, 2H), 1.50 – 1.40 (m, 1H), 1.33 – 0.97 (m, 6H),
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0.58 (d, J = 6.5 Hz, 3H), 0.52 (d, J = 6.5 Hz, 3H); 13C NMR (101 MHz, CD3OD) δ 172.8,
170.9, 163.2 (d, 1JCF = 242.7 Hz), 158.7, 156.1, 154.3, 136.5 (d, 4JCF = 3.2 Hz), 135.5, 135.3,
131.8 (d, 3JCF = 7.9 Hz), 131.7, 131.14, 131.10, 131.0, 129.5, 129.3, 127.8, 127.7, 126.6,
126.1, 125.5, 125.0, 122.2, 120.8, 117.2, 116.3, 116.2 (d, 2JCF = 21.3 Hz), 69.6, 69.3, 53.1,
42.1, 41.9, 39.5, 35.7, 30.5, 25.9, 25.8, 23.0, 22.7; IR (neat) ν̄max 3335, 3184, 2954, 2927,
2873, 2375, 2323, 1734, 1718, 1700, 1684, 1653, 1636, 1623, 1577, 1559, 1540, 1521, 1507,
1490, 1473, 1457, 1437, 1419, 1395, 1363, 1340, 1319, 1272, 1243, 1219, 1147, 1096, 1074,
1048, 1016, 920, 860, 807, 775, 748, 669, 620, 609 cm-1; MS (ESI +ve) m/z 692 ([M + H]+,
100%), 714 ([M + Na]+, 6%); HRMS (ESI +ve TOF) calcd for C41H47N5O4F 692.3612, found
692.3634 ([M + H]+).

Tert-butyl ((R)-6-azido-5-(2-(((S)-2'-(isopentyloxy)-[1,1'-binaphthalen]-2yl)oxy)acetamido)hexyl)carbamate (88)
Following General Procedure B, acid 42 (207 mg,
0.50 mmol), amine 22 (142 mg, 0.55 mmol), EDCI
(115 mg, 0.60 mmol) and HOBt (81 mg, 0.54 mmol)
were stirred in acetonitrile (5.0 mL) for 24 h to give
the product amide 88 (309 mg, 94%) as a translucent
tan gum after flash chromatography over SiO2 gel
23

(EtOAc). TLC (MeOH/CH2Cl2 – 5:95): RF = 0.45, (EtOAc/P.S. – 30:70) Rf = 0.17; [α] D

−28.7c 0.73, CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 8.01 (d, J = 9.1 Hz, 1H, ArH), 7.99 (d,
J = 8.9 Hz, 1H, ArH), 7.89 (app. t, J = 6.7 Hz, 2H, ArH), 7.48 (d, J = 9.1 Hz, 1H, ArH), 7.39
– 7.29 (m, 3H, ArH), 7.28 – 7.22 (m, 2H, ArH), 7.18 (app. t, J = 9.2 Hz, 2H, ArH), 5.60 (d,
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J = 9.1 Hz, 1H, N5-H), 4.48 (s, 2H, -OCH2-Cβ), 4.42 (br s, 1H, N1-H), 4.01 (dt, J = 9.4, 6.3
Hz, 1H, H1′′A or H1′′B), 3.94 (dt, J = 9.5, 6.4 Hz, 1H, H1′′B or H1′′A), 3.79 – 3.72 (m, 1H,
H5), 3.06 (dd, J = 12.3, 4.7 Hz, 1H, H6A or H6B), 2.99 – 2.88 (m, 3H, H1 and H6B or H6A),
1.44 (s, 9H, -C(CH3)3), 1.33 – 1.15 (m, 6H, H2, H4A or H4B, H2′′ and H3′′), 1.11 – 1.02 (m,
1H, H4B or H4A), 0.86 – 0.76 (m, 2H, H3), 0.60 (d, J = 6.5 Hz, 3H, H4′′ or H5′′), 0.56 (d, J
= 6.4 Hz, 3H, H5′′ or H4′′); 13C NMR (125 MHz, CDCl3) δ 167.9 (Cβ), 155.8 (Cα), 154.5
(CAr2′), 151.9 (CAr2), 133.8 (CAr8a or CAr8a′), 133.6 (CAr8a′ or CAr8a), 129.7 (CAr4a),
129.6 (CAr4), 129.4 (CAr4′), 129.1 (CAr4a′), 127.86 (CAr5), 127.92 (CAr5′), 126.6 (CAr7),
126.5 (CAr7′), 125.3 (CAr8), 124.9 (CAr8′), 124.0 (CAr6), 123.8 (CAr6′), 120.1 (CAr1),
119.5 (CAr1′), 115.7 (CAr3), 113.8 (CAr3′), 78.9 (-C(CH3)3), 68.1 (C1′′), 67.7 (-OCH2-Cβ),
54.2 (C6), 47.6 (C5), 40.1 (C1), 37.9 (C2′′), 31.0 (C4), 29.3 (C2), 28.3 (-C(CH3)3), 24.5
(C3′′), 22.6 (C3), 22.1 (C4′′ or C5′′), 22.0 (C5′′ or C4′′);IR (neat) ν̄max 3385, 2930, 2101,
1683, 1506, 1457, 1363, 1243, 1168, 1094, 807, 747 cm-1; MS (ESI +ve) m/z 676 ([M + Na]+,
100%); HRMS (ESI +ve TOF) calcd for C38H48N5O5 654.3655, found 654.3657 ([M + H]+).

N-((R)-6-Amino-1-(4-benzyl-1H-1,2,3-triazol-1-yl)hexan-2-yl)-2-(((S)-2'(isopentyloxy)-[1,1'-binaphthalen]-2-yl)oxy)acetamide hydrochloride (89a)
Following General Procedure A, azide 88 (50
mg, 0.08 mmol), 3-phenyl-1-propyne (27 mg,
0.23 mmol), Cu(OAc)2∙H2O (3 mg, 0.02 mmol)
and sodium ascorbate (6 mg, 0.03 mmol) were
stirred in t-BuOH (1.6 mL) and H2O (0.4 mL) for 20 h to give the intermediate triazole as a
light tan gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100  10:90).
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Following General Procedure C, the triazole was dissolved in CH2Cl2 (2.3 mL) and treated
with H2O (27 mg, 1.52 mmol) and CF3CO2H (2.3 mL) followed by work-up with ethereal
HCl to give the amine salt 89a (27 mg, 50% over two steps) as a light tan powder that rapidly
23

transitioned to a sticky gum. [α] D −14.5 (c 0.58, MeOH); 1H NMR (500 MHz, CD3OD)
δ 8.08 (d, J = 9.1 Hz, 1H, ArH), 8.04 (d, J = 9.1 Hz, 1H, ArH), 7.98 (d, J = 8.2 Hz, 1H, ArH),
7.93 (d, J = 8.2 Hz, 1H, ArH), 7.59 (d, J = 9.0 Hz, 1H, ArH), 7.44 – 7.34 (m, 3H, ArH), 7.31
– 7.22 (m, 2H, ArH), 7.22 – 7.08 (m, 8H, Hα and ArH), 4.38 and 4.11 (ABq, J = 14.6 Hz,
2H, -CHAHB-C=O), 4.31 (dd, J = 14.0, 4.3 Hz, 1H, H1A or H1B), 4.10 – 3.98 (m, 2H, H2 and
H1′′A or H1′′B ), 3.99 – 3.87 (m, 3H, H1′′B or H1′′A and -CH2Ph), 3.67 (dd, J = 14.0, 9.2 Hz,
1H, H1B or H1A), 2.81 – 2.66 (m, 2H, H6), 1.53 – 1.40 (m, 2H, H5), 1.36 – 1.25 (m, 1H, H3A
or H3B), 1.27 – 1.11 (m, 2H, H2′′), 1.14 – 1.02 (m, 1H, H3′′), 1.03 – 0.93 (m, 2H, H4), 0.88
– 0.76 (m, 1H, H3B or H3A), 0.52 (d, J = 6.6 Hz, 3H, H4′′ or H5′′), 0.48 (d, J = 6.6 Hz, 3H,
H5′′ or H4′′); 13C NMR (125 MHz, CD3OD) δ 170.7 (C=O), 156.1 (CAr2′), 153.7 (CAr2),
148.2 (Cβ), 140.4 (Phenyl CAr), 135.2 (CAr8a or CAr8a′), 135.1 (CAr8a′ or CAr8a), 131.5
(CAr4a), 131.1 (CAr4 and CAr4′), 130.8 (CAr4a′), 129.7 (Phenyl C Ar)*, 129.5 (CAr5 and
Phenyl CAr)*, 129.2 (CAr5′), 128.0 (Phenyl CAr), 127.7 (CAr7), 127.5 (CAr7′), 126.3 (CAr8),
126.1 (CAr8′), 125.3 (CAr6), 125.2 (CAr6′), 124.3 (Cα), 121.5 (CAr1), 121.1 (CAr1′), 117.3
(CAr3), 115.7 (CAr3′), 69.4 (C1′′), 68.9 (-OCH2-C=O), 54.3 (C1), 50.0 (C2), 40.5 (C6), 39.3
(C2′′), 32.5 (C3), 32.0 (-CH2Ph), 27.8 (C5), 25.5 (C3′′), 23.4 (C4), 22.8 (C4′′ or C5′′), 22.4
(C5′′ or C4′′); IR (neat) ν̄max 3650, 2957, 1734, 1683, 1653, 1558, 1506, 1457, 1244, 1073,
809, 750 cm-1; MS (ESI +ve) m/z 670 ([M + H]+, 100%), 692 ([M + Na]+, 10%); HRMS (ESI
+ve TOF) calcd for C42H47N5O3Na 692.3577, found 692.3611 ([M + Na]+).
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N-((R)-6-Amino-1-(4-phenyl-1H-1,2,3-triazol-1-yl)hexan-2-yl)-2-(((S)-2'(isopentyloxy)-[1,1'-binaphthalen]-2-yl)oxy)acetamide hydrochloride (89b)
Following General Procedure A, azide 88 (50 mg,
0.08 mmol), phenylacetylene (24 mg, 0.23 mmol),
Cu(OAc)2∙H2O (3 mg, 0.02 mmol) and sodium
ascorbate (6 mg, 0.03 mmol) were stirred in
t-BuOH (1.6 mL) and H2O (0.4 mL) for 20 h to give the intermediate triazole as a light tan
gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100  10:90). Following
General Procedure C, the triazole was dissolved in CH2Cl2 (2.3 mL) and treated with H2O
(27 mg, 1.52 mmol) and CF3CO2H (2.3 mL) followed by work-up with ethereal HCl to give
the amine salt 89b (37 mg, 70% over two steps) as a light tan powder that rapidly transitioned
23

to a sticky gum. [α] D −19.7 (c 1.22, MeOH); 1H NMR (500 MHz, CD3OD) δ 8.10 – 7.82 (m,
6H), 7.74 (d, J = 7.5 Hz, 2H), 7.51 (d, J = 9.0 Hz, 1H), 7.46 – 7.18 (m, 7H), 7.13 (d, J = 8.6
Hz, 1H), 7.09 (d, J = 8.6 Hz, 1H), 4.54 – 4.29 (m, 3H), 4.12 (br s, 1H), 4.00 – 3.80 (m, 3H),
2.86 – 2.64 (m, 2H), 1.59 – 1.39 (m, 2H), 1.35 – 1.22 (m, 1H), 1.22 – 1.08 (m, 2H), 1.08 –
0.93 (m, 3H), 0.93 – 0.74 (m, 1H), 0.50 (d, J = 6.6 Hz, 3H), 0.46 (d, J = 6.7 Hz, 3H); 13C
NMR (125 MHz, CD3OD) δ 171.0, 156.1, 153.8, 150.3, 135.2, 135.0, 131.6, 131.4, 131.1,
131.0, 130.0*, 129.44, 129.42, 129.2, 127.9, 127.6, 126.7*, 126.3, 126.1, 125.3, 125.2, 122.7,
121.5, 121.0, 117.3, 115.6, 69.4, 69.0, 54.2, 50.0, 40.5, 39.2, 31.9, 27.9, 25.5, 23.5, 22.7,
22.4; IR (neat) ν̄max 3373, 2954, 1683, 1653, 1558, 1506, 1244, 1147, 809, 765 cm-1; MS (ESI
+ve) m/z 656 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for C41H45N5O3Na 678.3420,
found 678.3448 ([M + Na]+).
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N-((R)-6-Amino-1-(4-isopentyl-1H-1,2,3-triazol-1-yl)hexan-2-yl)-2-(((S)-2'(isopentyloxy)-[1,1'-binaphthalen]-2-yl)oxy)acetamide hydrochloride (89c)
Following General Procedure A, azide 88 (50
mg, 0.08 mmol), 5-methyl-1-hexyne (22 mg, 0.23
mmol), Cu(OAc)2∙H2O (3 mg, 0.02 mmol) and
sodium ascorbate (6 mg, 0.03 mmol) were stirred
in t-BuOH (1.6 mL) and H2O (0.4 mL) for 20 h to give the intermediate triazole as a light tan
gum after flash chromatography over SiO2 gel (MeOH/CH2Cl2 – 0:100  10:90). Following
General Procedure C, the triazole was dissolved in CH2Cl2 (2.3 mL) and treated with H2O
(27 mg, 1.52 mmol) and CF3CO2H (2.3 mL) followed by work-up with ethereal HCl to give
the amine salt 89c (37 mg, 70% over two steps) as a light tan powder that rapidly transitioned
to a sticky gum. 1H NMR (500 MHz, CD3OD) δ 8.10 (d, J = 8.9 Hz, 1H), 8.04 (d, J = 9.0 Hz,
1H), 7.98 (d, J = 8.3 Hz, 1H), 7.92 (d, J = 8.1 Hz, 1H), 7.62 (d, J = 9.0 Hz, 1H), 7.44 – 7.33
(m, 3H), 7.27 (m, 2H), 7.20 (s, 1H), 7.15 (d, J = 8.6 Hz, 1H), 7.11 (d, J = 8.5 Hz, 1H), 4.45
and 4.34 (ABq, J = 14.6 Hz, 2H), 4.27 (dd, J = 13.9, 4.5 Hz, 1H), 4.13 – 4.01 (m, 2H), 4.01
– 3.90 (m, 1H), 3.74 (dd, J = 13.9, 8.7 Hz, 1H), 2.80 – 2.66 (m, 2H), 2.65 – 2.53 (m, 2H),
1.54 – 1.37 (m, 4H), 1.37 – 1.06 (m, 6H), 1.02 – 0.76 (m, 8H), 0.56 (d, J = 6.5 Hz, 3H), 0.51
(d, J = 6.6 Hz, 3H); 13C NMR (125 MHz, CD3OD) δ 170.8, 156.1, 153.8, 149.2, 135.2, 135.1,
131.5, 131.09, 131.05, 130.8, 129.5, 129.2, 127.9, 127.7, 126.3, 126.1, 125.3, 125.2, 123.4,
121.6, 121.1, 117.3, 115.8, 69.4, 69.1, 54.2, 49.9, 40.4, 39.7, 39.3, 32.0, 28.6, 27.8, 25.6,
24.2, 23.4, 22.8, 22.7*, 22.5; IR (neat) ν̄max 3363, 2956, 2361, 1680, 1653, 1507, 1272, 1203,
1136, 810 cm-1; MS (ESI +ve) m/z 650 ([M + H]+, 100%); HRMS (ESI +ve TOF) calcd for
C40H52N5O3 650.4070, found 650.4043 ([M + H]+).
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6.4 – Microbiology and pharmacology
6.4.1 – Minimum inhibitory concentration (MIC) and cytotoxicity assays
Primary screening (University of Western Australia)
The following experiments were performed by Dr. Katherine Hammer and/or Dr.
Daniel Knight. MIC assays were performed on Staphylococcus aureus (ATCC 29213),
methicillin-resistant Staphylococcus aureus (NCTC 10442), Enterococcus faecalis (ATCC
29212) and Escherichia coli (ATCC 25922) in Mueller Hinton broth and incubation was
performed in ambient air at 35 °C for 24 h. Streptococcus pneumoniae (ATCC 49619) was
cultivated in Mueller Hinton broth with 2.5% lysed horse blood and incubated with 5% CO2
at 35 °C for 24 h. MIC studies for Clostridium difficile (ATCC 700057) and Clostridium
difficile (NSW132 - RT027) were conducted in Brucella broth supplemented with haemin
and vitamin K and incubation was performed anaerobically at 35 °C for 48 h. Each compound
was dissolved in DMSO at 5 mg/mL and then diluted to 512 μg/mL with sterile, distilled
water. The compounds were then serially diluted in 100 μL volumes of sterile, distilled water
in a 96-well microtitre tray. Each test organism in double strength broth (100 μL) was then
added to each well and incubated as described above. Testing concentrations of the
compounds ranged from 0.25 μg/mL to 128 μg/mL. Vancomycin and a control well (i.e. no
antibacterial compound present) were included in the assays. A DMSO control (5% v/v) was
also tested to ensure that the solvent did not inhibit bacterial growth. The assay was
performed in triplicate for each organism/compound combination and the modal MIC values
were recorded. The MIC was recorded as the lowest concentration that inhibited bacterial
growth. The minimum bactericidal concentration (MBC) was also recorded as the lowest
concentration that caused cellular death.
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Secondary screening (Community for Open Antimicrobial Drug Discovery (CO-ADD))
Samples were provided to CO-ADD for antimicrobial screening by whole cell growth
inhibition assays. The inhibition of growth was measured against five bacteria: Escherichia
coli (ATCC 25922), Klebsiella pneumoniae (ATCC 700603), Acinetobacter baumannii
(ATCC 19606), Pseudomonas aeruginosa (ATCC 27853) and Staphylococcus aureus
(ATCC 43300), and two fungi: Candida albicans (ATCC 90028) and Cryptococcus
neoformans (ATCC 208821). In addition to MIC, compounds were screened for cytotoxicity
against a human embryonic kidney cell line (HEK293) by determining their CC50 value.
Samples were prepared in DMSO to a final testing concentration of 32 μg/mL and serially
diluted 1:2 fold for 8 times. Each sample concentration was prepared in 384-well plates, nonbinding surface (NBS) plate (Corning 3640) for each bacterial/fungal strain and tissue-culture
treated (Corning 3712/3764) black for mammalian cell types, all in duplicate (n = 2) and
keeping the final DMSO concentration to a maximum of 0.5%. All the sample preparation
was done using liquid handling robots.
Bacterial Inhibition
All bacteria were cultured in Cation-adjusted Mueller Hinton broth at 37 °C
overnight. A sample of each culture was then diluted 40-fold in fresh broth and incubated at
37 °C for 1 – 3.5 h. The resultant mid-log phase cultures were diluted (CFU/mL measured
by OD600), then added to each well of the compound-containing plates, giving a cell density
of 5 × 105 CFU/mL and a total volume of 50 μL. All plates were covered and incubated at 37
°C for 18 h without shaking. Inhibition of bacterial growth was determined by measuring
absorbance at 600 nm (OD600), using a Tecan M1000 Pro monochromator plate reader. The
percentage of growth inhibition was calculated for each well, using the negative control
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(media only) and positive control (bacteria without inhibitors) on the same plate as
references. The MIC was determined as the lowest concentration at which growth was fully
inhibited, defined by an inhibition ≥ 80%. Colistin and vancomycin were used as positive
bacterial inhibitor standards for Gram-negative and Gram-positive bacteria, respectively.
Each antibiotic standard was provided in four concentrations, with two above and two below
its MIC value, and plated into the first eight wells of column 23 of the 384-well NBS plates.
Fungal Inhibition
Fungi strains were cultured for three days on Yeast Extract-Peptone Dextrose agar at
30 °C. A yeast suspension of 1 × 106 to 5 × 106 CFU/mL (as determined by OD530) was
prepared from five colonies. The suspension was subsequently diluted and added to each well
of the compound-containing plates giving a final cell density of fungi suspension of 2.5 ×
103 CFU/mL and a total volume of 50 μL. All plates were covered and incubated at 35 °C for
36 h without shaking. Growth inhibition for C. albicans was determined by measuring
absorbance at 630 nm (OD630), while the growth inhibition of C. neoformans was determined
measuring the difference in absorbance between 600 and 570 nm (OD600-570), after the
addition of resazurin (0.001 % final concentration) and incubation at 35 °C for 2 h. The
absorbance was measured using a Biotek Multiflo Synergy HTX plate reader. In both cases,
the percentage of growth inhibition was calculated for each well, using the negative control
(media only) and positive control (fungi without inhibitors) on the same plate. The MIC was
determined as the lowest concentration at which the growth was fully inhibited, definied as
an inhibition ≥ 80% for C. albicans and an inhibition ≥ 70% for C. neoformans. Due to the
higher variance in growth and inhibition, a lower threshold was applied to the data for C.
neoformans. Fluconazole was used a positive fungal inhibitor standard for C. albicans and
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C. neoformans using the same control methodology as the bacterial inhibition assays. The
antifungal standard was provided in four concentrations, with two above and two below its
MIC value, and plated into the first eight wells of column 23 of the 384-well NBS plates.
Cytotoxicity Assay
HEK293 cells were counted manually in a Neubauer haemocytometer and then plated
in the 384-well plates containing the compounds to give a density of 5000 cells/well in a final
volume of 50 μL. Dulbecco’s modified eagle medium (DMEM) supplemented with 10% fetal
bovine serum (FBS) was used as a growth media and the cells were incubated together with
the compounds for 20 h at 37 °C in 5% CO2. Cytotoxicity (cell viability) was measured by
fluorescence, ex: 560/10 nm, em: 590/10 nm (F560/590), after addition of 5 μL of 25 μg/mL
resazurin (2.3 μg/mL final concentration) and after incubation for further 3 h at 37 °C in 5%
CO2. The fluorescence intensity was measured using a Tecan M1000 Pro monochromator
plate reader, using automatic gain calculation. CC50 (concentration at 50% cytotoxicity)
values were calculated by curve-fitting the inhibition values vs. log(concentration) using a
sigmoidal dose-response function, with variable fitting values for bottom, top and slope.
Tamoxifen was utilized as a positive cytotoxicity standard; it was used in eight concentrations
in two-fold serial dilutions with 50 μg/mL as the highest concentration tested.

6.4.2 – In vivo CDI mouse model (Monash University)
Study design
The foillowing in vivo study was performed by Prof. Dena Lyras, Dr. Melanie Hutton
and Dr. Amy King. Mice were pre-treated with an antibiotic cocktail containing kanamycin
(0.4 mg/ml; Amresco), gentamicin (0.035 mg/ml; Sigma), colistin (850 U/ml; Sigma),
metronidazole (0.215 mg/ml; Sigma), vancomycin (0.045 mg/ml; Sigma) and cefaclor (0.3
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mg/ml; Sigma) in the drinking water for seven days, followed by three days of cefaclor alone
to disrupt the commensal microbiota and induce susceptibility to infection with C. difficile.
The mice were switched to plain drinking water and given clean cages on the day of infection.
Groups of five mice were infected with 105 C. difficile spores of the RT027 strain M7404.
Six hours post-infection, mice were given 2.5 mg of the selected compounds (in 10% aqueous
DMSO) by oral gavage. The mice were then administered fresh compound every 12 hours
after the initial dose. The mice were monitored twice daily for weight loss and other
physiological signs of infection. Blood was also collected at euthanasia and left to clot at
room temperature prior to centrifugation. The serum was collected and frozen at −80 °C.
Faeces collected at euthanasia was also frozen −80 °C for subsequent pharmacokinetic
analysis. Note that mice were euthanised according to animal ethics guidelines: i.e. if the
mice lose ≥ 10 % of their total body weight in the first 24 h or ≥ 15 % at any point after 24 h.
Sample preparation
Each compound was suspended in 100% DMSO to obtain a stock concentration of
250 mg/mL. Twenty minutes prior to administration, the compounds were diluted (1:10) by
adding warm water (37 °C) to the compound stock solution to achieve a final concentration
of 25 mg/mL. The compounds were vortexed and carried to the animal house floating in
warm water in an attempt to maintain a homogeneous solution. They were then vortexed
again immediately prior to gavaging the mice. Each mouse received 100 μL of solution
containing 2.5 mg of compound – this equates to a dose of 100 mg/kg (based on an average
25 g mouse).
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6.4.3 – Pharmacokinetics assay
Mouse blood analysis: procedure
A 200 μL aliquot of the mouse blood was placed into a glass vial and diluted with
phosphate buffered saline (PBS) solution (3.3 mL). The solution was vortexed for 20 s and
then CH2Cl2 (3.5 mL) was added and the mixture was manually swirled to ensure adequate
mixing with minimal emulsion formation. The layers were allowed to separate and the
CH2Cl2 was removed by syringe. The aqueous blood layer was extracted again with another
aliquot of CH2Cl2 (3.5 mL). The two extracts were combined and evaporated under reduced
pressure to obtain an opaque residue. The residue was dissolved in MeOH (2.0 mL) with the
aid of ultrasonication (30 s); the solution was filtered through a PTFE membrane (0.45 μm).
The obtained solution was then subjected to LRMS analysis.
Mouse blood analysis: procedure verification
To ensure the mouse blood analysis procedure was sufficiently sensitive to detect
small amounts of drug absorption, unadulterated mouse blood (i.e. blood from an untreated
cohort) was doped with a small quantity of lead compound 2 and then subjected to the
analysis procedure. The volume of mouse blood was accounted for to ensure that an accurate
concentration representative of a 1% systemic bioavailability was achieved. To dope the
blood with the correct concentration, 50 μL of a 0.05 mg/mL solution of compound 2 in 0.1%
DMSO in H2O was added to the PBS diluent prior to extraction with CH2Cl2. The
corresponding doubly-protonated molecular ion (m/2 = 421 = [M + 2H]2+) was found in the
LRMS spectrum of the doped blood, verifying the sensitivity of the analysis procedure.
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Mouse faeces analysis: procedure
The obtained sample of mouse faeces (from the treated cohort) was added to a glass
vial with CH2Cl2 (2.0 mL) and the mixture was stirred vigorously for 30 min. The solution
was then filtered through a cotton plug and the solvent was removed under reduced pressure.
The residue was taken up in MeOH (1.0 mL), sonicated for 30 s and then filtered through a
PTFE membrane filter (0.45 μm). The obtained solution was then subjected to LRMS
analysis.

6.4.4 – Comparative solubility assay
Procedure
Five milligrams of the target compound was fully dissolved in 50 μL DMSO. Small
aliquots (5 μL) of H2O were added to the DMSO solution with manual agitation in between
each addition; additions were continued until a visible turbidity/cloudiness was apparent that
did not fade after mixing. The quantity of H2O required for precipitation of the compound
was recorded; this value was then divided by the standard value (i.e. 15 μL = quantity of H2O
required to precipitate lead compound 1) to obtain a comparative solubility ratio. This ratio
helped to approximate the observed change in solubility that was observed for various
compounds.
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Appendix A – Supplementary figures and schemes
A1 – Additional reaction mechanisms
Mechanism for alkynes 20 and 21

Scheme A1.1 – Mechanism of base-promoted ether
synthesis (i.e. Williamson ether synthesis).78

Mechanisms for N-Cbz and N-Boc protecting group installation

Scheme A1.2 – Mechanism of N-Cbz protection via nucleophilic substitution at the
carbonyl position.78

Scheme A1.3 – Mechanism of N-Boc protection via nucleophilic substitution at the
carbonyl position.78
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Mechanism for the mixed-anhydride reduction reaction

Scheme A1.4 – Mechanism showing formation of the mixed anhydride
intermediate followed by borohydride reduction78 to give the alcohol product. PG
= Protecting Group = Cbz or Fmoc.

Mechanism for mesylation and SN2 azidation

Scheme A1.5 – Mechanism showing the formation of the mesylate
followed by SN2-type displacement of the mesylate leaving group by the
azide anion78 to give the product azide. PG = Protecting Group = Cbz or
Fmoc.
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Mechanism for iodination and oxazolidinone by-product formation

Scheme A1.6 – Mechanism for the formation of azide 25 from the alcohol precursor:
iodination followed by azidation/N-Fmoc deprotection.59, 78 The potential oxazolidinone
by-product reaction (red pathway) is also displayed.
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Mechanism for base-promoted N-Fmoc deprotection

Scheme A1.7 – Mechanism of base-promoted Fmoc cleavage by piperidine
with the dibenzofulvene scavenging pathway (red) shown. In DMSO at
50 °C, an azide anion can also function as the catalytic base required for NFmoc cleavage.84

Mechanism for copper-catalysed diazotransfer reaction

Scheme A1.8 – Diazotransfer reaction mechanism86 for the formation of the α-azido
acid precursors.
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A2 – Additional figures and schemes

Figure A2.1 – Structure for compound 90 (made by a current PhD
student, Muni Kumar Mahadari, who is continuing the biarylpeptide
research).

Figure A2.2 – HPLC trace for compound 2 synthesized by N-Boc/N-Pbf deprotection
without H2O present; large quantities of N-sulfonation by-products were observed.
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Figure A2.3 – HPLC trace for compound 2 synthesized by N-Boc/N-Pbf deprotection
with H2O present; minimal impurities were observed (~95% pure).

Figure A2.4 – Recrystallization of compound 68b by passive evaporation of MeOH/CH2Cl2.
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Appendix B – Biological testing data and supplementary information
This appendix contains a complete set of the in vitro antimicrobial testing data
acquired for all final compounds – see Tables B1.1 – B2.9 in Sections B1 and B2. The
solubility assay data (Tables B3.1 – B3.6 in Section B3) and HPLC purity traces (Figures
B4.1 – B4.4 in Section B4) are also included.
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B1 – Primary MIC screening data (UWA)

S. aureus
Compound

Aromatic
Core

Biphenyl
64a
Biphenyl
64b
Biphenyl
64c
Biphenyl
65a
Biphenyl
65b
Biphenyl
65c
Binaphthyl
66a
Binaphthyl
66b
Binaphthyl
66c
Vancomycin

E.
faecalis

S.
pneumoniae

E. coli

C. difficile

AA

R

ATCC
29213

NCTC
10442

ATCC
29212

ATCC
49619

ATCC
25922

ATCC
700057

132
(RT027)

Lys
Lys
Lys
Arg
Arg
Arg
Arg
Arg
Arg

Bn
PhEt
OBn
Bn
PhEt
OBn
Bn
PhEt
OBn

8
8
16
16
16
4
4
4
4

8
4
16
16
16
4
4
4
4

8
8
16
16
16
8
8
8
8

8
8
32
16
32
16
8
8
8

32
16
32
64
64
32
32
>128
>128

32
8
8
64
128
32
64
16
32

32
16
32
16
16
32
64
16
32

1

1

4

1

>16

0.5

0.5

Table B1.1 – Antibacterial activities of Series A1 derivatives reported as MIC values (μg/mL).
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S. aureus
Compound

Aromatic
Core

Biphenyl
68a
Biphenyl
68b
Biphenyl
68c
Biphenyl
68d
Biphenyl
69a
Biphenyl
69b
Biphenyl
69c
Biphenyl
69d
Binaphthyl
70a
Binaphthyl
70b
Vancomycin

AA1

AA2

R

Lys
Lys
Lys
Lys
Arg
Arg
Arg
Arg
Lys
Lys

Arg
Arg
Arg
Arg
Lys
Lys
Lys
Lys
Arg
Arg

Bn
PhEt
Cy
CH2Cy
Bn
PhEt
Cy
N/A†
PhEt
CH2Cy

E.
faecalis

S.
pneumoniae

E. coli

C. difficile

ATCC
29213

MRSA
NCTC
10442

ATCC
29212

ATCC
49619

ATCC
25922

ATCC
700057

132
(RT027)

8
4
8
4
4
4
4
16
4
4
1

8
4
4
4
4
4
4
16
4
4
1

16
8
8
4
8
8
8
16
4
4
4

4
8
4
4
4
4
4
8
4
4
1

64
64
64
32
32
32
32
64
16
16
>16

16
8
4
4
64
16
32
64
16
8
0.5

16
8
8
4
64
16
32
32
16
16
0.5

Table B1.2 – Antibacterial activities of Series A2 derivatives reported as MIC values (μg/mL). † No terminal triazole – compound 69d contains
an unreacted azide terminus – see Section 2.2.2.2 for compound structure.
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S. aureus
Compound
73
74
Vancomycin

Aromatic
AA1
Core

AA2

R

Biphenyl
Biphenyl

Arg
Arg

Bn
Fmo†

Lys
Lys

E.
faecalis

S.
pneumoniae

E. coli

C. difficile

ATCC
29213

MRSA
NCTC
10442

ATCC
29212

ATCC
49619

ATCC
25922

ATCC
700057

132
(RT027)

8
4
1

8
4
1

8
4
4

8
4
1

32
64
>16

16
32
0.5

16
32
0.5

Table B1.3 – Antibacterial activities of Series A2 derivatives reported as MIC values (μg/mL). † Fluorenylmethyloxy (Fmo).
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S. aureus
Compound
76a
76b
76c
76d
76e
76f
77a
77b
77c
77d
Vancomycin

E.
faecalis

S.
pneumoniae

E. coli

C. difficile

Aromatic
Core

AA

R

ATCC
29213

NCTC
10442

ATCC
29212

ATCC
49619

ATCC
25922

ATCC
700057

132
(RT027)

Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl

Lys
Lys
Lys
Lys
Lys
Lys
Arg
Arg
Arg
Arg

Bn
PhEt
Cy
CH2Cy
4-CF3-Bn
4-F-PhEt
Bn
PhEt
Cy
CH2Cy

8
8
8
8
4
4
4
2
4
4

16
8
16
8
4
8
8
2
4
4

16
8
16
8
4
8
8
4
4
8

8
8
8
8
8
8
4
4
4
8

32
16
32
16
16
16
32
16
16
32

32
32
16
16
32
32
32
8
8
32

32
32
32
32
32
64
64
32
16
64

1

1

4

1

>16

0.5

0.5

Table B1.4 – Antibacterial activities of Series B1 derivatives reported as MIC values (μg/mL).
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S. aureus
Compound

Aromatic
Core

AA

77e
77f
77g
77h
77i
77j
77k

Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl

Arg
Arg
Arg
Arg
Arg
Arg
Arg

77l

Biphenyl

Binaphthyl
78a
Binaphthyl
78b
Vancomycin

R

4-CF3-Bn
4-F-PhEt
3,5-diF-Bn
3-F-Ph
Ph
3,5-diMeO-Bn
Cyclopropyl
Ethyl and
Arg
Cyclopropylmethyl
Arg
Bn
Arg
PhEt

E.
S.
faecalis pneumoniae

E. coli

C. difficile
ATCC
132
700057 (RT027)

ATCC
29213

NCTC
10442

ATCC
29212

ATCC
49619

ATCC
25922

16
4
8
4
2
4
16

16
4
8
8
2
4
32

16
4
8
8
2
4
32

32
4
16
8
2
4
8

64
32
32
32
16
32
64

128
64
32
32
16
32
64

128
64
32
64
32
32
128

4

4

4

2

32

16

16

4
8
1

8
8
1

2
4
4

8
16
1

>128
>128
>16

16
16
0.5

16
64
0.5

Table B1.5 – Antibacterial activities of Series B1 derivatives reported as MIC values (μg/mL).
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S. aureus
Compound
80a
80b
80c
80d
81a
81b
81c
81d
Vancomycin

Aromatic
Core

AA1

AA2

R

Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl

Lys
Lys
Lys
Lys
Arg
Arg
Arg
Arg

Arg
Arg
Arg
Arg
Lys
Lys
Lys
Lys

Bn
PhEt
Cy
CH2Cy
Bn
PhEt
Cy
CH2Cy

E.
faecalis

S.
pneumoniae

E. coli

C. difficile

ATCC
29213

NCTC
10442

ATCC
29212

ATCC
49619

ATCC
25922

ATCC
700057

132
(RT027)

4
4
16
4
8
4
8
4
1

4
4
16
4
8
8
8
4
1

8
8
16
4
8
8
8
4
4

4
8
32
8
4
2
2
2
1

32
16
64
32
32
16
16
16
>16

8
16
64
16
32
16
8
8
0.5

16
16
128
16
16
16
16
16
0.5

Table B1.6 – Antibacterial activities of Series B2 derivatives reported as MIC values (μg/mL).
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S. aureus
Compound
82a
82b
83a
83b
Vancomycin

Aromatic
Core

AA1

AA2

R

Binaphthyl
Binaphthyl
Binaphthyl
Binaphthyl

Lys
Lys
Arg
Arg

Arg
Arg
Lys
Lys

PhEt
CH2Cy
PhEt
CH2Cy

E.
faecalis

S.
pneumoniae

E. coli

C. difficile

ATCC
29213

NCTC
10442

ATCC
29212

ATCC
49619

ATCC
25922

ATCC
700057

132
(RT027)

4
4
4
4
1

4
4
4
4
1

4
4
4
4
4

4
4
2
2
1

16
16
8
8
>16

16
16
16
8
0.5

16
16
16
8
0.5

Table B1.7 – Antibacterial activities of Series B2 derivatives reported as MIC values (μg/mL).
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S. aureus
Compound

Aromatic
Core

Binaphthyl
85a
Binaphthyl
85b
Binaphthyl
85c
Vancomycin

AA1

AA2

R

Lys
Lys
Arg

Arg
Arg
Lys

Bn
PhEt
Piperidinyl†

E.
faecalis

S.
pneumoniae

E. coli

C. difficile

ATCC
29213

NCTC
10442

ATCC
29212

ATCC
49619

ATCC
25922

ATCC
700057

132
(RT027)

8
8
8
1

8
8
8
1

8
4
8
4

8
8
8
1

32
32
16
>16

16
16
16
0.5

16
32
32
0.5

Table B1.8 – Antibacterial activities of Series B2 derivatives reported as MIC values (μg/mL). † Piperidinyl amide – see Section 2.3.2.2 for
compound structure.
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S. aureus
Compound

R

87a
87b
87c
Vancomycin

Bn
PhEt
4-F-PhEt

E.
faecalis

S.
pneumoniae

E. coli

C. difficile

ATCC
29213

NCTC
10442

ATCC
29212

ATCC
49619

ATCC
25922

ATCC
700057

132
(RT027)

2
2
>128
1

2
2
>128
1

2
4
>128
4

2
2
>128
1

>128
>128
>128
>16

8†
32
>128
0.5

8†
32
64
0.5

Table B1.9 – Antibacterial activities of Series C derivatives reported as MIC values (μg/mL). Compound 87a
displayed an MIC value of 2 μg/mL against C. difficile (M7404 – RT027) when tested at the Monash University
laboratory.
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S. aureus
Compound

R

89a
89b
89c
Vancomycin

Ph
Bn
Isopentyl

E.
faecalis

S.
pneumoniae

E. coli

C. difficile

ATCC
29213

NCTC
10442

ATCC
29212

ATCC
49619

ATCC
25922

ATCC
700057

132
(RT027)

4
4
8
1

8
4
8
1

4
4
4
4

32
32
32
1

>128
>128
128
>16

16
8
16
0.5

16
8
16
0.5

Table B1.10 – Antibacterial activities of Series C derivatives reported as MIC values (μg/mL).
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B2 – Secondary MIC screening and cytotoxicity data (CO-ADD)

Control Data
S.
aureus
ATCC

Compound

43300
(MRSA)

Vancomycin
Colistin
Fluconazole
Tamoxifen

1
>32
-

P.
aeruginosa

K.
pneumoniae

A.
baumannii

E.
coli

C.
albicans

C.
Cytotoxicity
(CC50)
neoformans

ATCC

27853

ATCC
700603

ATCC
19606

ATCC
25922

ATCC
90028

208821

>32
0.25
-

>32
0.25
-

>32
0.25
-

>32
0.125
-

0.125
-

8
-

ATCC

(HEK-293)
ATCC
CRL-1573

13.06

Table B2.1 – MIC or CC50 values for the various control inhibitors – reported in μg/mL.
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S.
aureus
Compound
64a
64b
64c
65a
65b
65c
66a
66b
66c

ATCC

Aromatic
Core

AA

Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl
Binaphthyl
Binaphthyl
Binaphthyl

Lys
Lys
Lys
Arg
Arg
Arg
Arg
Arg
Arg

R

43300
(MRSA)

Bn
PhEt
OBn
Bn
PhEt
OBn
Bn
PhEt
OBn

16
16
16
16
16
8
4
4
4

P.
aeruginosa

K.
pneumoniae

A.
baumannii

E.
coli

C.
albicans

C.
Cytotoxicity
(CC50)
neoformans

ATCC

27853

ATCC
700603

ATCC
19606

ATCC
25922

ATCC
90028

208821

32
32
32
>32
>32
>32
>32
>32
>32

>32
32
>32
>32
>32
>32
>32
>32
>32

32
>32
32
>32
>32
>32
>32
>32
>32

>32
32
32
>32
>32
>32
>32
>32
>32

32
>32
16
>32
>32
8
32
32
16

32
16
32
32
32
16
8
8
4

ATCC

(HEK-293)
ATCC
CRL-1573

14.2
4.8
4.7
29.0
>32
>32
16.5
15.9
13.8

Table B2.2 – Antibacterial activities of Series A1 derivatives reported as MIC values (μg/mL). The cytotoxicity of each compound is also reported as the
CC50 (μg/mL).
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Compound

Aromatic
Core

AA1

AA2

R

68a
68b
68c
68d
69a
69b
69c
69d
70a
70b

Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl
Binaphthyl
Binaphthyl

Lys
Lys
Lys
Lys
Arg
Arg
Arg
Arg
Lys
Lys

Arg
Arg
Arg
Arg
Lys
Lys
Lys
Lys
Arg
Arg

Bn
PhEt
Cy
CH2Cy
Bn
PhEt
Cy
N/A†
PhEt
CH2Cy

S.
aur.
4
2
4
2
4
2
4
8
4
2

P.
aer.
16
8
8
16
16
8
8
32
32
32

K.
pneu.
16
16
16
16
32
16
32
32
>32
>32

A.
bau.
8
16
16
8
16
16
8
16
32
16

E.
coli
16
8
8
4
8
4
8
16
>32
32

C.
alb.
32
32
32
>32
32
32
32
>32
8
4

C.
neo.
32
4
4
4
4
2
2
4
2
2

Cytotoxicity
(CC50)

21.9
>32
14.2
>32
17.8
17.4
15.3
>32
>32
>32

Table B2.3 – Antibacterial activities of Series A2 derivatives reported as MIC values (μg/mL). The cytotoxicity of each compound is also
reported as the CC50 (μg/mL). † No terminal triazole – compound 69d contains an unreacted azide terminus – see Section 2.2.2.2 for
structure.
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Compound

Aromatic
Core

AA1

AA2

R

73
74

Biphenyl
Biphenyl

Lys
Lys

Arg
Arg

Fmo†
Bn

S.
aur.
4
4

P.
aer.
32
>32

K.
pneu.
32
>32

A.
bau.
32
>32

E.
coli
16
>32

C.
alb.
32
>32

C.
neo.
2
8

Cytotoxicity
(CC50)

28.7
16.5

Table B2.4 – Antibacterial activities of Series A2 derivatives reported as MIC values (μg/mL). The cytotoxicity of each compound is also
reported as the CC50 (μg/mL). † Fluorenylmethyloxy (Fmo).
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S.
aureus
Compound
76a
76b
76c
76d
76e
76f
77a
77b
77c
77d

ATCC

Aromatic
Core

AA

Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl

Lys
Lys
Lys
Lys
Lys
Lys
Arg
Arg
Arg
Arg

R

43300
(MRSA)

Bn
PhEt
Cy
CH2Cy
4-CF3-Bn
4-F-PhEt
Bn
PhEt
Cy
CH2Cy

16
8
8
8
8
8
8
8
4
4

P.
aeru.

K.
pneum.

A.
baumannii

E.
coli

C.
albicans

C.
Cytotoxicity
(CC50)
neoformans

ATCC

27853

ATCC
700603

ATCC
19606

ATCC
25922

ATCC
90028

208821

32
>32
32
>32
>32
>32
>32
>32
>32
>32

>32
>32
>32
>32
>32
>32
>32
>32
>32
>32

32
32
32
32
32
16
32
32
32
>32

>32
>32
>32
>32
>32
>32
>32
>32
>32
>32

>32
>32
32
32
>32
>32
16
16
16
32

>32*
>32*
32*
16*
32*
12*
16
32
16
32

ATCC

(HEK-293)
ATCC
CRL-1573

>32
>32
>32
5.6
>32
5.5
16.8
17.9
19.7
16.9

Table B2.5 – Antibacterial activities of Series B1 derivatives reported as MIC values (μg/mL). The cytotoxicity of each compound is also reported as
the CC50 (μg/mL). * Cryptococcus neoformans data was not consistent with initial screening data – compounds need to be rescreened.
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Compound

Aromatic
Core

77e
77f
77g
77h
77i

Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl

77j

Biphenyl

77k

Biphenyl

AA

R

S.
aureus

P.
aeru.

ATCC

ATC
C

43300

Arg
Arg
Arg
Arg
Arg

Arg

77l

Biphenyl

Arg

78a
78b

Binaphthyl
Binaphthyl

Arg
Arg

4-CF3-Bn
4-F-PhEt
3,5-diF-Bn
3-F-Ph
Ph
3,5-diMeOBn
Cyclopropyl
Ethyl and
cyclopropylmethyl
Bn
PhEt

A.
baum.

E.
coli

C.
albicans

C.
Cytotoxicity
(CC50)
neoformans

ATCC
700603

ATCC
19606

ATCC
25922

ATCC
90028

208821

>32
>32
>32
>32
>32

>32
>32
>32
>32
>32

>32
>32
>32
>32
>32

>32
>32
>32
>32
>32

32
32
>32
4
32

>32
19.1
22.9
>32
21.6

ATCC

(HEK-293)
ATCC
CRL-1573

16
16
16
4
8

2785
3
>32
>32
>32
>32
>32

8

>32

>32

>32

>32

>32

>32

12.2

32

>32

>32

>32

>32

>32

>32

20.0

8

>32

>32

>32

>32

32

32

19.7

8
8

>32
>32

>32
>32

>32
>32

>32
>32

16
32

8
16

16.5
>32

(MRSA)
Arg

K.
pneum.

Table B2.6 – Antibacterial activities of Series B1 derivatives reported as MIC values (μg/mL). The cytotoxicity of each compound is also reported as
the CC50 (μg/mL).
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Compound

Aromatic
Core

AA

80a
80b
80c
80d
81a
81b
81c
81d
82a
82b
83a
83b

Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl
Biphenyl
Binaphthyl
Binaphthyl
Binaphthyl
Binaphthyl

Lys
Lys
Lys
Lys
Arg
Arg
Arg
Arg
Lys
Lys
Arg
Arg

1

AA2

R

Arg
Arg
Arg
Arg
Lys
Lys
Lys
Lys
Arg
Arg
Lys
Lys

Bn
PhEt
Cy
CH2Cy
Bn
PhEt
Cy
CH2Cy
PhEt
CH2Cy
PhEt
CH2Cy

S.
aur.
4
2
4
2
8
4
4
8
2
2
4
32

P.
aer.
16
8
16
32
16
16
8
16
16
32
32
32

K.
pneu.
32
16
16
16
32
16
16
16
>32
>32
>32
>32

A.
bau.
16
8
8
8
32
32
16
16
8
8
32
32

E.
coli
8
8
8
8
>32
16
16
16
>32
>32
>32
>32

C.
alb.
32
32
32
16
32
32
32
32
4
4
32
32

C.
neo.
4
4
4
4
4*
2*
2*
2*
2
1
1*
1*

Cytotoxicity
(CC50)

17.1
16.4
19.8
19.1
>32
>32
>32
>32
>32
16.6
>32
>32

Table B2.7 – Antibacterial activities of Series B2 derivatives reported as MIC values (μg/mL). The cytotoxicity of each compound is also
reported as the CC50 (μg/mL). * Cryptococcus neoformans data was not consistent with initial screening data – compounds need to be
rescreened.
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Compound

Aromatic
Core

AA1

AA2

R

85a
85b

Binaphthyl
Binaphthyl

Lys
Lys

Arg
Arg

Bn
PhEt

85c

Binaphthyl

Lys

Arg

Piperidinyl†

S.
aur.
4
2

P.
aer.
32
32

K.
pneu.
32
16

A.
bau.
32
8

E.
coli
>32
>32

C.
alb.
16
16

C.
neo.
4
2

Cytotoxicity
(CC50)

2

16

16

8

32

16

4

16.8

17.4
15.2

Table B2.8 – Antibacterial activities of Series B2 derivatives reported as MIC values (μg/mL). The cytotoxicity of each compound is also
reported as the CC50 (μg/mL). † Piperidinyl amide – see Section 2.3.2.2 for compound structure.
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S.
aureus
ATCC

Compound

R

43300
(MRSA)

87a
87b
87c

Bn
PhEt
4-F-PhEt

4
4
4

P.
aeru.

K.
pneum.

A.
baumannii

E.
coli

C.
albicans

C.
Cytotoxicity
(CC50)
neoformans

ATCC

27853

ATCC
700603

ATCC
19606

ATCC
25922

ATCC
90028

208821

>32
>32
>32

>32
>32
>32

>32
>32
>32

>32
>32
>32

>32
32
>32

16*
16*
16*

ATCC

(HEK-293)
ATCC
CRL-1573

>32
>32
>32

Table B2.9 – Antibacterial activities of Series C derivatives reported as MIC values (μg/mL). The cytotoxicity of each compound is
also reported as the CC50 (μg/mL).
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B3 – Solubility assay data – Series A1

H2 O
ppt. vol
(µL)

Solubility Ratio
(Compound :
compound 1)

-

15

1

7.47

Arg

OBenzyl

20

1.33

6.61

Biphenyl

Arg

OBenzyl

65

4.33

4.26

Biphenyl

Lys

Benzyl

>300 (NP)

>20 (NP)

4.97

Compound

Aromatic
Core

AA

1

Binaphthyl

-

66c

Binaphthyl

65c
64a

R

CLogP

Table B3.1 – Solubility assay data for selected Series A1 derivatives. NP = No precipitation observed.
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Solubility assay data – Series A2

H2 O
ppt. vol
(µL)

Solubility Ratio
(Compound :
compound 1)

-

15

1

7.47

Arg

PhEt

45

3

5.76

Arg

Benzyl

15

1

3.02

Compound

Aromatic
Core

AA

AA

1

Binaphthyl

-

-

2

Binaphthyl

Lys

73

Biphenyl

Lys

R

CLogP

Table B3.2 – Solubility assay data for selected Series A2 derivatives.
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Solubility assay data – Series A2 (cont.)

H2 O
ppt. vol
(µL)

Solubility Ratio
(Compound :
compound 1)

-

15

1

7.47

Arg

PhEt

30

2

6.24

Lys

Arg

PhEt

35

2.33

3.89

Biphenyl

Lys

Arg

Cy

60

4

4.07

68d

Biphenyl

Lys

Arg

CH2Cy

45

3

4.60

69c

Biphenyl

Arg

Lys

Cy

30

2

4.07

Compound

Aromatic
Core

AA

AA

1

Binaphthyl

-

-

70a

Binaphthyl

Lys

68b

Biphenyl

68c

R

CLogP

Table B3.3 – Solubility assay data for selected Series A2 derivatives.
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Solubility assay data – Series B1

H2 O
ppt. vol
(µL)

Solubility Ratio
(Compound :
compound 1)

-

15

1

7.47

Arg

Cy

30

2

3.77

Lys

CH2Cy

>200 (NP)

>13.3 (NP)

5.81

Compound

Aromatic
Core

AA

1

Binaphthyl

-

77c

Biphenyl

76d

Biphenyl

R

CLogP

Table B3.4 – Solubility assay data for selected Series B1 derivatives. NP = No precipitation observed.
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Solubility assay data – Series B2

H2 O
ppt. vol
(µL)

Solubility Ratio
(Compound :
compound 1)

-

15

1

7.47

Lys

CH2Cy

15

1

6.94

Arg

Lys

CH2Cy

55

3.67

4.60

Lys

Arg

Cy

30

2

4.07

Compound

Aromatic
Core

AA

AA

1

Binaphthyl

-

-

83b

Binaphthyl

Arg

81d

Biphenyl

80c

Biphenyl

R

CLogP

Table B3.5 – Solubility assay data for selected Series B2 derivatives.
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Solubility assay data – Series C

Compound

Aromatic
Core

R

1

Binaphthyl

-

87a

Binaphthyl

Benzyl

H2 O
ppt. vol
(µL)

Solubility Ratio
(Compound :
compound 1)

CLogP

15

1

7.47

15

1

5.82

Table B3.6 – Solubility assay data for selected Series C derivatives.
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B4 – HPLC purity traces

Figure B4.1 – HPLC trace and peak integration table for compound 77c.
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Figure B4.2 – HPLC trace and peak integration table for compound 87a.

Figure B4.3 – HPLC trace and peak integration table for compound 68c.
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Figure B4.4 – HPLC trace and peak integration table for compound 68d.
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Appendix C – Selected 1H, 13C and 2-D NMR spectra

Figure C1.1 – 1H NMR spectrum of compound 62a (recorded in CDCl3). The new triazole proton is
marked with a red asterisk (*).
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Figure C1.2 – 13C NMR spectrum of compound 62a (recorded in CDCl3). The new triazole carbons
are marked with a red asterisk (*).

Figure C1.3 – Selected expansion of the gHMBC spectrum of compound 63a (recorded in CDCl3).
The expansion shows the relevant correlations (circled in red and blue) that prove the 1,4regioselectivity.
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Figure C1.4 – 1H NMR spectrum of compound 64c (recorded in CD3OD). Visible rotameric shoulder
peaks are marked with a red asterisk (*).

Figure C1.5 – Selected expansion of the 13C NMR spectrum of compound 64c (recorded in CD3OD).
Clearly visible rotameric shoulder peaks are marked with a red asterisk (*).
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Figure C1.6– Selected expansion of the 13C NMR spectrum of compound 64c recorded in CD3OD at
rt (blue), DMSO-d6 at rt (green) and DMSO-d6 at 90 °C (red). Visible rotameric shoulder peaks are
marked with a red asterisk (*). Note the reduced 13C NMR resonance splitting in the sample recorded
in DMSO-d6 at 90 °C.

Figure C1.7 – 1H NMR spectrum of compound 76d recorded in CD3OD. Visible rotameric shoulder
peaks are marked with a red asterisk (*).
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Figure C1.8 – Selected expansions of the 13C NMR spectrum of compound 76d recorded in CD3OD.
Visible rotameric splitting of 13C NMR resonances is marked with a red asterisk (*).

Figure C1.9 – Selected expansion of the 1H NMR spectrum of scaffold acid 84 recorded in DMSOd6. The rotameric splitting of 1H NMR resonances assigned to the amide (NH) and triazole (CH)
protons are noted.
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Figure C1.10 – 1H NMR spectrum of scaffold acid 84 recorded in DMSO-d6. Primary rotameric
splitting of 1H NMR resonances is marked with a red asterisk (*). Secondary rotameric splitting of
1
H NMR resonances is marked with a green asterisk (*).

Figure C1.11 – Selected expansions of the alkyl region of the 13C NMR spectrum of scaffold acid
84 recorded in CD3OD. Primary rotameric splitting of 13C NMR resonances is marked with a red
asterisk (*). Secondary rotameric splitting of 13C NMR resonances is marked with a green asterisk
(*).
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Figure C1.12 – Selected expansions of the aromatic region of the 13C NMR spectrum of scaffold
acid 84 recorded in CD3OD. Rotameric splitting of 13C NMR resonances is marked with a red asterisk
(*).

Figure C1.13 – Selected expansion of the 13C NMR spectrum of compound 84 recorded in CD3OD
at rt (blue), DMSO-d6 at rt (green) and DMSO-d6 at 90 °C (red). Primary rotameric splitting of 13C
NMR resonances is marked with a red asterisk (*). Secondary rotameric splitting of 13C NMR
resonances is marked with a green asterisk (*). Note the reduced amount of primary and secondary
rotameric splitting of 13C NMR resonances in the sample recorded in DMSO-d6 at 90 °C.
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Figure C1.14 – Selected expansion of the 13C NMR spectrum of compound 84 recorded in CD3OD
at rt (blue), DMSO-d6 at rt (green) and DMSO-d6 at 90 °C (red). Visible rotameric splitting of 13C
NMR resonances is marked with a red asterisk (*). Note the reduced number of split 13C NMR
resonances in the sample recorded in DMSO-d6 at 90 °C.

Figure C1.15– Selected expansion of the 1H NMR spectrum of compound 84 recorded in CD3OD at
rt (blue), DMSO-d6 at rt (green) and DMSO-d6 at 90 °C (red). Visible rotameric splitting of the
resonance assigned to the triazole methine proton is marked on the two 1H NMR spectra that were
recorded in DMSO-d6 (middle and bottom spectra). Note the observed change in the splitting pattern
and resolution.
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Figure C1.16 – Selected expansion of the 1H NMR spectra compound 63b (top spectra in blue recorded in CDCl3) and compound 62b (bottom spectra in red – recorded in CDCl3). The expansion
shows the various resonance patterns that are exhibited by the exchangeable protons on the N-Pbf
protected guanidine.

Figure C1.17 – 13C NMR spectrum of bis-triazole compound 68a recorded in CD3OD. The locations
of the missing 13C NMR resonances (as determined by gHSQC and gHMBC) are marked with a red
asterisk (*).
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Figure C1.18 – Selected expansion of the gHSQC NMR spectrum of bis-triazole compound 68a
recorded in CD3OD. The relevant correlations that allowed for assignment of the triazole methine
carbons are marked.

Figure C1.19 – Selected expansion of the gHMBC NMR spectrum of bis-triazole compound 68a
recorded in CD3OD. The relevant correlations that allowed for assignment of the both the methine
and quaternary triazole carbons are marked.
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Figure C1.20 – Selected expansion of the gHMBC NMR spectrum of bis-triazole compound 68b
recorded in CD3OD. The relevant correlations that allowed for assignment of the quaternary triazole
carbons are marked.

Figure C1.21 – Selected expansion of the gHSQC NMR spectrum of bis-triazole compound 68b
recorded in CD3OD. The relevant correlations that allowed for assignment of the triazole methine
carbons are marked.
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Figure C1.22 – Selected expansion of the 13C NMR spectra of compound 64c recorded in CD3OD
(blue) and DMSO-d6 (red). Note the new 13C NMR resonances that are observed with the use of
DMSO-d6 (marked with red arrows  ).

Figure C1.23 – Selected expansion of the 13C NMR spectra of compound 75a recorded in CD3OD
(blue) and DMSO-d6 (red). Note the new 13C NMR resonances that are observed with the use of
DMSO-d6 (marked with red arrows  ). Missing resonances are marked with a red asterisk (*); note
the missing methine (C2) resonance in the spectrum acquired in DMSO-d6.
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Figure C1.24 – Selected expansion of the 1H NMR spectrum of compound 75a recorded in CD3OD
(blue) and DMSO-d6 (red). Note the broadening of the labelled resonances (assigned to the triazole
and methine protons) in the spectrum acquired in CD3OD; reduced broadening was observed for the
resonance assigned to the triazole proton (H5′) in the spectrum acquired in DMSO-d6 (red arrow ).

Figure C1.25 – Selected expansion of the gHSQC NMR spectrum of alkyne 21 recorded in CDCl3.
The anomalous correlation is circled in red; note the reversed polarity of the DEPT Q 13C resonances
assigned to the alkyne carbons.
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